start-ver=1.4
cd-journal=joma
no-vol=17
cd-vols=
no-issue=1
article-no=
start-page=2709258
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260816
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Rotavirus-NSP5 interacts with and hijacks host ATP citrate lyase to viroplasms, enhancing lipid biosynthesis for facilitating rotavirus infection
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Rotavirus (RV) replication occurs within viroplasms (VMs) and is initiated by two RV non-structural proteins NSP2 and NSP5. Viruses exploit host cellular components for their replication and assembly; however, information on the roles of host proteins in VM dynamics and RV replication is limited. Thus, in the current study, we used proteomics to identify host proteins that interact with NSP5 during RV infection to delineate their role in virus replication. A large number of host proteins (n = 128) were found to interact with NSP5, and Gene Ontology enrichment analysis revealed the enrichment of various metabolic processes during RV infection. One of the essential host proteins, ATP citrate lyase (ACLY), which is involved in the de novo lipid synthesis pathway, was found to interact with C-terminal region of RV-NSP5 and colocalize within VMs. Following RV infection, the serine 455 phosphorylation of ACLY was induced, suggesting increased enzymatic activation. This correlates with enhanced lipid droplet production via increased acetyl-coenzyme A expression levels, which in turn supports VM formation. The ACLY inhibitors SB204990 or hydroxycitric acid tripotassium hydrate significantly reduced RV-infection in vitro. This anti-rotaviral effect of drug was further validated in BALB/c suckling mice by measuring viral protein expression and viral titers. In the presence of ACLY inhibitor, reduced viral titers, reduced viral protein expression, and improved small intestinal histopathology were observed. These findings suggest a protective effect of drugs against RV infection in vivo and highlight ACLY as a potential anti-rotaviral target for the development of new therapeutics.
en-copyright=
kn-copyright=

en-aut-name=SharmaRanjana
en-aut-sei=Sharma
en-aut-mei=Ranjana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=BanerjeeShreya
en-aut-sei=Banerjee
en-aut-mei=Shreya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ChaudhuriRatul Datta
en-aut-sei=Chaudhuri
en-aut-mei=Ratul Datta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=DeyKaushik Kumar
en-aut-sei=Dey
en-aut-mei=Kaushik Kumar
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=GopeAnimesh
en-aut-sei=Gope
en-aut-mei=Animesh
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MiyoshiShin-ichi
en-aut-sei=Miyoshi
en-aut-mei=Shin-ichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ImamuraDaisuke
en-aut-sei=Imamura
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=Chawla-SarkarMamta
en-aut-sei=Chawla-Sarkar
en-aut-mei=Mamta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Regional VRDL, ICMR- National Institute for Research in Bacterial Infections (formerly ICMR-NICED)
kn-affil=

affil-num=2
en-affil=Regional VRDL, ICMR- National Institute for Research in Bacterial Infections (formerly ICMR-NICED)
kn-affil=

affil-num=3
en-affil=Regional VRDL, ICMR- National Institute for Research in Bacterial Infections (formerly ICMR-NICED)
kn-affil=

affil-num=4
en-affil=Division of Applied Biosciences, ICMR- National Institute for Research in Bacterial Infections (Formerly ICMR-NICED)
kn-affil=

affil-num=5
en-affil=Department of Central Instrumental Facility, ICMR- National Institute for Research in Bacterial Infections (Formerly ICMR-NICED)
kn-affil=

affil-num=6
en-affil=ICMR- National Institute for Research in Bacterial Infections (Formerly ICMR-NICED), Collaborative Research Center of Okayama University for Infectious Diseases in India
kn-affil=

affil-num=7
en-affil=ICMR- National Institute for Research in Bacterial Infections (Formerly ICMR-NICED), Collaborative Research Center of Okayama University for Infectious Diseases in India
kn-affil=

affil-num=8
en-affil=Regional VRDL, ICMR- National Institute for Research in Bacterial Infections (formerly ICMR-NICED)
kn-affil=
en-keyword=Rotavirus
kn-keyword=Rotavirus
en-keyword=viroplasm
kn-keyword=viroplasm
en-keyword=non-structural protein 5 (NSP5)
kn-keyword=non-structural protein 5 (NSP5)
en-keyword=proteomics
kn-keyword=proteomics
en-keyword=host-pathogen interaction
kn-keyword=host-pathogen interaction
en-keyword=ATP citrate lyase
kn-keyword=ATP citrate lyase
END

start-ver=1.4
cd-journal=joma
no-vol=2026
cd-vols=
no-issue=
article-no=
start-page=7647492
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202601
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Association Between Early Posttransplant Graft Perfusion and CLAD‐Free Survival After Single Lung Transplantation
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background<br>
The physiological relevance of postoperative perfusion distribution after single lung transplantation (SLT) remains poorly defined, as asymmetric blood flow toward the graft is often regarded as an inherent consequence of the remaining native lung. This study aimed to determine whether the graft-directed perfusion ratio assessed by quantitative lung perfusion scintigraphy (QLPS) in the early postoperative period serves as an early physiological marker after SLT.<br>
Methods<br>
We retrospectively analyzed SLT recipients who underwent surgery at Okayama University Hospital between 1998 and 2021 and completed QLPS approximately 3 months posttransplant. The graft perfusion ratio (graft flow/total pulmonary flow × 100%) was quantified, and recipients were classified into high (≥ 80%) and low (< 80%) perfusion groups. CLAD-free survival, overall survival, and longitudinal perfusion changes were compared using Kaplan–Meier analysis and repeated-measures ANOVA.<br>
Results<br>
Recipients with higher graft perfusion demonstrated significantly better CLAD-free survival (p = 0.027). Overall survival was higher in the high-perfusion group, although the difference did not reach statistical significance (p = 0.075). Repeated-measures ANOVA revealed a significant group-by-time interaction (p = 0.019): recipients who developed CLAD had lower graft perfusion as early as 3 months after transplantation, followed by a progressive decline, whereas those who did not develop CLAD maintained stable perfusion. In the multivariable Cox analysis, higher graft perfusion was associated with a lower hazard of reaching the composite CLAD-free survival endpoint.<br>
Conclusions<br>
Early postoperative graft perfusion assessed by QLPS may serve as a noninvasive physiological marker after SLT. Higher graft-directed perfusion was associated with a lower hazard of reaching the composite CLAD-free survival endpoint and may aid early risk stratification and posttransplant surveillance.
en-copyright=
kn-copyright=

en-aut-name=TanakaShin
en-aut-sei=Tanaka
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IshiharaMegumi
en-aut-sei=Ishihara
en-aut-mei=Megumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KuboYujiro
en-aut-sei=Kubo
en-aut-mei=Yujiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamamotoHaruchika
en-aut-sei=Yamamoto
en-aut-mei=Haruchika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NakajimaKumi
en-aut-sei=Nakajima
en-aut-mei=Kumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TorigoeHidejiro
en-aut-sei=Torigoe
en-aut-mei=Hidejiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OkaharaShuji
en-aut-sei=Okahara
en-aut-mei=Shuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ShienKazuhiko
en-aut-sei=Shien
en-aut-mei=Kazuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SuzawaKen
en-aut-sei=Suzawa
en-aut-mei=Ken
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MiyoshiKentaroh
en-aut-sei=Miyoshi
en-aut-mei=Kentaroh
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=OkazakiMikio
en-aut-sei=Okazaki
en-aut-mei=Mikio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=SugimotoSeiichiro
en-aut-sei=Sugimoto
en-aut-mei=Seiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=ToyookaShinichi
en-aut-sei=Toyooka
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Department of General Thoracic, Breast, and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of General Thoracic Surgery and Organ Transplant Center, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Thoracic Surgery and Lung Transplantation, Hospital Universitario Puerta de Hierro-Majadahonda
kn-affil=

affil-num=4
en-affil=Department of General Thoracic, Breast, and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of General Thoracic, Breast, and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of General Thoracic, Breast, and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of General Thoracic, Breast, and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of General Thoracic, Breast, and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of General Thoracic, Breast, and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of General Thoracic, Breast, and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of General Thoracic, Breast, and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of General Thoracic, Breast, and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=chronic lung allograft dysfunction
kn-keyword=chronic lung allograft dysfunction
en-keyword=perfusion scintigraphy
kn-keyword=perfusion scintigraphy
en-keyword=single lung transplantation
kn-keyword=single lung transplantation
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=5
article-no=
start-page=299
end-page=308
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202610
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Prognostic Value of Combined Preoperative CALLY and SII Assessment in Patients Undergoing Resection for Esophageal Squamous Cell Carcinoma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This study evaluated the prognostic significance of the C-reactive protein–albumin–lymphocyte (CALLY) index and systemic immune-inflammation (SII) index in predicting postoperative outcomes in patients with esophageal squamous cell carcinoma (ESCC). A retrospective analysis was performed on clinical data from 102 patients with ESCC who underwent surgical resection at Western Theater General Hospital of China between January 2020 and July 2023. The associations between preoperative CALLY and SII indices and relapse-free survival (RFS) and overall survival (OS) were examined. Survival curves were generated using the Kaplan–Meier method, and prognostic factors were identified using Cox proportional hazards regression analysis. Patients with a high CALLY index had significantly longer RFS (HR=0.30, 95% CI: 0.13-0.71), and those with a low SII index also had significantly longer RFS (HR=2.23, 95% CI: 1.12-4.41). Similarly, patients with a high CALLY index had significantly longer OS (HR=0.27, 95% CI: 0.13-0.55), and those with a low SII index had significantly longer OS (HR=2.27, 95% CI: 1.09-4.71). When patients were stratified into four groups, the low-CALLY–high-SII group showed significantly shorter RFS than the high-CALLY–low-SII group (HR=0.26, 95% CI: 0.11-0.61; p=0.013), and OS was also significantly worse in the low-CALLY–high-SII group (HR=0.22, 95% CI: 0.09-0.54; p=0.016). Univariate Cox regression analysis identified both CALLY and SII as significant prognostic factors. In multivariate analysis, the CALLY index and N stage were independently associated with RFS, whereas only tumor size remained independently associated with OS. The combined assessment of preoperative CALLY and SII indices may be useful for prognostic stratification in patients with ESCC undergoing upfront surgical resection. It may help identify high-risk patient subgroups with distinct survival outcomes, thereby providing a potential rationale for stratifying postoperative surveillance and tailoring individualized adjuvant strategies, although validation in larger prospective cohorts is warranted.
en-copyright=
kn-copyright=

en-aut-name=XuTao
en-aut-sei=Xu
en-aut-mei=Tao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ZhengYing
en-aut-sei=Zheng
en-aut-mei=Ying
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HuangXuemei
en-aut-sei=Huang
en-aut-mei=Xuemei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=LuoHong
en-aut-sei=Luo
en-aut-mei=Hong
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Oncology, The General Hospital of Western Theater Command
kn-affil=

affil-num=2
en-affil=Department of Oncology, The General Hospital of Western Theater Command
kn-affil=

affil-num=3
en-affil=Department of Oncology, The General Hospital of Western Theater Command
kn-affil=

affil-num=4
en-affil=Department of Oncology, The General Hospital of Western Theater Command
kn-affil=
en-keyword=CALLY index
kn-keyword=CALLY index
en-keyword=SII index
kn-keyword=SII index
en-keyword=esophageal squamous cell carcinoma
kn-keyword=esophageal squamous cell carcinoma
en-keyword=prognosis
kn-keyword=prognosis
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=5
article-no=
start-page=289
end-page=298
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202610
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=High Accuracy of Pelvic Tilt Measurement Using Three-Dimensional Planning Software: A Validation Study Using Dry Bone Models
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The “CR Alignment” function was recently introduced in ZedHip®, the hip joint module of ZedView®, to evaluate pelvic tilt in non-supine positions via two-dimensional (2D)‒3D matching using radiographs. However, its ccuracy has not been validated. This study therefore evaluated the accuracy of pelvic tilt measurements using the CR Alignment function in dry pelvic bone specimens. Two cadaveric pelvic bone models were placed in nine orientations (anterior/posterior tilt and left/right rotation). Both radiographic and CT images were acquired in each position. In Study 1, pelvic tilt measured directly from CT images was defined as the “true value.” Three observers used the CR Alignment function to calculate pelvic tilt on radiographs, and measurement errors were determined relative to the true values. In Study 2, measurement errors were compared between matched (same position) and mismatched (different position) imaging. In Study 1, the mean measurement error was 1.28±0.64°. Intra- and interobserver intraclass correlation coefficients were 0.996-0.998 and 0.997, respectively. In Study 2, the mean errors were 1.20±0.88° (matched) and 1.32±1.03° (mismatched). This software exhibited high accuracy and reproducibility in 2D‒3D matching of pelvic tilt, with lower variability under matched acquisition, demonstrating its utility for pre- and postoperative assessment in joint arthroplasty.
en-copyright=
kn-copyright=

en-aut-name=KomutaYuki
en-aut-sei=Komuta
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ImaiNorio
en-aut-sei=Imai
en-aut-mei=Norio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HommaDaisuke
en-aut-sei=Homma
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FunayamaKazuhisa
en-aut-sei=Funayama
en-aut-mei=Kazuhisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HiranoYuki
en-aut-sei=Hirano
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HorigomeYoji
en-aut-sei=Horigome
en-aut-mei=Yoji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MinatoIzumi
en-aut-sei=Minato
en-aut-mei=Izumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KawashimaHiroyuki
en-aut-sei=Kawashima
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University
kn-affil=

affil-num=2
en-affil=Division of Comprehensive Musculoskeletal Medicine, Graduate School of Medical and Dental Sciences, Niigata University
kn-affil=

affil-num=3
en-affil=Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University
kn-affil=

affil-num=4
en-affil=Division of Legal Medicine, Graduate School of Medical and Dental Sciences, Niigata University
kn-affil=

affil-num=5
en-affil=Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University
kn-affil=

affil-num=6
en-affil=Division of Comprehensive Musculoskeletal Medicine, Graduate School of Medical and Dental Sciences, Niigata University
kn-affil=

affil-num=7
en-affil=Department of Orthopedic Surgery, Niigata Rinko Hospital
kn-affil=

affil-num=8
en-affil=Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University
kn-affil=
en-keyword=total hip arthroplasty
kn-keyword=total hip arthroplasty
en-keyword=pelvic tilt
kn-keyword=pelvic tilt
en-keyword=three-dimensional planning software
kn-keyword=three-dimensional planning software
en-keyword=two-dimensional and threedimensional matching
kn-keyword=two-dimensional and threedimensional matching
en-keyword=radiographic analysis
kn-keyword=radiographic analysis
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=5
article-no=
start-page=271
end-page=277
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202610
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Artificial Intelligence-Assisted Peroral Cholangioscopy for the Diagnosis and Management of Biliary Strictures: Current Evidence and Future Directions
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Peroral cholangioscopy (POCS) enables direct intraductal visualization and targeted biopsies for indeterminate biliary strictures. However, its diagnostic performance remains operator-dependent and is limited by sampling error. As artificial intelligence (AI) has rapidly advanced in gastrointestinal endoscopy, AI-assisted cholangioscopy has progressed from proof-of-concept image classification to multicenter validation, feature detection, and real-time application. Recent studies using digital single-operator cholangioscopy have reported diagnostic accuracy comparable to that of experts in differentiating malignant from benign strictures, and feature-based approaches can automatically detect tumor vessels and other key visual characteristics. Beyond classification, generative models may enhance mucosal and margin visualization through virtual chromoendoscopy, potentially improving lesion-margin assessment. Furthermore, new models compatible with multiple systems are emerging to address device heterogeneity, which is a key barrier to routine practice. This review summarizes the current evidence on AI-assisted POCS, discusses practical considerations for clinical translation, and highlights future directions, including real-time integration and multimodal decision support.
en-copyright=
kn-copyright=

en-aut-name=SatoRyosuke
en-aut-sei=Sato
en-aut-mei=Ryosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatsumotoKazuyuki
en-aut-sei=Matsumoto
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OtsukaMotoyuki
en-aut-sei=Otsuka
en-aut-mei=Motoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=
en-keyword=peroral cholangioscopy
kn-keyword=peroral cholangioscopy
en-keyword=artificial intelligence
kn-keyword=artificial intelligence
en-keyword=biliary stricture
kn-keyword=biliary stricture
en-keyword=deep learning
kn-keyword=deep learning
en-keyword=virtual chromoendoscopy
kn-keyword=virtual chromoendoscopy
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=10
article-no=
start-page=1697
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20261010
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Purification, Structural Characterization, and Genomic Insights of an Anti-MRSA Peptide from Mangrove-Derived Brevibacillus sp. A34
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The widespread prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in community and healthcare settings has driven the urgent search for novel antibacterial agents. Mangrove sediments are an underexplored source of antimicrobial-producing bacteria. This study characterized an antimicrobial fraction and the genome of the mangrove-derived isolate Brevibacillus sp. A34. The active fraction was purified via ammonium sulfate precipitation, cation-exchange chromatography, and reversed-phase chromatography. De novo MS/MS analysis assigned the octapeptide LLLLLLAH (905.19 Da), designated as A34 AMP, which was further confirmed by chemical synthesis. This active peptide inhibited all four tested S. aureus strains, including three MRSA strains, with a minimum inhibitory concentration (MIC) of 62 µg/mL. At 2× and 4× MIC, A34 AMP exhibited a concentration-dependent bactericidal effect within 20 h. Increased SYTOX Green uptake and morphological alterations supported a membrane permeabilization mechanism, and antimicrobial activity was retained following thermal, pH, protease, and surfactant treatments. Genome mining identified 23 putative biosynthetic gene clusters, including an 11-module nonribosomal peptide synthetase (NRPS) cluster linked to A34 AMP through three-dimensional adenylation-domain modeling. Collectively, these findings highlight A34 AMP from Brevibacillus sp. A34 as a promising bioactive anti-staphylococcal peptide scaffold.
en-copyright=
kn-copyright=

en-aut-name=ThonginThanyamai
en-aut-sei=Thongin
en-aut-mei=Thanyamai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SermkaewNamfa
en-aut-sei=Sermkaew
en-aut-mei=Namfa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=AtipairinApichart
en-aut-sei=Atipairin
en-aut-mei=Apichart
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KrobthongSucheewin
en-aut-sei=Krobthong
en-aut-mei=Sucheewin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=AonbangkhenChanat
en-aut-sei=Aonbangkhen
en-aut-mei=Chanat
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=UchiyamaJumpei
en-aut-sei=Uchiyama
en-aut-mei=Jumpei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SongnakaNuttapon
en-aut-sei=Songnaka
en-aut-mei=Nuttapon
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=School of Pharmacy, Walailak University
kn-affil=

affil-num=2
en-affil=School of Pharmacy, Walailak University
kn-affil=

affil-num=3
en-affil=School of Pharmacy, Walailak University
kn-affil=

affil-num=4
en-affil=Center of Excellence in Natural Products Chemistry (CENP), Department of Chemistry, Faculty of Science, Chulalongkorn University
kn-affil=

affil-num=5
en-affil=Center of Excellence in Natural Products Chemistry (CENP), Department of Chemistry, Faculty of Science, Chulalongkorn University
kn-affil=

affil-num=6
en-affil=Department of Infectious Diseases, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan
kn-affil=

affil-num=7
en-affil=School of Pharmacy, Walailak University
kn-affil=
en-keyword=Brevibacillus sp.
kn-keyword=Brevibacillus sp.
en-keyword=antimicrobial peptide
kn-keyword=antimicrobial peptide
en-keyword=AMP
kn-keyword=AMP
en-keyword=mangrove
kn-keyword=mangrove
en-keyword=genome
kn-keyword=genome
en-keyword=anti-MRSA
kn-keyword=anti-MRSA
END

start-ver=1.4
cd-journal=joma
no-vol=234
cd-vols=
no-issue=
article-no=
start-page=112260
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202612
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The eukaryotic host–microbe–phage–nutrition interplay determines the bacterial effectors of supplemental lysine’s health benefits: An experimental cellular senescence model of digestive conditions in older adults
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Recently, the consumption of various forms of the nutritive amino acid lysine (e.g., nutraceuticals and dietary supplements) has increased, particularly among the elderly, as it cannot be synthesized by the human body and plays a crucial role in several cellular physiological processes, including intestinal calcium and iron absorption, proteinogenesis, and fatty acid metabolism. However, the biochemical and immunological events that occur within the eukaryotic host-microbe-phage-nutrition interaction, especially when high amounts of lysine are consumed in nutraceutical or dietary supplement form by the elderly due to age-related requirements, as well as the impact on gut bacteria-derived metabolites, have not yet been fully studied. We hypothesized that (1) within an infectious-inflamed digestive milieu, the metabolism of excess extracellular lysine differs between young and senescent digestive cells, and (2) phages within the milieu exhibit alterations in host-microbe cometabolite signal profiles. To address this, we examined how gut microbes and phages, key regulators of eukaryotic host physiology, influence the immunometabolism of excess lysine. By combining two models of young and senescent digestive cells, the pathogenic P. aeruginosa PAO1, the Pseudomonas phage KPP22, and the anti-inflammatory bacterium Intestinimonas butyriciproducens, and simulating the pathogenesis of the interactive process of excessive lysine ingestion, we developed a five-way screening approach to explore key cell readouts, including viability, integrity, and function of the epithelial barrier, as well as cellular immunometabolic responses to exogenous lysine supplementation in cultures under infectious inflammation. Our findings are consistent with the possibility that host–microbe–microbe interactions involving lysine utilization and cross-feeding may influence the effects of lysine supplementation. These effects, whether beneficial or detrimental, can depend on the bacterial community, including the presence of pathogenic or potentially beneficial bacteria, interactions with intestinal phages, and the physiological conditions and metabolic requirements of the host and individual microbial taxa.
en-copyright=
kn-copyright=

en-aut-name=GhadimiDarab
en-aut-sei=Ghadimi
en-aut-mei=Darab
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=BlömerSophia
en-aut-sei=Blömer
en-aut-mei=Sophia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KAYAAysel ŞAHİN
en-aut-sei=KAYA
en-aut-mei=Aysel ŞAHİN
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KrügerSandra
en-aut-sei=Krüger
en-aut-mei=Sandra
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=RöckenChristoph
en-aut-sei=Röcken
en-aut-mei=Christoph
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SchäferHeiner
en-aut-sei=Schäfer
en-aut-mei=Heiner
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=de HeerGeraldine
en-aut-sei=de Heer
en-aut-mei=Geraldine
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=JarczakDominik
en-aut-sei=Jarczak
en-aut-mei=Dominik
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=UchiyamaJumpei
en-aut-sei=Uchiyama
en-aut-mei=Jumpei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MatsuzakiShigenobu
en-aut-sei=Matsuzaki
en-aut-mei=Shigenobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=BockelmannWilhelm
en-aut-sei=Bockelmann
en-aut-mei=Wilhelm
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Microbiology and Biotechnology, Max Rubner-Institut
kn-affil=

affil-num=2
en-affil=Faculty of Medicine, Christian-Albrechts-University of Kiel
kn-affil=

affil-num=3
en-affil=Department of Nutrition and Dietetics, Faculty of Health Sciences, Antalya Bilim University
kn-affil=

affil-num=4
en-affil=Institute of Pathology, Kiel University, University Hospital, Schleswig-Holstein
kn-affil=

affil-num=5
en-affil=Institute of Pathology, Kiel University, University Hospital, Schleswig-Holstein
kn-affil=

affil-num=6
en-affil=Laboratory of Molecular Gastroenterology & Hepatology, Christian-Albrechts-University & UKSH Campus Kiel
kn-affil=

affil-num=7
en-affil=University Center for Nutritional Medicine, University Medical Centre Hamburg-Eppendorf
kn-affil=

affil-num=8
en-affil=University Center for Nutritional Medicine, University Medical Centre Hamburg-Eppendorf
kn-affil=

affil-num=9
en-affil=Department of Bacteriology, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=10
en-affil=Department of Medical Laboratory Science, Faculty of Health Sciences, Kochi Gakuen University
kn-affil=

affil-num=11
en-affil=Department of Microbiology and Biotechnology, Max Rubner-Institut
kn-affil=
en-keyword=Inflammaging
kn-keyword=Inflammaging
en-keyword=Lysine
kn-keyword=Lysine
en-keyword=Host cells
kn-keyword=Host cells
en-keyword=Phages
kn-keyword=Phages
en-keyword=Syntrophy
kn-keyword=Syntrophy
en-keyword=Cell senescence
kn-keyword=Cell senescence
END

start-ver=1.4
cd-journal=joma
no-vol=61
cd-vols=
no-issue=5
article-no=
start-page=299
end-page=302
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202505
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Histological Features and Gene Expression Profiling in Lung Transplantation From Donation After Circulatory Death
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=OkazakiMikio
en-aut-sei=Okazaki
en-aut-mei=Mikio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SakaueTomohisa
en-aut-sei=Sakaue
en-aut-mei=Tomohisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TanakaShin
en-aut-sei=Tanaka
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KuboYujiro
en-aut-sei=Kubo
en-aut-mei=Yujiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HayashiTatsuya
en-aut-sei=Hayashi
en-aut-mei=Tatsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=RamilElvira
en-aut-sei=Ramil
en-aut-mei=Elvira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=Sánchez-LópezAntonio J.
en-aut-sei=Sánchez-López
en-aut-mei=Antonio J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=CoronadoMaría Jose
en-aut-sei=Coronado
en-aut-mei=María Jose
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HoyosLucas
en-aut-sei=Hoyos
en-aut-mei=Lucas
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=RomeroAlejandra
en-aut-sei=Romero
en-aut-mei=Alejandra
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=ToyookaShinichi
en-aut-sei=Toyooka
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=Gomez-de-AntonioDavid
en-aut-sei=Gomez-de-Antonio
en-aut-mei=David
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Cardiovascular and Thoracic Surgery, Ehime University Graduate School of Medicine
kn-affil=

affil-num=3
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Thoracic Surgery and Lung Transplantation, Hospital Universitario Puerta de Hierro-Majadahonda
kn-affil=

affil-num=5
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Sequencing and Molecular Biology Unit, Hospital Universitario Puerta de Hierro-Majadahonda
kn-affil=

affil-num=7
en-affil=Biobank, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana
kn-affil=

affil-num=8
en-affil=Confocal Microscopy Unit, Hospital Universitario Puerta de Hierro-Majadahonda
kn-affil=

affil-num=9
en-affil=Department of Thoracic Surgery and Lung Transplantation, Hospital Universitario Puerta de Hierro-Majadahonda
kn-affil=

affil-num=10
en-affil=Department of Thoracic Surgery and Lung Transplantation, Hospital Universitario Puerta de Hierro-Majadahonda
kn-affil=

affil-num=11
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Thoracic Surgery and Lung Transplantation, Hospital Universitario Puerta de Hierro-Majadahonda
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=1
end-page=14
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260923
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Direct evidence for water-filled yet hydraulically isolated xylem vessels in two temperate tree species
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Xylem vessels in sapwood are typically interpreted as either conductive or non-functional following embolism or occlusion, implicitly assuming that the presence of water within the lumen reflects participation in the transpiration stream. However, the relationship between lumen water content and hydraulic connectivity has rarely been examined directly at the cellular level. In this study, we combined cryo-scanning electron microscopy and fluorescence microscopy to compare lumen water status with hydraulic connectivity on the same xylem surface in current-year xylem of Carpinus tschonoskii and Aria alnifolia, using tension-driven dye uptake to identify conductive vessels. Most vessels were stained and water-filled, consistent with functional conduits, whereas unstained gas-filled vessels corresponded to embolized conduits. Notably, certain vessels retained water despite lacking dye signals, indicating hydraulic isolation from the conductive xylem network. Although these vessels represented a minor fraction of the conduit population, their occurrence suggests that the traditionally binary classification should be expanded to incorporate an additional conduit function. These vessels were observed in both species, suggesting that hydraulically disconnected vessels represent a common phenomenon across species. These findings reveal previously underrecognized heterogeneity in xylem hydraulic organisation and demonstrate that conduit status cannot always be inferred from the presence of water alone. Recognising this intermediate condition refines current interpretations of xylem function and highlights the value of integrating high-resolution imaging with hydraulic measurements.
en-copyright=
kn-copyright=

en-aut-name=OgasaMayumi Y.
en-aut-sei=Ogasa
en-aut-mei=Mayumi Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=UtsumiYasuhiro
en-aut-sei=Utsumi
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YazakiKenichi
en-aut-sei=Yazaki
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MikiNaoko H.
en-aut-sei=Miki
en-aut-mei=Naoko H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FukudaKenji
en-aut-sei=Fukuda
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Kansai Research Center, Forestry and Forest Products Research Institute
kn-affil=

affil-num=2
en-affil=Ashoro Research Forest, Kyushu University
kn-affil=

affil-num=3
en-affil=Hokkaido Research Center, Forestry and Forest Products Research Institute
kn-affil=

affil-num=4
en-affil=Faculty of Environmental, Life, Natural Science and Technology
kn-affil=

affil-num=5
en-affil=Graduate School of Agricultural and Life Sciences, The University of Tokyo
kn-affil=
en-keyword= cryo-scanning electron microscopy
kn-keyword= cryo-scanning electron microscopy
en-keyword=fluorescence microscopy
kn-keyword=fluorescence microscopy
en-keyword=hydraulic isolation
kn-keyword=hydraulic isolation
en-keyword=vessel function
kn-keyword=vessel function
en-keyword=water distribution
kn-keyword=water distribution
END

start-ver=1.4
cd-journal=joma
no-vol=13
cd-vols=
no-issue=1
article-no=
start-page=60
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260920
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Carbon solubility and liquid–liquid immiscibility in Fe–C–S ternary system up to 6 GPa: implications for the core of small planetary bodies
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=High-pressure, high-temperature experiments were conducted in a multi-anvil press using seven different starting compositions to investigate the phase relations of Fe–C–S liquids at pressures up to 6 GPa and temperatures up to 2000 K. Quenched samples revealed immiscible C-rich and S-rich metallic liquids at 2 and 4 GPa, manifesting as either large immiscible zones or emulsified smaller droplets. On the contrary, no immiscibility was observed at 5 or 6 GPa. At these higher pressures, the carbon solubility limit, significantly reduced by increasing sulfur content in the ternary liquid, prevents the formation of a liquid phase rich in both C and S. Our findings thus indicate that super-liquidus immiscibility in Fe-rich compositions does not occur at pressures above 5 GPa, due to the differential pressure dependence of C solubility and miscibility. The limited C solubility in S-rich liquids at higher pressures effectively suppresses immiscibility. Based on these results, terrestrial planetary bodies with fluid cores at pressures exceeding 5 GPa are unlikely to experience liquid–liquid immiscibility, even when both carbon and sulfur are abundant, as sulfur limits carbon solubility and promotes its exsolution. For the Moon, immiscibility-induced core stratification is not expected, though local emulsification could occur near the core–mantle boundary (CMB). In smaller bodies, a two-liquid Fe–C–S core may form at high temperatures, but progressive cooling may lead to graphite crystallization and the potential development of a graphitic crust.
en-copyright=
kn-copyright=

en-aut-name=ZhaoBin
en-aut-sei=Zhao
en-aut-mei=Bin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MorardGuillaume
en-aut-sei=Morard
en-aut-mei=Guillaume
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ManthilakeGeeth
en-aut-sei=Manthilake
en-aut-mei=Geeth
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ParisiadesParaskevas
en-aut-sei=Parisiades
en-aut-mei=Paraskevas
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YangJing
en-aut-sei=Yang
en-aut-mei=Jing
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FeiYingwei
en-aut-sei=Fei
en-aut-mei=Yingwei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=Le GodecYann
en-aut-sei=Le Godec
en-aut-mei=Yann
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KondoNozomi
en-aut-sei=Kondo
en-aut-mei=Nozomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YoshinoTakashi
en-aut-sei=Yoshino
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=AntonangeliDaniele
en-aut-sei=Antonangeli
en-aut-mei=Daniele
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Institute for Planetary Materials, Okayama University
kn-affil=

affil-num=2
en-affil=UMR CNRS 7590, Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, IMPMC, Muséum National d’Histoire Naturelle, Sorbonne Université
kn-affil=

affil-num=3
en-affil=Laboratoire Magmas et Volcans, Université Clermont-Auvergne
kn-affil=

affil-num=4
en-affil=UMR CNRS 7590, Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, IMPMC, Muséum National d’Histoire Naturelle, Sorbonne Université
kn-affil=

affil-num=5
en-affil=Earth and Planets Laboratory, Carnegie Institution for Science
kn-affil=

affil-num=6
en-affil=Earth and Planets Laboratory, Carnegie Institution for Science
kn-affil=

affil-num=7
en-affil=UMR CNRS 7590, Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, IMPMC, Muséum National d’Histoire Naturelle, Sorbonne Université
kn-affil=

affil-num=8
en-affil=Institute for Planetary Materials, Okayama University
kn-affil=

affil-num=9
en-affil=Institute for Planetary Materials, Okayama University
kn-affil=

affil-num=10
en-affil=UMR CNRS 7590, Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, IMPMC, Muséum National d’Histoire Naturelle, Sorbonne Université
kn-affil=
en-keyword=Iron–carbon–sulfur liquids
kn-keyword=Iron–carbon–sulfur liquids
en-keyword=Miscibility
kn-keyword=Miscibility
en-keyword=High pressure and high temperature
kn-keyword=High pressure and high temperature
en-keyword=Planetary cores
kn-keyword=Planetary cores
END

start-ver=1.4
cd-journal=joma
no-vol=7
cd-vols=
no-issue=3
article-no=
start-page=110
end-page=112
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2013
dt-pub=20130301
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=An Efficient Synthesis of Limipterin [2'-O-(2-Acetamido-2-deoxy-β- D-glucopyranosyl) -L- biopterin] via N2 - (N ,N -Dimethylamino )-methylene- 3-[2-(4-nitrophenyl)ethyl]-L-biopterin
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=YamamotoHiroshi
en-aut-sei=Yamamoto
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HanayaTadashi
en-aut-sei=Hanaya
en-aut-mei=Tadashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HaradaKoichiro
en-aut-sei=Harada
en-aut-mei=Koichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KawamotoHeizan
en-aut-sei=Kawamoto
en-aut-mei=Heizan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=PfleidererWolfgang
en-aut-sei=Pfleiderer
en-aut-mei=Wolfgang
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Chemistry, Faculty of Science, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Chemistry, Faculty of Science, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Chemistry, Faculty of Science, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Chemistry, Faculty of Science, Okayama University
kn-affil=

affil-num=5
en-affil=Universitat Konstanz, Fakultat fur Chemie
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=38
cd-vols=
no-issue=9
article-no=
start-page=e70259
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202609
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Marine flatworms as windows into the evolution of bilaterian neuropeptide signalling
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The evolutionary origin(s) of neuropeptide signalling is still largely unknown. It has been hypothesised that signal transmission via neuropeptides played a crucial role in the regulation of nervous systems in the bilaterian ancestor. Identification, expression and functional analyses of neuropeptides and their receptors across different taxonomic groups are important for better understanding the origin(s) of bilaterian neuropeptide signalling. An example is flatworms belonging to the Platyhelminthes (spiralian protostomes) and Xenacoelomorpha (sister to all Bilateria or sister to Ambulacraria). Despite their simple morphology (i.e., a body plan lacking a coelom and circulatory system), they often possess brain-like central nervous systems and a number of bilaterian-conserved neuropeptides. This feature makes them useful models for analyses of neuropeptides and their links to nervous systems. Although previous studies have revealed orthologous relationships between vertebrate neuropeptides and those found in both marine Platyhelminthes and Xenacoelomorpha, our work suggests possible ancestral functions of vasopressin/oxytocin (VP/OT) peptides (platytocin) in these groups.
en-copyright=
kn-copyright=

en-aut-name=NakamuraRyo
en-aut-sei=Nakamura
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HamadaMayuko
en-aut-sei=Hamada
en-aut-mei=Mayuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=BaillyXavier
en-aut-sei=Bailly
en-aut-mei=Xavier
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SakamotoHirotaka
en-aut-sei=Sakamoto
en-aut-mei=Hirotaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SakamotoTatsuya
en-aut-sei=Sakamoto
en-aut-mei=Tatsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Ushimado Marine Institute, Faculty of Science, Okayama University
kn-affil=

affil-num=2
en-affil=Ushimado Marine Institute, Faculty of Science, Okayama University
kn-affil=

affil-num=3
en-affil=Multicellular Marine Models Team, CNRS – Sorbonne University – Station Biologique de Roscoff
kn-affil=

affil-num=4
en-affil=Department of Biology, Faculty of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=5
en-affil=Ushimado Marine Institute, Faculty of Science, Okayama University
kn-affil=
en-keyword=Neuropeptide
kn-keyword=Neuropeptide
en-keyword=Nervous system evolution
kn-keyword=Nervous system evolution
en-keyword=Platyhelminthes
kn-keyword=Platyhelminthes
en-keyword=Xenacoelomorpha
kn-keyword=Xenacoelomorpha
END

start-ver=1.4
cd-journal=joma
no-vol=20
cd-vols=
no-issue=2
article-no=
start-page=e70089
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202606
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Species‐specific roles of cellular communication network proteins in cartilage development: A comparative study using in vitro chondrogenic models
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Cellular communication network (CCN) proteins are key matricellular regulators of cartilage development, yet their species-specific roles and network-level context remain unclear. This study integrated bulk RNA sequencing from chicken and mouse embryonic limb bud micromass cultures and human mesenchymal stem cell chondrogenesis with co-expression, protein–protein interaction, and ortholog analyses to construct CCN-centered regulatory networks across models. CCN1 and CCN2 emerged as dominant, conserved hubs enriched in collagen-containing extracellular matrix, cartilage development, and growth factor signaling modules, whereas CCN3–CCN6 showed lower context-dependent expression and connectivity. Functional and ortholog analyses revealed moderate pathway conservation, with high conservation of IGF, EGFR, and HIF-1 signaling, but reduced overlap in hypoxia and mechanosensing/Hippo categories, indicating species-specific tuning of environmental sensing. A focused ortholog screen identified multifunctional conserved hubs, including COL2A1, TGFBR1, SMAD3, RUNX2, HIF1A, IGF1, SPP1, and CD44. Single-cell RNA-seq meta-analysis of human iPSC-derived chondrogenesis and embryonic limb datasets showed CCN1/2 expression and homologous network activity peaking in mesenchymal and early chondrocyte populations, consistent with model-dependent persistence into hypertrophic and ossification stages in vivo. Overall, this work defines a conserved CCN1/2-centered axis integrating extracellular matrix formation with growth factor and mechanical cues, providing a framework for model selection and CCN-targeted cartilage regeneration strategies.
en-copyright=
kn-copyright=

en-aut-name=WangZhangzheng
en-aut-sei=Wang
en-aut-mei=Zhangzheng
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=VágóJudit
en-aut-sei=Vágó
en-aut-mei=Judit
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakácsRoland
en-aut-sei=Takács
en-aut-mei=Roland
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=PóliskaSzilárd
en-aut-sei=Póliska
en-aut-mei=Szilárd
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KimEe Hyun
en-aut-sei=Kim
en-aut-mei=Ee Hyun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=JinEun‐Jung
en-aut-sei=Jin
en-aut-mei=Eun‐Jung
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KubotaSatoshi
en-aut-sei=Kubota
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KleerCelina G
en-aut-sei=Kleer
en-aut-mei=Celina G
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=PerbalBernard
en-aut-sei=Perbal
en-aut-mei=Bernard
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MattaCsaba
en-aut-sei=Matta
en-aut-mei=Csaba
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Anatomy, Histology and Embryology Faculty of Medicine, University of Debrecen
kn-affil=

affil-num=2
en-affil=Department of Anatomy, Histology and Embryology Faculty of Medicine, University of Debrecen
kn-affil=

affil-num=3
en-affil=Department of Anatomy, Histology and Embryology Faculty of Medicine, University of Debrecen
kn-affil=

affil-num=4
en-affil=Genomic Medicine and Bioinformatics Core Facility Department of Biochemistry and Molecular Biology Faculty of Medicine, University of Debrecen
kn-affil=

affil-num=5
en-affil=Department of Biomedical Materials Science Graduate School of JABA, Wonkwang University
kn-affil=

affil-num=6
en-affil=Department of Biomedical Materials Science Graduate School of JABA, Wonkwang University
kn-affil=

affil-num=7
en-affil=Department of Biochemistry and Molecular Dentistry, Okayama University, Faculty of Medicine, Dentistry and Pharmaceutical Science
kn-affil=

affil-num=8
en-affil=Department of Pathology, University of Michigan Medical School
kn-affil=

affil-num=9
en-affil=International CCN Society
kn-affil=

affil-num=10
en-affil=Department of Anatomy, Histology and Embryology Faculty of Medicine, University of Debrecen
kn-affil=
en-keyword=cartilage regeneration
kn-keyword=cartilage regeneration
en-keyword=CCN
kn-keyword=CCN
en-keyword=chondrogenesis
kn-keyword=chondrogenesis
en-keyword=osteoarthritis
kn-keyword=osteoarthritis
en-keyword=regulatory network
kn-keyword=regulatory network
en-keyword=transcriptomics
kn-keyword=transcriptomics
END

start-ver=1.4
cd-journal=joma
no-vol=7
cd-vols=
no-issue=4
article-no=
start-page=399
end-page=409
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260403
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Graphene Oxide: Designing a Functional Smarter Material for Advanced Biomedicine
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Graphene oxide (GO) has emerged as one of the most extensively studied two-dimensional (2D) materials, thanks to its large surface area and abundance of functional groups, which enable applications across energy, catalysis, electronics, construction, and mobility. Its exceptional dispersibility in water further expands its use in the biomedical field. However, researchers have consistently expressed concerns about the limited control over GO chemical composition and structural heterogeneity. These factors are often overlooked, strongly affecting the reproducibility in both synthesis and applications. Because GO is considered a promising platform for advanced drug delivery, achieving reproducible preparation and precise structural control is essential to make it a reliable alternative to the many nanomaterials currently being explored for nanomedicine.<br>
Motivated by these challenges, we have focused our work on identifying and controlling the key parameters that govern GO structure and surface chemistry. Over the past decade, we have developed methods to produce GO with controlled and tunable chemical structures, clarified the reactivity of its major functional groups, and developed robust strategies for postfunctionalizing GO with therapeutic agents, targeting ligands, and imaging dyes. In parallel, we have established systematic approaches to evaluate GO biocompatibility and biodegradability, revealing how specific physicochemical features influence biological responses and clearance pathways.<br>
Together, these findings provide a unified framework linking GO synthesis, chemical modification, and biological behavior. By integrating chemical control, functional performance, and safety assessment, our work outlines a coherent strategy for the rational design of GO-based biomedical materials. We believe that this Account offers a solid foundation for the targeted exploitation of GO in nanomedicine and will help facilitate its eventual clinical translation.
en-copyright=
kn-copyright=

en-aut-name=Ménard-MoyonCécilia
en-aut-sei=Ménard-Moyon
en-aut-mei=Cécilia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NishinaYuta
en-aut-sei=Nishina
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=BiancoAlberto
en-aut-sei=Bianco
en-aut-mei=Alberto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR3572, University of Strasbourg, ISIS
kn-affil=

affil-num=2
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=3
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=4
article-no=
start-page=265
end-page=270
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202608
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Transcanal Cochlear Implantation Under Endoscopic Guidance with Canal Closure in a Pediatric Patient with CHARGE Syndrome: A Case Report and Surgical Technique
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Cochlear implantation (CI) in patients with CHARGE syndrome presents unique surgical challenges due to complex external, middle, and inner ear malformations. We describe the case of a 3-year-old Japanese boy for whom simultaneous transcanal CI under endoscopic guidance and external auditory canal closure were performed. This approach enabled safe electrode placement and resulted in favorable auditory outcomes, representing a potential novel surgical option for CI in patients with CHARGE syndrome. There are few reports of this type of surgical intervention, and the present case highlights the feasibility and clinical benefits of individualized surgical planning for CI in anatomically complex patients.
en-copyright=
kn-copyright=

en-aut-name=YamasakiTakuto
en-aut-sei=Yamasaki
en-aut-mei=Takuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SugayaAkiko
en-aut-sei=Sugaya
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NaoiYuto
en-aut-sei=Naoi
en-aut-mei=Yuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KariyaShin
en-aut-sei=Kariya
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=AndoMizuo
en-aut-sei=Ando
en-aut-mei=Mizuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Otolaryngology-Head and Neck Surgery, Kawasaki Medical School
kn-affil=

affil-num=5
en-affil=Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=CHARGE syndrome
kn-keyword=CHARGE syndrome
en-keyword=cochlear implantation
kn-keyword=cochlear implantation
en-keyword=transcanal approach
kn-keyword=transcanal approach
en-keyword=temporal bone anomaly
kn-keyword=temporal bone anomaly
en-keyword=pediatric otologic surgery
kn-keyword=pediatric otologic surgery
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=4
article-no=
start-page=259
end-page=264
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202608
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Spinous Process Plate Fixation Alone for an AO Spine Osteoporotic Fracture (OF) 5 Diffuse Idiopathic Skeletal Hyperostosis (DISH)-Associated Thoracolumbar Fracture in a Nonagenarian
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Diffuse idiopathic skeletal hyperostosis (DISH) predisposes the spine to highly unstable fractures because of long lever-arm biomechanics. Unstable injuries, including AO Spine Osteoporotic Fracture (OF) type 5, are typically treated with long-segment posterior instrumentation; however, pedicle-screw fixation may be infeasible in very elderly patients with severe osteoporosis, critically narrow pedicles, and/or significant comorbidities. A 93-year-old Japanese woman presented with severe back pain without apparent trauma. Computed tomography (CT) revealed a T12 fracture with DISH, classified as OF5. The pedicles were critically narrow (3.7-4.1 mm), and dual-energy X-ray absorptiometry confirmed severe osteoporosis. Because conventional pedicle-screw fixation was considered technically unsafe and excessively invasive, limited posterior stabilization was performed using a single spinous process plate spanning T10-L1. The operative time was 48 min and the estimated blood loss was 10 ml. Immediate postoperative CT confirmed appropriate implant positioning and maintained alignment. At the 1-year follow-up, CT demonstrated solid bony union with preserved alignment and no implant failure; the patient had remained pain-free and ambulatory. This case demonstrates that spinous process-plate fixation can be a minimally invasive salvage option for carefully selected very-elderly patients with DISH when pedicle-screw instrumentation is not feasible.
en-copyright=
kn-copyright=

en-aut-name=YabunoSatoru
en-aut-sei=Yabuno
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YunokiMasatoshi
en-aut-sei=Yunoki
en-aut-mei=Masatoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakeuchiSaori
en-aut-sei=Takeuchi
en-aut-mei=Saori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HirashitaKoji
en-aut-sei=Hirashita
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Neurosurgery, Kagawa Rosai Hospital
kn-affil=

affil-num=2
en-affil=Department of Neurosurgery, Kagawa Rosai Hospital
kn-affil=

affil-num=3
en-affil=Department of Neurosurgery, Kagawa Rosai Hospital
kn-affil=

affil-num=4
en-affil=Department of Neurosurgery, Kagawa Rosai Hospital
kn-affil=
en-keyword=DISH
kn-keyword=DISH
en-keyword=vertebral fracture
kn-keyword=vertebral fracture
en-keyword=osteoporosis
kn-keyword=osteoporosis
en-keyword=spinous process plate
kn-keyword=spinous process plate
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=4
article-no=
start-page=253
end-page=257
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202608
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Hemorrhage from a Jejunal Lymphangioma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Lymphangioma is a benign tumor arising from lymphatic vessel proliferation and most commonly occurs in the head, neck, or axilla. Involvement of the small intestine is rare and is often overlooked as a source of obscure gastrointestinal bleeding. Because jejunal lymphangiomas frequently present with nonspecific symptoms and may escape detection by conventional upper and lower gastrointestinal endoscopy or cross-sectional imaging, diagnosis is often delayed. Advances in balloon-assisted enteroscopy have enabled direct visualization of small intestinal lesions, facilitating accurate diagnosis and appropriate therapeutic decision-making. Here, we report a case of jejunal lymphangioma presenting with severe anemia due to active bleeding, which was detected by double-balloon endoscopy and successfully managed by laparoscopic-assisted resection. This case highlights the importance of considering small intestinal lymphangioma in the differential diagnosis of unexplained gastrointestinal bleeding and underscores the clinical utility of deep enteroscopy in identifying rare but clinically significant small bowel tumors.
en-copyright=
kn-copyright=

en-aut-name=IshikamiSachiko
en-aut-sei=Ishikami
en-aut-mei=Sachiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TamuraShuta
en-aut-sei=Tamura
en-aut-mei=Shuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TabuchiMotoyasu
en-aut-sei=Tabuchi
en-aut-mei=Motoyasu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamamotoNao
en-aut-sei=Yamamoto
en-aut-mei=Nao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OkamotoYuki
en-aut-sei=Okamoto
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YoshimatsuRika
en-aut-sei=Yoshimatsu
en-aut-mei=Rika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MatsumotoManabu
en-aut-sei=Matsumoto
en-aut-mei=Manabu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=IwataJun
en-aut-sei=Iwata
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OkabayashiTakehiro
en-aut-sei=Okabayashi
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=4
en-affil=Department of General Medicine, Kochi Health Sciences Center
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology and Hepatology, Kochi Health Sciences Center
kn-affil=

affil-num=6
en-affil=Department of Radiology, Kochi Health Sciences Center
kn-affil=

affil-num=7
en-affil=Department of Diagnostic Pathology, Kochi Health Sciences Center
kn-affil=

affil-num=8
en-affil=Department of Diagnostic Pathology, Kochi Health Sciences Center
kn-affil=

affil-num=9
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=
en-keyword=jejunal lymphangioma
kn-keyword=jejunal lymphangioma
en-keyword=double-balloon endoscopy
kn-keyword=double-balloon endoscopy
en-keyword=surgery
kn-keyword=surgery
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=4
article-no=
start-page=233
end-page=240
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202608
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Regional Prevalence of Carbapenemase-Producing Enterobacterales and Extended-Spectrum Beta-Lactamase-Producing Enterobacterales in Okayama and Neighboring Prefectures, Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Carbapenemase-producing Enterobacterales (CPE) and extended-spectrum β-lactamase (ESBL)-producing Enterobacterales (ESBL-E) are representative antimicrobial-resistant pathogens. We investigated the prevalence of CPE and ESBL-E in Okayama, Japan to clarify their current epidemiology and potential clinical burden. Active surveillance for CPE and ESBL-E was performed first, using stool samples submitted to the Okayama Medical Laboratory (Japan) in the years 2024-2025. Screening was performed using a selective agar (CHROMagar mSuper CARBA/ESBL). Phenotypic identification was conducted with the use of a modified carbapenem inactivation method and double-disk phenotypic confirmatory tests. Clinical information including patient age, sex, sampling date, and hospital address were collected, and the data were analyzed according to specimen origin (hospitals, clinics, and health checkups). A total of 2,000 stool samples were screened, of which two CPE isolates (0.1%) and 285 ESBL-E isolates (14.3%) were identified. By specimen origin, the ESBL-E positivity rate was significantly higher in hospitals (17.4%) than in clinics (11.8%). By age category, the late elderly (> 75 years) exhibited the highest ESBL-E positivity rate (22.6%) compared to other age groups. In the clinics and health checkups, infants (0 years) demonstrated high ESBL-E positivity rates (18.2% and 14.3%, respectively). Escherichia coli was the most common ESBL-E organism in the hospitals (77.2%), clinics (88.8%), and health checkups (87.5%). Our active screening demonstrated that the prevalences of CPE and ESBL-E were within the reported ranges; however, in this era of increasing internationalization, continuous surveillance of these notifiable pathogens is warranted.
en-copyright=
kn-copyright=

en-aut-name=OgawaSakura
en-aut-sei=Ogawa
en-aut-mei=Sakura
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FukushimaShinnosuke
en-aut-sei=Fukushima
en-aut-mei=Shinnosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=AkazawaHidemasa
en-aut-sei=Akazawa
en-aut-mei=Hidemasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NambaSachie
en-aut-sei=Namba
en-aut-mei=Sachie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HirotaChiyoko
en-aut-sei=Hirota
en-aut-mei=Chiyoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KishiueTomoyoshi
en-aut-sei=Kishiue
en-aut-mei=Tomoyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IbaraShohei
en-aut-sei=Ibara
en-aut-mei=Shohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KondoTakayuki
en-aut-sei=Kondo
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=FukudaGenshi
en-aut-sei=Fukuda
en-aut-mei=Genshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=IioKoji
en-aut-sei=Iio
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=TsujiShuma
en-aut-sei=Tsuji
en-aut-mei=Shuma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=GotohKazuyoshi
en-aut-sei=Gotoh
en-aut-mei=Kazuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=OtsukaFumio
en-aut-sei=Otsuka
en-aut-mei=Fumio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

affil-num=1
en-affil=Department of Infectious Diseases, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Infectious Diseases, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Infectious Diseases, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Laboratory Testing, Okayama Medical Laboratory Center
kn-affil=

affil-num=5
en-affil=Department of Laboratory Testing, Okayama Medical Laboratory Center
kn-affil=

affil-num=6
en-affil=Department of Laboratory Testing, Okayama Medical Laboratory Center
kn-affil=

affil-num=7
en-affil=Department of Laboratory Testing, Okayama Medical Laboratory Center
kn-affil=

affil-num=8
en-affil=Department of Laboratory Testing, Okayama Medical Laboratory Center
kn-affil=

affil-num=9
en-affil=Department of Sales Promotion, Okayama Medical Laboratory Center
kn-affil=

affil-num=10
en-affil=Microbiology Division, Clinical Laboratory, Okayama University Hospital
kn-affil=

affil-num=11
en-affil=Department of Medical Laboratory Science, Okayama University Graduate School of Health Sciences
kn-affil=

affil-num=12
en-affil=Department of Medical Laboratory Science, Okayama University Graduate School of Health Sciences
kn-affil=

affil-num=13
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=14
en-affil=Department of Infectious Diseases, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=antimicrobial resistance
kn-keyword=antimicrobial resistance
en-keyword=carbapenem-resistant Enterobacteriaceae
kn-keyword=carbapenem-resistant Enterobacteriaceae
en-keyword=extended-spectrum β-lactamase
kn-keyword=extended-spectrum β-lactamase
en-keyword=infection prevention and control
kn-keyword=infection prevention and control
en-keyword=Okayama Medical Laboratory
kn-keyword=Okayama Medical Laboratory
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=4
article-no=
start-page=227
end-page=231
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202608
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Impact of Migraine on Cerebral Artery Dissection
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The impact of migraines as a risk factor for cervicocerebral artery dissection was retrospectively investigated in patients who had a cervicocerebral artery dissection. We first evaluated the patients’ medical records and history of migraine and then calculated the proportion of patients with migraine as well as the relevant vascular risk factors. The prevalence of migraine with respect to the location of the cervicocerebral artery dissection was also identified. Sixty-two patients (37 men, 25 women) had both a cerebral artery dissection and a record of migraine. Among them, 93.5% presented with an isolated headache, and 6.5% presented with a related stroke. Regarding the locations of the artery dissection, 56 (90.3%) were in the intracranial vertebral artery (VA), three (4.8%) were in the internal carotid artery, and one case each (1.6%) was in an anterior cerebral artery, basilar artery (BA), and both the VA and BA. Among the patients with VA dissection, 42 (73.7%) presented with migraines. Among the four patients with dissection of an artery of anterior circulation, only one (25%) had a migraine history. The frequency of migraines tended to be higher in the patients with VA dissection compared to those with a dissection of arteries of anterior circulation. These data suggest that (i) migraine is a potent risk factor for cerebral artery dissection, especially intracranial VA dissection, and (ii) the intracranial VA may be more susceptible to dissection compared to arteries of anterior circulation.
en-copyright=
kn-copyright=

en-aut-name=KashiharaKenichi
en-aut-sei=Kashihara
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HamaguchiToshikazu
en-aut-sei=Hamaguchi
en-aut-mei=Toshikazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakedaYasuko
en-aut-sei=Takeda
en-aut-mei=Yasuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Okayama Neurology Clinic
kn-affil=

affil-num=2
en-affil=Department of Neurology, Okayama Kyokuto Hospital
kn-affil=

affil-num=3
en-affil=Okayama Neurology Clinic
kn-affil=
en-keyword=cervicocerebral artery dissection
kn-keyword=cervicocerebral artery dissection
en-keyword=isolated headache
kn-keyword=isolated headache
en-keyword=migraine
kn-keyword=migraine
en-keyword=risk factor
kn-keyword=risk factor
en-keyword=vertebral artery
kn-keyword=vertebral artery
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260514
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Updated ENIGMA recommendations for reporting germline variants in cancer susceptibility genes and their translation into twenty languages
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Genetic testing for cancer susceptibility underpins precision cancer prevention and care. Gaps in the healthcare providers’ genetic literacy and an ambiguous lexicon for variant description may hinder proper delivery and clinical application of consistently trustworthy test results. The Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) international consortium supports controlled terminology and recommends a framework for reporting germline variants in cancer susceptibility genes, using breast cancer as an exemplar. Moving forward towards terminological coherence across disciplines and borders, the ENIGMA Clinical Working Group launched a multinational effort to release consortium-approved translations of the published recommendations. The herein reported Vocabulary Translation Project offered an opportunity to reappraise and align the reference text to the recent BRCA1 and BRCA2 specifications to the American College of Medical Genetics and Genomics/Association for Molecular Pathology rules by the ENIGMA Variant Curation Expert Panel and to highlight country-specific differences in breast cancer risk assessment and management. The updated recommendations and their 20 translations are now provided as easy to handle documents, covering 11 of the most widely spoken languages in the world. They will contribute to minimised erroneous inferences, more informed decision-making, improved health outcomes and equity in the use of genetic testing for cancer predisposition and in translational oncology.
en-copyright=
kn-copyright=

en-aut-name=De NicoloArcangela
en-aut-sei=De Nicolo
en-aut-mei=Arcangela
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=EcclesDiana M
en-aut-sei=Eccles
en-aut-mei=Diana M
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=AaltonenKirsimari
en-aut-sei=Aaltonen
en-aut-mei=Kirsimari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AlhopuroPia
en-aut-sei=Alhopuro
en-aut-mei=Pia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=AriansenSarah Louise
en-aut-sei=Ariansen
en-aut-mei=Sarah Louise
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=BiancolellaMichela
en-aut-sei=Biancolella
en-aut-mei=Michela
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=CaputoSandrine M
en-aut-sei=Caputo
en-aut-mei=Sandrine M
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=CaronOlivier
en-aut-sei=Caron
en-aut-mei=Olivier
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=CavalliPietro
en-aut-sei=Cavalli
en-aut-mei=Pietro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=ChiangJianbang
en-aut-sei=Chiang
en-aut-mei=Jianbang
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=ClaesKathleen B M
en-aut-sei=Claes
en-aut-mei=Kathleen B M
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=CuaresmaEdgar Christian S
en-aut-sei=Cuaresma
en-aut-mei=Edgar Christian S
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=de la HoyaMiguel
en-aut-sei=de la Hoya
en-aut-mei=Miguel
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=De PauwAntoine
en-aut-sei=De Pauw
en-aut-mei=Antoine
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=DíezOrland
en-aut-sei=Díez
en-aut-mei=Orland
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=Domínguez-ValentinMev
en-aut-sei=Domínguez-Valentin
en-aut-mei=Mev
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=EhrencronaHans
en-aut-sei=Ehrencrona
en-aut-mei=Hans
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=FjeldværMagnhild K
en-aut-sei=Fjeldvær
en-aut-mei=Magnhild K
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=FostiraFlorentia
en-aut-sei=Fostira
en-aut-mei=Florentia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=FranciaMarie Belle D
en-aut-sei=Francia
en-aut-mei=Marie Belle D
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=Galego-CarroJavier
en-aut-sei=Galego-Carro
en-aut-mei=Javier
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=Gómez GarcíaEncarna B
en-aut-sei=Gómez García
en-aut-mei=Encarna B
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=HassanNur Tiara
en-aut-sei=Hassan
en-aut-mei=Nur Tiara
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=HaukeJan
en-aut-sei=Hauke
en-aut-mei=Jan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=HirasawaAkira
en-aut-sei=Hirasawa
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=HuangXin
en-aut-sei=Huang
en-aut-mei=Xin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=Ilagan-CargulloElaine Marisse H
en-aut-sei=Ilagan-Cargullo
en-aut-mei=Elaine Marisse H
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=ImotoIssei
en-aut-sei=Imoto
en-aut-mei=Issei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=JonnagadlaSowmya
en-aut-sei=Jonnagadla
en-aut-mei=Sowmya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=KarthikeyanManasadevi
en-aut-sei=Karthikeyan
en-aut-mei=Manasadevi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=KleiblovaPetra
en-aut-sei=Kleiblova
en-aut-mei=Petra
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=KonstantopoulouIrene
en-aut-sei=Konstantopoulou
en-aut-mei=Irene
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=KowalikArtur
en-aut-sei=Kowalik
en-aut-mei=Artur
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=KvistAnders
en-aut-sei=Kvist
en-aut-mei=Anders
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=LesueurFabienne
en-aut-sei=Lesueur
en-aut-mei=Fabienne
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

en-aut-name=LiShao-Tzu
en-aut-sei=Li
en-aut-mei=Shao-Tzu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=36
ORCID=

en-aut-name=López-FernándezAdrià
en-aut-sei=López-Fernández
en-aut-mei=Adrià
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=37
ORCID=

en-aut-name=MachackovaEva
en-aut-sei=Machackova
en-aut-mei=Eva
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=38
ORCID=

en-aut-name=MartinsAlexandra
en-aut-sei=Martins
en-aut-mei=Alexandra
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=39
ORCID=

en-aut-name=MensenkampArjen R
en-aut-sei=Mensenkamp
en-aut-mei=Arjen R
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=40
ORCID=

en-aut-name=MomozawaYukihide
en-aut-sei=Momozawa
en-aut-mei=Yukihide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=41
ORCID=

en-aut-name=MontalbanGemma
en-aut-sei=Montalban
en-aut-mei=Gemma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=42
ORCID=

en-aut-name=MonteiroAlvaro N A
en-aut-sei=Monteiro
en-aut-mei=Alvaro N A
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=43
ORCID=

en-aut-name=NevanlinnaHeli
en-aut-sei=Nevanlinna
en-aut-mei=Heli
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=44
ORCID=

en-aut-name=NgeowJoanne
en-aut-sei=Ngeow
en-aut-mei=Joanne
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=45
ORCID=

en-aut-name=PalmeroEdenir Inez
en-aut-sei=Palmero
en-aut-mei=Edenir Inez
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=46
ORCID=

en-aut-name=PedersenInge Sokilde
en-aut-sei=Pedersen
en-aut-mei=Inge Sokilde
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=47
ORCID=

en-aut-name=QueFrances Victoria F
en-aut-sei=Que
en-aut-mei=Frances Victoria F
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=48
ORCID=

en-aut-name=SantamariñaMarta
en-aut-sei=Santamariña
en-aut-mei=Marta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=49
ORCID=

en-aut-name=Santana dos SantosElizabeth
en-aut-sei=Santana dos Santos
en-aut-mei=Elizabeth
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=50
ORCID=

en-aut-name=SingerChristian F
en-aut-sei=Singer
en-aut-mei=Christian F
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=51
ORCID=

en-aut-name=SiołekMonika
en-aut-sei=Siołek
en-aut-mei=Monika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=52
ORCID=

en-aut-name=SolanoAngela R
en-aut-sei=Solano
en-aut-mei=Angela R
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=53
ORCID=

en-aut-name=SoukupovaJana
en-aut-sei=Soukupova
en-aut-mei=Jana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=54
ORCID=

en-aut-name=SureshPriyadharshini d/o
en-aut-sei=Suresh
en-aut-mei=Priyadharshini d/o
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=55
ORCID=

en-aut-name=SzczepaniakMagdalena
en-aut-sei=Szczepaniak
en-aut-mei=Magdalena
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=56
ORCID=

en-aut-name=TanYen Y
en-aut-sei=Tan
en-aut-mei=Yen Y
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=57
ORCID=

en-aut-name=TeoSoo Hwang
en-aut-sei=Teo
en-aut-mei=Soo Hwang
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=58
ORCID=

en-aut-name=ThamEmma
en-aut-sei=Tham
en-aut-mei=Emma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=59
ORCID=

en-aut-name=ThomassenMads
en-aut-sei=Thomassen
en-aut-mei=Mads
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=60
ORCID=

en-aut-name=TsaousisGeorgios
en-aut-sei=Tsaousis
en-aut-mei=Georgios
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=61
ORCID=

en-aut-name=HansenThomas van Overeem
en-aut-sei=Hansen
en-aut-mei=Thomas van Overeem
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=62
ORCID=

en-aut-name=VegaAna
en-aut-sei=Vega
en-aut-mei=Ana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=63
ORCID=

en-aut-name=Velasco-SampedroEladio A
en-aut-sei=Velasco-Sampedro
en-aut-mei=Eladio A
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=64
ORCID=

en-aut-name=WangensteenTeresia
en-aut-sei=Wangensteen
en-aut-mei=Teresia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=65
ORCID=

en-aut-name=WappenschmidtBarbara
en-aut-sei=Wappenschmidt
en-aut-mei=Barbara
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=66
ORCID=

en-aut-name=YannoukakosDrakoulis
en-aut-sei=Yannoukakos
en-aut-mei=Drakoulis
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=67
ORCID=

en-aut-name=YoonSook-Yee
en-aut-sei=Yoon
en-aut-mei=Sook-Yee
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=68
ORCID=

en-aut-name=SpurdleAmanda B
en-aut-sei=Spurdle
en-aut-mei=Amanda B
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=69
ORCID=

en-aut-name=RadicePaolo
en-aut-sei=Radice
en-aut-mei=Paolo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=70
ORCID=

affil-num=1
en-affil=Department of Experimental Oncology, Unit of Predictive Medicine: Molecular Bases of Genetic Risk, Fondazione IRCCS Istituto Nazionale dei Tumori
kn-affil=

affil-num=2
en-affil=Faculty of Medicine, University of Southampton
kn-affil=

affil-num=3
en-affil=Duodecim Medical Publications Ltd
kn-affil=

affil-num=4
en-affil=HUS Diagnostic Center, Laboratory of Genetics, Helsinki University Hospital and University of Helsinki
kn-affil=

affil-num=5
en-affil=Department of Medical Genetics, Oslo University Hospital
kn-affil=

affil-num=6
en-affil=Department of Biology, University of Rome Tor Vergata
kn-affil=

affil-num=7
en-affil=Department of Genetics, Institut Curie
kn-affil=

affil-num=8
en-affil=Département de Médecine Oncologique, Gustave Roussy
kn-affil=

affil-num=9
en-affil=Medical Genetics, IRCCS Humanitas Research Hospital
kn-affil=

affil-num=10
en-affil=Division of Medical Oncology, Cancer Genetics Service, National Cancer Centre Singapore
kn-affil=

affil-num=11
en-affil=Center for Medical Genetics, Ghent University Hospital
kn-affil=

affil-num=12
en-affil=St. Luke’s Medical Center
kn-affil=

affil-num=13
en-affil=Hospital Clínico San Carlos, Molecular Oncology Laboratory, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos
kn-affil=

affil-num=14
en-affil=Department of Genetics, Institut Curie
kn-affil=

affil-num=15
en-affil=Vall d’Hebron Hospital Universitari, Area of Clinical and Molecular Genetics, Vall d’Hebron Barcelona Hospital Campus
kn-affil=

affil-num=16
en-affil=Institute of Cancer Research, Department of Tumor Biology, The Norwegian Radium Hospital
kn-affil=

affil-num=17
en-affil=Department of Clinical Genetics, Pathology and Molecular Diagnostics, Skåne University Hospital
kn-affil=

affil-num=18
en-affil=Department of Medical Genetics, Oslo University Hospital
kn-affil=

affil-num=19
en-affil=INRASTES, Human Molecular Genetics Laboratory, National Centre for Scientific Research-Demokritos
kn-affil=

affil-num=20
en-affil=St. Luke’s Medical Center
kn-affil=

affil-num=21
en-affil=Fundación Pública Galega de Medicina Xenómica and Instituto de Investigación Sanitaria de Santiago de Compostela
kn-affil=

affil-num=22
en-affil=Department of Clinical Genetics, Maastricht University Medical Centre
kn-affil=

affil-num=23
en-affil=Cancer Research Malaysia
kn-affil=

affil-num=24
en-affil=Faculty of Medicine and Center for Familial Breast and Ovarian Cancer, University of Cologne, University Hospital Cologne
kn-affil=

affil-num=25
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of Clinical Genomic Medicine, Okayama University
kn-affil=

affil-num=26
en-affil=Department of Breast Surgery, Peking Union Medical College Hospital
kn-affil=

affil-num=27
en-affil=St. Luke’s Medical Center
kn-affil=

affil-num=28
en-affil=Aichi Cancer Center Research Institute
kn-affil=

affil-num=29
en-affil=Division of Medical Oncology, Cancer Genetics Service, National Cancer Centre Singapore, Si
kn-affil=

affil-num=30
en-affil=Division of Medical Oncology, Cancer Genetics Service, National Cancer Centre Singapore
kn-affil=

affil-num=31
en-affil=Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague
kn-affil=

affil-num=32
en-affil=INRASTES, Human Molecular Genetics Laboratory, National Centre for Scientific Research-Demokritos
kn-affil=

affil-num=33
en-affil=Department of Molecular Diagnostics, Holy Cross Cancer Centre
kn-affil=

affil-num=34
en-affil=Department of Clinical Sciences Lund, Division of Oncology, Lund University
kn-affil=

affil-num=35
en-affil=PSL Research University
kn-affil=

affil-num=36
en-affil=Division of Medical Oncology, Cancer Genetics Service, National Cancer Centre Singapore
kn-affil=

affil-num=37
en-affil=Hereditary Cancer Genetics Group, Vall d’Hebron Barcelona Hospital Campus, Vall d’Hebron Institute of Oncology (VHIO)
kn-affil=

affil-num=38
en-affil=Center for Medical Genetics, Masaryk Memorial Cancer Institute
kn-affil=

affil-num=39
en-affil=Univ Rouen Normandie, Inserm U1245
kn-affil=

affil-num=40
en-affil=Department of Human Genetics, Radboud University Medical Center
kn-affil=

affil-num=41
en-affil=Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences
kn-affil=

affil-num=42
en-affil=Department of Oncogenetics, MRC Holland
kn-affil=

affil-num=43
en-affil=Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute
kn-affil=

affil-num=44
en-affil=HUS Diagnostic Center, Laboratory of Genetics, Helsinki University Hospital and University of Helsinki
kn-affil=

affil-num=45
en-affil=Division of Medical Oncology, Cancer Genetics Service, National Cancer Centre Singapore
kn-affil=

affil-num=46
en-affil=Molecular Oncology Research Center, Barretos Cancer Hospital
kn-affil=

affil-num=47
en-affil=Molecular Diagnostics and Clinical Cancer Research Centre, Aalborg University Hospital
kn-affil=

affil-num=48
en-affil=St. Luke’s Medical Center
kn-affil=

affil-num=49
en-affil=Fundación Pública Galega de Medicina Xenómica and Instituto de Investigación Sanitaria de Santiago de Compostela
kn-affil=

affil-num=50
en-affil=Department of Medical Oncology, A.C. Camargo Cancer Center
kn-affil=

affil-num=51
en-affil=Comprehensive Cancer Center, Department of Obstetrics and Gynecology, Medical University of Vienna
kn-affil=

affil-num=52
en-affil=Genetic Clinic, Holy Cross Cancer Centre
kn-affil=

affil-num=53
en-affil=Departmento de Analisis Clinicos, Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno" (CEMIC)
kn-affil=

affil-num=54
en-affil=Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague
kn-affil=

affil-num=55
en-affil=Division of Medical Oncology, Cancer Genetics Service, National Cancer Centre Singapore
kn-affil=

affil-num=56
en-affil=Department of Molecular Diagnostics, Holy Cross Cancer Centre
kn-affil=

affil-num=57
en-affil=Comprehensive Cancer Center, Department of Obstetrics and Gynecology, Medical University of Vienna
kn-affil=

affil-num=58
en-affil=Cancer Research Malaysia
kn-affil=

affil-num=59
en-affil=Department of Clinical Genetics and Genomics, Karolinska University Hospital
kn-affil=

affil-num=60
en-affil=Department of Clinical Genetics, Odense University Hospital
kn-affil=

affil-num=61
en-affil=Genekor Medical S.A
kn-affil=

affil-num=62
en-affil=Department of Clinical Genetics, Copenhagen University Hospital Rigshospitalet
kn-affil=

affil-num=63
en-affil=Fundación Pública Galega de Medicina Xenómica and Instituto de Investigación Sanitaria de Santiago de Compostela
kn-affil=

affil-num=64
en-affil=Instituto de Biología y Genética Molecular, Splicing and Genetic Susceptibility to Cancer, Consejo Superior de Investigaciones Científicas - Universidad de Valladolid (CSIC-UVa)
kn-affil=

affil-num=65
en-affil=Department of Medical Genetics, Oslo University Hospital
kn-affil=

affil-num=66
en-affil=Faculty of Medicine and Center for Familial Breast and Ovarian Cancer, University of Cologne, University Hospital Cologne
kn-affil=

affil-num=67
en-affil=INRASTES, Human Molecular Genetics Laboratory, National Centre for Scientific Research-Demokritos
kn-affil=

affil-num=68
en-affil=Cancer Research Malaysia
kn-affil=

affil-num=69
en-affil=Population Health Program, QIMR Berghofer Medical Research Institute
kn-affil=

affil-num=70
en-affil=Department of Experimental Oncology, Unit of Predictive Medicine: Molecular Bases of Genetic Risk, Fondazione IRCCS Istituto Nazionale dei Tumori
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=32
cd-vols=
no-issue=6
article-no=
start-page=103486
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202609
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Students’ perceptions of an electronic one-minute paper in a radiography training programme: An exploratory cross-sectional questionnaire study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction: Formative assessment can support health professions education; however, reports on electronic 1-min papers as classroom feedback and engagement tools in radiography programmes remain limited. This study explored radiography students’ perceptions of an electronic 1-min paper, focusing on in-class reflection, ease of asking questions, and instructor feedback.<br>
Methods: An electronic 1-min paper was used in a radiotherapy course across 45 class sessions in the 2024 academic year for third-year students enrolled in a 4-year radiography programme. Each 90-min class comprised a 60-min lecture, 10-min completion of the paper, and 20-min instructor feedback. After the course, a de-identified online questionnaire was administered. Eleven 5-point Likert-scale items were analysed using descriptive statistics and Spearman's rank correlations. Free-text responses were analysed using inductive qualitative content analysis.<br>
Results: Of the 77 eligible students, 74 responded (96.1%). Ease of use received the highest rating (mean, 4.76; standard deviation [SD], 0.52), followed by ease of asking questions (mean, 4.32), question resolution (mean, 4.16), and usefulness of instructor feedback (mean, 4.08). Motivation to review after class was lowest (mean, 3.04; SD, 1.16). Active participation showed a strong positive association with in-class concentration (rs = 0.815; P < 0.001). Free-text responses indicated reflection and improved understanding, anonymous sharing of questions, active listening and concentration, and suggestions for improvement.<br>
Conclusion: The electronic 1-min paper was widely accepted and perceived to support in-class reflection, question expression, and immediate feedback. However, students’ perceptions of its influence on out-of-class review motivation were limited. The findings indicate perceived value and engagement rather than demonstrated educational effectiveness.<br>
Implications for practice: Electronic 1-min papers may help instructors identify students’ questions and respond during class, providing a practical approach to in-class feedback.
en-copyright=
kn-copyright=

en-aut-name=KomatsuY.
en-aut-sei=Komatsu
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=AbeS.
en-aut-sei=Abe
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TsudouS.
en-aut-sei=Tsudou
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamamotoY.
en-aut-sei=Yamamoto
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TanabeY.
en-aut-sei=Tanabe
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Division of Radiological Technology, Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Radiological Technology, Faculty of Health Care Sciences, Jikei University of Health Care Sciences
kn-affil=

affil-num=3
en-affil=Department of Radiological Technology, Faculty of Health Care Sciences, Jikei University of Health Care Sciences
kn-affil=

affil-num=4
en-affil=Division of Radiological Technology, Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Faculty of Health Sciences, Department of Radiological Technology, Okayama University Medical School, Okayama University
kn-affil=
en-keyword=Electronic 1-min paper
kn-keyword=Electronic 1-min paper
en-keyword=Formative assessment
kn-keyword=Formative assessment
en-keyword=Radiography education
kn-keyword=Radiography education
en-keyword=Immediate feedback
kn-keyword=Immediate feedback
en-keyword=Student engagement
kn-keyword=Student engagement
en-keyword=Health professions education
kn-keyword=Health professions education
END

start-ver=1.4
cd-journal=joma
no-vol=53
cd-vols=
no-issue=14
article-no=
start-page=e2026GL121981
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260710
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Calcium Solubility of Bridgmanite in Subducted Basalt in Earth's Lower Mantle
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The calcium solubility in bridgmanite and the resulting abundance of davemaoite under lower-mantle pressure-temperature conditions have been under debate following a recent report of extensive calcium dissolution in bridgmanite. We experimentally investigated the calcium solubility in bridgmanite in a basaltic composition at pressures up to 125 GPa and temperatures up to 3,520 K. Our experimental data are modeled thermodynamically along the bridgmanite-davemaoite solvus to quantify the calcium solubility in bridgmanite and the davemaoite proportion in basaltic and pyrolitic assemblages along lower mantle geotherms. Our results indicate that bridgmanite hosts only 0.001–0.03 Ca cations per formula unit in the lower mantle, while davemaoite remains as an abundant mineral, accounting for 8 and 25 vol% of pyrolitic and basaltic mineralogical models, respectively, along representative lower-mantle geotherms. Our thermoelastic modeling further indicates that the effect of calcium dissolution on the density and bulk sound velocity of lower-mantle assemblages is negligible.
en-copyright=
kn-copyright=

en-aut-name=ZhangChengwei
en-aut-sei=Zhang
en-aut-mei=Chengwei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YoshinoTakashi
en-aut-sei=Yoshino
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=El GhazaouiElias
en-aut-sei=El Ghazaoui
en-aut-mei=Elias
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=CharitonStella
en-aut-sei=Chariton
en-aut-mei=Stella
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=PrakapenkaVitali B.
en-aut-sei=Prakapenka
en-aut-mei=Vitali B.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=LiLuo
en-aut-sei=Li
en-aut-mei=Luo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ZhangYanyao
en-aut-sei=Zhang
en-aut-mei=Yanyao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=LinJung‐Fu
en-aut-sei=Lin
en-aut-mei=Jung‐Fu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Earth and Planetary Sciences, Jackson School of Geosciences The University of Texas at Austin
kn-affil=

affil-num=2
en-affil=Institute for Planetary Materials, Okayama University
kn-affil=

affil-num=3
en-affil=School of Earth and Environmental Sciences, Seoul National University
kn-affil=

affil-num=4
en-affil=Center for Advanced Radiation Sources, The University of Chicago
kn-affil=

affil-num=5
en-affil=Center for Advanced Radiation Sources, The University of Chicago
kn-affil=

affil-num=6
en-affil=Department of Earth and Planetary Sciences, Jackson School of Geosciences The University of Texas at Austin
kn-affil=

affil-num=7
en-affil=Earth and Planetary Sciences, Stanford University
kn-affil=

affil-num=8
en-affil=Department of Earth and Planetary Sciences, Jackson School of Geosciences The University of Texas at Austin
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=1
article-no=
start-page=14404
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260217
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Boulder populations and orientation trends on asteroid Ryugu: implications for rubble-pile surface processes
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Asteroid (162173) Ryugu is a spinning-top shaped, rubble-pile C-type asteroid with a surface dominated by boulders spanning a broad size-range. Using Hayabusa2 ONC-T mosaics for mapping, we present the most extensive global boulder dataset to date, representing an eleven-fold increase over the earliest survey and greater completeness than later AI-based estimates. Crucially, this work provides the first global boulder orientation dataset. The cumulative size-frequency distribution follows a power-law slope of − 2.665 ± 0.066 (boulders ≥ 3 m), indicating its fragmented nature. Boulder density is lower along the equatorial ridge, consistent with regolith accumulation during earlier YORP-driven spin-up and poleward migration of blocks during the present spin-down phase. Orientation analyses reveal systematic hemispheric trends in what we define as slope-breaker zones (i.e., regions of high slope differentials), with NW–SE alignment in the northern hemisphere and NE–SW in the southern hemisphere, but absent at the equatorial ridge and poles. We interpret these as reorientations that developed during downslope boulder migration, as despite ongoing spin-down, the current spin rate remains high enough to drive such motion. In addition, fresh craters exhibit locally heightened boulder densities, recording ongoing resurfacing by impact events that exhume buried subsurface boulders and segregate them from finer regolith via seismic shaking induced granular convection. Together, these results yield new insights into rubble-pile surface evolution, rotational dynamics, and impact-driven resurfacing, with boulder orientations providing critical evidence of spin-related downslope transport and establish a framework for comparative asteroid studies.
en-copyright=
kn-copyright=

en-aut-name=RayAditya
en-aut-sei=Ray
en-aut-mei=Aditya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=RujTrishit
en-aut-sei=Ruj
en-aut-mei=Trishit
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KomatsuGoro
en-aut-sei=Komatsu
en-aut-mei=Goro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=VincentLisa M.
en-aut-sei=Vincent
en-aut-mei=Lisa M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KikuchiHiroshi
en-aut-sei=Kikuchi
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HemmiRyodo
en-aut-sei=Hemmi
en-aut-mei=Ryodo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OrmöJens
en-aut-sei=Ormö
en-aut-mei=Jens
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Institute for Planetary Materials, Okayama University
kn-affil=

affil-num=2
en-affil=Institute for Planetary Materials, Okayama University
kn-affil=

affil-num=3
en-affil=International Research School of Planetary Sciences, Università G. d‘Annunzio
kn-affil=

affil-num=4
en-affil=Department of Earth Sciences, Utrecht University
kn-affil=

affil-num=5
en-affil=Gakushuin University
kn-affil=

affil-num=6
en-affil=Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency
kn-affil=

affil-num=7
en-affil=Centro de Astrobiología (CAB), CSIC-INTA
kn-affil=
en-keyword=Asteroid Ryugu
kn-keyword=Asteroid Ryugu
en-keyword=Asteroidal surfaces
kn-keyword=Asteroidal surfaces
en-keyword=Regolith
kn-keyword=Regolith
en-keyword=Geological processes
kn-keyword=Geological processes
en-keyword=Impact processes
kn-keyword=Impact processes
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=3
article-no=
start-page=219
end-page=223
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202606
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Common Bile Duct Stone Formed Around an Ingested Fish Bone
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=An 86-year-old man presented with epigastric pain. He had previously undergone distal gastrectomy with Roux-en-Y reconstruction. Computed tomography (CT) revealed a 32×17 mm common bile duct (CBD) stone with an internal 20 mm linear hyperdense component. Endoscopic removal was unsuccessful due to the size and impaction of the stone. Open choledochotomy retrieved multiple stones and a calcified fish bone, which was confirmed by infrared spectroscopy using the potassium bromide (KBr) wafer method. Although fish bone ingestion is relatively common, this case highlights that such foreign bodies can occasionally serve as a nidus for CBD stone formation, leading to unexpected and clinically significant pathologies. When CT demonstrates a linear high-attenuation intraductal structure, clinicians should suspect a bone fragment and follow a stepwise approach, considering early surgical intervention when endoscopic extraction is unsuccessful or likely to be challenging.
en-copyright=
kn-copyright=

en-aut-name=HigashiKaitaro
en-aut-sei=Higashi
en-aut-mei=Kaitaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TabuchiMotoyasu
en-aut-sei=Tabuchi
en-aut-mei=Motoyasu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SakamotoShinya
en-aut-sei=Sakamoto
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TamuraShuta
en-aut-sei=Tamura
en-aut-mei=Shuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=UemuraSunao
en-aut-sei=Uemura
en-aut-mei=Sunao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TokumaruTeppei
en-aut-sei=Tokumaru
en-aut-mei=Teppei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OkabayashiTakehiro
en-aut-sei=Okabayashi
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=5
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=7
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=
en-keyword=common bile duct stone
kn-keyword=common bile duct stone
en-keyword=fish bone
kn-keyword=fish bone
en-keyword=Roux-en-Y
kn-keyword=Roux-en-Y
en-keyword=choledochotomy
kn-keyword=choledochotomy
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=3
article-no=
start-page=213
end-page=217
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202606
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Novel Flap Design to Reduce Urethral Complications in Anterolateral Thigh Phalloplasty: The Pipe Flap Technique
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Phalloplasty is one of the most challenging procedures in gender-affirming surgery, and urethral complications remain common despite numerous preventive efforts. No definitive solution has been established, and many patients still require subsequent corrective procedures. We designed a novel anterolateral thigh flap that creates a planned external fistula at the penile base to mitigate urethral complications. The fistula was closed in a second-stage procedure one year later, and the postoperative course was uneventful. We report a case of a transgender man treated with this two-stage “pipe flap” technique, resulting in satisfactory urinary function. This approach may offer a safe and less invasive option for mitigating urethral complications in phalloplasty.
en-copyright=
kn-copyright=

en-aut-name=ImaiToshiro
en-aut-sei=Imai
en-aut-mei=Toshiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=WatanabeToshiyuki
en-aut-sei=Watanabe
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=WatanabeShiho
en-aut-sei=Watanabe
en-aut-mei=Shiho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HayashiMasanobu
en-aut-sei=Hayashi
en-aut-mei=Masanobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TominagaYusuke
en-aut-sei=Tominaga
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NambaYuzaburo
en-aut-sei=Namba
en-aut-mei=Yuzaburo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Plastic and Reconstructive Surgery, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Plastic and Reconstructive Surgery, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Plastic and Reconstructive Surgery, National Hospital Organization Tokyo Medical Center
kn-affil=

affil-num=4
en-affil=Department of Plastic and Reconstructive Surgery, Tohoku University Graduate School of Medicine
kn-affil=

affil-num=5
en-affil=Department of Urology, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Gender Center, Okayama University Hospital
kn-affil=
en-keyword=phalloplasty
kn-keyword=phalloplasty
en-keyword=surgical flaps
kn-keyword=surgical flaps
en-keyword=transgender persons
kn-keyword=transgender persons
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=3
article-no=
start-page=179
end-page=184
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202606
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Oral Eicosapentaenoic Acid and Paclitaxel-Associated Peripheral Neuropathy: A Retrospective Study at Okayama University Hospital
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This retrospective study investigated whether eicosapentaenoic acid (EPA) reduces paclitaxel-associated chemotherapy-induced peripheral neuropathy (CIPN) and acute neuropathic pain in dyslipidemic cancer patients. The medical records of cancer patients treated with paclitaxel or nab-paclitaxel at Okayama University Hospital between January 2018 and December 2022 were reviewed. Patients receiving concomitant therapy for dyslipidemia were categorized as EPA users or non-EPA users. Numbness and pain severity were extracted from medical records. The primary endpoint was the change from baseline in Common Terminology Criteria for Adverse Events (CTCAE) grade for peripheral neuropathy and pain; groups were analyzed using the Mann–Whitney U test. Of 184 eligible patients, 18 received EPA. Bleeding events were more frequent in the EPA group; however, changes in numbness and pain did not differ significantly between groups at any time point. Overall, EPA did not show a preventive effect on paclitaxel-associated CIPN or acute neuropathic pain. Future studies should evaluate EPA in combination with other neuroprotective agents to better define its potential role in CIPN prevention.
en-copyright=
kn-copyright=

en-aut-name=MoritaAyako
en-aut-sei=Morita
en-aut-mei=Ayako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KatayamaHideki
en-aut-sei=Katayama
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IchiharaEiki
en-aut-sei=Ichihara
en-aut-mei=Eiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MaedaYoshinobu
en-aut-sei=Maeda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Center for Clinical Oncology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Center for Clinical Oncology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Center for Clinical Oncology, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=
en-keyword=eicosapentaenoic acid
kn-keyword=eicosapentaenoic acid
en-keyword=cancer patients
kn-keyword=cancer patients
en-keyword=chemotherapy
kn-keyword=chemotherapy
en-keyword=peripheral neuropathy
kn-keyword=peripheral neuropathy
en-keyword=cancer pain
kn-keyword=cancer pain
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=3
article-no=
start-page=169
end-page=178
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202606
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Peripheral Blood T-Cell Receptor Repertoire and Host Immune Background in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The association between peripheral blood T-cell receptor (TCR) repertoire and chemotherapy response remains unclear. We evaluated peripheral blood TCR repertoire and gut microbiota in 21 breast cancer patients receiving neoadjuvant chemotherapy (NAC) who were enrolled in the SBP-14 prospective cohort study between October 2019 and March 2022. We analyzed stool samples obtained pre-NAC and peripheral blood samples obtained pre- and post-NAC. The primary endpoint was the association between baseline peripheral blood TCR repertoire and treatment response. Eleven patients (52%) had hormone receptor-positive breast cancer. All patients received anthracyclines and taxanes, with anti-HER2 therapy for HER2-positive disease. TCR diversity (TCR alpha chain [TRA], p=0.095; TCR beta chain [TRB], p=0.051) and clonality (TRA, p=0.271; TRB, p=0.500) were not significantly associated with treatment response. Gut microbiota diversity was not correlated with TCR diversity (TRA: ρ=0.046, p=0.845; TRB: ρ=0.021, p=0.929); however, three bacterial orders (Erysipelotrichales, Bacillales, and Pasteurellales) were significantly associated with TCR repertoire. Baseline TCR repertoire was not associated with treatment response in this cohort of breast cancer patients.
en-copyright=
kn-copyright=

en-aut-name=NakamuraYuki
en-aut-sei=Nakamura
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IwamotoTakayuki
en-aut-sei=Iwamoto
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KajiwaraYukiko
en-aut-sei=Kajiwara
en-aut-mei=Yukiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HidaAkira
en-aut-sei=Hida
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NakamotoShogo
en-aut-sei=Nakamoto
en-aut-mei=Shogo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MiyoshiYuichiro
en-aut-sei=Miyoshi
en-aut-mei=Yuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=IkedaMasahiko
en-aut-sei=Ikeda
en-aut-mei=Masahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=DoiharaHiroyoshi
en-aut-sei=Doihara
en-aut-mei=Hiroyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OgataRyohei
en-aut-sei=Ogata
en-aut-mei=Ryohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KoikeYoshikazu
en-aut-sei=Koike
en-aut-mei=Yoshikazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=NomuraTsunehisa
en-aut-sei=Nomura
en-aut-mei=Tsunehisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TanakaKatsuhiro
en-aut-sei=Tanaka
en-aut-mei=Katsuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=NakashimaKazutaka
en-aut-sei=Nakashima
en-aut-mei=Kazutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=YamatsujiTomoki
en-aut-sei=Yamatsuji
en-aut-mei=Tomoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

affil-num=1
en-affil=Department of Breast and Thyroid Surgery, Kawasaki Medical School Hospital
kn-affil=

affil-num=2
en-affil=Department of Breast and Thyroid Surgery, Kawasaki Medical School Hospital
kn-affil=

affil-num=3
en-affil=Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=4
en-affil=Department of Pathology, Matsuyama Shimin Hospital
kn-affil=

affil-num=5
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Breast Endocrine Surgery, Kagawa Prefectural Center Hospital
kn-affil=

affil-num=7
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Breast and Thyroid Surgery, Fukuyama City Hospital
kn-affil=

affil-num=9
en-affil=Department of General Surgery, Kawasaki Medical School General Medical Center
kn-affil=

affil-num=10
en-affil=Department of Breast and Thyroid Surgery, Kawasaki Medical School Hospital
kn-affil=

affil-num=11
en-affil=Department of Breast and Thyroid Surgery, Kawasaki Medical School Hospital
kn-affil=

affil-num=12
en-affil=Department of Breast and Thyroid Surgery, Kawasaki Medical School Hospital
kn-affil=

affil-num=13
en-affil=Department of Breast and Thyroid Surgery, Kawasaki Medical School Hospital
kn-affil=

affil-num=14
en-affil=Department of General Surgery, Kawasaki Medical School General Medical Center
kn-affil=

affil-num=15
en-affil=Department of General Surgery, Kawasaki Medical School General Medical Center
kn-affil=

affil-num=16
en-affil=Department of Breast and Thyroid Surgery, Kawasaki Medical School Hospital
kn-affil=
en-keyword=TCR repertoire
kn-keyword=TCR repertoire
en-keyword=gut microbiota
kn-keyword=gut microbiota
en-keyword=neoadjuvant chemotherapy
kn-keyword=neoadjuvant chemotherapy
en-keyword=breast cancer
kn-keyword=breast cancer
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=3
article-no=
start-page=159
end-page=168
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202606
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Self-Reported Adolescent Menstrual Symptoms and Delayed Gynecologic Consultation among Japanese Women with Endometriosis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Endometriosis symptoms often first appear during adolescence, yet delays in seeking gynecologic consultation remain a persistent challenge worldwide. Despite growing international evidence, the specific patterns of symptom recognition and consultation delay among Japanese women — particularly in relation to self-monitoring behaviors and cultural barriers — remain poorly understood. This study aimed to provide foundational data to guide menstrual education and preconception care strategies by conducting a cross-sectional online survey with retrospective recall among women with endometriosis to assess menstrual characteristics and symptom patterns from adolescence to initial care seeking. The survey was conducted in Japan in January 2024 and enrolled 166 women with endometriosis and 200 controls. Participants reported current and adolescent menstrual characteristics, symptom recognition, analgesic and low-dose estrogen–progestin use, school/work impact, and age at first gynecologic consultation for menstrual problems. Women with endometriosis reported heavier bleeding, stronger pain, and greater school/work absence than controls, both currently and retrospectively. The median age at first recognition of heavy bleeding or school/work absence was 16 years, whereas consultation occurred at approximately 21-23 years, indicating a consultation delay of 5-6 years. Notably, while self-monitoring of symptoms was more frequent among women with endometriosis, it only modestly shortened consultation delays. This study provides evidence from Japan that consultation delay persists despite active self-monitoring of symptoms, highlighting the influence of educational and cultural barriers on health-seeking behavior. These findings underscore the importance of integrating menstrual education with clinical guidance to promote timely gynecologic consultation.
en-copyright=
kn-copyright=

en-aut-name=IkedaTomoko
en-aut-sei=Ikeda
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakatsukaMikiya
en-aut-sei=Nakatsuka
en-aut-mei=Mikiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Faculty of Health Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Faculty of Health Sciences, Okayama University
kn-affil=
en-keyword=endometriosis
kn-keyword=endometriosis
en-keyword=adolescence
kn-keyword=adolescence
en-keyword=menstrual disorders
kn-keyword=menstrual disorders
en-keyword=consultation delay
kn-keyword=consultation delay
en-keyword=health-seeking behavior
kn-keyword=health-seeking behavior
END

start-ver=1.4
cd-journal=joma
no-vol=33
cd-vols=
no-issue=4
article-no=
start-page=829
end-page=838
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260416
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Breast cancer is a highly heterogeneous disease, with biological factors like estrogen receptor, progesterone receptor, and HER2 receptor differing between primary and metastatic sites, potentially affecting treatment response.<br>
This exploratory analysis aims to differentiate drug efficacy and long-term prognosis between these sites in stage IV breast cancer.<br>
Methods Patients from JCOG1017, a phase III trial evaluating the role of primary tumor resection, who received primary systemic therapy (PST) were evaluated at three months. In this analysis, treatment response was assessed separately in primary and metastatic sites. Patients were categorized into four groups: discordant I (primary non-PD, metastatic PD), concordant I (both PD), discordant II (primary PD, metastatic non-PD), and concordant II (both non-PD).<br>
Results Among 271 patients, overall discordance proportion of treatment response between primary and metastatic sites was 25.1%. Group distribution was 24.7% (discordant I), 9.6% (concordant I), 0.4% (discordant II), and 65.3% (concordant II). Discordance was more frequent in luminal (28.9%), triple-negative (25.0%), and luminal-HER2 (22.0%) subtypes than in HER2-enriched (11.1%). Survival analysis showed prognostic differences: concordant II, with both sites non-PD, demonstrated the most favorable outcome compared with discordant I (HR 0.556; 95% confidence interval, 0.396–0.782).<br>
Conclusions One-fourth of patients exhibited discordant responses between primary and metastatic sites in early treatment phases. These discrepancies were associated with survival differences, emphasizing the importance of evaluating both primary and metastatic lesions when assessing efficacy and determining treatment strategies in de novo stage IV breast cancer.
en-copyright=
kn-copyright=

en-aut-name=TanakaKiyo
en-aut-sei=Tanaka
en-aut-mei=Kiyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShimomuraAkihiko
en-aut-sei=Shimomura
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IshitobiMakoto
en-aut-sei=Ishitobi
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamanakaTakashi
en-aut-sei=Yamanaka
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TsukiokiTakahiro
en-aut-sei=Tsukioki
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IwataHiroji
en-aut-sei=Iwata
en-aut-mei=Hiroji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HaraFumikata
en-aut-sei=Hara
en-aut-mei=Fumikata
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=FujisawaTomomi
en-aut-sei=Fujisawa
en-aut-mei=Tomomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SasakiKeita
en-aut-sei=Sasaki
en-aut-mei=Keita
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=SadachiRyo
en-aut-sei=Sadachi
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KajikawaRiku
en-aut-sei=Kajikawa
en-aut-mei=Riku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=SakaiTakehiko
en-aut-sei=Sakai
en-aut-mei=Takehiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=SagaraYasuaki
en-aut-sei=Sagara
en-aut-mei=Yasuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=ShigematsuHideo
en-aut-sei=Shigematsu
en-aut-mei=Hideo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=OzakiYukinori
en-aut-sei=Ozaki
en-aut-mei=Yukinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=NozawaKazuki
en-aut-sei=Nozawa
en-aut-mei=Kazuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=SudoKazuki
en-aut-sei=Sudo
en-aut-mei=Kazuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=NaitoYoichi
en-aut-sei=Naito
en-aut-mei=Yoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=TerataKaori
en-aut-sei=Terata
en-aut-mei=Kaori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=IshibaToshiyuki
en-aut-sei=Ishiba
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=FukudaHaruhiko
en-aut-sei=Fukuda
en-aut-mei=Haruhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

affil-num=1
en-affil=Department of Breast Surgery, Toranomon Hospital
kn-affil=

affil-num=2
en-affil=Department of Breast and Medical Oncology, National Center for Global Health and Medicine
kn-affil=

affil-num=3
en-affil=Department of Breast Surgery, Osaka Habikino Medical Center
kn-affil=

affil-num=4
en-affil=Department of Breast Surgery, Kanagawa Cancer Center
kn-affil=

affil-num=5
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Advanced Clinical Research and Development, Nagoya City University Graduate School of Medical Sciences
kn-affil=

affil-num=7
en-affil=Department of Breast Oncology, Aichi Cancer Center
kn-affil=

affil-num=8
en-affil=Department of Breast Oncology, Gunma Prefectural Cancer Center
kn-affil=

affil-num=9
en-affil=Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital
kn-affil=

affil-num=10
en-affil=Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital
kn-affil=

affil-num=11
en-affil=Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital
kn-affil=

affil-num=12
en-affil=Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research
kn-affil=

affil-num=13
en-affil=Department of Breast Surgery, Sagara Hospital
kn-affil=

affil-num=14
en-affil=Department of Breast Surgery, Hiroshima University Hospital
kn-affil=

affil-num=15
en-affil=Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research
kn-affil=

affil-num=16
en-affil=Department of Advanced Clinical Research and Development, Nagoya City University Graduate School of Medical Sciences
kn-affil=

affil-num=17
en-affil=Department of Medical Oncology, National Cancer Center Hospital
kn-affil=

affil-num=18
en-affil=Department of General Internal Medicine, National Cancer Center Hospital East
kn-affil=

affil-num=19
en-affil=Department of Breast and Endocrine Surgery, Akita University Hospital
kn-affil=

affil-num=20
en-affil=Department of Breast Surgery, Institute of Science Tokyo Hospital
kn-affil=

affil-num=21
en-affil=Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital
kn-affil=

affil-num=22
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
en-keyword=Discordance of treatment response between primary and metastatic sites
kn-keyword=Discordance of treatment response between primary and metastatic sites
en-keyword=De novo stage IV breast cancer
kn-keyword=De novo stage IV breast cancer
en-keyword=Primary systemic therapy
kn-keyword=Primary systemic therapy
en-keyword=Overall survival
kn-keyword=Overall survival
END

start-ver=1.4
cd-journal=joma
no-vol=107
cd-vols=
no-issue=6
article-no=
start-page=002255
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260609
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=ICTV Virus Taxonomy Profile: Rhabdoviridae 2026
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The family Rhabdoviridae comprises viruses with unsegmented, bi-segmented or tri-segmented negative-sense (−) RNA genomes of 10–16 kb. Virions are typically enveloped, with bullet-shaped or bacilliform morphology, but can also be non-enveloped filaments. Rhabdoviruses infect plants or animals, including vertebrates or invertebrates such as arthropods, which can serve as single hosts or act as biological vectors for transmission to animals or plants. Rhabdoviruses include important pathogens of humans, livestock, fish or agricultural crops. This is a summary of the International Committee on Taxonomy of Viruses (ICTV) Report on the family Rhabdoviridae, which is available at ictv.global/report/rhabdoviridae.
en-copyright=
kn-copyright=

en-aut-name=WalkerPeter J.
en-aut-sei=Walker
en-aut-mei=Peter J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=BejermanNicolas
en-aut-sei=Bejerman
en-aut-mei=Nicolas
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=BlasdellKim R.
en-aut-sei=Blasdell
en-aut-mei=Kim R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=DebatHumberto
en-aut-sei=Debat
en-aut-mei=Humberto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=DietzgenRalf G.
en-aut-sei=Dietzgen
en-aut-mei=Ralf G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FooksAnthony R.
en-aut-sei=Fooks
en-aut-mei=Anthony R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=Freitas-AstúaJuliana
en-aut-sei=Freitas-Astúa
en-aut-mei=Juliana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=GarverKyle
en-aut-sei=Garver
en-aut-mei=Kyle
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KondoHideki
en-aut-sei=Kondo
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=Ramos-GonzálezPedro Luis
en-aut-sei=Ramos-González
en-aut-mei=Pedro Luis
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=ShiMang
en-aut-sei=Shi
en-aut-mei=Mang
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TeshRobert B.
en-aut-sei=Tesh
en-aut-mei=Robert B.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TordoNoël
en-aut-sei=Tordo
en-aut-mei=Noël
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=VasilakisNikos
en-aut-sei=Vasilakis
en-aut-mei=Nikos
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=WhitfieldAnna E.
en-aut-sei=Whitfield
en-aut-mei=Anna E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

affil-num=1
en-affil=University of Queensland
kn-affil=

affil-num=2
en-affil=Consejo Nacional de Investigaciones and Instituto Nacional de Tecnología Agropecuaria (INTA)
kn-affil=

affil-num=3
en-affil=CSIRO Health and Biosecurity
kn-affil=

affil-num=4
en-affil=Consejo Nacional de Investigaciones and Instituto Nacional de Tecnología Agropecuaria (INTA)
kn-affil=

affil-num=5
en-affil=University of Queensland
kn-affil=

affil-num=6
en-affil=Animal and Plant Health Agency Addlestone
kn-affil=

affil-num=7
en-affil=Brazilian Agricultural Research Corporation
kn-affil=

affil-num=8
en-affil=Fisheries & Oceans Canada
kn-affil=

affil-num=9
en-affil=Okayama University
kn-affil=

affil-num=10
en-affil=Instituto Biológico
kn-affil=

affil-num=11
en-affil=Sun Yat Sen University
kn-affil=

affil-num=12
en-affil=University of Texas Medical Branch
kn-affil=

affil-num=13
en-affil=Gamal Abdel Nasser University
kn-affil=

affil-num=14
en-affil=University of Texas Medical Branch
kn-affil=

affil-num=15
en-affil=North Carolina State University
kn-affil=
en-keyword=ICTV Report
kn-keyword=ICTV Report
en-keyword=Rhabdoviridae
kn-keyword=Rhabdoviridae
en-keyword=taxonomy
kn-keyword=taxonomy
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260526
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Optimizing low-dose rituximab protocol for ABO-mismatched kidney transplantation: long-term outcomes in a single-center retrospective cohort study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background ABO-mismatched kidney transplantation (KTx) expands donor availability but increases risks of antibody-mediated rejection and passenger lymphocyte syndrome (PLS). While rituximab (Rit) potentially mitigates these complications, conventional high-dose regimens (375 mg/m2) elevate infectious and hematologic toxicity. We implemented low-dose Rit induction (200 mg/body) for desensitization in minor/major ABO-mismatched and DSA-positive KTx, evaluating its efficacy and safety over 15-years.<br>
Methods This single-center retrospective cohort (May 2009–April 2024) analyzed 161 adult KTx recipients: Rit (n = 107) and Non-Rit (n = 54) groups. All received tacrolimus, mycophenolate mofetil, prednisolone, and basiliximab; high-risk patients also underwent plasmapheresis. Outcomes included graft survival, biopsy-proven acute rejection, de novo donor-specific antibody (DSA) formation, infection, severe neutropenia, and PLS.<br>
Results 1-year graft survival was 100% in both groups. 5-year death-censored graft survival was 95.8% (Rit) vs 95.9% (Non-Rit), respectively (log-rank P = 0.43). Biopsy-proven acute rejection (7.5% vs 3.7%, P = 0.50) and de novo DSA production were equivalent (Class I: 5.5% vs 2.2%; Class II: 6.6% vs 8.7%; both P = 1.00), with lower mean fluorescent intensity (MFI) in the Rit group. Cytomegalovirus disease, urinary tract infection and fungal infection rates were comparable between both groups. Grade 4 neutropenia was not associated with Rit (OR 2.65; 95% CI 0.63–11.0; P = 0.18). Blood transfusion for hemoglobin declines occurred in 5.6% vs 7.4%, with preserved haptoglobin in all cases, indicating no PLS.<br>
Conclusions Low-dose Rit induction achieves excellent graft survival and effective PLS prevention, without increasing toxicity, supporting its adoption as an optimal desensitization strategy.
en-copyright=
kn-copyright=

en-aut-name=YamanoiTomoaki
en-aut-sei=Yamanoi
en-aut-mei=Tomoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SekitoTakanori
en-aut-sei=Sekito
en-aut-mei=Takanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TokunagaMoto
en-aut-sei=Tokunaga
en-aut-mei=Moto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TsuboiIchiro
en-aut-sei=Tsuboi
en-aut-mei=Ichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YoshinagaKasumi
en-aut-sei=Yoshinaga
en-aut-mei=Kasumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MaruyamaYuki
en-aut-sei=Maruyama
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KawadaTatsushi
en-aut-sei=Kawada
en-aut-mei=Tatsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KubotaRisa
en-aut-sei=Kubota
en-aut-mei=Risa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TominagaYusuke
en-aut-sei=Tominaga
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=SadahiraTakuya
en-aut-sei=Sadahira
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KatayamaSatoshi
en-aut-sei=Katayama
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=IwataTakehiro
en-aut-sei=Iwata
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=NishimuraShingo
en-aut-sei=Nishimura
en-aut-mei=Shingo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=BekkuKensuke
en-aut-sei=Bekku
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=OnishiYasuhiro
en-aut-sei=Onishi
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=TakeuchiHidemi
en-aut-sei=Takeuchi
en-aut-mei=Hidemi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=TanabeKatsuyuki
en-aut-sei=Tanabe
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=MorinagaHiroshi
en-aut-sei=Morinaga
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=WadaKoichiro
en-aut-sei=Wada
en-aut-mei=Koichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=ArakiMotoo
en-aut-sei=Araki
en-aut-mei=Motoo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

affil-num=1
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
kn-affil=

affil-num=3
en-affil=Department of Urology, NHO Okayama Medical Center
kn-affil=

affil-num=4
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
kn-affil=

affil-num=7
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Urology, NHO Okayama Medical Center
kn-affil=

affil-num=9
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=14
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=15
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=16
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=17
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=18
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=19
en-affil=Department of Urology, Shimane University Faculty of Medicine
kn-affil=

affil-num=20
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=Kidney transplantation
kn-keyword=Kidney transplantation
en-keyword=ABO-mismatch
kn-keyword=ABO-mismatch
en-keyword=Low-dose rituximab
kn-keyword=Low-dose rituximab
en-keyword=Graft survival
kn-keyword=Graft survival
en-keyword=Passenger lymphocyte syndrome
kn-keyword=Passenger lymphocyte syndrome
END

start-ver=1.4
cd-journal=joma
no-vol=20
cd-vols=
no-issue=1
article-no=
start-page=ra.2025-0153
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=2026
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Current Status of Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: An International Perspective Including Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Middle meningeal artery embolization (MMAE) for chronic subdural hematoma (CSDH) is gaining global prevalence as a minimally invasive treatment aimed at serving as an adjunct to or method of avoiding surgery; however, its optimal positioning remains unclear. This study outlines the current status of MMAE in Japan, Germany, and the United States based on nationwide survey reports, recently published consensus guidelines, and meta-analyses including randomized controlled trials (RCTs) reported in the New England Journal of Medicine (NEJM; EMBOLISE, STEM, and MAGIC-MT) and examines its efficacy and limitations. Real-world clinical data from Japan, Germany, and the United States indicate that MMAE is primarily used as an adjunctive therapy following surgery for older and high-risk or recurrent cases, or as a stand-alone therapy in selected cases to safely reduce the risk of recurrence and reoperation. While a multidisciplinary consensus statement takes a cautious stance that limits MMAE to recurrent or inoperable cases such as those at high risk associated with interrupting antithrombotic medication, the Society of Vascular and Interventional Neurology guidelines published after the RCTs strongly recommend the concurrent use of MMAE with standard therapy in de novo cases. Meta-analyses integrating the 3 NEJM trials and other RCTs showed that MMAE suppressed recurrence and reoperation versus standard treatment, with particularly pronounced effects in the nonsurgical (conservative treatment) group; however, the additive effect was limited in the surgical adjunct group. No improvement in functional outcomes (modified Rankin Scale score) was observed. Cost-effectiveness analyses suggest that, while MMAE reduces reoperations, routine implementation for all cases is difficult to justify economically because of high procedural costs, indicating the need to narrow the indication to populations at high risk of recurrence. In conclusion, although MMAE is an effective treatment option, the current evidence does not support its uniform introduction in all patients with CSDH. Thus, it is necessary to individualize and adapt the indications for specific patient subgroups, such as those at high risk of recurrence or those for whom surgery is difficult. Finally, we propose a pragmatic treatment strategy for MMAE stratified by disease stage (de novo vs. recurrent) and clinical severity to guide the individualized selection of adjunctive and stand-alone embolization.
en-copyright=
kn-copyright=

en-aut-name=KawakamiMasato
en-aut-sei=Kawakami
en-aut-mei=Masato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SugiuKenji
en-aut-sei=Sugiu
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HiramatsuMasafumi
en-aut-sei=Hiramatsu
en-aut-mei=Masafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HarumaJun
en-aut-sei=Haruma
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KimuraRyu
en-aut-sei=Kimura
en-aut-mei=Ryu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SoutomeYuta
en-aut-sei=Soutome
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=FujitaJuntaro
en-aut-sei=Fujita
en-aut-mei=Juntaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HirataYuichi
en-aut-sei=Hirata
en-aut-mei=Yuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=BabaFukiko
en-aut-sei=Baba
en-aut-mei=Fukiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TanakaShota
en-aut-sei=Tanaka
en-aut-mei=Shota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=middle meningeal artery embolization
kn-keyword=middle meningeal artery embolization
en-keyword=chronic subdural hematoma
kn-keyword=chronic subdural hematoma
en-keyword=current status
kn-keyword=current status
END

start-ver=1.4
cd-journal=joma
no-vol=687
cd-vols=
no-issue=
article-no=
start-page=120087
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202608
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Phase diagram of Fe-C-S ternary system under planetary core conditions
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=High-pressure, high-temperature experiments were conducted to investigate melting relations and phase assemblages in the Fe-C-S ternary system at 5 and 15 GPa, covering a temperature range of 1300–1900 K, conditions directly relevant to the Moon’s and Mercury’s cores. At 1300 K, the system is primarily governed by Fe-S eutectic melting, exhibiting notable complexity in the carbon-rich and sulfur-poor regions. With increasing temperature, the phase diagram simplifies: at 5 GPa and 1700 K, the Fe-Fe₃C-FeS system features three regions (Fe+L, C + L, and L). Similar phase assemblages are observed at 15 GPa, with Fe7C3 and diamond replacing Fe3C and graphite, respectively. Extensive Fe+L, C + L, and L regions are observed at 1900 K.<br>
For a Moon’s core composed of a Fe-C-S alloy, nearly pure Fe is the only viable inner core phase above 1700 K. Below this temperature, both Fe and Fe₃C are potential solid inner core phases, depending on carbon content; a two-phase solid inner core is also theoretically possible. The inferred compositions of the outer core suggest densities of 6200–7300 kg/m³, with tighter constraints for models featuring an Fe₃C core.<br>
At Mercury-relevant pressures, either Fe or Fe₇C₃ may form the solid inner core, again depending on carbon content. If the inner core is nearly pure Fe, the liquid outer core density ranges from 7300 to 7900 kg/m³. In both scenarios, a “snow” regime is plausible, though with distinct settling times. The ternary phase diagram indicates that Mercury is likely to develop a structurally layered inner core during secular cooling.<br>
en-copyright=
kn-copyright=

en-aut-name=ZhaoBin
en-aut-sei=Zhao
en-aut-mei=Bin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ZhuJintao
en-aut-sei=Zhu
en-aut-mei=Jintao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=AntonangeliDaniele
en-aut-sei=Antonangeli
en-aut-mei=Daniele
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MorardGuillaume
en-aut-sei=Morard
en-aut-mei=Guillaume
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ChenQi
en-aut-sei=Chen
en-aut-mei=Qi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YoshinoTakashi
en-aut-sei=Yoshino
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Institute for Planetary Materials, Okayama University
kn-affil=

affil-num=2
en-affil=Institute for Planetary Materials, Okayama University
kn-affil=

affil-num=3
en-affil=Muséum National d’Histoire Naturelle, Sorbonne Université, UMR CNRS 7590, Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, IMPMC
kn-affil=

affil-num=4
en-affil=Muséum National d’Histoire Naturelle, Sorbonne Université, UMR CNRS 7590, Institut de Minéralogie, de Physique des Matériaux et de Cosmochimie, IMPMC
kn-affil=

affil-num=5
en-affil=Center for Advanced Radiation Sources, University of Chicago
kn-affil=

affil-num=6
en-affil=Institute for Planetary Materials, Okayama University
kn-affil=
en-keyword=planetary core
kn-keyword=planetary core
en-keyword=phase diagram
kn-keyword=phase diagram
en-keyword=multi-anvil experiments
kn-keyword=multi-anvil experiments
en-keyword=iron alloy
kn-keyword=iron alloy
END

start-ver=1.4
cd-journal=joma
no-vol=53
cd-vols=
no-issue=9
article-no=
start-page=e2025GL121619
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260508
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Apollo 17 Lunar Surface Gravimeter as a Seismometer: Relocating Shallow‐Moonquake Sources and Implications for Source Mechanism
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Among the reported seismic events on the Moon, shallow moonquakes are known for their unique features, such as high-frequency energy excitation, similarity to intraplate earthquakes, and the largest energy release of all reported moonquakes. Despite these interesting features, a small number of samples (<80 events) and sparse seismic network observations prevented us from gaining an in-depth understanding of shallow moonquakes. In this study, by using the Apollo 17 gravimeter as a pseudo-seismometer, we extend the Apollo lunar seismic network and located a few shallow moonquakes more accurately. In addition, comparing the located shallow-moonquake epicenters with surface/subsurface geological features indicates that at least one event may be better explained by deep-seated faults within the crust. Along with a previous demonstration of low-frequency moonquakes, our analysis of high-frequency events shows that the Apollo 17 gravimeter can serve as a seismometer over a broader frequency range than previously considered.
en-copyright=
kn-copyright=

en-aut-name=OnoderaKeisuke
en-aut-sei=Onodera
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KawamuraTaichi
en-aut-sei=Kawamura
en-aut-mei=Taichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Institute for Planetary Materials, Okayama University
kn-affil=

affil-num=2
en-affil=Institut de Physique du Globe de Paris, Université Paris Cité
kn-affil=
en-keyword=Moon
kn-keyword=Moon
en-keyword=lunar seismology
kn-keyword=lunar seismology
en-keyword=tectonism
kn-keyword=tectonism
en-keyword=moonquake
kn-keyword=moonquake
END

start-ver=1.4
cd-journal=joma
no-vol=131
cd-vols=
no-issue=
article-no=
start-page=e2025JE009453
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260430
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Lateral Variations in Lunar Crustal Thickness Inferred From Apollo Seismic and GRAIL Gravity Data
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The internal structure of the Moon is key to understanding its formation, evolution, and bulk composition. In particular, determining the structure of the crust–mantle interface (Moho), including its lateral variations, is of significant importance, but current knowledge is still insufficient to fully constrain it. To address this, we used seismic wave arrivals from impact events, which yield constraints on the crust at both the impact sites and the Apollo stations, to invert for local crustal thickness. Based on a series of assumed crust and mantle density models, we compared Moho depths inferred from global gravity recovery and interior laboratory gravity data with those from seismic observations. Although the gravity‐derived results broadly capture the overall Moho relief, local discrepancies remain, with differences reaching up to 10 km in the vicinity of the Apollo 17 Saturn IVB impact site. These results may reflect regional geological anomalies and highlight the importance of incorporating multiple seismically constrained crustal thickness estimates as anchors in gravity inversions. Using seven seismic anchor points and assuming an upper mantle velocity of Vp = 7.68 km/ s, an upper mantle density of 3,280 kg/m3, and a crustal density of 2,693 kg/m3, we obtain an average lunar crustal thickness of 43.6 ± 1.9 km. The findings also provide valuable guidance for future global 3D modeling of the Moon.
en-copyright=
kn-copyright=

en-aut-name=ZhangXiang
en-aut-sei=Zhang
en-aut-mei=Xiang
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KawamuraTaichi
en-aut-sei=Kawamura
en-aut-mei=Taichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=DrilleauMélanie
en-aut-sei=Drilleau
en-aut-mei=Mélanie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=LognonnéPhilippe
en-aut-sei=Lognonné
en-aut-mei=Philippe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HenriSamuel
en-aut-sei=Henri
en-aut-mei=Samuel
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=XuZongbo
en-aut-sei=Xu
en-aut-mei=Zongbo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OnoderaKeisuke
en-aut-sei=Onodera
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=BodinThomas
en-aut-sei=Bodin
en-aut-mei=Thomas
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Université Paris Cité, Institut de physique du globe de Paris, CNRS
kn-affil=

affil-num=2
en-affil=Université Paris Cité, Institut de physique du globe de Paris, CNRS
kn-affil=

affil-num=3
en-affil=Université Paris Cité, Institut de physique du globe de Paris, CNRS
kn-affil=

affil-num=4
en-affil=Université Paris Cité, Institut de physique du globe de Paris, CNRS
kn-affil=

affil-num=5
en-affil=Université Paris Cité, Institut de physique du globe de Paris, CNRS
kn-affil=

affil-num=6
en-affil=Université Paris Cité, Institut de physique du globe de Paris, CNRS
kn-affil=

affil-num=7
en-affil=Institute for Planetary Materials, Okayama University
kn-affil=

affil-num=8
en-affil=Instituto de Ciencias del Mar (ICM)–CSIC
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=2
article-no=
start-page=147
end-page=152
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202604
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Complete Transection of the Common Bile Duct Caused by Blunt Abdominal Trauma: A Rare Case Report
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Common bile duct (CBD) injury after blunt abdominal trauma is rare and difficult to diagnose. Delayed recognition leads to severe morbidity. A 70-year-old Japanese man was admitted after sustaining blunt abdominal trauma. Ultrasonography revealed intra-abdominal fluid, suggesting bleeding. Contrast-enhanced computed tomography revealed pancreatic head injury, intra-abdominal bleeding, and pseudoaneurysm of the anterior superior pancreatoduodenal artery (ASPDA). Bile duct injury was not evident. The application of transarterial embolization (TAE) controlled the bleeding. Canulation into the pancreatic or biliary duct was not possible during endoscopic retrograde cholangiopancreatography. An emergency laparotomy revealed severe pancreatic head and extrahepatic bile duct injuries. Pancreaticoduodenectomy/Child reconstruction was performed. Complete CBD transection was confirmed. The patient was ultimately discharged without complications. Early recognition, timely surgical management, and intensive care are essential for favorable outcomes in patients who have sustained abdominal trauma.
en-copyright=
kn-copyright=

en-aut-name=SakamotoShinya
en-aut-sei=Sakamoto
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TabuchiMotoyasu
en-aut-sei=Tabuchi
en-aut-mei=Motoyasu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HamadaAkira
en-aut-sei=Hamada
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YoshimatsuRika
en-aut-sei=Yoshimatsu
en-aut-mei=Rika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SaisakaYuichi
en-aut-sei=Saisaka
en-aut-mei=Yuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MatsumotoManabu
en-aut-sei=Matsumoto
en-aut-mei=Manabu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IwataJun
en-aut-sei=Iwata
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OkabayashiTakehiro
en-aut-sei=Okabayashi
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=3
en-affil=Department of Intensive Care Medicine, Kochi Health Sciences Center
kn-affil=

affil-num=4
en-affil=Department of Radiology, Kochi Health Sciences Center
kn-affil=

affil-num=5
en-affil=Department of Emergency and Critical Care Medicine, Kochi Health Sciences Center
kn-affil=

affil-num=6
en-affil=Department of Diagnostic Pathology, Kochi Health Sciences Center
kn-affil=

affil-num=7
en-affil=Department of Diagnostic Pathology, Kochi Health Sciences Center
kn-affil=

affil-num=8
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=
en-keyword=blunt abdominal trauma
kn-keyword=blunt abdominal trauma
en-keyword=intensive care
kn-keyword=intensive care
en-keyword=emergency laparotomy
kn-keyword=emergency laparotomy
en-keyword=pancreatoduodenectomy
kn-keyword=pancreatoduodenectomy
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=2
article-no=
start-page=141
end-page=145
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202604
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Necrotizing Fasciitis Caused by ESBL-Producing Raoultella ornithinolytica in an Immunocompromised Patient with VEXAS Syndrome
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory somatic) syndrome has a poor prognosis, with infections being a major cause of death. Raoultella ornithinolytica is an environmental bacterium found predominantly in soil and water. Although R. ornithinolytica can cause various infections, necrotizing fasciitis due to this bacterium has not been reported. We describe the case of an 84-year-old Japanese male with VEXAS syndrome who developed septic shock and necrotizing fasciitis while he was under immunosuppressive therapy. The pathogen was initially misidentified as R. planticola by mass spectrometry but later confirmed by whole-genome sequencing as extended spectrum β-lactamase (ESBL) produced by R. ornithinolytica. Although a life-saving leg amputation was required, the patient recovered with appropriate antibiotic therapy. R. ornithinolytica is thus able to cause severe skin infections in immunocompromised individuals.
en-copyright=
kn-copyright=

en-aut-name=Sakamoto-TokunagaMoe
en-aut-sei=Sakamoto-Tokunaga
en-aut-mei=Moe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KatsuyamaTakayuki
en-aut-sei=Katsuyama
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatobaMasaki
en-aut-sei=Matoba
en-aut-mei=Masaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TamuraTomokazu
en-aut-sei=Tamura
en-aut-mei=Tomokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KubotaNatsuki
en-aut-sei=Kubota
en-aut-mei=Natsuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TerajimaYuya
en-aut-sei=Terajima
en-aut-mei=Yuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ShidaharaKenta
en-aut-sei=Shidahara
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HiroseKei
en-aut-sei=Hirose
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MatsumotoKazuya
en-aut-sei=Matsumoto
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NawachiShoichi
en-aut-sei=Nawachi
en-aut-mei=Shoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=NakadoiTakato
en-aut-sei=Nakadoi
en-aut-mei=Takato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KatayamaYu
en-aut-sei=Katayama
en-aut-mei=Yu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=HayashiKeigo
en-aut-sei=Hayashi
en-aut-mei=Keigo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=MiyawakiYoshia
en-aut-sei=Miyawaki
en-aut-mei=Yoshia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=KatsuyamaEri
en-aut-sei=Katsuyama
en-aut-mei=Eri
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=WatanabeHaruki
en-aut-sei=Watanabe
en-aut-mei=Haruki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=Takano-NarazakiMariko
en-aut-sei=Takano-Narazaki
en-aut-mei=Mariko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=MatsumotoYoshinori
en-aut-sei=Matsumoto
en-aut-mei=Yoshinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=SadaKen-Ei
en-aut-sei=Sada
en-aut-mei=Ken-Ei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=TsujiShuma
en-aut-sei=Tsuji
en-aut-mei=Shuma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=GotohKazuyoshi
en-aut-sei=Gotoh
en-aut-mei=Kazuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=FukushimaShinnosuke
en-aut-sei=Fukushima
en-aut-mei=Shinnosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

affil-num=1
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=14
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=15
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=16
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=17
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=18
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=19
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=20
en-affil=Department of Medical Laboratory Science, Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=21
en-affil=Department of Medical Laboratory Science, Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=22
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=23
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=24
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=necrotizing fasciitis
kn-keyword=necrotizing fasciitis
en-keyword=Raoultella ornithinolytica
kn-keyword=Raoultella ornithinolytica
en-keyword=VEXAS syndrome
kn-keyword=VEXAS syndrome
en-keyword=whole-genome sequence
kn-keyword=whole-genome sequence
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=2
article-no=
start-page=131
end-page=139
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202604
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Impact of Proteinuria on Postoperative Complications Following Colorectal Cancer Surgery
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Colorectal surgery is associated with a high incidence of postoperative complications regardless of the advances in surgical techniques and multidisciplinary treatment. Proteinuria is common in patients with malignancies, but few studies have investigated the association between preoperative proteinuria and patient prognoses, especially postoperative complications. We investigated the impact of proteinuria on patients undergoing colorectal surgery in a single-center, retrospective cohort study of 767 patients who underwent surgical resection for colorectal cancer between January 2016 and December 2022 at the National Hospital Organization Shikoku Cancer Center. Among them, 81 patients with preoperative proteinuria were compared with the control group of 686 patients without proteinuria. Our analyses revealed that the patients with proteinuria had malnutrition with a significantly lower prognostic nutritional index compared to the no-proteinuria control group (p<0.001). The proteinuria group had a significantly advanced tumor stage (p=0.005), experienced more bleeding during the surgery (p=0.002), and required more transfusions (p<0.001). Postoperative complications were significantly more frequent in the proteinuria group (p=0.03), thus demonstrating that proteinuria was independently associated with postoperative complications (p=0.045). Proteinuria in patients undergoing colorectal cancer surgery can therefore be considered a risk factor for postoperative complications.
en-copyright=
kn-copyright=

en-aut-name=NakataShunsuke
en-aut-sei=Nakata
en-aut-mei=Shunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakatsuFumiaki
en-aut-sei=Takatsu
en-aut-mei=Fumiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MikuriyaYoshihiro
en-aut-sei=Mikuriya
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KakishitaTomokazu
en-aut-sei=Kakishita
en-aut-mei=Tomokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HatoShinji
en-aut-sei=Hato
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OhtaKoji
en-aut-sei=Ohta
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KobatakeTakaya
en-aut-sei=Kobatake
en-aut-mei=Takaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=5
en-affil=Department of Gastroenterological Surgery, National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=7
en-affil=Department of Gastroenterological Surgery, National Hospital Organization Shikoku Cancer Center
kn-affil=
en-keyword=colorectal cancer
kn-keyword=colorectal cancer
en-keyword=surgery
kn-keyword=surgery
en-keyword=proteinuria
kn-keyword=proteinuria
en-keyword=complication
kn-keyword=complication
en-keyword=malnutrition
kn-keyword=malnutrition
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=2
article-no=
start-page=99
end-page=107
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202604
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Consistent Clinical Outcomes of Anteroinferior Minimally Invasive Plate Osteosynthesis for Midshaft Clavicle Fractures Across AO/OTA Fracture Types
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Although the performance of minimally invasive plate osteosynthesis (MIPO) via the anteroinferior approach is increasingly adopted for midshaft clavicle fractures, the influence of fracture morphology on clinical outcomes under a standardized protocol is unclear. We retrospectively analyzed the cases of 54 patients who underwent anteroinferior MIPO for an acute midshaft clavicle fracture (AO/OTA types B1, B2, B3) performed by a single surgeon across three affiliated institutions (2009-2022). We evaluated the clinical outcomes, i.e., the surgical time, incision length, radiographic union, reduction accuracy, range of motion, pain (visual analog scale [VAS]), and complications and compared them among the three AO/OTA subtypes. The mean incision length (3.4 cm) and surgical time (71-79 min) were similar among the groups (both p>0.2). All fractures achieved radiographic union at a mean of 3.5 months. Postoperative alignment and clavicular length were maintained (length reduction −1.0±2.2 mm [B1], −0.5±2.0 mm [B2], −0.6±1.8 mm [B3]; p=0.825; angulation −0.8±3.4°, −1.1±3.1°, −0.3±3.3°; p=0.888). At 3 months, shoulder elevation and abduction were 169°-175° (p=0.079) and 164°-175° (p=0.324). Pain was minimal (100-mm VAS: ≤1 mm; p=0.782). One plate-fatigue failure occurred; no supraclavicular-nerve symptoms were recorded. Anteroinferior MIPO yielded consistent outcomes across AO/OTA types, with excellent union rates, functional recovery, and few complications, indicating that this technique is safe and reproducible for the surgical management of midshaft clavicle fractures.
en-copyright=
kn-copyright=

en-aut-name=Nguyen Trung Thanh
en-aut-sei=Nguyen Trung Thanh
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakamichiRyo
en-aut-sei=Nakamichi
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ShimamuraYasunori
en-aut-sei=Shimamura
en-aut-mei=Yasunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SaitoTaichi
en-aut-sei=Saito
en-aut-mei=Taichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IshiharaTakeshi
en-aut-sei=Ishihara
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FurutaniTomoki
en-aut-sei=Furutani
en-aut-mei=Tomoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ShitozawaHisakazu
en-aut-sei=Shitozawa
en-aut-mei=Hisakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NodaTomoyuki
en-aut-sei=Noda
en-aut-mei=Tomoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Kousei Hospital
kn-affil=

affil-num=4
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, Kawasaki Medical School General Medical Center
kn-affil=

affil-num=9
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=clavicle fracture
kn-keyword=clavicle fracture
en-keyword=minimally invasive plate osteosynthesis
kn-keyword=minimally invasive plate osteosynthesis
en-keyword=anteroinferior plating
kn-keyword=anteroinferior plating
en-keyword=AO/OTA classification
kn-keyword=AO/OTA classification
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=2
article-no=
start-page=85
end-page=97
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202604
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effects of Nonsurgical Periodontal Treatment on Bacterial and Clinical Parameters in Down Syndrome Patients Based on 16S rRNA Gene Amplicon Sequencing
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Individuals with Down syndrome (DS) are more susceptible to periodontal disease; however, microbial changes following treatment remain insufficiently understood. This study evaluated the effects of nonsurgical periodontal therapy on clinical outcomes and oral microbiome dynamics in 6 patients with DS using 16S rRNA gene amplicon sequencing. Bacterial diversity, composition, network structure, and predicted functional pathways were analyzed using dental plaque samples. Bleeding on probing decreased significantly (p=0.047) after treatment, with a trend toward reduction in periodontal inflamed surface area (p=0.05). The abundance of Fusobacteria at the class level decreased significantly after treatment. The abundance of Mogibacterium timidum was higher in the pretreatment group than in the posttreatment group. M. timidum was positively correlated with Treponema denticola and associated with multiple bacterial taxa in the network during pretreatment. Predicted functional pathways related to aromatic compound degradation were more abundant in posttreatment samples than in pretreatment samples. An increase in the abundance of Fusobacterium and the positive correlation between T. denticola and M. timidum, together with their associations with other periodontal pathogens before treatment, may contribute to the development of periodontitis in individuals with DS. Nonsurgical periodontal therapy produces measurable clinical improvement and promotes microbial shifts in patients with DS.
en-copyright=
kn-copyright=

en-aut-name=ShibaTakahiko
en-aut-sei=Shiba
en-aut-mei=Takahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakamoriMitsuhito
en-aut-sei=Takamori
en-aut-mei=Mitsuhito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KatagiriSayaka
en-aut-sei=Katagiri
en-aut-mei=Sayaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KobayashiRyota
en-aut-sei=Kobayashi
en-aut-mei=Ryota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KawauchiAki
en-aut-sei=Kawauchi
en-aut-mei=Aki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OhsugiYujin
en-aut-sei=Ohsugi
en-aut-mei=Yujin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=LinPeiya
en-aut-sei=Lin
en-aut-mei=Peiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=EkuniDaisuke
en-aut-sei=Ekuni
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=EgusaMasahiko
en-aut-sei=Egusa
en-aut-mei=Masahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=IwataTakanori
en-aut-sei=Iwata
en-aut-mei=Takanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MaedaShigeru
en-aut-sei=Maeda
en-aut-mei=Shigeru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Periodontology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo
kn-affil=

affil-num=2
en-affil=Department of Oral Physiology, Graduate School of Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Oral Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo
kn-affil=

affil-num=4
en-affil=Department of Periodontology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo
kn-affil=

affil-num=5
en-affil=Department of Dental Anesthesiology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo
kn-affil=

affil-num=6
en-affil=Department of Oral Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo
kn-affil=

affil-num=7
en-affil=Department of Oral Biology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo
kn-affil=

affil-num=8
en-affil=Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=9
en-affil=The center for Special Needs Dentistry, Medical Development Field, Okayama University
kn-affil=

affil-num=10
en-affil=Department of Periodontology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo
kn-affil=

affil-num=11
en-affil=Department of Dental Anesthesiology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo
kn-affil=
en-keyword=Down Syndrome
kn-keyword=Down Syndrome
en-keyword=16S rRNA Gene Amplicon Sequencing
kn-keyword=16S rRNA Gene Amplicon Sequencing
en-keyword=periodontitis
kn-keyword=periodontitis
en-keyword=nonsurgical periodontal treatment
kn-keyword=nonsurgical periodontal treatment
en-keyword=oral microbiome
kn-keyword=oral microbiome
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=2
article-no=
start-page=75
end-page=83
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202604
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Involvement of ADAM12 in TGF-β1-Induced Proliferation of Rheumatoid Arthritis Synovial Fibroblasts
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A disintegrin and metalloproteinase 12 (ADAM12) is known to be involved in chondrocyte proliferation and is upregulated in the synovial tissue of osteoarthritis (OA). However, the underlying mechanisms of ADAM12 on rheumatoid arthritis (RA) synovial cell proliferation remain unknown. Here, we investigated the role of ADAM12 in the proliferation of RA synovial fibroblasts (RASFs). The expression and localization of ADAM12 in RA synovial tissues were examined by immunohistochemistry and compared with OA and healthy control (HC) synovial tissues. The effect of inflammatory cytokines (TNF-α, TGF-β1, and PDGF-BB) on ADAM12 expression in RASFs from RA patients was examined by real-time RT-PCR. The effect of ADAM12 knock-down by ADAM12 siRNA and ADAM12 overexpression on cell proliferation of RASFs were examined by WST-1 assay. ADAM12 was identified predominantly in RA synovial tissue rather than OA and HC synovial tissues. Stimulation with TGF-β1 upregulated the expression of ADAM12 and cell proliferation of RASFs. ADAM12 siRNA suppressed TGF-β1-induced cell proliferation of RASFs, while ADAM12 overexpression promoted the cell proliferation of RASFs. These findings demonstrate that ADAM12 may have a key role in TGF-β1-induced cell proliferation of synovial fibroblasts in patients with RA.
en-copyright=
kn-copyright=

en-aut-name=LinDeting
en-aut-sei=Lin
en-aut-mei=Deting
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HoritaMasahiro
en-aut-sei=Horita
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=WatanabeMasahito
en-aut-sei=Watanabe
en-aut-mei=Masahito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HaseiJoe
en-aut-sei=Hasei
en-aut-mei=Joe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OhtsukiTakashi
en-aut-sei=Ohtsuki
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OtsukaNoriaki
en-aut-sei=Otsuka
en-aut-mei=Noriaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IchikawaChinatsu
en-aut-sei=Ichikawa
en-aut-mei=Chinatsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ShimizuNoriyuki
en-aut-sei=Shimizu
en-aut-mei=Noriyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NaniwaShuichi
en-aut-sei=Naniwa
en-aut-mei=Shuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=NishidaKeiichiro
en-aut-sei=Nishida
en-aut-mei=Keiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Orthopaedic Surgery, Faculty of Medical Development Field, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Muscat Orthopaedic Clinic
kn-affil=

affil-num=4
en-affil=Medical Information and Assistive Technology Development, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Medical Technology, Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Division of Chronic Pain Medicine and Division of Comprehensive Rheumatology, Locomotive Pain Center, Faculty of Medical Development Field, Okayama University
kn-affil=
en-keyword=rheumatoid arthritis
kn-keyword=rheumatoid arthritis
en-keyword=synovial tissue
kn-keyword=synovial tissue
en-keyword=TGF-β1
kn-keyword=TGF-β1
en-keyword=ADAM12
kn-keyword=ADAM12
en-keyword=cell proliferation
kn-keyword=cell proliferation
END

start-ver=1.4
cd-journal=joma
no-vol=131
cd-vols=
no-issue=4
article-no=
start-page=e2025JE009432
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202604
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Investigating the Detectability of Body Wave Phases From Tidal Ice Cracking Events on Titan With the Dragonfly Short-Period Seismometer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Detecting seismic activity on Saturn's icy moon Titan during the Dragonfly mission could provide crucial information on its internal structure. The geological complexity of the moon's surface suggests significant cyclic tidal deformation, likely leading to the fracturing of the ice shell. Considering realistic source locations and fault geometries, we assess whether a vertical short-period seismometer can detect body waves from a Mw 4.0 icequake. Signal-to-noise ratios are evaluated by comparing the high-frequency content with the expected background noise and instrument capabilities for several ice attenuation scenarios and 1D interior models. Our results indicate that the high-frequency content (≥1Hz) of Mw≤4.0 tidal-induced icequakes is likely undetectable under the most unfavorable attenuation scenarios and atmospheric conditions. However, seismic signals in the 0.5–1 Hz band—where P wave reflections dominate—may still be observable for events occurring in potential seismically active regions at ∼800–1,000 km from the Dragonfly's landing site. These signals could provide constraints on the thickness of Titan's outer ice shell, provided that intrinsic attenuation is low and environmental conditions are favorable.
en-copyright=
kn-copyright=

en-aut-name=DelaroqueL.
en-aut-sei=Delaroque
en-aut-mei=L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KawamuraT.
en-aut-sei=Kawamura
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=LucasA.
en-aut-sei=Lucas
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=RodriguezS.
en-aut-sei=Rodriguez
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OnoderaK.
en-aut-sei=Onodera
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ShiraishiH.
en-aut-sei=Shiraishi
en-aut-mei=H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YamadaR.
en-aut-sei=Yamada
en-aut-mei=R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TanakaS.
en-aut-sei=Tanaka
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=PanningM. P.
en-aut-sei=Panning
en-aut-mei=M. P.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=LorenzR. D.
en-aut-sei=Lorenz
en-aut-mei=R. D.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Université Paris Cité, Institut de Physique du Globe de Paris, CNRS
kn-affil=

affil-num=2
en-affil=Université Paris Cité, Institut de Physique du Globe de Paris, CNRS
kn-affil=

affil-num=3
en-affil=Université Paris Cité, Institut de Physique du Globe de Paris, CNRS
kn-affil=

affil-num=4
en-affil=Université Paris Cité, Institut de Physique du Globe de Paris, CNRS
kn-affil=

affil-num=5
en-affil=Institute for Planetary Materials, Okayama University
kn-affil=

affil-num=6
en-affil=Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency
kn-affil=

affil-num=7
en-affil=The University of Aizu
kn-affil=

affil-num=8
en-affil=Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency
kn-affil=

affil-num=9
en-affil=Jet Propulsion Laboratory, California Institute of Technology
kn-affil=

affil-num=10
en-affil=The Johns Hopkins University Applied Physics Laboratory
kn-affil=
en-keyword=body waves
kn-keyword=body waves
en-keyword=planetary seismology
kn-keyword=planetary seismology
en-keyword=interior structure
kn-keyword=interior structure
en-keyword=dragonfly mission
kn-keyword=dragonfly mission
en-keyword=icy moons
kn-keyword=icy moons
en-keyword=Titan
kn-keyword=Titan
END

start-ver=1.4
cd-journal=joma
no-vol=27
cd-vols=
no-issue=2
article-no=
start-page=831
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260114
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Porphyromonas gingivalis Vesicles Control Osteoclast–Macrophage Lineage Fate
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Porphyromonas gingivalis (Pg), a keystone pathogen of chronic periodontitis, releases outer membrane vesicles (OMVs) that act as nanoscale vehicles to disseminate virulence factors within periodontal tissues and systemically beyond the oral cavity. Although Pg-OMVs are increasingly recognized as critical mediators of host–pathogen interactions, their effects on the differentiation and function of monocyte–macrophage/osteoclast lineage cells remain unclear. Here, we examined the impact of Pg-OMVs on the differentiation of RAW264.7 monocyte/macrophage-like cells into osteoclasts (OC) and/or macrophages (MΦ) in the presence of receptor activator of nuclear factor-κB ligand (RANKL). OMVs were isolated from Pg W83 and applied to RANKL-primed RAW264.7 cells using three distinct stimulation schedules: (1) simultaneous treatment with Pg-OMVs and RANKL at Day 0; (2) RANKL priming at Day 0 followed by Pg-OMV stimulation at Day 1; and (3) RANKL priming at Day 0 followed by Pg-OMV stimulation at Day 3. In all schedules, cells were cultured for 7 days from the initial RANKL exposure. Remarkably, simultaneous exposure to Pg-OMVs and RANKL (Schedule 1) markedly suppressed osteoclastogenesis (OC-genesis) while promoting M1 macrophage polarization. In contrast, delayed Pg-OMV stimulation of RANKL-primed cells (Schedules 2 and 3) significantly enhanced OC-genesis while reducing M1 polarization. These schedule-dependent effects were consistent with altered expression of osteoclastogenic markers, including dc-stamp, oc-stamp, nfatc1, and acp5. Importantly, a monoclonal antibody against OC-STAMP counteracted the Pg-OMV-induced upregulation of OC-genesis in Schedules 2 and 3. Furthermore, levels of Pg-OMV phagocytosis were inversely correlated with osteoclast formation. Finally, co-stimulation with RANKL and Pg-OMVs (Schedule 1) enhanced macrophage migratory capacity, whereas delayed stimulation with Pg-OMVs (Schedules 2 and 3) did not. Collectively, these findings indicate that Pg-OMVs exert stage-specific effects on the OC/MΦ lineage: stimulation at early stages of RANKL priming suppresses OC-genesis and promotes M1 polarization, whereas stimulation at later stages enhances OC-genesis without inducing M1 differentiation. Thus, Pg-OMVs may critically influence the fate of the OC/MΦ unit in periodontal lesions, contributing to disease progression and tissue destruction.
en-copyright=
kn-copyright=

en-aut-name=LeonElizabeth
en-aut-sei=Leon
en-aut-mei=Elizabeth
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakamuraShin
en-aut-sei=Nakamura
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ShindoSatoru
en-aut-sei=Shindo
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=PastoreMaria Rita
en-aut-sei=Pastore
en-aut-mei=Maria Rita
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KumagaiTomoki
en-aut-sei=Kumagai
en-aut-mei=Tomoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HeidariAlireza
en-aut-sei=Heidari
en-aut-mei=Alireza
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=AbdolahiniaElaheh Dalir
en-aut-sei=Abdolahinia
en-aut-mei=Elaheh Dalir
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=UedaTomoya
en-aut-sei=Ueda
en-aut-mei=Tomoya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MemidaTakumi
en-aut-sei=Memida
en-aut-mei=Takumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=Duran-PinedoAna
en-aut-sei=Duran-Pinedo
en-aut-mei=Ana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=Frias-LopezJorge
en-aut-sei=Frias-Lopez
en-aut-mei=Jorge
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HanXiaozhe
en-aut-sei=Han
en-aut-mei=Xiaozhe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=ChenXin
en-aut-sei=Chen
en-aut-mei=Xin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=HuangShengyuan
en-aut-sei=Huang
en-aut-mei=Shengyuan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=CaoGuoqin
en-aut-sei=Cao
en-aut-mei=Guoqin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=RuizSunniva
en-aut-sei=Ruiz
en-aut-mei=Sunniva
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=PotempaJan
en-aut-sei=Potempa
en-aut-mei=Jan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=KawaiToshihisa
en-aut-sei=Kawai
en-aut-mei=Toshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

affil-num=1
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=2
en-affil=Department of Periodontics and Endodontics, Division of Dentistry, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=4
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=5
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=6
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=7
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=8
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=9
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=10
en-affil=Department of Oral Biology, College of Dentistry, University of Florida
kn-affil=

affil-num=11
en-affil=Department of Oral Biology, College of Dentistry, University of Florida
kn-affil=

affil-num=12
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=13
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=14
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=15
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=16
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=17
en-affil=Department of Oral Immunology and Infectious Diseases, School of Dentistry, University of Louisville
kn-affil=

affil-num=18
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University, Fort Lauderdale, FL 33314, USA
kn-affil=
en-keyword=Porphyromonas gingivalis
kn-keyword=Porphyromonas gingivalis
en-keyword=outer membrane vesicle
kn-keyword=outer membrane vesicle
en-keyword=periodontitis pathogenesis
kn-keyword=periodontitis pathogenesis
en-keyword=macrophage polarization
kn-keyword=macrophage polarization
en-keyword=osteoclastogenesis
kn-keyword=osteoclastogenesis
en-keyword=OC/MΦ unit
kn-keyword=OC/MΦ unit
END

start-ver=1.4
cd-journal=joma
no-vol=75
cd-vols=
no-issue=3-4
article-no=
start-page=656
end-page=588
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260318
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Le contrat social dans la Déclaration des droits de l’homme et du citoyen de 1789
kn-title=1789年フランス人権宣言と社会契約
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=HatanoS.
en-aut-sei=Hatano
en-aut-mei=S.
kn-aut-name=波多野敏
kn-aut-sei=波多野
kn-aut-mei=敏
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学名誉教授
END

start-ver=1.4
cd-journal=joma
no-vol=45
cd-vols=
no-issue=6
article-no=
start-page=657
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202603
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Adolescent screen use in the pre-internet era and subsequent health and well-being: an outcome-wide longitudinal study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This study used data from the National Longitudinal Study of Adolescent to Adult Health (Add Health, N = 11,054) to assess whether increases in screen-based leisure during adolescence (Wave II, from 1996) predicted adult well-being (Wave IV, from 2008-09), adjusting for a wide range of covariates (Wave I, from 1995). Using an outcome-wide analytic approach, we examined associations between screen time and 38 adult outcomes, adjusting for prior screen time, values of most outcomes, and confounders. Most associations were null. Modest evidence was found for links between screen time (continuous) and reduced sense of control, illicit drug use, and allostatic load. High screen time (14 h/week) or more also showed weak associations with lower depression and preventive care use. Because the data predate widespread internet use, the findings help establish a baseline for the long-term effects of non-internet screen activities, which appeared to behave had limited impact on adult health and well-being.
en-copyright=
kn-copyright=

en-aut-name=de la Rosa Fernández-PachecoPedro Antonio
en-aut-sei=de la Rosa Fernández-Pacheco
en-aut-mei=Pedro Antonio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=WilkinsonRenae
en-aut-sei=Wilkinson
en-aut-mei=Renae
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=CowdenRichard G.
en-aut-sei=Cowden
en-aut-mei=Richard G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ChenYing
en-aut-sei=Chen
en-aut-mei=Ying
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=CaseBrendan
en-aut-sei=Case
en-aut-mei=Brendan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SuzukiEtsuji
en-aut-sei=Suzuki
en-aut-mei=Etsuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=VanderWeeleTyler J.
en-aut-sei=VanderWeele
en-aut-mei=Tyler J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Youth in Transition, Institute for Culture and Society, Universidad de Navarra
kn-affil=

affil-num=2
en-affil=Human Flourishing Program, Institute for Quantitative Social Science, Harvard University
kn-affil=

affil-num=3
en-affil=Human Flourishing Program, Institute for Quantitative Social Science, Harvard University
kn-affil=

affil-num=4
en-affil=Human Flourishing Program, Institute for Quantitative Social Science, Harvard University
kn-affil=

affil-num=5
en-affil=Human Flourishing Program, Institute for Quantitative Social Science, Harvard University
kn-affil=

affil-num=6
en-affil=Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=Leisure
kn-keyword=Leisure
en-keyword=Television
kn-keyword=Television
en-keyword=Outcome-wide epidemiology
kn-keyword=Outcome-wide epidemiology
en-keyword=Video games
kn-keyword=Video games
en-keyword=Adolescence
kn-keyword=Adolescence
en-keyword=Well-being
kn-keyword=Well-being
END

start-ver=1.4
cd-journal=joma
no-vol=61
cd-vols=
no-issue=
article-no=
start-page=31
end-page=46
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260316
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Current Status and Challenges in Reproductive Health and Rights in South Australia:Insights from Adelaide
kn-title=南オーストラリア州（アデレード）のリプロダクティブ・ヘルス＆ライツをめぐる現状と課題
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=SAITOKeisuke
en-aut-sei=SAITO
en-aut-mei=Keisuke
kn-aut-name=齋藤圭介
kn-aut-sei=齋藤
kn-aut-mei=圭介
aut-affil-num=1
ORCID=

en-aut-name=SUGANOSetsuko
en-aut-sei=SUGANO
en-aut-mei=Setsuko
kn-aut-name=菅野摂子
kn-aut-sei=菅野
kn-aut-mei=摂子
aut-affil-num=2
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院社会文化科学研究科

affil-num=2
en-affil=
kn-affil=東京科学大学社会連携・DE&I本部
END

start-ver=1.4
cd-journal=joma
no-vol=8
cd-vols=
no-issue=11
article-no=
start-page=e2543107
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251112
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non–Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Importance  Brain metastases reduce overall survival rates of patients with non–small cell lung cancer (NSCLC); patients with epidermal growth factor receptor 2 (ERBB2 [formerly HER2])–mutant NSCLC are more likely to have baseline brain metastases. Trastuzumab deruxtecan (T-DXd) is an approved ERBB2-directed treatment for previously treated unresectable or metastatic ERBB2-mutant NSCLC.<br>
Objective  To assess the clinical effectiveness and safety of T-DXd 5.4 mg/kg and 6.4 mg/kg doses in patients with previously treated ERBB2-mutant metastatic NSCLC with or without untreated or previously treated stable brain metastases.<br>
Design, Setting, and Participants  This post hoc secondary analysis pooled patients from the DESTINY-Lung01 (data cutoff date: December 3, 2021) and DESTINY-Lung02 (data cutoff date: December 23, 2022) clinical trials by T-DXd dose (5.4 mg/kg and 6.4 mg/kg). DESTINY-Lung01 was a multicenter, open-label, 2-cohort, nonrandomized phase 2 study, while DESTINY-Lung02 was a dose-blinded, multicenter, 2-cohort, randomized phase 2 study. Participants had a previously treated ERBB2-mutant metastatic NSCLC with or without untreated or previously treated stable brain metastases at baseline. All statistical analyses were performed from April 2023 to October 2024.<br>
Intervention  Patients received a T-DXd dose of either 5.4 mg/kg or 6.4 mg/kg intravenously every 3 weeks.<br>
Main Outcome and Measure  Systemic and intracranial effectiveness by blinded independent central review using RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1, sites of progression, and safety.<br>
Results  This analysis included 102 patients in the T-DXd 5.4-mg/kg dose group (65 females [64%]; median [range] age, 57.5 [37.0-83.0] years and 59.5 [30.0-79.0] years in patients with and without brain metastases, respectively) and 141 patients in the T-DXd 6.4-mg/kg dose group (94 females [67%]; median [range] age, 62.5 [29.0-88.0] years and 59.0 [27.0-83.0] years in patients with and without brain metastases, respectively). In each group, 31% (32 of 102) and 38% (54 of 141) of patients, respectively, had baseline brain metastases and 53% (17 of 32) and 44% (24 of 54), respectively, received prior brain metastasis treatment. In patients with and without brain metastases, systemic confirmed objective response rates (ORRs) were 47% (15 of 32; 95% CI, 29%-65%) and 50% (35 of 70; 95% CI, 38%-62%), respectively, with the T-DXd 5.4-mg/kg dose, and 50% (27 of 54; 95% CI, 36%-64%) and 59% (51 of 87; 95% CI, 48%-69%) with the T-DXd 6.4-mg/kg dose. Median progression-free survival was 7.1 (95% CI, 5.5-9.7) months in the T-DXd 5.4-mg/kg dose group and 7.1 (95% CI, 4.5-9.6) months in the T-DXd 6.4-mg/kg dose group of patients with baseline brain metastases. Among patients with measurable baseline brain metastases, intracranial confirmed ORRs were 50% (7 of 14; 95% CI, 23%-77%) with the T-DXd 5.4-mg/kg dose and 30% (9 of 30; 95% CI, 15%-49%) with the T-DXd 6.4-mg/kg dose. At both doses, the safety profile of T-DXd was generally manageable, regardless of baseline brain metastases, favoring the T-DXd 5.4 mg/kg dose.<br>
Conclusions and Relevance  In this secondary analysis, T-DXd at the approved dose of 5.4 mg/kg showed antitumor activity in patients with previously treated ERBB2-mutant metastatic NSCLC with or without brain metastases. This finding supports T-DXd 5.4 mg/kg use in this population.
en-copyright=
kn-copyright=

en-aut-name=JännePasi A.
en-aut-sei=Jänne
en-aut-mei=Pasi A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=PlanchardDavid
en-aut-sei=Planchard
en-aut-mei=David
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=GotoKoichi
en-aut-sei=Goto
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SmitEgbert F.
en-aut-sei=Smit
en-aut-mei=Egbert F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=de LangenAdrianus Johannes
en-aut-sei=de Langen
en-aut-mei=Adrianus Johannes
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=GotoYasushi
en-aut-sei=Goto
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NinomiyaKiichiro
en-aut-sei=Ninomiya
en-aut-mei=Kiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KuboToshio
en-aut-sei=Kubo
en-aut-mei=Toshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=PérolMaurice
en-aut-sei=Pérol
en-aut-mei=Maurice
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=FelipEnriqueta
en-aut-sei=Felip
en-aut-mei=Enriqueta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HayashiHidetoshi
en-aut-sei=Hayashi
en-aut-mei=Hidetoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=NakagawaKazuhiko
en-aut-sei=Nakagawa
en-aut-mei=Kazuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=ShimizuJunichi
en-aut-sei=Shimizu
en-aut-mei=Junichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=NagasakaMisako
en-aut-sei=Nagasaka
en-aut-mei=Misako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=PereiraKaline
en-aut-sei=Pereira
en-aut-mei=Kaline
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=TaguchiAyumi
en-aut-sei=Taguchi
en-aut-mei=Ayumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=AliAhmed
en-aut-sei=Ali
en-aut-mei=Ahmed
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=KarnoubMaha
en-aut-sei=Karnoub
en-aut-mei=Maha
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=YonemochiRie
en-aut-sei=Yonemochi
en-aut-mei=Rie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=LeungDavid
en-aut-sei=Leung
en-aut-mei=David
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=LiBob T.
en-aut-sei=Li
en-aut-mei=Bob T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

affil-num=1
en-affil=Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
kn-affil=

affil-num=2
en-affil=Department of Medical Oncology, Thoracic Cancer Group, Gustave Roussy, Medical Oncology
kn-affil=

affil-num=3
en-affil=Department of Thoracic Oncology, Nation Cancer Center Hospital East
kn-affil=

affil-num=4
en-affil=Department of Pulmonary Diseases, Leiden University Medical Center
kn-affil=

affil-num=5
en-affil=Department of Thoracic Oncology, Netherlands Cancer Institute
kn-affil=

affil-num=6
en-affil=Department of Thoracic Oncology, National Cancer Center Hospital
kn-affil=

affil-num=7
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Center for Clinical Oncology, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Medical Oncology, Centre Léon Bérard
kn-affil=

affil-num=10
en-affil=Department of Medical Oncology, Vall d’Hebron University and Vall d’Hebron Institute of Oncology
kn-affil=

affil-num=11
en-affil=Department of Medical Oncology, Kindai University Faculty of Medicine
kn-affil=

affil-num=12
en-affil=Department of Medical Oncology, Kindai University Faculty of Medicine
kn-affil=

affil-num=13
en-affil=Department of Thoracic Oncology, Aichi Cancer Center
kn-affil=

affil-num=14
en-affil=Division of Hematology-Oncology, Department of Medicine, University of California Irvine
kn-affil=

affil-num=15
en-affil=Daiichi Sankyo Inc
kn-affil=

affil-num=16
en-affil=Daiichi Sankyo Co Ltd
kn-affil=

affil-num=17
en-affil=Daiichi Sankyo Europe GmbH
kn-affil=

affil-num=18
en-affil=Daiichi Sankyo Inc
kn-affil=

affil-num=19
en-affil=Daiichi Sankyo Inc
kn-affil=

affil-num=20
en-affil=Daiichi Sankyo Inc
kn-affil=

affil-num=21
en-affil=Thoracic Oncology and Early Drug Development Service, Global Research Program, Memorial Sloan Kettering Cancer Center
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=20
cd-vols=
no-issue=12
article-no=
start-page=1814
end-page=1828
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction: Trastuzumab deruxtecan (T-DXd) demonstrated strong and durable responses in patients with previously treated HER2 (ERBB2) mutant (HER2m) metastatic NSCLC (mNSCLC) in the DESTINY-Lung02 primary analysis (December 23, 2022, data cutoff). This final analysis evaluated T-DXd efficacy and safety after 8 additional months of follow-up, including clinically relevant subgroups and patient-reported outcomes.<br>
Methods: DESTINY-Lung02 was a randomized, dose-blinded, multicenter, phase 2 trial. Patients with previously treated HER2m mNSCLC were randomized 2:1 to receive T-DXd 5.4 or 6.4 mg/kg once every 3 weeks. Primary end point was confirmed objective response rate by blinded independent central review.<br>
Results: As of August 25, 2023, 102 and 50 patients had received T-DXd 5.4 or 6.4 mg/kg, respectively. Median follow-up (Q1–Q3) was 15.8 (8.2–20.7) months and 16.5 (9.4–20.8) months, respectively. Confirmed objective response rate (95% confidence interval) was 50.0% (51/102; 39.9%–60.1%) and 56.0% (28/50; 41.3%–70.0%), respectively. Safety profile was acceptable and generally manageable. Accordingly, median treatment duration (Q1–Q3) was 7.7 (3.7–14.4) months and 8.3 (2.8–13.1) months; drug-related grade 3 or higher treatment-emergent adverse events occurred in 39.6% (40/101) and 60.0% (30/50), with nausea most common (67.3% [68/101], 82.0% [41/50]). Adjudicated drug-related interstitial lung disease occurred in 14.9% (15/101) and 32.0% (16/50), mostly grade 1 or 2 with one grade 5 in each arm. Health-related quality of life was preserved for the duration of T-DXd treatment while sample size was sufficient for analysis, with no adverse effects on health-related quality of life observed at either dose.<br>
Conclusions: T-DXd demonstrated strong and durable responses at both doses, with no clinically significant changes in toxicity. The approved 5.4-mg/kg dose demonstrated a more favorable benefit-risk profile, including lower adjudicated drug-related interstitial lung disease incidence.<br>
ClinicalTrials.gov identifier: NCT04644237
en-copyright=
kn-copyright=

en-aut-name=JännePasi A.
en-aut-sei=Jänne
en-aut-mei=Pasi A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=GotoYasushi
en-aut-sei=Goto
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KuboToshio
en-aut-sei=Kubo
en-aut-mei=Toshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NinomiyaKiichiro
en-aut-sei=Ninomiya
en-aut-mei=Kiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KimSang-We
en-aut-sei=Kim
en-aut-mei=Sang-We
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=PlanchardDavid
en-aut-sei=Planchard
en-aut-mei=David
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=AhnMyung-Ju
en-aut-sei=Ahn
en-aut-mei=Myung-Ju
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SmitEgbert
en-aut-sei=Smit
en-aut-mei=Egbert
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=Johannes de LangenAdrianus
en-aut-sei=Johannes de Langen
en-aut-mei=Adrianus
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=PérolMaurice
en-aut-sei=Pérol
en-aut-mei=Maurice
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=Pons-TostivintElvire
en-aut-sei=Pons-Tostivint
en-aut-mei=Elvire
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=NovelloSilvia
en-aut-sei=Novello
en-aut-mei=Silvia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=HayashiHidetoshi
en-aut-sei=Hayashi
en-aut-mei=Hidetoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=ShimizuJunichi
en-aut-sei=Shimizu
en-aut-mei=Junichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=KimDong-Wan
en-aut-sei=Kim
en-aut-mei=Dong-Wan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=PereiraKaline
en-aut-sei=Pereira
en-aut-mei=Kaline
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=ChengFu-Chih
en-aut-sei=Cheng
en-aut-mei=Fu-Chih
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=TaguchiAyumi
en-aut-sei=Taguchi
en-aut-mei=Ayumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=ChengYingkai
en-aut-sei=Cheng
en-aut-mei=Yingkai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=DuntonKyle
en-aut-sei=Dunton
en-aut-mei=Kyle
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=AliAhmed
en-aut-sei=Ali
en-aut-mei=Ahmed
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=GotoKoichi
en-aut-sei=Goto
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

affil-num=1
en-affil=Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
kn-affil=

affil-num=2
en-affil=Department of Thoracic Oncology, National Cancer Central Hospital
kn-affil=

affil-num=3
en-affil=Center for Clinical Oncology, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Center for Comprehensive Genomic Medicine, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Oncology Department, Asan Medical Center, Seoul, and University of Ulsan College of Medicine, Ulsan
kn-affil=

affil-num=6
en-affil=Department of Medical Oncology, Thoracic Cancer Group, Gustave Roussy, and Faculty of Medicine, Paris-Saclay University
kn-affil=

affil-num=7
en-affil=Department of Hematology and Oncology, Samsung Medical Center Sungkyunkwan, and University School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Pulmonary Diseases, Leiden University Medical Center
kn-affil=

affil-num=9
en-affil=Department of Thoracic Oncology, Netherlands Cancer Institute
kn-affil=

affil-num=10
en-affil=Department of Medical Oncology, Léon Berard Centre
kn-affil=

affil-num=11
en-affil=Centre Hospitalier Universitaire Nantes, Nantes University
kn-affil=

affil-num=12
en-affil=Department of Oncology, University of Turin, Turin, and Azienda Ospedaliero-Universitaria San Luigi Gonzaga
kn-affil=

affil-num=13
en-affil=Department of Medical Oncology, Kindai University Hospital
kn-affil=

affil-num=14
en-affil=Department of Thoracic Oncology, Aichi Cancer Center Hospital
kn-affil=

affil-num=15
en-affil=Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital
kn-affil=

affil-num=16
en-affil=Daiichi Sankyo
kn-affil=

affil-num=17
en-affil=Daiichi Sankyo
kn-affil=

affil-num=18
en-affil=Daiichi Sankyo
kn-affil=

affil-num=19
en-affil=Daiichi Sankyo
kn-affil=

affil-num=20
en-affil=Daiichi Sankyo UK
kn-affil=

affil-num=21
en-affil=Daiichi Sankyo Europe GmbH
kn-affil=

affil-num=22
en-affil=Department of Thoracic Oncology, National Cancer Center Hospital East
kn-affil=
en-keyword=HER2-directed therapy
kn-keyword=HER2-directed therapy
en-keyword=HER2-mutant
kn-keyword=HER2-mutant
en-keyword=HER2-targeted
kn-keyword=HER2-targeted
en-keyword=Non–small cell lung cancer
kn-keyword=Non–small cell lung cancer
en-keyword=Trastuzumab deruxtecan
kn-keyword=Trastuzumab deruxtecan
END

start-ver=1.4
cd-journal=joma
no-vol=2026
cd-vols=
no-issue=2
article-no=
start-page=023F01
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260120
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Feedback-Controlled Beam Pattern Measurement Method Using a Power-Variable Calibration Source for Cosmic Microwave Background Telescopes
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We demonstrate a novel beam pattern measurement method for the side lobe characterization of cosmic microwave background telescopes. The method employs a power-variable artificial microwave source under feedback control from the detector under test on the telescope. It enables us to extend the dynamic range of the beam pattern measurement without introducing nonlinearity effects from the detector. We conducted a laboratory-based proof-of-concept experiment, measuring the H-plane beam pattern of a horn antenna coupled to a diode detector at 81 GHz. We gained an additional dynamic range of 60.3 dB attributed to the feedback control. In addition, we verified the measurement by comparing it with other reference measurements obtained using conventional methods. The method is also applicable to general optical measurements requiring a high dynamic range to detect subtle nonidealities in the characteristics of optical devices.
en-copyright=
kn-copyright=

en-aut-name=HiroseHaruaki
en-aut-sei=Hirose
en-aut-mei=Haruaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HasegawaMasaya
en-aut-sei=Hasegawa
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KanekoDaisuke
en-aut-sei=Kaneko
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NagasakiTaketo
en-aut-sei=Nagasaki
en-aut-mei=Taketo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakakuRyota
en-aut-sei=Takaku
en-aut-mei=Ryota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=de HaanTijmen
en-aut-sei=de Haan
en-aut-mei=Tijmen
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakakuraSatoru
en-aut-sei=Takakura
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=FujinoTakuro
en-aut-sei=Fujino
en-aut-mei=Takuro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Physics, Graduate School of Engineering Science, Yokohama National University
kn-affil=

affil-num=2
en-affil=Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK)
kn-affil=

affil-num=3
en-affil=International Center for Quantum-field Measurement Systems for Studies of the Universe and Particles (WPI-QUP), High Energy Accelerator Research Organization (KEK)
kn-affil=

affil-num=4
en-affil=Accelerator Laboratory (ACCL), High Energy Accelerator Research Organization (KEK)
kn-affil=

affil-num=5
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=6
en-affil=Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK)
kn-affil=

affil-num=7
en-affil=Department of Physics, Faculty of Science, The University of Tokyo
kn-affil=

affil-num=8
en-affil=International Center for Quantum-field Measurement Systems for Studies of the Universe and Particles (WPI-QUP), High Energy Accelerator Research Organization (KEK)
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=18
cd-vols=
no-issue=4
article-no=
start-page=715
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=20260223
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Antigen Remodeling in Colorectal Cancer: How Radiotherapy and Chemotherapy Enhance Immunotherapy Responsiveness
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Colorectal cancer (CRC) is traditionally considered a “cold tumor” characterized by low immunogenicity and limited responsiveness to immune checkpoint inhibitors (ICIs). However, recent findings reveal that cytotoxic modalities can reprogram this immunologically inert landscape. This review integrates these evolving concepts to guide the optimization of future treatments. Radiotherapy induces extensive DNA double-strand breaks, which may generate de novo mutations through error-prone repair while simultaneously exposing cryptic antigens via increased transcriptional instability, alternative splicing, and enhanced proteasomal processing. Chemoradiation also amplifies epigenetic and epitranscriptomic sources of neoepitope diversity, including RNA editing and stress-induced splicing alterations, expanding the immunopeptidome beyond canonical mutation-driven neoantigens. These changes collectively enhance antigen presentation and facilitate T-cell priming. Chemotherapy further reduces immunosuppressive cell populations and promotes dendritic cell activation, creating a permissive milieu for subsequent immune engagement. Clinically, the VOLTAGE studies demonstrated that long-course chemoradiotherapy can sensitize even mismatch repair–proficient rectal cancers to PD-1 blockade, yielding clinically meaningful pathological responses. In contrast, mismatch repair–deficient rectal tumors may respond completely to ICIs alone. Short-course radiotherapy combined with chemotherapy and ICIs has also shown encouraging activity in the setting of total neoadjuvant therapy. Collectively, these findings support a paradigm in which radiotherapy, chemotherapy, and epigenetic/epitranscriptomic alterations—including RNA editing—act as potent modulators of tumor antigenicity. By expanding the neoantigen repertoire and reshaping the tumor microenvironment, these strategies can transform CRC from a cold tumor into one that is increasingly responsive to immunotherapy.
en-copyright=
kn-copyright=

en-aut-name=MatsumiYuki
en-aut-sei=Matsumi
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShigeyasuKunitoshi
en-aut-sei=Shigeyasu
en-aut-mei=Kunitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakahashiToshiaki
en-aut-sei=Takahashi
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MoriwakeKazuya
en-aut-sei=Moriwake
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KayanoMasashi
en-aut-sei=Kayano
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=colorectal cancer
kn-keyword=colorectal cancer
en-keyword=immunotherapy
kn-keyword=immunotherapy
en-keyword=radiotherapy
kn-keyword=radiotherapy
en-keyword=chemotherapy
kn-keyword=chemotherapy
en-keyword=neoantigens
kn-keyword=neoantigens
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=69
end-page=74
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effective Treatment of Advanced Hepatocellular Carcinoma with Extensive Peritoneal Dissemination Using Lenvatinib
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Patients with hepatocellular carcinoma (HCC) and extensive peritoneal dissemination generally have a poor prognosis and are often resistant to systemic therapy. We report the case of a 47-year-old woman with HCC and massive peritoneal dissemination who presented with malignant ascites requiring repeated cell-free and concentrated ascites reinfusion therapy and peritoneovenous shunt placement, as well as malignant pleural effusion requiring pleurodesis. Combined immunotherapy with durvalumab/tremelimumab was initiated;however, disease progression was observed after three treatment courses, prompting a switch to lenvatinib therapy. Two months after initiation of lenvatinib, CT imaging demonstrated complete disappearance of arterial enhancement in the primary hepatic lesion, along with reduction in the size of peritoneal dissemination nodules. Thirteen months after switching to lenvatinib (16 months after the initial diagnosis), the alpha-fetoprotein level continued to decrease, and the disease remained stable under treatment. Despite the extremely high tumor burden, lenvatinib achieved disease stabilization and symptomatic improvement.
en-copyright=
kn-copyright=

en-aut-name=WakatsukiShinya
en-aut-sei=Wakatsuki
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SakamotoShinya
en-aut-sei=Sakamoto
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=UenoAkiko
en-aut-sei=Ueno
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NambaTakaomi
en-aut-sei=Namba
en-aut-mei=Takaomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YamamotoYorito
en-aut-sei=Yamamoto
en-aut-mei=Yorito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MatsumotoManabu
en-aut-sei=Matsumoto
en-aut-mei=Manabu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IwataJun
en-aut-sei=Iwata
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OkabayashiTakehiro
en-aut-sei=Okabayashi
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Obstetrics and Gynecology, Kochi Health Sciences Center
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=3
en-affil=Department of Obstetrics and Gynecology, Kochi Health Sciences Center
kn-affil=

affil-num=4
en-affil=Department of Obstetrics and Gynecology, Kochi Health Sciences Center
kn-affil=

affil-num=5
en-affil=Department of Obstetrics and Gynecology, Kochi Health Sciences Center
kn-affil=

affil-num=6
en-affil=Department of Diagnostic Pathology, Kochi Health Sciences Center
kn-affil=

affil-num=7
en-affil=Department of Diagnostic Pathology, Kochi Health Sciences Center
kn-affil=

affil-num=8
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=
en-keyword=diagnostic laparoscopy
kn-keyword=diagnostic laparoscopy
en-keyword=hepatocellular carcinoma
kn-keyword=hepatocellular carcinoma
en-keyword=peritoneal dissemination
kn-keyword=peritoneal dissemination
en-keyword=lenvatinib
kn-keyword=lenvatinib
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=63
end-page=67
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Metastatic Intraocular Tumor Likely from Hepatocellular Carcinoma Mimicking Panuveitis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A 77-year-old man undergoing treatment for hepatocellular carcinoma (HCC) presented with blurred vision in his right eye, persisting for 2 months. Slit-lamp microscopy and fundus examination revealed inflammatory cells in the anterior chamber, severe vitreous opacities, and retinal vasculitis in the right eye. The patient underwent vitreous surgery with biopsy, and vitreous cytology confirmed a metastatic intraocular tumor originating from the HCC. Radiotherapy was administered to the right eye, with no recurrence of intraocular inflammation observed at 10 months post-irradiation.
en-copyright=
kn-copyright=

en-aut-name=TakasuEri
en-aut-sei=Takasu
en-aut-mei=Eri
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShiodeYusuke
en-aut-sei=Shiode
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KindoHiroya
en-aut-sei=Kindo
en-aut-mei=Hiroya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KimuraShuhei
en-aut-sei=Kimura
en-aut-mei=Shuhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HosokawaMio
en-aut-sei=Hosokawa
en-aut-mei=Mio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MatobaRyo
en-aut-sei=Matoba
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KanzakiYuki
en-aut-sei=Kanzaki
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MoritaTetsuro
en-aut-sei=Morita
en-aut-mei=Tetsuro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=AdachiTakuya
en-aut-sei=Adachi
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OtsukaMotoyuki
en-aut-sei=Otsuka
en-aut-mei=Motoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MorizaneYuki
en-aut-sei=Morizane
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Ophthalmology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=metastatic intraocular tumor
kn-keyword=metastatic intraocular tumor
en-keyword=hepatocellular carcinoma
kn-keyword=hepatocellular carcinoma
en-keyword=panuveitis
kn-keyword=panuveitis
en-keyword=uveitis masquerade syndrome
kn-keyword=uveitis masquerade syndrome
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=47
end-page=54
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Time Course of the Development and Loss of Delta-9-tetrahydrocannabinol Tolerance: Effects on Hypothermia and Spontaneous Locomotor Activity in Mice
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Deregulation of cannabis use is gradually expanding in Europe and the United States. However, the biological processes driving tolerance to delta-9-tetrahydrocannabinol (Δ9-THC), the main psychoactive component of cannabis, remain unclear. Thus, this study aimed to investigate the mechanisms and time course of tolerance development and loss to Δ9-THC in mice. Male ICR mice (7 weeks old) were administered Δ9-THC once daily for 3 days and then divided into three groups according to the washout period (3-, 10-, and 17-day washout groups). After each washout, changes in body temperature and locomotor activity were measured following re-exposure to Δ9-THC. Furthermore, the mRNA expression levels of CB1 and CB2 receptors in the brain were evaluated using real-time PCR. On day 1, significant hypothermia and reduced spontaneous locomotor activity were observed in the Δ9-THC-treated mice compared with the vehicle-treated mice. Tolerance to the hypothermic and locomotor-suppressing effects of Δ9-THC developed on days 2 and 3, respectively, and dissipated after 3 and 11 days of washout, respectively. These differences in the rates of tolerance development and recovery may reflect distinct underlying mechanisms. No significant changes in receptor mRNA expression were observed. These findings highlight the complexity of Δ9-THC tolerance and its potential implications for long-term cannabis use.
en-copyright=
kn-copyright=

en-aut-name=EguchiYukiomi
en-aut-sei=Eguchi
en-aut-mei=Yukiomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=UshioSoichiro
en-aut-sei=Ushio
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IrieKeiichi
en-aut-sei=Irie
en-aut-mei=Keiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamashitaYuta
en-aut-sei=Yamashita
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=EguchiMiyu
en-aut-sei=Eguchi
en-aut-mei=Miyu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakanoTakafumi
en-aut-sei=Nakano
en-aut-mei=Takafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MishimaKenichi
en-aut-sei=Mishima
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=

affil-num=2
en-affil=Department of Emergency and Disaster Medical Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=

affil-num=3
en-affil=Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=

affil-num=4
en-affil=Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=

affil-num=5
en-affil=Department of Emergency and Disaster Medical Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=

affil-num=6
en-affil=Department of Oncology and Infectious Disease Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=

affil-num=7
en-affil=Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University
kn-affil=
en-keyword=delta-9-tetrahydrocannabinol
kn-keyword=delta-9-tetrahydrocannabinol
en-keyword=cannabis
kn-keyword=cannabis
en-keyword=tolerance
kn-keyword=tolerance
en-keyword=locomotor
kn-keyword=locomotor
en-keyword=hypothermic
kn-keyword=hypothermic
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=39
end-page=46
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Kinesiophobia Is Associated with Disability, Poor Quality of Life, Psychological Morbidity, and Surgery Dissatisfaction in Patients with Lumbar Microdiscetomy: A Cross-Sectional Controlled Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The study aimed to determine the prevalence of kinesiophobia in patients who had undergone lumbar microdiscectomy and to examine its associations with pain intensity, disability, quality of life, depression, anxiety, and satisfaction with surgery. Forty-eight patients with microdiscectomy and 48 healthy controls were enrolled. The Tampa Scale for Kinesiophobia (TSK), Roland-Morris Disability Index (RMDI), Hospital Anxiety and Depression Scale (HADS-A and HADS-D, respectively), and Short Form-36 Health Survey (SF-36) were administered to both groups. The scores of TSK, RMDI, HADS-A, and HADS-D were significantly higher and SF-36 scores were significantly lower in the microdiscectomy than the control group (p<0.001 for all). In the microdiscectomy group, median (min-max) RMDI, HADS-A, and HADS-D scores were 19 (4-34), 10 (0-18), and 9 (0-18), respectively, in kinesiophobic patients, and were significantly higher than 6 (2-20), 3 (0-11), 2.5 (0-11) in non-kinesiophobic patients (all p<0.001). The median (min-max) SF-36 PCS, SF-36 MCS, and VAS scores for surgery satisfaction were 36.5 (8.7-75), 52.1 (11-95), 5, 5 (0-10), respectively, in kinesiophobic patients and were significantly lower than 71 (28-95), 85.5 (9-93), 8.5 (3-10) in non-kinesiophobic patients (all p<0.05). TSK scores were significantly correlated with RMDI, HADS-A, HADS-D, SF-36, and surgery satisfaction scores (all p<0.05). Kinesiophobic patients with lumbar microdiscectomy therefore showed greater disability and psychological morbidity, poorer quality of life, and lower satisfaction with surgery.
en-copyright=
kn-copyright=

en-aut-name=TezelNihal
en-aut-sei=Tezel
en-aut-mei=Nihal
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=CanAslı Gençay
en-aut-sei=Can
en-aut-mei=Aslı Gençay
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Department of Physical and Rehabilitation Medicine, Health Sciences University
kn-affil=

affil-num=2
en-affil=Department of Physical and Rehabilitation Medicine, Faculty of Medicine, Ankara Yıldırım Beyazıt University
kn-affil=
en-keyword=kinesiophobia
kn-keyword=kinesiophobia
en-keyword=microdiscectomy
kn-keyword=microdiscectomy
en-keyword=disability
kn-keyword=disability
en-keyword=quality of life
kn-keyword=quality of life
en-keyword=depression
kn-keyword=depression
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=31
end-page=37
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Preoperative Anterior Pelvic Plane Angle Predicts Cup Anteversion Changes at 1 Year after Total Hip Arthroplasty
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We investigated global alignment changes following total hip arthroplasty (THA) and predictive alignment parameters for increased cup anteversion (CA) by retrospectively analyzing the primary THA data of 75 patients treated at our hospital (49 women, 26 men; age 65.1±5.7 years, BMI 28.3±3.4 kg/m2). Global alignment parameters, i.e., the anterior pelvic plane angle (APPa) and proximal femoral shaft angle (PFSa) and other alignment parameters were measured. CA was evaluated based on the patients’ standing coronal radiographs. ΔCA was defined as the difference in CA from 2 weeks before to 1 year after each THA. We classified the cases as stable (S) (CA < 10°; n=63) and pelvic retroversion (R) (CA ≥ 10°; n=12) groups. Associations between ΔCA and alignment parameters were evaluated by linear regression and a receiver operating characteristic (ROC) analysis. A significant decrease in the PFSa occurred between the 2-week and 1-year post-THA timepoints (7.8±4.3° vs. 4.2±3.6°, p<0.001), with no notable change in other alignment parameters. At 1-year post-THA, the CA of 12 (16%) patients had increased to 4.5±4.4°. Only the preoperative APPa was positively associated with ΔCA (β=0.165, p=0.020). The ROC analysis revealed that the optimal cut-off value for increased CA in the APPa is 2.1° (area under the curve, 0.700; p=0.020; odds ratio, 4.80). The APPa change predicted increased CA, which emphasizes the importance of the use of preoperative standing radiography for identifying the optimal cup positioning for post-THA changes in CA.
en-copyright=
kn-copyright=

en-aut-name=IshibashiKyota
en-aut-sei=Ishibashi
en-aut-mei=Kyota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OishiHirotaka
en-aut-sei=Oishi
en-aut-mei=Hirotaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ArakiRyo
en-aut-sei=Araki
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KawamuraKosuke
en-aut-sei=Kawamura
en-aut-mei=Kosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SasakiIsamu
en-aut-sei=Sasaki
en-aut-mei=Isamu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SasakiEiji
en-aut-sei=Sasaki
en-aut-mei=Eiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KamadaHikaru
en-aut-sei=Kamada
en-aut-mei=Hikaru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KogawaMasakazu
en-aut-sei=Kogawa
en-aut-mei=Masakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TanakaSunao
en-aut-sei=Tanaka
en-aut-mei=Sunao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NumasawaTakuya
en-aut-sei=Numasawa
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=IshibashiYasuyuki
en-aut-sei=Ishibashi
en-aut-mei=Yasuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=2
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=3
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=4
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=5
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=6
en-affil=Department of Orthopedic Surgery, Hirosaki University Graduate School of Medicine
kn-affil=

affil-num=7
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=8
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=9
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=10
en-affil=Department of Orthopedic Surgery, Hachinohe City Hospital
kn-affil=

affil-num=11
en-affil=Department of Orthopedic Surgery, Hirosaki University Graduate School of Medicine
kn-affil=
en-keyword=total hip arthroplasty
kn-keyword=total hip arthroplasty
en-keyword=global alignment
kn-keyword=global alignment
en-keyword=anterior pelvic plane
kn-keyword=anterior pelvic plane
en-keyword=cup anteversion
kn-keyword=cup anteversion
en-keyword=pelvic tilt
kn-keyword=pelvic tilt
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=17
end-page=30
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Development of a Stroke Discharge Support Evaluation Scale for Ward Nurses in Acute Care Hospitals
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This study aimed to develop a scale enabling nurses to objectively evaluate their own stroke discharge support, as a basis for enhancing its overall effectiveness. A draft scale was created based on a literature review, and consisted of a 51-item, 5-point Likert-type questionnaire administered to ward nurses engaged in stroke discharge support at acute care hospitals. Factor analysis was performed to refine the scale. Construct validity was assessed using the known-groups method, and reliability was evaluated through internal consistency analysis. The resulting Stroke Discharge Support Evaluation Scale comprises 29 items across 5 factors, each rated on a 5-point Likert scale. Analysis of the data collected from 237 valid responses demonstrated good internal consistency and supported the scale’s construct validity. The Stroke Discharge Support Evaluation Scale is a reliable and valid tool enabling ward nurses in acute care hospitals to evaluate their own stroke discharge support.
en-copyright=
kn-copyright=

en-aut-name=YanoHideki
en-aut-sei=Yano
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakahataYoko
en-aut-sei=Takahata
en-aut-mei=Yoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamaguchiTakeshi
en-aut-sei=Yamaguchi
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SaitoShinya
en-aut-sei=Saito
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Nursing, Faculty of Human Health Sciences, Niimi University
kn-affil=

affil-num=2
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Faculty of Nursing, Shikoku University
kn-affil=

affil-num=4
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=
en-keyword=stroke
kn-keyword=stroke
en-keyword=discharge support
kn-keyword=discharge support
en-keyword=scale development
kn-keyword=scale development
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=9
end-page=16
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Novel Nomogram that Predicts Chronic Hemodialysis Patients’ Survival Based on Their Sedentary Behavior
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Appropriate treatments for chronic hemodialysis patients are a public health challenge in Japan. Sedentary behavior appears to be closely associated with these patients’ survival. We thus sought to develop a nomogram that predicts survival based on the duration of chronic hemodialysis patients’ sedentary behavior. One hundred twenty-four patients under chronic hemodialysis (73 men, 51 women, age 71.7±11.1 years) were enrolled in this cohort study. The patients wore a triaxial accelerometer that measured both their sedentary behavior, i.e., total sedentary behavior (minutes) and their maximum sedentary bouts (min) on non-hemodialysis days. We obtained the Kaplan-Meier curve and used the log-rank test and a Cox proportional hazards model to evaluate the relationship between the patients’ sedentary behavior and their survival. We also used a Cox proportional hazards model to develop a nomogram for the patients’ 5-year survival rate. Forty-six patients died during the follow-up period. When we stratified the patients by the medians of total sedentary behavior and maximum sedentary bouts, we observed significant between-group differences. After adjustment for confounding factors in a Cox proportional hazards model, total sedentary behavior and maximum sedentary bouts were identified as critical survival factors, and we generated a nomogram using an index of sedentary behavior. Our analysis results demonstrated that sedentary behavior on non-dialysis days was closely associated with the survival of the chronic hemodialysis patients, suggesting that a decrease in sedentary behavior would prolong their survival. The nomogram developed herein based on sedentary behavior may be useful for predicting the outcomes of chronic hemodialysis patients.
en-copyright=
kn-copyright=

en-aut-name=SugaharaKentaro
en-aut-sei=Sugahara
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KondoTakashi
en-aut-sei=Kondo
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MiyatakeNobuyuki
en-aut-sei=Miyatake
en-aut-mei=Nobuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NishiHiroyuki
en-aut-sei=Nishi
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=UjikeKazuhiro
en-aut-sei=Ujike
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KoumotoKiichi
en-aut-sei=Koumoto
en-aut-mei=Kiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NamioKeiichi
en-aut-sei=Namio
en-aut-mei=Keiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HishiiShuhei
en-aut-sei=Hishii
en-aut-mei=Shuhei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KatayamaAkihiko
en-aut-sei=Katayama
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=SuzukiHiromi
en-aut-sei=Suzuki
en-aut-mei=Hiromi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=YamamotoYorimasa
en-aut-sei=Yamamoto
en-aut-mei=Yorimasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Hygiene, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=2
en-affil=Innoshima General Hospital
kn-affil=

affil-num=3
en-affil=Department of Hygiene, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=4
en-affil=Innoshima General Hospital
kn-affil=

affil-num=5
en-affil=Innoshima General Hospital
kn-affil=

affil-num=6
en-affil=Innoshima General Hospital
kn-affil=

affil-num=7
en-affil=Department of Hygiene, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=8
en-affil=Department of Hygiene, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=9
en-affil=Faculty of Social Studies, Shikokugakuin University
kn-affil=

affil-num=10
en-affil=Department of Hygiene, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=11
en-affil=Innoshima General Hospital
kn-affil=
en-keyword=nomogram
kn-keyword=nomogram
en-keyword=chronic hemodialysis
kn-keyword=chronic hemodialysis
en-keyword=sedentary behavior
kn-keyword=sedentary behavior
en-keyword=Cox proportional hazards model
kn-keyword=Cox proportional hazards model
en-keyword=Kaplan- Meier curve
kn-keyword=Kaplan- Meier curve
END

start-ver=1.4
cd-journal=joma
no-vol=80
cd-vols=
no-issue=1
article-no=
start-page=1
end-page=7
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=202602
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Usefulness of D-dimer Assay to Confirm the Course of Overt Venous Thromboembolism (VTE) in Cancer Patients
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Venous thromboembolism (VTE) is a serious complication in patients with cancer. In this population, the presence of thrombi is often assessed at cancer diagnosis by measuring D-dimer levels, which have high sensitivity but low specificity for identifying VTE at this clinical time point. However, the usefulness of D-dimer measurement during anticoagulation therapy has not been fully established, despite its widespread use. In this retrospective observational study, we investigated whether D-dimer measurement during anticoagulation therapy in cancer patients could predict overt VTE at follow-up. The study included patients who underwent D-dimer testing and contrast-enhanced computed tomography between 30 and 100 days after initiation of anticoagulation therapy. Eighty-two patients were included: 60 with cancer and 22 without. The diagnostic performance of D-dimer for overt VTE was as follows: sensitivity, 85.7%; specificity, 87.2%; positive predictive value, 78.3%; and negative predictive value, 89.2%. These findings suggest that D-dimer measurement at follow-up has high sensitivity and specificity for overt VTE in cancer patients and may aid in assessing thrombotic status. Clinically, if anticoagulation therapy is continued until D-dimer levels become negative, the absence of overt VTE could be inferred without additional invasive testing.
en-copyright=
kn-copyright=

en-aut-name=YamaokaHidenaru
en-aut-sei=Yamaoka
en-aut-mei=Hidenaru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YoshidaMasashi
en-aut-sei=Yoshida
en-aut-mei=Masashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SarashinaToshihiro
en-aut-sei=Sarashina
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AkagiSatoshi
en-aut-sei=Akagi
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MiyoshiToru
en-aut-sei=Miyoshi
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MunemasaMitsuru
en-aut-sei=Munemasa
en-aut-mei=Mitsuru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NakamuraKazufumi
en-aut-sei=Nakamura
en-aut-mei=Kazufumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=ItoHiroshi
en-aut-sei=Ito
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YuasaShinsuke
en-aut-sei=Yuasa
en-aut-mei=Shinsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Cardiovascular Medicine, IMS Tokyo Katsushika General Hospital
kn-affil=

affil-num=2
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Seisukai Kuroda Clinic
kn-affil=

affil-num=4
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Cardiovascular Medicine, Okayama Rosai Hospital
kn-affil=

affil-num=7
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of General Internal Medicine 3, Kawasaki Medical School General Medical Center
kn-affil=

affil-num=9
en-affil=Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=D-dimer
kn-keyword=D-dimer
en-keyword=venous
kn-keyword=venous
en-keyword=thromboembolism
kn-keyword=thromboembolism
en-keyword=cancer
kn-keyword=cancer
END

start-ver=1.4
cd-journal=joma
no-vol=19
cd-vols=
no-issue=02
article-no=
start-page=113
end-page=125
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2026
dt-pub=2026
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Clinical genetics in comitant strabismus and idiopathic superior oblique muscle palsy
kn-title=斜視の遺伝子研究
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=共同性斜視は遺伝要因と環境要因からなる多因子疾患で、内斜視と外斜視に大別される。遺伝要因は家族歴、一卵性双生児の表現型一致率から推定され、環境要因には妊娠・分娩時の低酸素状態がある。一方、遺伝要因がある非共同性（麻痺性）斜視として上斜筋腱低形成を呈する特発性上斜筋麻痺がある。遺伝統計学の連鎖解析を使って、内斜視と外斜視の小家系群で4番染色体MGST2を疾患感受性遺伝子候補と同定し、MGST2ノックアウトマウスを作成した。小動物用MRIで解析すると、そのホモ接合体では野生型と比べて眼球形状が有意に横長で体積が大きいことを見出した。次いで遺伝統計学別法の全ゲノム関連解析を内斜視、外斜視、特発性上斜筋麻痺を対象として行った。Infinium Asian Screening Array-24 v1.0でSNPを決めた内斜視253検体、外斜視356検体、上斜筋麻痺102検体を疾患群とした。対照集団としては、バイオバンクジャパン (BBJ) の疾患群とは違うアレイ(OmniExpress)でSNPを決めた182,476検体「BBJ (180K)」、疾患群と同じアレイでSNPを決めたBBJの53409検体「BBJ (ASA)」および長浜コホート3570検体を使った。３対照集団との比較で共通して検出された遺伝子は、上斜筋麻痺群で神経細胞移動に関与するDAB1であった。最も大きい対照集団「BBJ (180K)」との比較では内斜視、外斜視、上斜筋麻痺を含む疾患群全体で眼発生に関与するRARB (retinoic acid receptor β) が検出された。斜視関連遺伝子は眼球形態に関与する可能性がある。特発性上斜筋麻痺は共同性斜視とは独立した疾患と理解されるが、共通の遺伝基盤もあるかもしれない。
en-copyright=
kn-copyright=

en-aut-name=MatsuoToshihiko
en-aut-sei=Matsuo
en-aut-mei=Toshihiko
kn-aut-name=松尾俊彦
kn-aut-sei=松尾
kn-aut-mei=俊彦
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=岡山大学学術研究院ヘルスシステム統合科学学域
en-keyword=双生児調査
kn-keyword=双生児調査
en-keyword=斜視頻度
kn-keyword=斜視頻度
en-keyword=家族歴
kn-keyword=家族歴
en-keyword=全ゲノム関連解析
kn-keyword=全ゲノム関連解析
en-keyword=連鎖解析
kn-keyword=連鎖解析
END

start-ver=1.4
cd-journal=joma
no-vol=60
cd-vols=
no-issue=
article-no=
start-page=89
end-page=107
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251210
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Filler Usage of 'De' in Modern Japanese Conversation
kn-title=現代日本語の会話における「で」のフィラー的な使用について
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=LIUYANG
en-aut-sei=LIU
en-aut-mei=YANG
kn-aut-name=劉洋
kn-aut-sei=劉
kn-aut-mei=洋
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院社会文化科学研究科
END

start-ver=1.4
cd-journal=joma
no-vol=38
cd-vols=
no-issue=2
article-no=
start-page=222
end-page=225
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250104
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Ethical Use of Cadaveric Images in Anatomical Textbooks, Atlases, and Journals: A Consensus Response From Authors and Editors
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Nowadays, consent to use donor bodies for medical education and research is obtained from the body donors and their families before the donation. Recently, the International Federation of Associations of Anatomists (IFAA) published guidelines that could restrict the appearance of cadaveric images in commercial anatomical resources such as textbooks and other educational products. These guidelines state that the donor must expressly consent to using such images for this purpose. Cadaveric photos and drawings made from dissections of cadavers have been used in anatomy textbooks and atlases for hundreds of years. They are invaluable for anatomy students and clinical/surgical practitioners. The IFAA guidelines should not restrict the use of those older books; to do so would infringe the rights of those seeking knowledge from these resources. As the images in such textbooks and atlases are anonymized and are used for teaching and research, and the donors and their families are informed about this before the donation, we believe no additional consent is needed. It is impossible to separate educational from “commercial” usage entirely in any situation, e.g., publications from publishers and the use of cadavers in medical schools. Therefore, our best efforts to avoid unethical use of cadaveric images by following traditional consent processes are still needed so that more people will reap the benefits from them. As senior textbook/atlas authors/editors from over 10 countries, we believe that using cadaveric images in anatomy textbooks is appropriate, and no additional consent should be necessary. Such usage falls within the good faith of professionals using these invaluable gifts.
en-copyright=
kn-copyright=

en-aut-name=IwanagaJoe
en-aut-sei=Iwanaga
en-aut-mei=Joe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KimHee‐Jin
en-aut-sei=Kim
en-aut-mei=Hee‐Jin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=AkitaKeiichi
en-aut-sei=Akita
en-aut-mei=Keiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=LoganBari M.
en-aut-sei=Logan
en-aut-mei=Bari M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HutchingsRalph T.
en-aut-sei=Hutchings
en-aut-mei=Ralph T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OttoneNicolás
en-aut-sei=Ottone
en-aut-mei=Nicolás
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NonakaYoichi
en-aut-sei=Nonaka
en-aut-mei=Yoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=AnandMahindra
en-aut-sei=Anand
en-aut-mei=Mahindra
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=BurnsDanny
en-aut-sei=Burns
en-aut-mei=Danny
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=SinghVishram
en-aut-sei=Singh
en-aut-mei=Vishram
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=Peris‐CeldaMaria
en-aut-sei=Peris‐Celda
en-aut-mei=Maria
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=Martinez‐SorianoFrancisco
en-aut-sei=Martinez‐Soriano
en-aut-mei=Francisco
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=ApaydinNihal
en-aut-sei=Apaydin
en-aut-mei=Nihal
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=HannaAmgad
en-aut-sei=Hanna
en-aut-mei=Amgad
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=YoshiokaNobutaka
en-aut-sei=Yoshioka
en-aut-mei=Nobutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=Fernandez‐MirandaJuan
en-aut-sei=Fernandez‐Miranda
en-aut-mei=Juan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=HurMi‐Sun
en-aut-sei=Hur
en-aut-mei=Mi‐Sun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=ShojaMohammadali M.
en-aut-sei=Shoja
en-aut-mei=Mohammadali M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=SaremiFarhood
en-aut-sei=Saremi
en-aut-mei=Farhood
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=ReinaFrancisco
en-aut-sei=Reina
en-aut-mei=Francisco
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=TabiraYoko
en-aut-sei=Tabira
en-aut-mei=Yoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=CarreraAnna
en-aut-sei=Carrera
en-aut-mei=Anna
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=SprattJonathan D.
en-aut-sei=Spratt
en-aut-mei=Jonathan D.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=HoS. Yen
en-aut-sei=Ho
en-aut-mei=S. Yen
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=MoriShumpei
en-aut-sei=Mori
en-aut-mei=Shumpei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=KomuneNoritaka
en-aut-sei=Komune
en-aut-mei=Noritaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=WatanabeKoichi
en-aut-sei=Watanabe
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=Prats‐GalinoAlberto
en-aut-sei=Prats‐Galino
en-aut-mei=Alberto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=De AndrésJose
en-aut-sei=De Andrés
en-aut-mei=Jose
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=ReinaMiguel Angel
en-aut-sei=Reina
en-aut-mei=Miguel Angel
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=AbrahamsPeter H.
en-aut-sei=Abrahams
en-aut-mei=Peter H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=AndersonRobert H.
en-aut-sei=Anderson
en-aut-mei=Robert H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=IbaragiSoichiro
en-aut-sei=Ibaragi
en-aut-mei=Soichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=LoukasMarios
en-aut-sei=Loukas
en-aut-mei=Marios
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=TubbsR. Shane
en-aut-sei=Tubbs
en-aut-mei=R. Shane
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

affil-num=1
en-affil=Department of Neurosurgery, Tulane University School of Medicine
kn-affil=

affil-num=2
en-affil=Division in Anatomy & Development Biology, Department of Oral Biology, Yonsei University College of Dentistry
kn-affil=

affil-num=3
en-affil=Department of Clinical Anatomy, Tokyo Medical and Dental University (TMDU)
kn-affil=

affil-num=4
en-affil=UK
kn-affil=

affil-num=5
en-affil=UK
kn-affil=

affil-num=6
en-affil=Department of Integral Adult Dentistry, Center for Research in Dental Sciences (CICO), Dental School, Universidad de La Frontera
kn-affil=

affil-num=7
en-affil=Department of Neurosurgery, Tokai University School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Anatomy, Rama Medical College & Research Centre
kn-affil=

affil-num=9
en-affil=Department of Anatomical Sciences, School of Medicine, St. George's University
kn-affil=

affil-num=10
en-affil=Department of Anatomy, Kasturba Medical College Mangalore, Manipal Academy of Higher Education
kn-affil=

affil-num=11
en-affil=Department of Neurologic Surgery, Mayo Clinic
kn-affil=

affil-num=12
en-affil=Department of Anatomy, University of Valencia
kn-affil=

affil-num=13
en-affil=Department of Anatomy, Faculty of Medicine, Ankara University
kn-affil=

affil-num=14
en-affil=Department of Neurological Surgery, University of Wisconsin
kn-affil=

affil-num=15
en-affil=Department of Neuroplastic and Reconstructive Surgery Social Medical Corporation Kotobukikai Tominaga Hospital
kn-affil=

affil-num=16
en-affil=Department of Neurosurgery, Stanford University School of Medicine
kn-affil=

affil-num=17
en-affil=Department of Anatomy, Daegu Catholic University School of Medicine
kn-affil=

affil-num=18
en-affil=Department of Medical Education, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University (NSU) 
kn-affil=

affil-num=19
en-affil=Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Ronald Reagan UCLA Medical Center 
kn-affil=

affil-num=20
en-affil=Medical Sciences Department, Faculty of Medicine, Clinical Anatomy, Embryology and Neuroscience Research Group, University of Girona
kn-affil=

affil-num=21
en-affil=Division of Gross and Clinical Anatomy, Department of Anatomy, Kurume University School of Medicine
kn-affil=

affil-num=22
en-affil=Medical Sciences Department, Faculty of Medicine, Clinical Anatomy, Embryology and Neuroscience Research Group, University of Girona
kn-affil=

affil-num=23
en-affil=University Hospital of North Durham
kn-affil=

affil-num=24
en-affil=Cardiac Morphology, Royal Brompton & Harefield Hospitals
kn-affil=

affil-num=25
en-affil=University of California Los Angeles (UCLA) Cardiac Arrhythmia Center, Cardiovascular and Interventional Programs, UCLA Health System, David Geffen School of Medicine at UCLA 
kn-affil=

affil-num=26
en-affil=Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=27
en-affil=Division of Gross and Clinical Anatomy, Department of Anatomy, Kurume University School of Medicine
kn-affil=

affil-num=28
en-affil=Laboratory of Surgical NeuroAnatomy (LSNA), director of the Body Donation and Dissection Rooms Service, Faculty of Medicine and Health of Science, University of Barcelona
kn-affil=

affil-num=29
en-affil=Surgery Specialties Department, University of Valencia
kn-affil=

affil-num=30
en-affil=CEU‐San‐Pablo University School of Medicine
kn-affil=

affil-num=31
en-affil=Warwick Medical School
kn-affil=

affil-num=32
en-affil=Biosciences Institute, Newcastle University
kn-affil=

affil-num=33
en-affil=Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=34
en-affil=Department of Anatomical Sciences, School of Medicine, St. George's University
kn-affil=

affil-num=35
en-affil=Department of Neurosurgery, Tulane University School of Medicine
kn-affil=
en-keyword=anatomy
kn-keyword=anatomy
en-keyword=cadaver
kn-keyword=cadaver
en-keyword=commercial
kn-keyword=commercial
en-keyword=consent
kn-keyword=consent
en-keyword=dissection
kn-keyword=dissection
en-keyword=donors
kn-keyword=donors
en-keyword=medical education
kn-keyword=medical education
en-keyword=medical ethics
kn-keyword=medical ethics
en-keyword=publishing
kn-keyword=publishing
END

start-ver=1.4
cd-journal=joma
no-vol=18
cd-vols=
no-issue=1
article-no=
start-page=cr.25-00065
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=2025
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Successful Surgical Treatment of a Spontaneous Rupture of the Left Iliac Vein: What Is the Optimal and Radical Treatment?
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Spontaneous rupture of the iliac vein (SRIV) requires surgical hemostasis and venous return restoration. We herein report a case treated with initial thrombus removal and direct venous repair. Because of early occlusion, a 2nd surgery was performed for iliac vein reconstruction using a 14-mm ringed Gore-Tex graft (W. L. Gore & Associates, Newark, DE, USA), and a 4-mm Gore-Tex arteriovenous shunt was created between the femoral artery and the femoral vein to prevent reocclusion. The patient had an uneventful recovery without recurrence. A single-stage procedure including hemostasis, vein replacement, and arteriovenous bypass may be ideal for radical SRIV treatment.
en-copyright=
kn-copyright=

en-aut-name=MoriokaKei
en-aut-sei=Morioka
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HirotaMasanori
en-aut-sei=Hirota
en-aut-mei=Masanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KasaharaShingo
en-aut-sei=Kasahara
en-aut-mei=Shingo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Department of Cardiovascular Surgery, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Cardiovascular Surgery, Showa Medical University Fujigaoka Hospital
kn-affil=

affil-num=3
en-affil=Department of Cardiovascular Surgery, Okayama University Hospital
kn-affil=
en-keyword=spontaneous rupture of the iliac vein
kn-keyword=spontaneous rupture of the iliac vein
en-keyword=deep vein thrombosis
kn-keyword=deep vein thrombosis
en-keyword=arteriovenous shunt
kn-keyword=arteriovenous shunt
END

start-ver=1.4
cd-journal=joma
no-vol=11
cd-vols=
no-issue=
article-no=
start-page=100998
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202508
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Robustness of the RGB image-based estimation for rice above-ground biomass by utilizing the dataset collected across multiple locations
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Above-ground biomass (AGB) is a critical phenotype representing crop growth. Non-invasive evaluations of AGB, including deep-learning-based red-green-blue (RGB) image analyses, are often specific to the training data. The robustness of the estimation model across untrained conditions is essential to monitor crop productivity globally, but it has yet to be fully assessed. This study aims to assess the robustness of a convolutional neural network (CNN) model for rice AGB estimation across five locations in three countries, and to demonstrate the feasibility of robust model via a practical approach. From transplanting to heading, 1957 RGB images were captured vertically downward over the rice canopy, covering approximately 1 m2. First, a base model was established using data collected from a single location. Then, its robustness was assessed using test datasets taken from the other four locations. The CNN model showed a significant variation in estimation accuracy across the untrained four locations, indicating insufficient robustness of the base model. Subsequently, we quantitatively tested the impact of improving training data diversity on model robustness by adding data from each of the four locations to the base model's training data. Adding at most 48 data points from a location achieved practical accuracy for the added location, with R2Ad above 0.8. Interestingly, adding data from one location sometimes improved the accuracy for other untrained locations as well. These findings suggest that collecting diverse training data for RGB-based estimation, combined with evaluation of robustness paves the way for on-site and instant AGB monitoring of rice.
en-copyright=
kn-copyright=

en-aut-name=NakajimaKota
en-aut-sei=Nakajima
en-aut-mei=Kota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SaitoKazuki
en-aut-sei=Saito
en-aut-mei=Kazuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TsujimotoYasuhiro
en-aut-sei=Tsujimoto
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TakaiToshiyuki
en-aut-sei=Takai
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MochizukiAtsushi
en-aut-sei=Mochizuki
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YamaguchiTomoaki
en-aut-sei=Yamaguchi
en-aut-mei=Tomoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IbrahimAli
en-aut-sei=Ibrahim
en-aut-mei=Ali
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MairouaSalifou Goube
en-aut-sei=Mairoua
en-aut-mei=Salifou Goube
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=AndrianaryBruce Haja
en-aut-sei=Andrianary
en-aut-mei=Bruce Haja
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KatsuraKeisuke
en-aut-sei=Katsura
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=TanakaYu
en-aut-sei=Tanaka
en-aut-mei=Yu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Graduate School of Agriculture, Kyoto University
kn-affil=

affil-num=2
en-affil=International Rice Research Institute (IRRI)
kn-affil=

affil-num=3
en-affil=Japan International Research Center for Agricultural Sciences
kn-affil=

affil-num=4
en-affil=Japan International Research Center for Agricultural Sciences
kn-affil=

affil-num=5
en-affil=CHIBA Prefectural Agriculture and Forestry Research Center
kn-affil=

affil-num=6
en-affil=Faculty of Applied Biological Sciences, Gifu University
kn-affil=

affil-num=7
en-affil= Africa Rice Center (AfricaRice), Regional Station for the Sahel
kn-affil=

affil-num=8
en-affil=Africa Rice Center (AfricaRice)
kn-affil=

affil-num=9
en-affil=Laboratoire des Radioisotopes, Université d′Antananarivo
kn-affil=

affil-num=10
en-affil=Graduate School of Agriculture, Kyoto University
kn-affil=

affil-num=11
en-affil=Graduate School of Environment, Life, Natural Science and Technology, Okayama University
kn-affil=
en-keyword=Robustness
kn-keyword=Robustness
en-keyword=RGB image
kn-keyword=RGB image
en-keyword=Rice, Above-ground biomass
kn-keyword=Rice, Above-ground biomass
en-keyword=Convolutional neural network
kn-keyword=Convolutional neural network
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=6
article-no=
start-page=469
end-page=474
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Ileus Tube-Related Intussusception: A Case Report and Review of 80 Previously Reported Cases
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We report a rare case of ileus tube-related intussusception in an adult. A 56-year-old man with adhesive bowel obstruction was treated with a nasointestinal ileus tube. Although his condition initially improved, persistent abdominal pain led to the diagnosis of intussusception via CT imaging. Manual repositioning of the tube resolved the intussusception without the need for bowel resection. A review of 80 previously reported cases of ileus tube-associated intussusception (total 81 cases, 95 lesions) highlighted the timing of onset, treatment strategies, and precautions. Early detection and diagnosis are crucial to prevent severe complications and preserve bowel function.
en-copyright=
kn-copyright=

en-aut-name=TsujiiTeruyuki
en-aut-sei=Tsujii
en-aut-mei=Teruyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatsudaTatsuo
en-aut-sei=Matsuda
en-aut-mei=Tatsuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KimuraYuji
en-aut-sei=Kimura
en-aut-mei=Yuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KatsubeRyoichi
en-aut-sei=Katsube
en-aut-mei=Ryoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IwadouHironori
en-aut-sei=Iwadou
en-aut-mei=Hironori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FunabikiSadami
en-aut-sei=Funabiki
en-aut-mei=Sadami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KamikawaYasuaki
en-aut-sei=Kamikawa
en-aut-mei=Yasuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MatsudaTadakazu
en-aut-sei=Matsuda
en-aut-mei=Tadakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Surgery, Matsuda Hospital
kn-affil=

affil-num=2
en-affil=Department of Surgery, Matsuda Hospital
kn-affil=

affil-num=3
en-affil=Department of Surgery, Matsuda Hospital
kn-affil=

affil-num=4
en-affil=Department of Surgery, Matsuda Hospital
kn-affil=

affil-num=5
en-affil=Department of Surgery, Matsuda Hospital
kn-affil=

affil-num=6
en-affil=Department of Surgery, Matsuda Hospital
kn-affil=

affil-num=7
en-affil=Department of Surgery, Matsuda Hospital
kn-affil=

affil-num=8
en-affil=Department of Surgery, Matsuda Hospital
kn-affil=
en-keyword=nasointestinal ileus tube
kn-keyword=nasointestinal ileus tube
en-keyword=intussusception
kn-keyword=intussusception
en-keyword=small bowel obstruction
kn-keyword=small bowel obstruction
en-keyword=enterectomy
kn-keyword=enterectomy
en-keyword=conservative treatment
kn-keyword=conservative treatment
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=6
article-no=
start-page=437
end-page=444
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Frailty at 1 Month before ICU Admission Poses a Hospital Mortality Risk in Cancer Survivors whose Condition Has Deteriorated due to Medical Factors
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The optimal indications for intensive care unit (ICU) treatment for critically ill cancer survivors whose condition has deteriorated due to medical factors are unclear. To test our hypothesis that frailty before deterioration was associated with hospital mortality in this patient population, we retrospective analyzed the cases of the patients admitted to the ICU at the National Cancer Center Hospital, Japan (April 2014-March 2022). We excluded patients who underwent surgery within 28 days or were denied critical care within 24 h or admitted after cardiopulmonary arrest. Their Clinical Frailty Scale (CFS) scores at 1 month before ICU admission (Pre-ICU) were obtained. Frailty was defined as CFS scores ≥4 points. We analyzed 298 admissions and observed that the mortality rate at hospital discharge was significantly higher in the frailty group (n=119). A multivariate analysis demonstrated that the following factors were significantly associated with hospital mortality: Pre-ICU frailty (OR 2.00, 95%CI: 1.19-3.36, p=0.009), cancer type (hematological: OR 2.93, 95%CI: 1.42-6.05, p=0.004), and Sequential Organ Failure Assessment score at ICU admission (OR 0.88, 95%CI: 0.82-0.95, p=0.0008). Frailty retrospectively assessed using the CFS at 1 month pre-ICU admission is a risk factor for hospital mortality in these cancer survivors.
en-copyright=
kn-copyright=

en-aut-name=MatsumiJunya
en-aut-sei=Matsumi
en-aut-mei=Junya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SatoTetsufumi
en-aut-sei=Sato
en-aut-mei=Tetsufumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Department of Anesthesiology and Intensive Care Medicine, National Cancer Center Hospital
kn-affil=

affil-num=2
en-affil=Department of Anesthesiology and Intensive Care Medicine, National Cancer Center Hospital
kn-affil=
en-keyword=frailty
kn-keyword=frailty
en-keyword=cancer survivor
kn-keyword=cancer survivor
en-keyword=clinical frailty scale
kn-keyword=clinical frailty scale
en-keyword=cancer
kn-keyword=cancer
en-keyword=critically ill
kn-keyword=critically ill
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=6
article-no=
start-page=413
end-page=419
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=COVID-19 and the Risks of Migraine and Headache: A Mendelian Randomization Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Several observational studies suggested that migraine headache attacks were associated with coronavirus disease 2019 (COVID-19). We investigated genetic causal links between COVID-19 phenotypes and the development of headache and migraine, including migraine with aura (MA) and migraine without aura (MO). We conducted a two-sample Mendelian randomization (MR) analysis to estimate the genetic association in European populations. The inverse-variance weighted (IVW) method was used as the main approach in the MR analyses, together with weighted median and MR-Egger methods. We also performed a series of sensitivity tests to assess the robustness of the MR results. The MR results demonstrated that COVID-19 severity, hospitalization, and susceptibility had no causal effect on the risks of headache, migraine, MA, or MO. No horizontal pleiotropy was detected, and the results were robust as supported by the sensitivity analysis findings. Our analyses identified no casual effect of COVID-19 severity, hospitalization, or susceptibility on the risks of headache or migraine in European populations.
en-copyright=
kn-copyright=

en-aut-name=JiangZhiyun
en-aut-sei=Jiang
en-aut-mei=Zhiyun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=XiYing
en-aut-sei=Xi
en-aut-mei=Ying
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University
kn-affil=

affil-num=2
en-affil=Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University
kn-affil=
en-keyword=headache
kn-keyword=headache
en-keyword=migraine
kn-keyword=migraine
en-keyword=Mendelian randomization
kn-keyword=Mendelian randomization
en-keyword=COVID-19
kn-keyword=COVID-19
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=JCO-24-02835
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202512
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Purpose For patients with advanced non–small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor (EGFR) mutations (eg, S768I, L861Q, G719X), efficacy of current treatment options is limited.<br>
Patients and Methods CHRYSALIS-2 Cohort C enrolled participants with NSCLC harboring atypical EGFR mutations (G719X, S768I, L861Q, etc) and ≤2 previous lines of therapy. Participants were treatment-naïve or previously received first- or second-generation EGFR tyrosine kinase inhibitors. Coexisting exon 20 insertions, exon 19 deletions, or exon 21 L858R mutations were exclusionary. Participants received 1,050 mg (1,400 mg if ≥80 kg) intravenous amivantamab once weekly for the first 4 weeks and then once every 2 weeks plus 240 mg oral lazertinib once daily. The primary end point was investigator-assessed objective response rate (ORR).<br>
Results As of January 12, 2024, 105 participants received amivantamab-lazertinib. Most common atypical mutations were G719X (56%), L861X (26%), and S768I (23%), including single and compound mutations. In the overall population (median follow-up: 16.1 months), the ORR was 52% (95% CI, 42 to 62). The median duration of response (mDoR) was 14.1 months (95% CI, 9.5 to 26.2). The median progression-free survival (mPFS) was 11.1 months (95% CI, 7.8 to 17.8); median overall survival (mOS) was not estimable (NE; 95% CI, 22.8 to NE). Adverse events were consistent with previous studies and primarily grade 1 and 2. Among treatment-naïve participants, the ORR was 57% (95% CI, 42 to 71). The mPFS was 19.5 months (95% CI, 11.2 to NE), the mDoR was 20.7 months (95% CI, 9.9 to NE), and mOS was NE (95% CI, 26.3 to NE). Solitary or compound EGFR mutations had no major impact on ORR. The ORR in participants with P-loop and αC-helix compressing, classical-like, and T790M-like mutations was 45% (n = 38), 64% (n = 14), and 67% (n = 3), respectively.<br>
Conclusion In participants with atypical EGFR-mutated advanced NSCLC, amivantamab-lazertinib demonstrated clinically meaningful antitumor activity with no new safety signals.
en-copyright=
kn-copyright=

en-aut-name=TomasiniPascale
en-aut-sei=Tomasini
en-aut-mei=Pascale
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=WangYongsheng
en-aut-sei=Wang
en-aut-mei=Yongsheng
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=LiYongsheng
en-aut-sei=Li
en-aut-mei=Yongsheng
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FelipEnriqueta
en-aut-sei=Felip
en-aut-mei=Enriqueta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=WuLin
en-aut-sei=Wu
en-aut-mei=Lin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=CuiJiuwei
en-aut-sei=Cui
en-aut-mei=Jiuwei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=BesseBenjamin
en-aut-sei=Besse
en-aut-mei=Benjamin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SpiraAlexander I.
en-aut-sei=Spira
en-aut-mei=Alexander I.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NealJoel W.
en-aut-sei=Neal
en-aut-mei=Joel W.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=GotoKoichi
en-aut-sei=Goto
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=BaikChristina S.
en-aut-sei=Baik
en-aut-mei=Christina S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MarmarelisMelina E.
en-aut-sei=Marmarelis
en-aut-mei=Melina E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=IchiharaEiki
en-aut-sei=Ichihara
en-aut-mei=Eiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=ZhangYiping
en-aut-sei=Zhang
en-aut-mei=Yiping
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=LeeJong-Seok
en-aut-sei=Lee
en-aut-mei=Jong-Seok
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=LeeSe-Hoon
en-aut-sei=Lee
en-aut-mei=Se-Hoon
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=YangJames Chih-Hsin
en-aut-sei=Yang
en-aut-mei=James Chih-Hsin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=MichelsSebastian
en-aut-sei=Michels
en-aut-mei=Sebastian
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=AnastasiouZacharias
en-aut-sei=Anastasiou
en-aut-mei=Zacharias
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=CurtinJoshua C.
en-aut-sei=Curtin
en-aut-mei=Joshua C.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=LyuXuesong
en-aut-sei=Lyu
en-aut-mei=Xuesong
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=MahoneyJanine
en-aut-sei=Mahoney
en-aut-mei=Janine
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=DemirdjianLevon
en-aut-sei=Demirdjian
en-aut-mei=Levon
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=MeyerCraig S.
en-aut-sei=Meyer
en-aut-mei=Craig S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=ZhangYouyi
en-aut-sei=Zhang
en-aut-mei=Youyi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=LeconteIsabelle
en-aut-sei=Leconte
en-aut-mei=Isabelle
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=LorenziniPatricia
en-aut-sei=Lorenzini
en-aut-mei=Patricia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=KnoblauchRoland E.
en-aut-sei=Knoblauch
en-aut-mei=Roland E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=TraniLeonardo
en-aut-sei=Trani
en-aut-mei=Leonardo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=BaigMahadi
en-aut-sei=Baig
en-aut-mei=Mahadi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=BaumlJoshua M.
en-aut-sei=Bauml
en-aut-mei=Joshua M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=ChoByoung Chul
en-aut-sei=Cho
en-aut-mei=Byoung Chul
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

affil-num=1
en-affil=Aix Marseille University - CNRS, INSERM, CRCM; CEPCM - AP-HM Hôpital de La Timone
kn-affil=

affil-num=2
en-affil=Division of Thoracic Tumor Multimodality Treatment, Cancer Center and Clinical Trial Center, West China Hospital, Sichuan University
kn-affil=

affil-num=3
en-affil=Chongqing University Cancer Hospital
kn-affil=

affil-num=4
en-affil=Medical Oncology Service, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona
kn-affil=

affil-num=5
en-affil=Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
kn-affil=

affil-num=6
en-affil=The First Hospital of Jilin University
kn-affil=

affil-num=7
en-affil=Paris-Saclay University, Institut Gustave Roussy
kn-affil=

affil-num=8
en-affil=Virginia Cancer Specialists
kn-affil=

affil-num=9
en-affil=Stanford Cancer Institute, Stanford University
kn-affil=

affil-num=10
en-affil=National Cancer Center Hospital East
kn-affil=

affil-num=11
en-affil=University of Washington Fred Hutchinson Cancer Research Center
kn-affil=

affil-num=12
en-affil=Perelman School of Medicine, University of Pennsylvania
kn-affil=

affil-num=13
en-affil=Center for Clinical Oncology, Okayama University Hospital
kn-affil=

affil-num=14
en-affil=Zhejiang Cancer Hospital
kn-affil=

affil-num=15
en-affil=Seoul National University College of Medicine and Seoul National University Hospital
kn-affil=

affil-num=16
en-affil=Samsung Medical Center, Sungkyunkwan University School of Medicine
kn-affil=

affil-num=17
en-affil=National Taiwan University Cancer Center
kn-affil=

affil-num=18
en-affil=Department I for Internal Medicine, Faculty of Medicine and University Hospital Cologne, Lung Cancer Group Cologne, Center for Integrated Oncology Aachen Köln Bonn Düsseldorf, University of Cologne
kn-affil=

affil-num=19
en-affil=Johnson & Johnson
kn-affil=

affil-num=20
en-affil=Johnson & Johnson
kn-affil=

affil-num=21
en-affil=Johnson & Johnson
kn-affil=

affil-num=22
en-affil=Johnson & Johnson
kn-affil=

affil-num=23
en-affil=Johnson & Johnson
kn-affil=

affil-num=24
en-affil=Johnson & Johnson
kn-affil=

affil-num=25
en-affil=Johnson & Johnson
kn-affil=

affil-num=26
en-affil=Johnson & Johnson
kn-affil=

affil-num=27
en-affil=Johnson & Johnson
kn-affil=

affil-num=28
en-affil=Johnson & Johnson
kn-affil=

affil-num=29
en-affil=Johnson & Johnson
kn-affil=

affil-num=30
en-affil=Johnson & Johnson
kn-affil=

affil-num=31
en-affil=Johnson & Johnson
kn-affil=

affil-num=32
en-affil=Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=20
cd-vols=
no-issue=5
article-no=
start-page=651
end-page=664
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202505
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction: Treatment options for patients with EGFR-mutated NSCLC with disease progression on or after osimertinib and platinum-based chemotherapy are limited.<br>
Methods: CHRYSALIS-2 cohort A evaluated amivantamab plus lazertinib in patients with EGFR exon 19 deletion- or L858R-mutated NSCLC with disease progression on or after osimertinib and platinum-based chemotherapy. Primary end point was investigator-assessed objective response rate (ORR). The patients received 1050 mg of intravenous amivantamab (1400 mg if ≥ 80 kg) plus 240 mg of oral lazertinib.<br>
Results: In cohort A (N = 162), the investigator-assessed ORR was 28% (95% confidence interval [CI]: 22–36). The blinded independent central review–assessed ORR was 35% (95% CI: 27–42), with a median duration of response of 8.3 months (95% CI: 6.7–10.9) and a clinical benefit rate of 58% (95% CI: 50–66). At a median follow-up of 12 months, 32 of 56 responders (57%) achieved a duration of response of more than or equal to 6 months. Median progression-free survival by blinded independent central review was 4.5 months (95% CI: 4.1–5.8); median overall survival was 14.8 months (95% CI: 12.2–18.0). Preliminary evidence of central nervous system antitumor activity was reported in seven patients with baseline brain lesions and no previous brain radiation or surgery. Exploratory biomarker analyses using next-generation sequencing of circulating tumor DNA revealed responses in patients with and without EGFR- or MET-dependent resistance. The most frequent adverse events were rash (grouped term; 81%), infusion-related reaction (68%), and paronychia (52%). The most common grade greater than or equal to 3 treatment-related adverse events were rash (grouped term; 10%), infusion-related reaction (9%), and hypoalbuminemia (6%).<br>
Conclusions: For patients with limited treatment options, amivantamab plus lazertinib demonstrated an antitumor activity with a safety profile characterized by EGFR- or MET-related adverse events, which were generally manageable.
en-copyright=
kn-copyright=

en-aut-name=BesseBenjamin
en-aut-sei=Besse
en-aut-mei=Benjamin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=GotoKoichi
en-aut-sei=Goto
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=WangYongsheng
en-aut-sei=Wang
en-aut-mei=Yongsheng
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=LeeSe-Hoon
en-aut-sei=Lee
en-aut-mei=Se-Hoon
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MarmarelisMelina E.
en-aut-sei=Marmarelis
en-aut-mei=Melina E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OheYuichiro
en-aut-sei=Ohe
en-aut-mei=Yuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=Bernabe CaroReyes
en-aut-sei=Bernabe Caro
en-aut-mei=Reyes
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KimDong-Wan
en-aut-sei=Kim
en-aut-mei=Dong-Wan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=LeeJong-Seok
en-aut-sei=Lee
en-aut-mei=Jong-Seok
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=CousinSophie
en-aut-sei=Cousin
en-aut-mei=Sophie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=IchiharaEiki
en-aut-sei=Ichihara
en-aut-mei=Eiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=LiYongsheng
en-aut-sei=Li
en-aut-mei=Yongsheng
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=Paz-AresLuis
en-aut-sei=Paz-Ares
en-aut-mei=Luis
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=OnoAkira
en-aut-sei=Ono
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=SanbornRachel E.
en-aut-sei=Sanborn
en-aut-mei=Rachel E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=WatanabeNaohiro
en-aut-sei=Watanabe
en-aut-mei=Naohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=de MiguelMaria Jose
en-aut-sei=de Miguel
en-aut-mei=Maria Jose
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=HelisseyCarole
en-aut-sei=Helissey
en-aut-mei=Carole
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=ShuCatherine A.
en-aut-sei=Shu
en-aut-mei=Catherine A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=SpiraAlexander I.
en-aut-sei=Spira
en-aut-mei=Alexander I.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=TomasiniPascale
en-aut-sei=Tomasini
en-aut-mei=Pascale
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=YangJames Chih-Hsin
en-aut-sei=Yang
en-aut-mei=James Chih-Hsin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=ZhangYiping
en-aut-sei=Zhang
en-aut-mei=Yiping
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=FelipEnriqueta
en-aut-sei=Felip
en-aut-mei=Enriqueta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=GriesingerFrank
en-aut-sei=Griesinger
en-aut-mei=Frank
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=WaqarSaiama N.
en-aut-sei=Waqar
en-aut-mei=Saiama N.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=CallesAntonio
en-aut-sei=Calles
en-aut-mei=Antonio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=NealJoel W.
en-aut-sei=Neal
en-aut-mei=Joel W.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=BaikChristina S.
en-aut-sei=Baik
en-aut-mei=Christina S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=JännePasi A.
en-aut-sei=Jänne
en-aut-mei=Pasi A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=ShreeveS. Martin
en-aut-sei=Shreeve
en-aut-mei=S. Martin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=CurtinJoshua C.
en-aut-sei=Curtin
en-aut-mei=Joshua C.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=PatelBharvin
en-aut-sei=Patel
en-aut-mei=Bharvin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=GormleyMichael
en-aut-sei=Gormley
en-aut-mei=Michael
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=LyuXuesong
en-aut-sei=Lyu
en-aut-mei=Xuesong
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

en-aut-name=ChenJun
en-aut-sei=Chen
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=36
ORCID=

en-aut-name=ChuPei-Ling
en-aut-sei=Chu
en-aut-mei=Pei-Ling
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=37
ORCID=

en-aut-name=MahoneyJanine
en-aut-sei=Mahoney
en-aut-mei=Janine
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=38
ORCID=

en-aut-name=TraniLeonardo
en-aut-sei=Trani
en-aut-mei=Leonardo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=39
ORCID=

en-aut-name=BaumlJoshua M.
en-aut-sei=Bauml
en-aut-mei=Joshua M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=40
ORCID=

en-aut-name=ThayuMeena
en-aut-sei=Thayu
en-aut-mei=Meena
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=41
ORCID=

en-aut-name=KnoblauchRoland E.
en-aut-sei=Knoblauch
en-aut-mei=Roland E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=42
ORCID=

en-aut-name=ChoByoung Chul
en-aut-sei=Cho
en-aut-mei=Byoung Chul
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=43
ORCID=

affil-num=1
en-affil=Paris-Saclay University, Institut Gustave Roussy
kn-affil=

affil-num=2
en-affil=National Cancer Center Hospital East
kn-affil=

affil-num=3
en-affil=Institute of Clinical Trial Center and Cancer Center, West China Hospital, Sichuan University
kn-affil=

affil-num=4
en-affil=Samsung Medical Center, Sungkyunkwan University School of Medicine
kn-affil=

affil-num=5
en-affil=University of Pennsylvania, Perelman School of Medicine
kn-affil=

affil-num=6
en-affil=National Cancer Center Hospital
kn-affil=

affil-num=7
en-affil=Hospital Universitario Virgen Del Rocio
kn-affil=

affil-num=8
en-affil=Seoul National University College of Medicine and Seoul National University Hospital
kn-affil=

affil-num=9
en-affil=Seoul National University College of Medicine and Seoul National University Hospital
kn-affil=

affil-num=10
en-affil=Institut Bergonié
kn-affil=

affil-num=11
en-affil=Center for Clinical Oncology, Okayama University Hospital
kn-affil=

affil-num=12
en-affil=Chongqing University Cancer Hospital
kn-affil=

affil-num=13
en-affil=Hospital Universitario 12 de Octubre
kn-affil=

affil-num=14
en-affil=Shizuoka Cancer Center
kn-affil=

affil-num=15
en-affil=Earle A. Chiles Research Institute, Providence Cancer Institute
kn-affil=

affil-num=16
en-affil=Department of Thoracic Oncology, Aichi Cancer Center Hospital
kn-affil=

affil-num=17
en-affil=START Madrid-CIOCC, Hospital HM Sanchinarro
kn-affil=

affil-num=18
en-affil=Clinical Research unit, Military Hospital Begin
kn-affil=

affil-num=19
en-affil=Columbia University Medical Center
kn-affil=

affil-num=20
en-affil=Virginia Cancer Specialists
kn-affil=

affil-num=21
en-affil=Aix Marseille University - CNRS, INSERM, CRCM; CEPCM - AP-HM Hopital de La Timone
kn-affil=

affil-num=22
en-affil=National Taiwan University Cancer Center
kn-affil=

affil-num=23
en-affil=Zhejiang Cancer Hospital
kn-affil=

affil-num=24
en-affil=Medical Oncology Service, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital Campus, Universitat Autonoma de Barcelona
kn-affil=

affil-num=25
en-affil=Pius-Hospital, University Medicine of Oldenburg
kn-affil=

affil-num=26
en-affil=Division of Oncology, Washington University School of Medicine
kn-affil=

affil-num=27
en-affil=Hospital General Universitario Gregorio Marañón
kn-affil=

affil-num=28
en-affil=Stanford University Medical Center
kn-affil=

affil-num=29
en-affil=University of Washington, Fred Hutchinson Cancer Center
kn-affil=

affil-num=30
en-affil=Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute
kn-affil=

affil-num=31
en-affil=Johnson & Johnson
kn-affil=

affil-num=32
en-affil=Johnson & Johnson
kn-affil=

affil-num=33
en-affil=Johnson & Johnson
kn-affil=

affil-num=34
en-affil=Johnson & Johnson
kn-affil=

affil-num=35
en-affil=Johnson & Johnson
kn-affil=

affil-num=36
en-affil=Johnson & Johnson
kn-affil=

affil-num=37
en-affil=Johnson & Johnson
kn-affil=

affil-num=38
en-affil=Johnson & Johnson
kn-affil=

affil-num=39
en-affil=Johnson & Johnson
kn-affil=

affil-num=40
en-affil=Johnson & Johnson
kn-affil=

affil-num=41
en-affil=Johnson & Johnson
kn-affil=

affil-num=42
en-affil=Johnson & Johnson
kn-affil=

affil-num=43
en-affil=Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
kn-affil=
en-keyword=Amivantamab
kn-keyword=Amivantamab
en-keyword=Biomarker analyses
kn-keyword=Biomarker analyses
en-keyword=Lazertinib
kn-keyword=Lazertinib
en-keyword=NSCLC
kn-keyword=NSCLC
END

start-ver=1.4
cd-journal=joma
no-vol=26
cd-vols=
no-issue=11
article-no=
start-page=e13960
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250603
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Missing the Target: A Scoping Review of the Use of Percent Weight Loss for Obesity Management
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Introduction: To co-create comprehensive targets for obesity management, we need to understand the genesis and current use of percent weight loss targets in research. The goals of our scoping review are to (1) synthesize the literature on percent weight loss targets for adults with obesity and (2) discuss the percent weight loss targets in context with their health benefits.<br>
Methods: We searched Cochrane, MEDLINE, and EMBASE for English language, pharmaceutical, and/or behavioral intervention studies in adults with obesity where the explicit aim of the study was weight reduction defined as a percent of body weight. Reviewers screened citations and extracted data including study characteristics.<br>
Results: From 16,164 abstracts, we included 30 citations which were mostly randomized controlled trials (RCTs) (n = 17) or quasi-experimental studies (n = 12) published between 1992 and 2024. Most of the studies had target weight loss goals between 3% and 10% of body weight (n = 28), while n = 2 had body weight loss goals of 15% or 30%. The proportion of participants who met the percent weight loss target ranged from 5.9% (nutrition only study) to 85% (pharmaceutical study). The studies reported different reasons for targeting a percentage of weight loss such as disease-specific outcomes, reduced risk of disease, or patient-reported outcomes.<br>
Conclusion: Percent weight loss targets were based on similar research and were often not feasible nor sustainable for most participants. The design of these interventions and evaluation of obesity management would benefit from more patient-focused parameters which could help to co-design comprehensive targets for research and practice.
en-copyright=
kn-copyright=

en-aut-name=SherifaliDiana
en-aut-sei=Sherifali
en-aut-mei=Diana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=RaceyMegan
en-aut-sei=Racey
en-aut-mei=Megan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=Fitzpatrick‐LewisDonna
en-aut-sei=Fitzpatrick‐Lewis
en-aut-mei=Donna
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=GreenwayMichelle
en-aut-sei=Greenway
en-aut-mei=Michelle
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SockalingamSanjeev
en-aut-sei=Sockalingam
en-aut-mei=Sanjeev
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TeohSoo Huat
en-aut-sei=Teoh
en-aut-mei=Soo Huat
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=PattonIan
en-aut-sei=Patton
en-aut-mei=Ian
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MacklinDavid
en-aut-sei=Macklin
en-aut-mei=David
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=van RossumElizabeth F. C.
en-aut-sei=van Rossum
en-aut-mei=Elizabeth F. C.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=BusettoLuca
en-aut-sei=Busetto
en-aut-mei=Luca
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HornDeborah Bade
en-aut-sei=Horn
en-aut-mei=Deborah Bade
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=Patricia NeceJ. D.
en-aut-sei=Patricia Nece
en-aut-mei=J. D.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=LeguedeMorgan Emile Gabriel Salmon
en-aut-sei=Leguede
en-aut-mei=Morgan Emile Gabriel Salmon
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=PearceNicole
en-aut-sei=Pearce
en-aut-mei=Nicole
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=Le RouxCarel
en-aut-sei=Le Roux
en-aut-mei=Carel
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=ArdJamy
en-aut-sei=Ard
en-aut-mei=Jamy
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=AlbergaAngela S.
en-aut-sei=Alberga
en-aut-mei=Angela S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=KaplanLee
en-aut-sei=Kaplan
en-aut-mei=Lee
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=SharmaArya M.
en-aut-sei=Sharma
en-aut-mei=Arya M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=WhartonSean
en-aut-sei=Wharton
en-aut-mei=Sean
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

affil-num=1
en-affil=McMaster Evidence Review and Synthesis Team; School of Nursing, McMaster University
kn-affil=

affil-num=2
en-affil=McMaster Evidence Review and Synthesis Team; School of Nursing, McMaster University
kn-affil=

affil-num=3
en-affil=McMaster Evidence Review and Synthesis Team; School of Nursing, McMaster University
kn-affil=

affil-num=4
en-affil=McMaster Evidence Review and Synthesis Team; School of Nursing, McMaster University
kn-affil=

affil-num=5
en-affil=Obesity Canada
kn-affil=

affil-num=6
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Clinical Medicine, Advanced Medical and Dental Institute, Universiti Sains Malaysia
kn-affil=

affil-num=8
en-affil=Obesity Canada
kn-affil=

affil-num=9
en-affil=Temerty Faculty of Medicine, University of Toronto
kn-affil=

affil-num=10
en-affil=Department of Internal Medicine, Division of Endocrinology, and Obesity Center CGG, Erasmus MC, University Medical Center Rotterdam
kn-affil=

affil-num=11
en-affil=Department of Medicine, University of Padova
kn-affil=

affil-num=12
en-affil=Center of Obesity Medicine and Metabolic Performance, Department of Surgery, University of Texas McGovern Medical School
kn-affil=

affil-num=13
en-affil=Obesity Action Coalition
kn-affil=

affil-num=14
en-affil=ABHispalis Spain, Alianza Hispana de Personas con Obesidad Latin America
kn-affil=

affil-num=15
en-affil=Obesity Canada
kn-affil=

affil-num=16
en-affil=School of Medicine, University College Dublin
kn-affil=

affil-num=17
en-affil=School of Medicine, Wake Forest University
kn-affil=

affil-num=18
en-affil=Department of Health, Kinesiology, and Applied Physiology, Concordia University
kn-affil=

affil-num=19
en-affil=Obesity, Metabolism and Nutrition Institute Massachusetts General Hospital and Harvard Medical School
kn-affil=

affil-num=20
en-affil=Department of Medicine, University of Alberta
kn-affil=

affil-num=21
en-affil=Temerty Faculty of Medicine, University of Toronto
kn-affil=
en-keyword=obesity management
kn-keyword=obesity management
en-keyword=percent body weight
kn-keyword=percent body weight
en-keyword=scoping review
kn-keyword=scoping review
en-keyword=target
kn-keyword=target
en-keyword=weight loss
kn-keyword=weight loss
END

start-ver=1.4
cd-journal=joma
no-vol=190
cd-vols=
no-issue=
article-no=
start-page=73
end-page=83
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20251128
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Study of Perspectives Based on Semiotics that Capture the Interaction Between Creators and Their Artworks: Literature Research for Qualitative Considerations Based on the Theories of Ferdinand de Saussure and Keizaburo Maruyama
kn-title=制作者と造形物の対話を捉える「記号学」に基づいた視点の研究 ― ソシュールと丸山圭三郎の理論に基づく質的な考察のための文献の検討 ―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　本研究では，制作者が造形行為の過程で実践する造形物との対話に着目し，造形行為において制作者に経験される学びを捉え質的に考察するための視点を， 丸山が解説するソシュール(Ferdinand de Saussure)の「記号学」と，「記号学」に基づいた丸山の理論に立ち検討した。まず，「記号学」の基礎概念の1 つとして，「表現」を示す「シニフィアン」と，その「表現」に結び付いた「意味」を示す「シニフィエ」から成る「記号」の構造を文献により検討した。次に，丸山の理論の中で，「無意識から噴出」される力としての「欲動」と，その「欲動」を捉える「深層」の「言葉」の能力である「パトス」，及び「表層」の「言葉」の能力である「ロゴス」の関係を文献により検討した。「記号」の構造と丸山の理論に基づき，制作者が造形行為の過程で実践する造形物との対話を捉える視点を研究成果として提示した。
en-copyright=
kn-copyright=

en-aut-name=OHIRAShuya
en-aut-sei=OHIRA
en-aut-mei=Shuya
kn-aut-name=大平修也
kn-aut-sei=大平
kn-aut-mei=修也
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Faculty of Education, Okayama University
kn-affil=岡山大学学術研究院教育学域
en-keyword=記号学
kn-keyword=記号学
en-keyword=欲動
kn-keyword=欲動
en-keyword=ロゴス
kn-keyword=ロゴス
en-keyword=パトス
kn-keyword=パトス
en-keyword=造形行為
kn-keyword=造形行為
END

start-ver=1.4
cd-journal=joma
no-vol=106
cd-vols=
no-issue=7
article-no=
start-page=002115
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250725
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Summary of taxonomy changes ratified by the International Committee on Taxonomy of Viruses (ICTV) from the Fungal and Protist Viruses Subcommittee, 2025
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The Fungal and Protist Viruses Subcommittee (SC) of the International Committee on Taxonomy of Viruses (ICTV) has received a total of eight taxonomic proposals for the 2024 annual cycle. The extent of proposed changes varied, including nomenclatural updates, creation of new taxa and reorganization of established taxa. Following the ICTV procedures, all proposals were reviewed and voted upon by the members of the Executive Committee with ratification in March 2025. As a result, a total of 52 species in the families Botourmiaviridae and Marnaviridae were renamed to comply with the mandated binomial format. A new genus has been added to the dsRNA virus family Amalgaviridae, while two new families, Splipalmiviridae (Wolframvirales) and Mycoalphaviridae (Hepelivirales), were created to classify new groups of positive-sense (+) RNA mycoviruses. The class Arfiviricetes (Cressdnaviricota) was expanded by a new order Lineavirales and a new family Oomyviridae of ssDNA viruses. Additionally, a new class Orpoviricetes was created in the kingdom Orthornavirae to classify a group of bisegmented (+)RNA viruses reported from fungi and oomycetes. Finally, the order Pimascovirales was reorganized to better depict evolutionary relationships of pithoviruses and related viruses with large dsDNA genomes. The summary of updates in the taxonomy of fungal and protist viruses presented here is limited to taxa within the remit of this Subcommittee. For information on taxonomy changes on other fungal viruses closely related to animal and/or plant viruses, please see reports from sister ICTV Subcommittees (i.e. Plant Virus SC and Animal dsRNA and ssRNA(−) Viruses SC).
en-copyright=
kn-copyright=

en-aut-name=SabanadzovicSead
en-aut-sei=Sabanadzovic
en-aut-mei=Sead
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=AbergelChantal
en-aut-sei=Abergel
en-aut-mei=Chantal
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=AyllónMarı́a A.
en-aut-sei=Ayllón
en-aut-mei=Marı́a A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=BotellaLeticia
en-aut-sei=Botella
en-aut-mei=Leticia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=CanutiMarta
en-aut-sei=Canuti
en-aut-mei=Marta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ChibaYuto
en-aut-sei=Chiba
en-aut-mei=Yuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ClaverieJean-Michel
en-aut-sei=Claverie
en-aut-mei=Jean-Michel
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=CouttsRobert H.A.
en-aut-sei=Coutts
en-aut-mei=Robert H.A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=DaghinoStefania
en-aut-sei=Daghino
en-aut-mei=Stefania
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=DonaireLivia
en-aut-sei=Donaire
en-aut-mei=Livia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=ForgiaMarco
en-aut-sei=Forgia
en-aut-mei=Marco
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HejnaOndřej
en-aut-sei=Hejna
en-aut-mei=Ondřej
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=JiaJichun
en-aut-sei=Jia
en-aut-mei=Jichun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=JiangDaohong
en-aut-sei=Jiang
en-aut-mei=Daohong
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=Kotta-LoizouIoly
en-aut-sei=Kotta-Loizou
en-aut-mei=Ioly
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=KrupovicMart
en-aut-sei=Krupovic
en-aut-mei=Mart
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=LangAndrew S.
en-aut-sei=Lang
en-aut-mei=Andrew S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=LegendreMatthieu
en-aut-sei=Legendre
en-aut-mei=Matthieu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=Lee MarzanoShin-Yi
en-aut-sei=Lee Marzano
en-aut-mei=Shin-Yi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=NervaLuca
en-aut-sei=Nerva
en-aut-mei=Luca
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=PénzesJudit
en-aut-sei=Pénzes
en-aut-mei=Judit
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=PoimalaAnna
en-aut-sei=Poimala
en-aut-mei=Anna
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=RigouSofia
en-aut-sei=Rigou
en-aut-mei=Sofia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=SatoYukiyo
en-aut-sei=Sato
en-aut-mei=Yukiyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=ShamsiWajeeha
en-aut-sei=Shamsi
en-aut-mei=Wajeeha
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=SuzukiNobuhiro
en-aut-sei=Suzuki
en-aut-mei=Nobuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=TurinaMassimo
en-aut-sei=Turina
en-aut-mei=Massimo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=UrayamaSyun-ichi
en-aut-sei=Urayama
en-aut-mei=Syun-ichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=VainioEeva J.
en-aut-sei=Vainio
en-aut-mei=Eeva J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=XieJiatao
en-aut-sei=Xie
en-aut-mei=Jiatao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

affil-num=1
en-affil=Institute for Genomics, Biocomputing and Biotechnology, Mississippi State University
kn-affil=

affil-num=2
en-affil=Information Génomique & Structurale, UMR7256, CNRS & Aix-Marseille Université, Marseille, IMM, IM2B, IOM
kn-affil=

affil-num=3
en-affil=Departamento de Biotecnología-Biología Vegetal, Escuela Técnica Superior de Ingeniería Agronómica, Alimentaria y de Biosistemas, Universidad Politécnica de Madrid (UPM)
kn-affil=

affil-num=4
en-affil=Forest Protection and Wildlife Management Mendel University in Brno
kn-affil=

affil-num=5
en-affil=Department of Veterinary and Animal Sciences, University of Copenhagen
kn-affil=

affil-num=6
en-affil=School of Agriculture, Meiji University
kn-affil=

affil-num=7
en-affil=Information Génomique & Structurale, UMR7256, CNRS & Aix-Marseille Université, Marseille, IMM, IM2B, IOM
kn-affil=

affil-num=8
en-affil=School of Health, Medicine and Life Sciences, University of Hertfordshire
kn-affil=

affil-num=9
en-affil=Institute for Sustainable Plant Protection, National Research Council of Italy
kn-affil=

affil-num=10
en-affil=Centro de Edafología y Biología Aplicada del Segura-CSIC
kn-affil=

affil-num=11
en-affil=Institute for Sustainable Plant Protection, CNR
kn-affil=

affil-num=12
en-affil=Department of Genetics and Biotechnologies, University of South Bohemia
kn-affil=

affil-num=13
en-affil=College of Plant Protection, Shanxi Agricultural University
kn-affil=

affil-num=14
en-affil=College of Plant Science and Technology, Huazhong Agricultural University
kn-affil=

affil-num=15
en-affil=School of Health, Medicine and Life Sciences, University of Hertfordshire
kn-affil=

affil-num=16
en-affil=Institut Pasteur, Université Paris Cité, CNRS UMR6047, Archaeal Virology Unit
kn-affil=

affil-num=17
en-affil=Department of Biology, Memorial University of Newfoundland
kn-affil=

affil-num=18
en-affil=Information Génomique & Structurale, UMR7256, CNRS & Aix-Marseille Université, Marseille, IMM, IM2B, IOM
kn-affil=

affil-num=19
en-affil=United States Department of Agriculture, Agricultural Research Service, Application Technology Research Unit
kn-affil=

affil-num=20
en-affil=Council for Agricultural Research and Economics - Research Centre for Viticulture and Enology
kn-affil=

affil-num=21
en-affil=Department of Entomology, Texas A&M University
kn-affil=

affil-num=22
en-affil=Natural Resources Institute Finland (Luke)
kn-affil=

affil-num=23
en-affil=Information Génomique & Structurale, UMR7256, CNRS & Aix-Marseille Université, Marseille, IMM, IM2B, IOM
kn-affil=

affil-num=24
en-affil=Department of Biology, Institute for Plant Sciences, University of Cologne
kn-affil=

affil-num=25
en-affil=Department of Molecular Biology and Genetics, Aarhus University
kn-affil=

affil-num=26
en-affil=Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=27
en-affil=Department of Plant Protection, School of Agriculture, The University of Jordan
kn-affil=

affil-num=28
en-affil=Department of Life and Environmental Sciences, University of Tsukuba
kn-affil=

affil-num=29
en-affil=Natural Resources Institute Finland (Luke)
kn-affil=

affil-num=30
en-affil=College of Plant Science and Technology, Huazhong Agricultural University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=106
cd-vols=
no-issue=7
article-no=
start-page=002079
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250725
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Virus taxonomy proposal summaries: a searchable and citable resource to disseminate virus taxonomy advances
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Taxonomic classification of cellular organisms requires the publication of descriptions and proposed names of species and the deposition of specimens. Virus taxonomy is developed through a different system of annual submission of formal taxonomy proposals (TPs) that can be submitted by anyone but are typically prepared by a study group appointed by the International Committee on Taxonomy of Viruses (ICTV) and consisting of experts on a particular group of viruses. These are initially evaluated by an expert subcommittee and by the executive committee (EC) of the ICTV. EC-approved TPs are then submitted for evaluation and a ratification vote by the wider ICTV membership. Following ratification, the new taxonomy is annually updated in the Master Species List, associated databases and bioinformatic resources. The process is consistent, creates traceability in assignments and supports a fully evaluated, hierarchical classification and nomenclature of all taxonomic ranks from species to realms. The structure also facilitates large-scale and coordinated changes to virus taxonomy, such as the recent introduction of a binomial species nomenclature.<br>
TPs are available on the ICTV website after ratification, but they are not indexed in bibliographic databases and are not easily cited. Authors of TPs do not receive citation credit for adopted proposals, and their voluntary contributions are largely invisible in the published literature. For greater visibility of TPs and their authors, the ICTV will commence the annual publication of summaries of all TPs from each ICTV subcommittee. These summaries will provide a searchable compendium of all annual taxonomy changes and additions as well as direct links to the Master Species List and other ICTV bioinformatic resources. Their publication will provide due credit and citations for their authors, form the basis for disseminating taxonomy decisions and promote greater visibility and accessibility to taxonomy changes for the virology community.
en-copyright=
kn-copyright=

en-aut-name=MayneRichard
en-aut-sei=Mayne
en-aut-mei=Richard
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SimmondsPeter
en-aut-sei=Simmonds
en-aut-mei=Peter
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SmithDonald B.
en-aut-sei=Smith
en-aut-mei=Donald B.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AdriaenssensEvelien M.
en-aut-sei=Adriaenssens
en-aut-mei=Evelien M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=LefkowitzElliot J.
en-aut-sei=Lefkowitz
en-aut-mei=Elliot J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OksanenHanna M.
en-aut-sei=Oksanen
en-aut-mei=Hanna M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ZerbiniFrancisco Murilo
en-aut-sei=Zerbini
en-aut-mei=Francisco Murilo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=Alfenas-ZerbiniPoliane
en-aut-sei=Alfenas-Zerbini
en-aut-mei=Poliane
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=AylwardFrank O
en-aut-sei=Aylward
en-aut-mei=Frank O
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=Freitas-AstúaJuliana
en-aut-sei=Freitas-Astúa
en-aut-mei=Juliana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HendricksonR. Curtis
en-aut-sei=Hendrickson
en-aut-mei=R. Curtis
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HughesHolly R.
en-aut-sei=Hughes
en-aut-mei=Holly R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=KrupovicMart
en-aut-sei=Krupovic
en-aut-mei=Mart
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=KuhnJens H.
en-aut-sei=Kuhn
en-aut-mei=Jens H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=ŁobockaMałgorzata
en-aut-sei=Łobocka
en-aut-mei=Małgorzata
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=MushegianArcady R.
en-aut-sei=Mushegian
en-aut-mei=Arcady R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=PenzesJudit
en-aut-sei=Penzes
en-aut-mei=Judit
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=MuñozAlejandro Reyes
en-aut-sei=Muñoz
en-aut-mei=Alejandro Reyes
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=RobertsonDavid L.
en-aut-sei=Robertson
en-aut-mei=David L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=RouxSimon
en-aut-sei=Roux
en-aut-mei=Simon
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=RubinoLuisa
en-aut-sei=Rubino
en-aut-mei=Luisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=SabanadzovicSead
en-aut-sei=Sabanadzovic
en-aut-mei=Sead
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=SuzukiNobuhiro
en-aut-sei=Suzuki
en-aut-mei=Nobuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=TurnerDann
en-aut-sei=Turner
en-aut-mei=Dann
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=Van DoorslaerKoenraad
en-aut-sei=Van Doorslaer
en-aut-mei=Koenraad
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=VarsaniArvind
en-aut-sei=Varsani
en-aut-mei=Arvind
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

affil-num=1
en-affil=Nuffield Department of Medicine, University of Oxford
kn-affil=

affil-num=2
en-affil=Nuffield Department of Medicine, University of Oxford
kn-affil=

affil-num=3
en-affil=Nuffield Department of Medicine, University of Oxford
kn-affil=

affil-num=4
en-affil=Quadram Institute Bioscience
kn-affil=

affil-num=5
en-affil=Department of Microbiology, University of Alabama at Birmingham
kn-affil=

affil-num=6
en-affil=Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki
kn-affil=

affil-num=7
en-affil=Departamento de Fitopatologia/BIOAGRO, Universidade Federal de Viçosa
kn-affil=

affil-num=8
en-affil=Departamento de Microbiologia, Universidade Federal de Viçosa
kn-affil=

affil-num=9
en-affil=Department of Biological Sciences, Virginia Tech
kn-affil=

affil-num=10
en-affil=Embrapa Cassava and Fruits, Cruz das Almas
kn-affil=

affil-num=11
en-affil=Department of Microbiology, University of Alabama at Birmingham
kn-affil=

affil-num=12
en-affil=Centers for Disease Control and Prevention
kn-affil=

affil-num=13
en-affil=Institut Pasteur, Université Paris Cité, CNRS UMR6047, Archaeal Virology Unit
kn-affil=

affil-num=14
en-affil=Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health
kn-affil=

affil-num=15
en-affil=Institute of Biochemistry and Biophysics of the Polish Academy of Sciences
kn-affil=

affil-num=16
en-affil=Division of Molecular and Cellular Biosciences, National Science Foundation
kn-affil=

affil-num=17
en-affil=Institute for Quantitative Biomedicine, Rutgers University
kn-affil=

affil-num=18
en-affil=Departamento de Ciencias Biológicas, Universidad de los Andes
kn-affil=

affil-num=19
en-affil=MRC-University of Glasgow Centre for Virus Research
kn-affil=

affil-num=20
en-affil=Department of Energy, Joint Genome Institute, Lawrence Berkeley National Laboratory
kn-affil=

affil-num=21
en-affil=Consiglio Nazionale delle Ricerche, Istituto per la Protezione Sostenibile delle Piante, Sede Secondaria di Bari
kn-affil=

affil-num=22
en-affil=Department of Agricultural Science and Plant Protection, Mississippi State University
kn-affil=

affil-num=23
en-affil=Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=24
en-affil=Molecular Biology, University of the West of England
kn-affil=

affil-num=25
en-affil=Department of Immunobiology, School of Animal and Comparative Biomedical Sciences, BIO5 Institute, University of Arizona Cancer Center
kn-affil=

affil-num=26
en-affil=The Biodesign Center for Fundamental and Applied Microbiomics, School of Life Sciences, Center for Evolution and Medicine, Arizona State University
kn-affil=
en-keyword=ICTV
kn-keyword=ICTV
en-keyword=master species list
kn-keyword=master species list
en-keyword=taxonomy proposal
kn-keyword=taxonomy proposal
en-keyword=virus taxonomy
kn-keyword=virus taxonomy
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=5
article-no=
start-page=393
end-page=398
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202510
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Gastroduodenal Artery-Preserving Pancreatoduodenectomy after Esophagectomy with Gastric Conduit Reconstruction
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Pancreatoduodenectomy (PD) after esophagectomy with gastric conduit reconstruction is technically challenging. Preserving the blood supply of the gastric conduit is crucial in performing PD after esophagectomy. We report the case of a 66-year-old man who underwent gastroduodenal artery-preserving PD after esophagectomy with gastric conduit reconstruction for intraductal papillary mucinous neoplasm. The patient developed pseudoaneurysm rupture postoperatively, but was successfully treated with interventional radiology. Precise assessment is important in developing a surgical strategy depending on the patient’s specific anatomy and tumor characteristics. Moreover, special attention should be paid to avoid accidental injuries of the gastric conduit and gastric vessels during surgery.
en-copyright=
kn-copyright=

en-aut-name=MasunagaAkari
en-aut-sei=Masunaga
en-aut-mei=Akari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakagiKosei
en-aut-sei=Takagi
en-aut-mei=Kosei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NagaiYasuo
en-aut-sei=Nagai
en-aut-mei=Yasuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YasuiKazuya
en-aut-sei=Yasui
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FujiTomokazu
en-aut-sei=Fuji
en-aut-mei=Tomokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YamadaMotohiko
en-aut-sei=Yamada
en-aut-mei=Motohiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NishiyamaTakeyoshi
en-aut-sei=Nishiyama
en-aut-mei=Takeyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KanehiraNoriyuki
en-aut-sei=Kanehira
en-aut-mei=Noriyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SotaYumi
en-aut-sei=Sota
en-aut-mei=Yumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=pancreatoduodenectomy
kn-keyword=pancreatoduodenectomy
en-keyword=esophagectomy
kn-keyword=esophagectomy
en-keyword=gastric conduit
kn-keyword=gastric conduit
en-keyword=fluorescence imaging
kn-keyword=fluorescence imaging
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=5
article-no=
start-page=387
end-page=392
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202510
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Utility of a Preoperative 3D Imaging Analysis System for Trigonal Meningioma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Trigonal meningiomas are rare and pose surgical challenges due to their deep location and proximity to critical neuroanatomical structures. We present the case of a 67-year-old woman with a growing trigonal meningioma successfully resected with guidance by a preoperative 3D imaging analysis system. Integration of CT and MRI including diffusion tensor imaging (DTI) enabled precise mapping of the optic radiation, guiding a middle temporal gyrus approach. Preoperative embolization reduced tumor vascularity, facilitating gross total resection with minimal blood loss. This case highlights the effectiveness of preoperative 3D imaging systems in optimizing surgical planning and improving outcomes in complex neurosurgical cases.
en-copyright=
kn-copyright=

en-aut-name=MoriYusuke
en-aut-sei=Mori
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OtaniYoshihiro
en-aut-sei=Otani
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OmaeRyo
en-aut-sei=Omae
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HiranoShuichiro
en-aut-sei=Hirano
en-aut-mei=Shuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IshidaJoji
en-aut-sei=Ishida
en-aut-mei=Joji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FujiiKentaro
en-aut-sei=Fujii
en-aut-mei=Kentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HarumaJun
en-aut-sei=Haruma
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HiramatsuMasafumi
en-aut-sei=Hiramatsu
en-aut-mei=Masafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MatsushitaToshi
en-aut-sei=Matsushita
en-aut-mei=Toshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HigakiFumiyo
en-aut-sei=Higaki
en-aut-mei=Fumiyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=SugiuKenji
en-aut-sei=Sugiu
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TanakaShota
en-aut-sei=Tanaka
en-aut-mei=Shota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Division of Radiological Technology, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Radiology, Medical Development Field, Okayama University
kn-affil=

affil-num=11
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=trigonal meningioma
kn-keyword=trigonal meningioma
en-keyword=imaging analysis
kn-keyword=imaging analysis
en-keyword=diffusion tensor imaging
kn-keyword=diffusion tensor imaging
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=5
article-no=
start-page=381
end-page=385
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202510
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Immunoglobulin G4-related Disease Mimicking Portal Vein Tumor Thrombus
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We report the case of a 72-year-old Japanese man with an incidental portal vein mass that was surgically resected and diagnosed as immunoglobulin G4 (IgG4)-related disease. The mass was discovered during an atrial fibrillation examination. The patient had a history of gastric cancer and was also diagnosed with rectal cancer, raising concerns about metastasis. Due to technical challenges, a biopsy was not feasible. Imaging findings suggested portal vein tumor thrombosis, complicating the diagnosis. This case highlights a rare presentation of IgG4-related disease mimicking portal vein tumor thrombus.
en-copyright=
kn-copyright=

en-aut-name=SakuraiAtsunobu
en-aut-sei=Sakurai
en-aut-mei=Atsunobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YabukiTakayuki
en-aut-sei=Yabuki
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=AokiHideki
en-aut-sei=Aoki
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IsekiAkiko
en-aut-sei=Iseki
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Radiology, NHO Iwakuni Clinical Center
kn-affil=

affil-num=2
en-affil=Department of Radiology, NHO Iwakuni Clinical Center
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, NHO Iwakuni Clinical Center
kn-affil=

affil-num=4
en-affil=Department of Pathology, NHO Iwakuni Clinical Center
kn-affil=
en-keyword=immunoglobulin G4-related disease
kn-keyword=immunoglobulin G4-related disease
en-keyword=inflammatory pseudotumor
kn-keyword=inflammatory pseudotumor
en-keyword=mass
kn-keyword=mass
en-keyword=portal vein
kn-keyword=portal vein
en-keyword=pericarditis
kn-keyword=pericarditis
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=5
article-no=
start-page=369
end-page=379
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202510
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Blood Pressure and Heart Rate Patterns Identified by Unsupervised Machine Learning and Their Associations with Subclinical Cerebral and Renal Damage in a Japanese Community: The Masuda Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We applied unsupervised machine learning to analyze blood pressure (BP) and resting heart rate (HR) patterns measured during a 1-year period to assess their cross-sectional relationships with subclinical cerebral and renal target damage. Dimension reduction via uniform manifold approximation and projection, followed by K-means++ clustering, was used to categorize 362 community-dwelling participants (mean age, 56.2 years; 54.9% women) into three groups: Low BP and Low HR (Lo-BP/Lo-HR), High BP and High HR (Hi-BP/Hi-HR), and Low BP and High HR (Lo-BP/Hi-HR). Cerebral vessel lesions were defined as the presence of at least one of the following magnetic resonance imaging findings: lacunar infarcts, white matter hyperintensities, cerebral microbleeds, or intracranial artery stenosis. A high urinary albumin-to-creatinine ratio (UACR) was defined as the top 10% (≥ 12 mg/g) of the mean value from ≥2 measurements. Poisson regression with robust error variance, adjusted for demographics, lifestyle, and medical history, showed that the Hi-BP/Hi-HR group had relative risks of 3.62 (95% confidence interval, 1.75-7.46) for cerebral vessel lesions and 3.58 (1.33-9.67) for high UACR, and the Lo-BP/Hi-HR group had a relative risk of 3.09 (1.12-8.57) for high UACR, compared with the Lo-BP/Lo-HR group. These findings demonstrate the utility of an unsupervised, data-driven approach for identifying physiological patterns associated with subclinical target organ damage.
en-copyright=
kn-copyright=

en-aut-name=HisamatsuTakashi
en-aut-sei=Hisamatsu
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KinutaMinako
en-aut-sei=Kinuta
en-aut-mei=Minako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MunetomoSosuke
en-aut-sei=Munetomo
en-aut-mei=Sosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FukudaMari
en-aut-sei=Fukuda
en-aut-mei=Mari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KojimaKatsuhide
en-aut-sei=Kojima
en-aut-mei=Katsuhide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TaniguchiKaori
en-aut-sei=Taniguchi
en-aut-mei=Kaori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NakahataNoriko
en-aut-sei=Nakahata
en-aut-mei=Noriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KandaHideyuki
en-aut-sei=Kanda
en-aut-mei=Hideyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Environmental Medicine and Public Health, Izumo, Shimane University Faculty of Medicine
kn-affil=

affil-num=7
en-affil=Department of Health and Nutrition, The University of Shimane Faculty of Nursing and Nutrition
kn-affil=

affil-num=8
en-affil=Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=blood pressure
kn-keyword=blood pressure
en-keyword=heart rate
kn-keyword=heart rate
en-keyword=subclinical disease
kn-keyword=subclinical disease
en-keyword=uniform manifold approximation and projection
kn-keyword=uniform manifold approximation and projection
en-keyword=unsupervised machine learning
kn-keyword=unsupervised machine learning
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=5
article-no=
start-page=339
end-page=343
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202510
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Evaluation of Scleral Adjustment Method: A Novel Adjustable Suture Technique in Strabismus Surgery
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=To determine whether passing a pole suture through the sclera at two points provides fixation comparable to that of a sliding noose, we measured the tensile strength of the suture‒sclera interface during simulated traction. In this in vitro study, three suture patterns were evaluated in porcine eyeballs, using 6-0 polyglycolic acid sutures. Patterns A (control), B (second suture pass perpendicular), and C (second suture pass in the same direction) were compared. The tensile strength of each pattern was measured 20 times using a KANON TK300CN, and the results were analyzed using the Kruskal‒Wallis test. Pattern A showed a tensile strength of 2±4 gram-force (gf) (range: 0-12). Pattern B showed 112±38 gf (range: 61-184). Pattern C showed 139±31 gf (range: 97-204). Patterns B and C had significantly higher tensile strengths than Pattern A (p<0.001). Although Pattern C was not significantly different from Pattern B (p=0.363), it exhibited the highest tensile strength. Lifting the suture between the first and second suture passes allows for an adjustable suture length, suggesting that adjustability can be achieved using only the sclera. This scleral adjustment method with a second suture pass offers a durable means of securing extraocular muscles and may represent a valuable addition to adjustable suturing techniques.
en-copyright=
kn-copyright=

en-aut-name=HamasakiIchiro
en-aut-sei=Hamasaki
en-aut-mei=Ichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShibataKiyo
en-aut-sei=Shibata
en-aut-mei=Kiyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Lino Eye Clinic
kn-affil=

affil-num=2
en-affil=Lino Eye Clinic
kn-affil=
en-keyword=scleral adjustment method
kn-keyword=scleral adjustment method
en-keyword=adjustable suture technique
kn-keyword=adjustable suture technique
en-keyword=hang-loose method
kn-keyword=hang-loose method
en-keyword=tensile strength
kn-keyword=tensile strength
en-keyword=polyglycolic acid sutures
kn-keyword=polyglycolic acid sutures
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=5
article-no=
start-page=329
end-page=337
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202510
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Current Status of Extracorporeal Membrane Oxygenation as a Treatment Strategy for Primary Graft Dysfunction after Lung Transplantation
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Primary graft dysfunction (PGD) is one of the major risk factors affecting patients’ short- and long-term survival after lung transplantation. No particular management strategy has been established for PGD; supportive care is the mainstay of PGD treatment. When a supportive strategy fails, the patient may require the introduction of extracorporeal membrane oxygenation (ECMO) as the last-resort measure for severe PGD. A variety of study of ECMO as a PGD treatment was reported and the management of PGD patients developed so far. Early recognition of a patient’s need for ECMO and its prompt initiation are critical to improved outcomes. The use of venovenous-ECMO became the preferred procedure for PGD rather than venoarterial-ECMO. However, the current ECMO strategy has limitations, and using ECMO to manage patients with PGD is not sufficiently effective. Further studies are required to develop this promising technology.
en-copyright=
kn-copyright=

en-aut-name=MatsubaraKei
en-aut-sei=Matsubara
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MiyoshiKentaroh
en-aut-sei=Miyoshi
en-aut-mei=Kentaroh
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ToyookaShinichi
en-aut-sei=Toyooka
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=2
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=lung transplantation
kn-keyword=lung transplantation
en-keyword=primary graft dysfunction
kn-keyword=primary graft dysfunction
en-keyword=extracorporeal membrane oxygenation
kn-keyword=extracorporeal membrane oxygenation
en-keyword=ex vivo lung perfusion
kn-keyword=ex vivo lung perfusion
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=5
article-no=
start-page=321
end-page=328
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202510
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Review of the Endoscopic Treatment for Bile Leak Following Cholecystectomy and Hepatic Surgery
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Bile leak occurs in 2-25% of liver transplant, 3-27% of hepatic resection, and 0.1-4% of cholecystectomy cases. The clinical course of bile leak varies depending on the type of surgery that caused the fistula, as well as the type, severity, and timing of bile duct injury. Although infections resulting from bile leak can be life-threatening, the introduction of endoscopic treatment has enabled some patients to avoid reoperation and has reduced the negative impact on quality of life associated with external fistulas for percutaneous drainage. Endoscopic interventions, such as sphincterotomy and stent placement, reduce the pressure gradient between the bile duct and duodenum, facilitating bile drainage through the papilla and promoting the closure of the leak. We reviewed the literature from 2004 to 2024 regarding bile leak following cholecystectomy and liver surgery, examining recommended techniques, timing, and treatment outcomes. In cases of bile leak following cholecystectomy, clinical success was achieved in 72-96% of cases, while success rates for bile leak following liver surgery ranged from 50% to 100%. Although endoscopic treatment is effective, it is not universally applicable, and its limitations must be carefully considered.
en-copyright=
kn-copyright=

en-aut-name=ObataTaisuke
en-aut-sei=Obata
en-aut-mei=Taisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatsumotoKazuyuki
en-aut-sei=Matsumoto
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OtsukaMotoyuki
en-aut-sei=Otsuka
en-aut-mei=Motoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=
en-keyword=bile leak
kn-keyword=bile leak
en-keyword=cholecystectomy
kn-keyword=cholecystectomy
en-keyword=hepatic surgery
kn-keyword=hepatic surgery
en-keyword=endoscopic retrograde cholangiography
kn-keyword=endoscopic retrograde cholangiography
en-keyword=bridging stent placement
kn-keyword=bridging stent placement
END

start-ver=1.4
cd-journal=joma
no-vol=135
cd-vols=
no-issue=7
article-no=
start-page=1329
end-page=1343
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250417
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Molecular polymorphisms of the nuclear and chloroplast genomes among African melon germplasms reveal abundant and unique genetic diversity, especially in Sudan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background and Aims Africa is rich in wild species of Cucumis and is considered one of the places of origin of melon. However, our knowledge of African melon is limited, and genetic studies using melon germplasms with wide geographical coverage are required. Here, we analysed the genetic structure of African melons, with emphasis on Sudan.<br>
Methods Ninety-seven accessions of African melon were examined along with 77 reference accessions representing Asian melon and major horticultural groups. Molecular polymorphisms in the nuclear and chloroplast genomes were investigated using 12 RAPD, 7 SSR and 3 SNP markers. Horticultural traits, including seed size, were measured for 46 accessions, mainly from Sudan.<br>
Key Results African melons were divided into large and small seed-types based on seed length: large seed-type from Northern Africa and small seed-type from Western and Southern Africa. Both seed types are common in Sudan. Molecular genetic diversity in these geographical populations was as high as in India, the Asian centre of melon domestication. Large seed-types from Northern Africa were assigned to Pop4 by structure analysis and had Ib cytoplasm in common with Cantalupensis, Inodorus and Flexuosus. Small seed-types were highly diversified and geographically differentiated; specifically, Pop1 with Ia cytoplasm in Southern Africa and South Asia, Pop2 with Ia in East Asia, including Conomon and Makuwa, and Pop3 with Ia or Ic in Africa. Sudanese small seed-types were grouped in Pop3, while their cytoplasm type was a mixture of Ia and Ic. Sudanese Tibish had Ic cytoplasm, which was unique in Africa, common in Western Africa and Sudan, and also found in wild or feral types.<br>
Conclusions Melon of Ic lineage, including Tibish, originated from wild melon in the ‘western Sudan region’, and independently of melon with Ia or Ib cytoplasm, which originated in Asia. This clearly indicates the polyphyletic origin of melon.
en-copyright=
kn-copyright=

en-aut-name=ImohOdirichi Nnennaya
en-aut-sei=Imoh
en-aut-mei=Odirichi Nnennaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShigitaGentaro
en-aut-sei=Shigita
en-aut-mei=Gentaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SugiyamaMitsuhiro
en-aut-sei=Sugiyama
en-aut-mei=Mitsuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=DungTran Phuong
en-aut-sei=Dung
en-aut-mei=Tran Phuong
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TanakaKatsunori
en-aut-sei=Tanaka
en-aut-mei=Katsunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TakahashiMami
en-aut-sei=Takahashi
en-aut-mei=Mami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NishimuraKazusa
en-aut-sei=Nishimura
en-aut-mei=Kazusa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MondenYuki
en-aut-sei=Monden
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NishidaHidetaka
en-aut-sei=Nishida
en-aut-mei=Hidetaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=GodaMashaer
en-aut-sei=Goda
en-aut-mei=Mashaer
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=PitratMichel
en-aut-sei=Pitrat
en-aut-mei=Michel
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KatoKenji
en-aut-sei=Kato
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=3
en-affil=Institute of Vegetable and Floriculture Science, National Agriculture and Food Research Organization (NARO)
kn-affil=

affil-num=4
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=5
en-affil=Faculty of Agriculture and Life Science, Hirosaki University
kn-affil=

affil-num=6
en-affil=Graduate School of Environmental and Life Science, Okayama University
kn-affil=

affil-num=7
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=8
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=9
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=10
en-affil=Plant Genetic Resources Conservation and Research Center, Agricultural Research Corporation
kn-affil=

affil-num=11
en-affil=INRAE, UR1052, Génétique et amélioration des fruits et légumes
kn-affil=

affil-num=12
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=
en-keyword=Cucumis melo
kn-keyword=Cucumis melo
en-keyword=Africa
kn-keyword=Africa
en-keyword=chloroplast genome
kn-keyword=chloroplast genome
en-keyword=domestication
kn-keyword=domestication
en-keyword=genetic diversity
kn-keyword=genetic diversity
en-keyword=genetic resources
kn-keyword=genetic resources
en-keyword=maternal lineage
kn-keyword=maternal lineage
en-keyword=melon
kn-keyword=melon
en-keyword=phylogeny
kn-keyword=phylogeny
en-keyword=polyphyletic origin
kn-keyword=polyphyletic origin
en-keyword=seed size
kn-keyword=seed size
en-keyword=Tibish
kn-keyword=Tibish
END

start-ver=1.4
cd-journal=joma
no-vol=13
cd-vols=
no-issue=11
article-no=
start-page=102658
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202511
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic Cardiomyopathy
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Hypertrophic cardiomyopathy (HCM) affects individuals worldwide with an estimated prevalence of over 1 in 500 individuals. Nonobstructive HCM accounts for approximately 30% to 70% of cases, is extremely heterogeneous, and is associated with a notable degree of morbidity, including daily life limitations, ventricular tachyarrhythmias, progression to heart failure, and atrial fibrillation. No approved pharmaceutical therapies target the pathophysiology of nonobstructive HCM, although several clinical trials are underway. This narrative review provides a comprehensive overview of nonobstructive HCM, focusing on epidemiology, natural history, genetics, pathophysiology, clinical manifestations, diagnosis, burden of disease, and current treatments and ongoing clinical trials.
en-copyright=
kn-copyright=

en-aut-name=DesaiMilind Y.
en-aut-sei=Desai
en-aut-mei=Milind Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MauriziNiccolo
en-aut-sei=Maurizi
en-aut-mei=Niccolo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=BiaginiElena
en-aut-sei=Biagini
en-aut-mei=Elena
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=CharronPhilippe
en-aut-sei=Charron
en-aut-mei=Philippe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FernandesFabio
en-aut-sei=Fernandes
en-aut-mei=Fabio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=González-LópezEsther
en-aut-sei=González-López
en-aut-mei=Esther
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=van HaelstPaul L.
en-aut-sei=van Haelst
en-aut-mei=Paul L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HaugaaKristina Hermann
en-aut-sei=Haugaa
en-aut-mei=Kristina Hermann
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KramerChristopher M.
en-aut-sei=Kramer
en-aut-mei=Christopher M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MederBenjamin
en-aut-sei=Meder
en-aut-mei=Benjamin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MichelsMichelle
en-aut-sei=Michels
en-aut-mei=Michelle
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=OwensAnjali
en-aut-sei=Owens
en-aut-mei=Anjali
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=YuasaShinsuke
en-aut-sei=Yuasa
en-aut-mei=Shinsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=ElliottPerry
en-aut-sei=Elliott
en-aut-mei=Perry
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

affil-num=1
en-affil=HCM Center, Department of Cardiovascular Medicine, Cleveland Clinic
kn-affil=

affil-num=2
en-affil=Cardiomyopathy Unit, Careggi University Hospital
kn-affil=

affil-num=3
en-affil=Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna
kn-affil=

affil-num=4
en-affil=European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart)
kn-affil=

affil-num=5
en-affil=InCor, Faculdade de Medicina da Universidade de São Paulo
kn-affil=

affil-num=6
en-affil=Puerta de Hierro Majadahonda University Hospital, Health Research Institute of the Puerta de Hierro Majadahonda-Segovia de Arana University Hospital (IDIPHISA)
kn-affil=

affil-num=7
en-affil=Cardiovascular Division, Department of Medicine, University of Virginia Health
kn-affil=

affil-num=8
en-affil=Cardiovascular Division, Department of Medicine, University of Virginia Health
kn-affil=

affil-num=9
en-affil=Cardiovascular Division, Department of Medicine, University of Virginia Health
kn-affil=

affil-num=10
en-affil=Department of Internal Medicine III, Institute for Cardiomyopathies, University of Heidelberg
kn-affil=

affil-num=11
en-affil=European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart (ERN GUARD-Heart)
kn-affil=

affil-num=12
en-affil=Center for Inherited Cardiovascular Disease, Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine, University of Pennsylvania
kn-affil=

affil-num=13
en-affil=Department of Cardiovascular Medicine, Academic Field, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=14
en-affil=UCL Institute of Cardiovascular Science and St Bartholomew’s Hospital
kn-affil=
en-keyword=heart failure
kn-keyword=heart failure
en-keyword=hypertrophic cardiomyopathy
kn-keyword=hypertrophic cardiomyopathy
en-keyword=nonobstructive
kn-keyword=nonobstructive
END

start-ver=1.4
cd-journal=joma
no-vol=19
cd-vols=
no-issue=3
article-no=
start-page=e70004
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202509
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Oregon Wolfe barley genetic stocks – Research and teaching tools for next generation scientists
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The Oregon Wolfe Barley (OWB) mapping population (Reg. no. MP-4, NSL 554937 MAP) is a resource for genetics research and instruction. The OWBs are a set of doubled haploid barley (Hordeum vulgare L.) lines developed at Oregon State University from the F1 of a cross between Dr. Robert Wolfe's dominant and recessive marker stocks. Exhibiting a high level of genetic and phenotypic diversity, the OWBs are used throughout the world as a research tool for barley genetics. To date, these endeavors have led to 56 peer-reviewed publications, as well as three reports in the Barley Genetics Newsletter. At the same time, the OWBs are widely used as an instructor resource at the K–12, undergraduate, graduate, and professional levels. They are currently used at universities and/or institutes in German, Italy, Norway, Spain, and the United States and are currently being developed further for educational use in other countries. Genotype and phenotype data, lesson plans, and seed availability information are available herein and online.
en-copyright=
kn-copyright=

en-aut-name=KrauseMargaret R.
en-aut-sei=Krause
en-aut-mei=Margaret R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ArbelaezJuan David
en-aut-sei=Arbelaez
en-aut-mei=Juan David
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=AsdalÅsmund
en-aut-sei=Asdal
en-aut-mei=Åsmund
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=BelkodjaRamzi
en-aut-sei=Belkodja
en-aut-mei=Ramzi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=BouryNancy
en-aut-sei=Boury
en-aut-mei=Nancy
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=BlakeVictoria C.
en-aut-sei=Blake
en-aut-mei=Victoria C.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=BrownPatrick J.
en-aut-sei=Brown
en-aut-mei=Patrick J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=CasasAna
en-aut-sei=Casas
en-aut-mei=Ana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=CistuéLuis
en-aut-sei=Cistué
en-aut-mei=Luis
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=Farré‐MartínezAlba
en-aut-sei=Farré‐Martínez
en-aut-mei=Alba
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=FiskScott
en-aut-sei=Fisk
en-aut-mei=Scott
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=FuerstGregory S.
en-aut-sei=Fuerst
en-aut-mei=Gregory S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=GiménezEstela
en-aut-sei=Giménez
en-aut-mei=Estela
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=Guijarro‐RealCarla
en-aut-sei=Guijarro‐Real
en-aut-mei=Carla
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=GuthrieKaty
en-aut-sei=Guthrie
en-aut-mei=Katy
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=HalsteadMargaret
en-aut-sei=Halstead
en-aut-mei=Margaret
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=HelgersonLaura
en-aut-sei=Helgerson
en-aut-mei=Laura
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=HisanoHiroshi
en-aut-sei=Hisano
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=IgartuaErnesto
en-aut-sei=Igartua
en-aut-mei=Ernesto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=LillemoMorten
en-aut-sei=Lillemo
en-aut-mei=Morten
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=Martínez‐GarcíaMarina
en-aut-sei=Martínez‐García
en-aut-mei=Marina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=Martínez‐SubiràMariona
en-aut-sei=Martínez‐Subirà
en-aut-mei=Mariona
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=McCouchSusan
en-aut-sei=McCouch
en-aut-mei=Susan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=McGheeLaurie
en-aut-sei=McGhee
en-aut-mei=Laurie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=NickolsTravis
en-aut-sei=Nickols
en-aut-mei=Travis
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=PetersNick
en-aut-sei=Peters
en-aut-mei=Nick
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=PorterRaymond
en-aut-sei=Porter
en-aut-mei=Raymond
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=RomagosaIgnacio
en-aut-sei=Romagosa
en-aut-mei=Ignacio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=RuudAnja Karine
en-aut-sei=Ruud
en-aut-mei=Anja Karine
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=SatoKazuhiro
en-aut-sei=Sato
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=SalviSilvio
en-aut-sei=Salvi
en-aut-mei=Silvio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=SangiorgiGiuseppe
en-aut-sei=Sangiorgi
en-aut-mei=Giuseppe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=SchüllerRebekka
en-aut-sei=Schüller
en-aut-mei=Rebekka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=SenTaner Z.
en-aut-sei=Sen
en-aut-mei=Taner Z.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=SorianoJosé Miguel
en-aut-sei=Soriano
en-aut-mei=José Miguel
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

en-aut-name=StuparRobert M.
en-aut-sei=Stupar
en-aut-mei=Robert M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=36
ORCID=

en-aut-name=TingTo‐Chia
en-aut-sei=Ting
en-aut-mei=To‐Chia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=37
ORCID=

en-aut-name=ViningKelly
en-aut-sei=Vining
en-aut-mei=Kelly
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=38
ORCID=

en-aut-name=von KorffMaria
en-aut-sei=von Korff
en-aut-mei=Maria
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=39
ORCID=

en-aut-name=WallaAgatha
en-aut-sei=Walla
en-aut-mei=Agatha
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=40
ORCID=

en-aut-name=WangDiane R.
en-aut-sei=Wang
en-aut-mei=Diane R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=41
ORCID=

en-aut-name=WaughRobbie
en-aut-sei=Waugh
en-aut-mei=Robbie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=42
ORCID=

en-aut-name=WiseRoger P.
en-aut-sei=Wise
en-aut-mei=Roger P.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=43
ORCID=

en-aut-name=WolfeRobert
en-aut-sei=Wolfe
en-aut-mei=Robert
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=44
ORCID=

en-aut-name=YaoEric
en-aut-sei=Yao
en-aut-mei=Eric
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=45
ORCID=

en-aut-name=HayesPatrick M.
en-aut-sei=Hayes
en-aut-mei=Patrick M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=46
ORCID=

affil-num=1
en-affil=Department of Crop and Soil Science, Oregon State University
kn-affil=

affil-num=2
en-affil=Department of Crop Sciences, University of Illinois at Urbana-Champaign
kn-affil=

affil-num=3
en-affil=Nordic Genetic Resource Centre
kn-affil=

affil-num=4
en-affil=CIHEAM-Zaragoza
kn-affil=

affil-num=5
en-affil=Department of Plant Pathology, Entomology, and Microbiology, Iowa State University
kn-affil=

affil-num=6
en-affil=Department of Plant Sciences and Plant Pathology, Montana State University
kn-affil=

affil-num=7
en-affil=Department of Plant Sciences, University of California-Davis
kn-affil=

affil-num=8
en-affil=Departamento de Genética y Producción Vegetal, Estación Experimental Aula Dei–CSIC
kn-affil=

affil-num=9
en-affil=Departamento de Genética y Producción Vegetal, Estación Experimental Aula Dei–CSIC
kn-affil=

affil-num=10
en-affil=AGROTECNIO-CERCA Center, Universidad de Lleida
kn-affil=

affil-num=11
en-affil=Department of Crop and Soil Science, Oregon State University
kn-affil=

affil-num=12
en-affil=U.S. Department of Agriculture-Agricultural Research Service, Corn Insects and Crop Genetics Research Unit, Iowa State University
kn-affil=

affil-num=13
en-affil=Department of Biotechnology-Plant Biology, School of Agricultural, Food and Biosystems Engineering, Universidad Politécnica de Madrid
kn-affil=

affil-num=14
en-affil=Department of Biotechnology-Plant Biology, School of Agricultural, Food and Biosystems Engineering, Universidad Politécnica de Madrid
kn-affil=

affil-num=15
en-affil=Department of Agronomy and Plant Genetics, University of Minnesota
kn-affil=

affil-num=16
en-affil=Aardevo North America
kn-affil=

affil-num=17
en-affil=Department of Crop and Soil Science, Oregon State University
kn-affil=

affil-num=18
en-affil=Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=19
en-affil=Departamento de Genética y Producción Vegetal, Estación Experimental Aula Dei–CSIC
kn-affil=

affil-num=20
en-affil=Department of Plant Sciences, Norwegian University of Life Sciences
kn-affil=

affil-num=21
en-affil=Department of Biotechnology-Plant Biology, School of Agricultural, Food and Biosystems Engineering, Universidad Politécnica de Madrid
kn-affil=

affil-num=22
en-affil=AGROTECNIO-CERCA Center, Universidad de Lleida
kn-affil=

affil-num=23
en-affil=Plant Breeding and Genetics Section, School of Integrative Plant Science, Cornell University
kn-affil=

affil-num=24
en-affil=Colfax-Mingo Community High School
kn-affil=

affil-num=25
en-affil=Department of Crop and Soil Science, Oregon State University
kn-affil=

affil-num=26
en-affil=Department of Plant Pathology, Entomology, and Microbiology, Iowa State University
kn-affil=

affil-num=27
en-affil=Haupert Institute for Agricultural Studies, Huntington University
kn-affil=

affil-num=28
en-affil=AGROTECNIO-CERCA Center, Universidad de Lleida
kn-affil=

affil-num=29
en-affil=Department of Plant Sciences, Norwegian University of Life Sciences
kn-affil=

affil-num=30
en-affil=Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=31
en-affil=Department of Agricultural and Food Sciences, University of Bologna
kn-affil=

affil-num=32
en-affil=Department of Agricultural and Food Sciences, University of Bologna
kn-affil=

affil-num=33
en-affil=Department of Crop Sciences, University of Illinois at Urbana-Champaign
kn-affil=

affil-num=34
en-affil=Crop Improvement and Genetics Research Unit, U.S. Department of Agriculture-Agricultural Research Service
kn-affil=

affil-num=35
en-affil=AGROTECNIO-CERCA Center, Universidad de Lleida
kn-affil=

affil-num=36
en-affil=Department of Agronomy and Plant Genetics, University of Minnesota
kn-affil=

affil-num=37
en-affil=Agronomy Department, Purdue University
kn-affil=

affil-num=38
en-affil=Department of Crop and Soil Science, Oregon State University
kn-affil=

affil-num=39
en-affil=Institute of Plant Genetics, Heinrich-Heine-Universität Düsseldorf
kn-affil=

affil-num=40
en-affil=Institute of Plant Genetics, Heinrich-Heine-Universität Düsseldorf
kn-affil=

affil-num=41
en-affil=Agronomy Department, Purdue University
kn-affil=

affil-num=42
en-affil=Division of Plant Sciences, School of Life Sciences, University of Dundee
kn-affil=

affil-num=43
en-affil=Department of Plant Pathology, Entomology, and Microbiology, Iowa State University
kn-affil=

affil-num=44
en-affil=Agriculture and Agri-Food Canada
kn-affil=

affil-num=45
en-affil=Crop Improvement and Genetics Research Unit, U.S. Department of Agriculture-Agricultural Research Service
kn-affil=

affil-num=46
en-affil=Department of Crop and Soil Science, Oregon State University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250811
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=RNA Delivery Using a Graphene Oxide-Polyethylenimine Hybrid Inhibiting Myotube Differentiation
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Graphene oxide (GO) conjugated with short polyethylenimine (PEI) chains (GO-PEI) has been designed as a candidate nanocarrier for small interfering RNA (siRNA) delivery to mammalian cells based on the efficient interaction between the positively charged GO-based platform and the negatively charged siRNA. The function and efficiency of siRNA delivery using GO-PEI were compared to those using the positive control Lipofectamine RNAiMax by analyzing the differentiation to myotubes, and myogenin gene and protein expression in C2C12 cells. RNAiMax transfection induced cellularization and reduction of both myogenin gene and protein expression, suggesting that the differentiation of C2C12 cells was triggered by gene silencing. While GO-PEI also promoted cellularization, the myogenin gene expression remained comparable to scrambled controls, whereas the protein levels were higher than those observed with RNAiMax. Mechanistically, we attributed the reduced gene silencing efficiency of GO-PEI to a poor endosomal escape, despite strong siRNA complexation. This limitation was likely due to a low buffering capacity of GO-PEI, as a significant fraction of nitrogen atoms were already protonated, reducing the availability of free amines necessary for endosomal disruption. An appropriate chemical modification to enhance siRNA release from the endosomes is therefore essential for advancing the development of GO-based platforms as versatile and efficient nanocarriers in gene therapy applications.
en-copyright=
kn-copyright=

en-aut-name=MatsuuraKoji
en-aut-sei=Matsuura
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ReinaGiacomo
en-aut-sei=Reina
en-aut-mei=Giacomo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=GaoZhengfeng
en-aut-sei=Gao
en-aut-mei=Zhengfeng
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NishinaYuta
en-aut-sei=Nishina
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=BiancoAlberto
en-aut-sei=Bianco
en-aut-mei=Alberto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR3572, University of Strasbourg, ISIS
kn-affil=

affil-num=2
en-affil=CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR3572, University of Strasbourg, ISIS
kn-affil=

affil-num=3
en-affil=CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR3572, University of Strasbourg, ISIS
kn-affil=

affil-num=4
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=5
en-affil=CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR3572, University of Strasbourg, ISIS
kn-affil=
en-keyword=graphene oxide
kn-keyword=graphene oxide
en-keyword=polyethylenimine
kn-keyword=polyethylenimine
en-keyword=myotubes
kn-keyword=myotubes
en-keyword=myogenin
kn-keyword=myogenin
en-keyword=small interfering RNA
kn-keyword=small interfering RNA
en-keyword=transfection
kn-keyword=transfection
END

start-ver=1.4
cd-journal=joma
no-vol=60
cd-vols=
no-issue=4
article-no=
start-page=e70059
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250528
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=When Confidence in Institutions Backfires: Power‐Distance Orientation Moderates the Relationship Between Institutional Trust and Civic Honesty Across Eight Countries
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Confidence in institutions is a key predictor of civic honesty, yet evidence shows that this relationship varies across contexts and individuals. This study examined whether power-distance orientation (PDO)—the extent to which individuals accept hierarchical power relations—moderates this association. High-PDO individuals tend to view institutional authorities as entitled to privilege, inclined to engage in patronage relationships and potentially corrupt. We hypothesised that for individuals high in PDO, confidence in institutions could backfire and be linked to the rejection of civic honesty. Using data from 2088 participants across eight countries, we found support for this hypothesis. Specifically, the positive link between institutional confidence and civic honesty was reversed among those who strongly endorse PDO. These findings suggest that individual-level variation in the link between confidence in institutions and civic honesty partly reflects broader beliefs about authorities. We discuss implications of this interaction and outline directions for future research.
en-copyright=
kn-copyright=

en-aut-name=D'OttoneSilvana
en-aut-sei=D'Ottone
en-aut-mei=Silvana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TravaglinoGiovanni A.
en-aut-sei=Travaglino
en-aut-mei=Giovanni A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=BurgmerPascal
en-aut-sei=Burgmer
en-aut-mei=Pascal
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=GiammussoIsabella
en-aut-sei=Giammusso
en-aut-mei=Isabella
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ImadaHirotaka
en-aut-sei=Imada
en-aut-mei=Hirotaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MaoYanhui
en-aut-sei=Mao
en-aut-mei=Yanhui
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MirisolaAlberto
en-aut-sei=Mirisola
en-aut-mei=Alberto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MoonChanki
en-aut-sei=Moon
en-aut-mei=Chanki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NawataKengo
en-aut-sei=Nawata
en-aut-mei=Kengo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OzekiMiki
en-aut-sei=Ozeki
en-aut-mei=Miki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=School of Psychology, Pontificia Universidad Católica de Chile
kn-affil=

affil-num=2
en-affil=Institute for the Study of Power, Crime and Society, Department of Law and Criminology, Royal Holloway University of London
kn-affil=

affil-num=3
en-affil=School of Psychology, University of Southampton
kn-affil=

affil-num=4
en-affil=Department of Psychology, Educational Science and Human Movement, University of Palermo
kn-affil=

affil-num=5
en-affil=Institute for the Study of Power, Crime and Society, Department of Law and Criminology, Royal Holloway University of London
kn-affil=

affil-num=6
en-affil=Institute of Applied Psychology, Psychological Research and Counseling Center, Southwest Jiaotong University
kn-affil=

affil-num=7
en-affil=Department of Psychology, Educational Science and Human Movement, University of Palermo
kn-affil=

affil-num=8
en-affil=Institute for the Study of Power, Crime and Society, Department of Law and Criminology, Royal Holloway University of London
kn-affil=

affil-num=9
en-affil=Faculty of Humanities, Fukuoka University
kn-affil=

affil-num=10
en-affil=Faculty of Humanities and Social Sciences, Okayama University
kn-affil=
en-keyword=civic honesty
kn-keyword=civic honesty
en-keyword=confidence in institutions
kn-keyword=confidence in institutions
en-keyword=corruption
kn-keyword=corruption
en-keyword=power-distance orientation
kn-keyword=power-distance orientation
END

start-ver=1.4
cd-journal=joma
no-vol=21
cd-vols=
no-issue=7
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202507
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Animal–chlorophyte photosymbioses: evolutionary origins and ecological diversity
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Photosynthetic symbiosis occurs across diverse animal lineages, including Porifera, Cnidaria, Xenacoelomorpha and Mollusca. These associations between animal hosts and photosynthetic algae often involve the exchange of essential macronutrients, supporting adaptation to a wide range of aquatic environments. A small yet taxonomically widespread subset of animals host photosymbionts from the core chlorophytes, a phylogenetically expansive clade of green algae. These rare instances of ‘plant-like’ animals have arisen independently across distantly related lineages, resulting in striking ecological and physiological diversity. Although such associations provide valuable insights into the evolution of symbiosis and adaptation to novel ecological niches, animal–chlorophyte photosymbioses remain relatively understudied. Here, we present an overview of photosymbioses between animals and chlorophytes, highlighting their independent evolutionary origins, ecological diversity and emerging genomic resources. Focusing on Porifera, Cnidaria and Xenacoelomorpha, we review shared and lineage-specific adaptations underlying these associations. We also contrast them with dinoflagellate-based systems to demonstrate their distinct ecological and cellular features. Our work sets the stage for elucidating the molecular mechanisms underlying these associations, enhancing our understanding of how interspecies interactions drive adaptation to unique ecological niches through animal–chlorophyte symbiosis.
en-copyright=
kn-copyright=

en-aut-name=LiaoIsabel Jiah-Yih
en-aut-sei=Liao
en-aut-mei=Isabel Jiah-Yih
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SakagamiTosuke
en-aut-sei=Sakagami
en-aut-mei=Tosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=LewinThomas D.
en-aut-sei=Lewin
en-aut-mei=Thomas D.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=BaillyXavier
en-aut-sei=Bailly
en-aut-mei=Xavier
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HamadaMayuko
en-aut-sei=Hamada
en-aut-mei=Mayuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=LuoYi-Jyun
en-aut-sei=Luo
en-aut-mei=Yi-Jyun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Biodiversity Research Center, Academia Sinica
kn-affil=

affil-num=2
en-affil=Biodiversity Research Center, Academia Sinica
kn-affil=

affil-num=3
en-affil=Biodiversity Research Center, Academia Sinica
kn-affil=

affil-num=4
en-affil=Laboratoire des Modèles Marins Multicellulaires, Station Biologique de Roscoff
kn-affil=

affil-num=5
en-affil=Ushimado Marine Institute, Okayama University
kn-affil=

affil-num=6
en-affil=Biodiversity Research Center, Academia Sinica
kn-affil=
en-keyword=hydra
kn-keyword=hydra
en-keyword=photosymbiosis
kn-keyword=photosymbiosis
en-keyword=green algae
kn-keyword=green algae
en-keyword=acoels
kn-keyword=acoels
en-keyword=sponges
kn-keyword=sponges
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=1
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250225
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Age-related behavioural abnormalities in C57BL/6.KOR–Apoe shl mice
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Spontaneously hyperlipidaemic (Apoeshl) mice were discovered in 1999 as mice lacking apolipoprotein E (ApoE) owing to a mutation in the Apoe gene. However, age-related behavioural changes in commercially available Apoeshl mice have not yet been clarified. The behavioural abnormalities of ApoE-deficient mice, which are genetically modified mice artificially deficient in ApoE, have been investigated in detail, and it has been reported that they can serve as a model of Alzheimer’s disease (AD). To understand whether Apoeshl mice can also serve as a murine model of AD, it is necessary to investigate age-related behavioural abnormalities in Apoeshl mice. In this study, we conducted a series of behavioural experiments on 7- and 11-month-old Apoeshl mice to investigate the behavioural abnormalities associated with ageing in Apoeshl mice. In this study, 7-month-old Apoeshl mice showed decreased body weight and grip strength compared to age-matched wild-type mice. In the open field test, 7-month-old Apoeshl mice showed increased anxiety-like behaviour compared to wild-type mice, whereas 11-month-old Apoeshl mice showed decreased anxiety-like behaviour. Moreover, Apoeshl mice aged 7 and 11 months had increased serum cholesterol levels. These results indicate that the behaviour of Apoeshl mice changes with age. However, 11-month-old Apoeshl mice did not show a decline in cognitive function or memory ability similar to murine models of AD. Our findings indicate that Apoeshl mice can be used to investigate the function of ApoE in the central nervous system.
en-copyright=
kn-copyright=

en-aut-name=UenoHiroshi
en-aut-sei=Ueno
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakahashiYu
en-aut-sei=Takahashi
en-aut-mei=Yu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MoriSachiko
en-aut-sei=Mori
en-aut-mei=Sachiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KitanoEriko
en-aut-sei=Kitano
en-aut-mei=Eriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MurakamiShinji
en-aut-sei=Murakami
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=WaniKenta
en-aut-sei=Wani
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MiyazakiTetsuji
en-aut-sei=Miyazaki
en-aut-mei=Tetsuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MatsumotoYosuke
en-aut-sei=Matsumoto
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OkamotoMotoi
en-aut-sei=Okamoto
en-aut-mei=Motoi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=IshiharaTakeshi
en-aut-sei=Ishihara
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Medical Technology, Kawasaki University of Medical Welfare
kn-affil=

affil-num=2
en-affil=Department of Psychiatry, Kawasaki Medical School
kn-affil=

affil-num=3
en-affil=Department of Psychiatry, Kawasaki Medical School
kn-affil=

affil-num=4
en-affil=Department of Psychiatry, Kawasaki Medical School
kn-affil=

affil-num=5
en-affil=Department of Psychiatry, Kawasaki Medical School
kn-affil=

affil-num=6
en-affil=Department of Psychiatry, Kawasaki Medical School
kn-affil=

affil-num=7
en-affil=Department of Psychiatry, Kawasaki Medical School
kn-affil=

affil-num=8
en-affil=Department of Neuropsychiatry, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=9
en-affil=Department of Medical Technology, Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=10
en-affil=Department of Psychiatry, Kawasaki Medical School
kn-affil=
en-keyword=age
kn-keyword=age
en-keyword=apolipoprotein
kn-keyword=apolipoprotein
en-keyword=behavioural test
kn-keyword=behavioural test
en-keyword=central nervous system
kn-keyword=central nervous system
en-keyword=mouse
kn-keyword=mouse
END

start-ver=1.4
cd-journal=joma
no-vol=16
cd-vols=
no-issue=1
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250222
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Rearing in an envy-like environment increases anxiety-like behaviour in mice
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Interest in the societal and psychological harm caused by widespread envy and social comparison is increasing. Envy is associated with anxiety and depression, though the mechanism by which envy affects neuropsychiatric disorders, such as depression, remains unclear. Clarifying the neurobiological basis of envy’s effects on behaviour and emotion regulation in experimental mice is essential for developing disease-prevention and treatment strategies. As mice recognize other mice in neighbouring cages, this study investigated whether they recognize neighbouring cages housed in environmentally enriched cages and suffer psychological stress due to envy. After being raised in an envy-like environment for 3 weeks, we revealed changes in the behaviour of the mice through a series of behavioural experiments. Mice raised in an envious environment showed increased body weight and anxiety-like behaviour but decreased social behaviour and serum corticosterone levels compared to control mice. Thus, mice recognize their neighbouring cages and experience psychological stress due to envy. This study revealed a part of the scientific basis for why envy increased anxiety. Using this novel experimental breeding environment, it may be possible to create an experimental animal model of anxiety disorders.
en-copyright=
kn-copyright=

en-aut-name=UenoHiroshi
en-aut-sei=Ueno
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KitanoEriko
en-aut-sei=Kitano
en-aut-mei=Eriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakahashiYu
en-aut-sei=Takahashi
en-aut-mei=Yu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MoriSachiko
en-aut-sei=Mori
en-aut-mei=Sachiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MurakamiShinji
en-aut-sei=Murakami
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=WaniKenta
en-aut-sei=Wani
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MatsumotoYosuke
en-aut-sei=Matsumoto
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OkamotoMotoi
en-aut-sei=Okamoto
en-aut-mei=Motoi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=IshiharaTakeshi
en-aut-sei=Ishihara
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Medical Technology, Kawasaki University of Medical Welfare
kn-affil=

affil-num=2
en-affil=Department of Psychiatry, Kawasaki Medical School
kn-affil=

affil-num=3
en-affil=Department of Psychiatry, Kawasaki Medical School
kn-affil=

affil-num=4
en-affil=Department of Psychiatry, Kawasaki Medical School
kn-affil=

affil-num=5
en-affil=Department of Psychiatry, Kawasaki Medical School
kn-affil=

affil-num=6
en-affil=Department of Psychiatry, Kawasaki Medical School
kn-affil=

affil-num=7
en-affil=Department of Neuropsychiatry, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Medical Technology, Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=9
en-affil=Department of Psychiatry, Kawasaki Medical School
kn-affil=
en-keyword=behaviour
kn-keyword=behaviour
en-keyword=anxiety
kn-keyword=anxiety
en-keyword=mouse
kn-keyword=mouse
en-keyword=envy
kn-keyword=envy
en-keyword=rodent
kn-keyword=rodent
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250704
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: Several prospective studies have evaluated the benefit of primary tumour resection (PTR) in de novo Stage IV breast cancer (BC) patients, but it remains controversial. We aimed to investigate whether PTR improves the survival of de novo stage IV BC patients.<br>
Methods: De novo stage IV BC patients were enrolled in the first registration and received systemic therapies according to clinical subtypes. Patients without progression after primary systemic therapy for 3 months were randomly assigned 1:1 to systemic therapy alone (arm A) or PTR plus systemic therapy (arm B). The primary endpoint was overall survival (OS), and the secondary endpoints included local relapse-free survival (LRFS).<br>
Results: Five hundred seventy patients were enrolled between May 5, 2011, and May 31, 2018. Of these, 407 were randomised to arm A (N = 205) or arm B (N = 202). The median follow-up time of all randomised patients was 60 months. The difference in OS was not statistically significant (HR 0.86 90% CI 0.69–1.07, one-sided p = 0.13). Median OS was 69 months (arm A) and 75 months (arm B). In the subgroup analysis, PTR was associated with improved OS in pre-menopausal patients, or those with single-organ metastasis. LRFS in arm B was significantly longer than that in arm A (median LRFS 20 vs. 63 months: HR 0.42, 95% CI 0.33–0.53, p < 0.0001). There were no treatment-related deaths.<br>
Conclusions: PTR did not prolong OS. However, it improved local control and might benefit a subset of patients, such as those with premenopausal status or with single-organ metastasis. It also improved local relapse-free survival (LRFS), which is a clinically meaningful outcome in trials of systemic therapy.<br>
Clinical trial registration: UMIN Clinical Trials Registry (UMIN000005586); Japan Registry of Clinical Trials (jRCTs031180151).
en-copyright=
kn-copyright=

en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HaraFumikata
en-aut-sei=Hara
en-aut-mei=Fumikata
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=AogiKenjiro
en-aut-sei=Aogi
en-aut-mei=Kenjiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YanagidaYasuhiro
en-aut-sei=Yanagida
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TsuneizumiMichiko
en-aut-sei=Tsuneizumi
en-aut-mei=Michiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YamamotoNaohito
en-aut-sei=Yamamoto
en-aut-mei=Naohito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MatsumotoHiroshi
en-aut-sei=Matsumoto
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SutoAkihiko
en-aut-sei=Suto
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=WatanabeKenichi
en-aut-sei=Watanabe
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HaraoMichiko
en-aut-sei=Harao
en-aut-mei=Michiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KanbayashiChizuko
en-aut-sei=Kanbayashi
en-aut-mei=Chizuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=ItohMitsuya
en-aut-sei=Itoh
en-aut-mei=Mitsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=KadoyaTakayuki
en-aut-sei=Kadoya
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=AnanKeisei
en-aut-sei=Anan
en-aut-mei=Keisei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=MaedaShigeto
en-aut-sei=Maeda
en-aut-mei=Shigeto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=SasakiKeita
en-aut-sei=Sasaki
en-aut-mei=Keita
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=OgawaGakuto
en-aut-sei=Ogawa
en-aut-mei=Gakuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=SajiShigehira
en-aut-sei=Saji
en-aut-mei=Shigehira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=FukudaHaruhiko
en-aut-sei=Fukuda
en-aut-mei=Haruhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=IwataHiroji
en-aut-sei=Iwata
en-aut-mei=Hiroji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

affil-num=1
en-affil=Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Cancer Institute Hospital
kn-affil=

affil-num=3
en-affil=National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=4
en-affil=Shizuoka General Hospital
kn-affil=

affil-num=5
en-affil=Gunma Prefectural Cancer Center
kn-affil=

affil-num=6
en-affil=Chiba Prefectural Cancer Center
kn-affil=

affil-num=7
en-affil=Saitama Prefectural Cancer Center
kn-affil=

affil-num=8
en-affil=National Cancer Center Hospital
kn-affil=

affil-num=9
en-affil=Hokkaido Cancer Center
kn-affil=

affil-num=10
en-affil=Jichi Medical University Hospital
kn-affil=

affil-num=11
en-affil=Niigata Prefectural Cancer Center
kn-affil=

affil-num=12
en-affil=Hiroshima City Hiroshima Citizen’s Hospital
kn-affil=

affil-num=13
en-affil=Hiroshima University Hospital
kn-affil=

affil-num=14
en-affil=Kitakyushu Municipal Medical Center
kn-affil=

affil-num=15
en-affil=Nagasaki Municipal Medical Center
kn-affil=

affil-num=16
en-affil=National Cancer Center Hospital
kn-affil=

affil-num=17
en-affil=National Cancer Center Hospital
kn-affil=

affil-num=18
en-affil=Fukushima Medical University
kn-affil=

affil-num=19
en-affil=National Cancer Center Hospital
kn-affil=

affil-num=20
en-affil=Aichi Cancer Center Hospital
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=207
cd-vols=
no-issue=
article-no=
start-page=108683
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202509
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Objectives: To assess the efficacy and safety of sotorasib in patients with brain metastases using data from the phase 3 CodeBreaK 200 study, which evaluated sotorasib in adults with pretreated advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC).<br>
Materials and methods: Patients with KRAS G12C-mutated NSCLC who progressed after platinum-based chemotherapy and checkpoint inhibitor therapy were randomized 1:1 to sotorasib or docetaxel. An exploratory post-hoc analysis evaluated central nervous system (CNS) progression-free survival (PFS) and time to CNS progression in patients with treated and stable brain metastases at baseline. Measures were assessed by blinded independent central review per study-modified Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria.<br>
Results: Of the patients randomly assigned to receive sotorasib (n=171) or docetaxel (n=174), baseline CNS metastases were present in 40 (23%) and 29 (17%) patients, respectively. With a median follow-up of 20.0 months for this patient subgroup, median CNS PFS was longer with sotorasib compared with docetaxel (9.6 vs 4.5 months; hazard ratio, 0.43 [95% CI, 0.20–0.92]; P=0.02). Among patients with baseline treated CNS lesions of ≥10 mm, the percentage of patients who achieved CNS tumor shrinkage of ≥30% was two-fold higher with sotorasib than docetaxel (33.3% vs 15.4%). Treatment-related adverse events among patients with CNS lesions at baseline were consistent with those of the overall study population.<br>
Conclusions: These results suggest intracranial activity with sotorasib complements the overall PFS benefit observed with sotorasib vs docetaxel, with safety outcomes similar to those in the general CodeBreaK 200 population.<br>
Clinical trials registration number: NCT04303780.
en-copyright=
kn-copyright=

en-aut-name=DingemansAnne-Marie C.
en-aut-sei=Dingemans
en-aut-mei=Anne-Marie C.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SyrigosKonstantinos
en-aut-sei=Syrigos
en-aut-mei=Konstantinos
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=LiviLorenzo
en-aut-sei=Livi
en-aut-mei=Lorenzo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=PaulusAstrid
en-aut-sei=Paulus
en-aut-mei=Astrid
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KimSang-We
en-aut-sei=Kim
en-aut-mei=Sang-We
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ChenYuanbin
en-aut-sei=Chen
en-aut-mei=Yuanbin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=FelipEnriqueta
en-aut-sei=Felip
en-aut-mei=Enriqueta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=GriesingerFrank
en-aut-sei=Griesinger
en-aut-mei=Frank
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OhashiKadoaki
en-aut-sei=Ohashi
en-aut-mei=Kadoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=ZalcmanGerard
en-aut-sei=Zalcman
en-aut-mei=Gerard
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HughesBrett G.M.
en-aut-sei=Hughes
en-aut-mei=Brett G.M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=SørensenJens Benn
en-aut-sei=Sørensen
en-aut-mei=Jens Benn
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=BlaisNormand
en-aut-sei=Blais
en-aut-mei=Normand
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=FerreiraCarlos G.M.
en-aut-sei=Ferreira
en-aut-mei=Carlos G.M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=LindsayColin R.
en-aut-sei=Lindsay
en-aut-mei=Colin R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=DziadziuszkoRafal
en-aut-sei=Dziadziuszko
en-aut-mei=Rafal
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=WardPatrick J.
en-aut-sei=Ward
en-aut-mei=Patrick J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=ObiozorCynthia Chinedu
en-aut-sei=Obiozor
en-aut-mei=Cynthia Chinedu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=WangYang
en-aut-sei=Wang
en-aut-mei=Yang
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=PetersSolange
en-aut-sei=Peters
en-aut-mei=Solange
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

affil-num=1
en-affil=Erasmus MC Cancer Institute, University Medical Center
kn-affil=

affil-num=2
en-affil=Sotiria General Hospital
kn-affil=

affil-num=3
en-affil=Department of Biomedical, Experimental and Clinical Sciences “Mario Serio”, University of Florence
kn-affil=

affil-num=4
en-affil=Centre Hospitalier Universitaire de Liège
kn-affil=

affil-num=5
en-affil=Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine
kn-affil=

affil-num=6
en-affil=The Cancer & Hematology Centers of Western Michigan
kn-affil=

affil-num=7
en-affil=Medical Oncology Department, Vall d’Hebron University Hospital
kn-affil=

affil-num=8
en-affil=Pius-Hospital Oldenburg
kn-affil=

affil-num=9
en-affil=Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Hospital Bichat-Claude Bernard
kn-affil=

affil-num=11
en-affil=The Prince Charles Hospital, University of Queensland
kn-affil=

affil-num=12
en-affil=Rigshospitalet
kn-affil=

affil-num=13
en-affil=Department of Medicine, Centre Hospitalier de l’Université de Montréal
kn-affil=

affil-num=14
en-affil=Oncoclinicas
kn-affil=

affil-num=15
en-affil=Division of Cancer Sciences, University of Manchester and The Christie NHS Foundation Trust
kn-affil=

affil-num=16
en-affil=University Clinical Centre, Medical University of Gdansk
kn-affil=

affil-num=17
en-affil=SCRI at OHC
kn-affil=

affil-num=18
en-affil=Amgen Inc.
kn-affil=

affil-num=19
en-affil=Amgen Inc.
kn-affil=

affil-num=20
en-affil=Lausanne University Hospital
kn-affil=
en-keyword=Brain metastases
kn-keyword=Brain metastases
en-keyword=KRAS G12C-mutated
kn-keyword=KRAS G12C-mutated
en-keyword=Non-small cell lung cancer
kn-keyword=Non-small cell lung cancer
en-keyword=NSCLC
kn-keyword=NSCLC
en-keyword=Randomized controlled trial
kn-keyword=Randomized controlled trial
en-keyword=Sotorasib
kn-keyword=Sotorasib
en-keyword=Survival
kn-keyword=Survival
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=4
article-no=
start-page=311
end-page=315
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202508
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Mimicking Contralateral Pneumothorax during Thoracoscopic Bullectomy Associated with Intraoperative Hyperinflation of a Large Bulla in an Obese Patient
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A 55-year-old obese Japanese male with left pneumothorax presented to our hospital. Bilateral pulmonary emphysema was confirmed. Persistent air leakage was observed, and a thoracoscopic bullectomy was performed. Although the thoracoscopic bullectomy was completed uneventfully, pre-extubation chest X-ray imaging indicated hyper-lucency occupying the right upper part of the thoracic cavity, suggesting right-sided pneumothorax. CT imaging indicated a right-upper-lobe expanded bulla. Extubation was performed, and the hyperinflated bulla gradually deflated. Careful management of bulla expansion and respiratory status may be necessary for patients with obesity and large bullae, especially in one-lung ventilation cases.
en-copyright=
kn-copyright=

en-aut-name=MatsubaraKei
en-aut-sei=Matsubara
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatsubaraKei
en-aut-sei=Matsubara
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HiranoYutaka
en-aut-sei=Hirano
en-aut-mei=Yutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FujiwaraToshiya
en-aut-sei=Fujiwara
en-aut-mei=Toshiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=2
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=3
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=4
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=
en-keyword=giant bulla
kn-keyword=giant bulla
en-keyword=pneumothorax
kn-keyword=pneumothorax
en-keyword=obesity
kn-keyword=obesity
en-keyword=positive pressure ventilation
kn-keyword=positive pressure ventilation
en-keyword=one lung ventilation
kn-keyword=one lung ventilation
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=4
article-no=
start-page=293
end-page=297
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202508
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effectiveness of Pallidal Stimulation for Dystonic Storm and Subsequent Ssevere Posterior Reversible Encephalopathy Syndrome in a Patient with GNAO1 Variant
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=GNAO1 variant affects primarily the brain and neurodevelopment, leading to a range of motor disorders including seizures beginning in infancy and involuntary movements such as dyskinesia and dystonia. Our patient, a 15-year-old Japanese female, began exhibiting involuntary movements at age 4. A de novo missense mutation (NM_020988.3: c.228C>G, NP_066268.1: p.(Asn76Lys)) in the GNAO1 gene was identified when the patient was 15, and during the same year she developed influenza pneumonia, accompanied by dystonic storm. She required intensive care with mechanical ventilation and underwent a tracheostomy. She also developed posterior reversible encephalopathy syndrome. Globus pallidal stimulation was administered, leading to an improvement in the dystonic storm. Early consideration of globus pallidal stimulation is recommended when treating difficult-to-manage dystonic storms.
en-copyright=
kn-copyright=

en-aut-name=KawaiKoji
en-aut-sei=Kawai
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SasakiTatsuya
en-aut-sei=Sasaki
en-aut-mei=Tatsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TanimotoShun
en-aut-sei=Tanimoto
en-aut-mei=Shun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SaijoTomoya
en-aut-sei=Saijo
en-aut-mei=Tomoya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SasadaSusumu
en-aut-sei=Sasada
en-aut-mei=Susumu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=AkiyamaTomoyuki
en-aut-sei=Akiyama
en-aut-mei=Tomoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HiraideTakuya
en-aut-sei=Hiraide
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SaitsuHirotomo
en-aut-sei=Saitsu
en-aut-mei=Hirotomo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TanakaShota
en-aut-sei=Tanaka
en-aut-mei=Shota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Pediatric Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Biochemistry, Hamamatsu University School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Biochemistry, Hamamatsu University School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=GNAO1 variant
kn-keyword=GNAO1 variant
en-keyword=dystonic storm
kn-keyword=dystonic storm
en-keyword=globus pallidal stimulation
kn-keyword=globus pallidal stimulation
en-keyword=posterior reversible encephalopathy syndrome
kn-keyword=posterior reversible encephalopathy syndrome
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=4
article-no=
start-page=253
end-page=259
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202508
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Study of Periprosthetic Femoral Stem Fractures in Hip Arthroplasty for Femoral Neck Fracture
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This study investigated the risk factors for bone fragility and perioperative periprosthetic femoral stem fractures in patients undergoing hip arthroplasty for femoral neck fractures. The records of 215 patients (42 male, 173 female; mean age, 84.4 years) were analyzed to assess correlations among periprosthetic fracture rates and sex, age, body mass index (BMI), Dorr classification, femoral stem fixation type (cemented/cementless), and bone mineral density (BMD) of the contralateral proximal femur. The overall prevalence of perioperative periprosthetic fractures was 4.7%. All patients with periprosthetic fractures were female, and all but one were ≥ 80 years of age. Fracture rates were higher in patients with lower BMI, although this difference was not significant. The fracture rates were 0%, 4.7%, and 7.9% for Dorr types A, B, and C, respectively, and 0% and 5.3% for patients who received cemented and cementless stems, respectively. The findings indicated that female patients, those of advanced age, those with lower BMI, and those with Dorr type C had lower BMDs. Although BMD was significantly lower in patients who received cemented stems compared to those who received cementless stems, no fractures were observed in the former group, suggesting that the use of cemented stems is safe for this high-risk population.
en-copyright=
kn-copyright=

en-aut-name=MiyakeYoshiaki
en-aut-sei=Miyake
en-aut-mei=Yoshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakagiToru
en-aut-sei=Takagi
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KonishiikeTaizo
en-aut-sei=Konishiike
en-aut-mei=Taizo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Japanese Red Cross Okayama Hospital
kn-affil=

affil-num=2
en-affil=Department of Orthopaedic Surgery, Japanese Red Cross Okayama Hospital
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Japanese Red Cross Okayama Hospital
kn-affil=
en-keyword=bone mineral density
kn-keyword=bone mineral density
en-keyword=cemented stem
kn-keyword=cemented stem
en-keyword=Dorr classification
kn-keyword=Dorr classification
en-keyword=femoral neck fracture
kn-keyword=femoral neck fracture
en-keyword=periprosthetic femoral stem fracture
kn-keyword=periprosthetic femoral stem fracture
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=4
article-no=
start-page=243
end-page=251
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202508
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Work Productivity of Cancer-survivor and Non-cancer-survivor Workers
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We investigated the work productivity levels of employed cancer survivors and non-cancer-survivor workers by conducting a cross-sectional study in Japan between February and March 2019, using an online survey. A total of 561 employed individuals aged 20-64 years were analyzed. Work productivity was assessed using the Work Productivity and Activity Impairment-General Health questionnaire which evaluates absenteeism, presenteeism, and overall work productivity loss. The questionnaire responses demonstrated that the cancer survivors within 1 year of diagnosis had significantly higher absenteeism compared to the non-cancer workers (p=0.048). Although presenteeism and overall work productivity loss were also higher in the non-cancer-survivor group, the differences were not significant. Cancer survivors within 1 year of diagnosis exhibited higher absenteeism, but their work productivity appeared to recover to levels comparable to those of the non-cancer workers over time. These findings may contribute to workplace policies supporting cancer survivors’ return to work.
en-copyright=
kn-copyright=

en-aut-name=KamanoMika
en-aut-sei=Kamano
en-aut-mei=Mika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KandaKanae
en-aut-sei=Kanda
en-aut-mei=Kanae
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NgatuNlandu Roger
en-aut-sei=Ngatu
en-aut-mei=Nlandu Roger
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MurakamiAkitsu
en-aut-sei=Murakami
en-aut-mei=Akitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YamadoriYusuke
en-aut-sei=Yamadori
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HiraoTomohiro
en-aut-sei=Hirao
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Public Health, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=2
en-affil=Department of Public Health, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=3
en-affil=Department of Public Health, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=4
en-affil=Cancer Center, Kagawa University Hospital
kn-affil=

affil-num=5
en-affil=Department of Anesthesiology, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=6
en-affil=Department of Public Health, Faculty of Medicine, Kagawa University
kn-affil=
en-keyword=cancer survivor
kn-keyword=cancer survivor
en-keyword=work productivity
kn-keyword=work productivity
en-keyword=absenteeism
kn-keyword=absenteeism
en-keyword=presenteeism
kn-keyword=presenteeism
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=4
article-no=
start-page=231
end-page=242
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202508
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Bloodstream Infections Caused by Gram-Negative Bacteria in Geriatric Patients: Epidemiology, Antimicrobial Resistance and The Factors Affecting Mortality
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Bloodstream infections (BSIs) are an important cause of morbidity and mortality in geriatric patients. We retrospectively analyzed the cases of geriatric patients who developed BSIs due to gram-negative bacteria in order to evaluate the epidemiology, antimicrobial resistance, and the factors affecting mortality. The cases of 110 patients aged ≥ 65 years admitted to our hospital between January 1, 2017, and December 31, 2022 were assessed; 70 (63.6%) of the BSIs were healthcare-associated BSIs. The urinary system was the most common detectable source of infection at 43.6%. The most frequently isolated bacteria were Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae, in that order. Carbapenem resistance was detected in 17 patients (15.5%), and extended-spectrum beta-lactamase (ESBL) production from Enterobacterales family members was detected in 37 (51.4%) patients. Multivariate analysis revealed that (i) the probability of mortality in the patients with total bilirubin was increased by approx. sixfold and (ii) the likelihood of mortality for those with a Pitt bacteremia score (PBS) ≥ 4 points was approx. 17 times higher. PBS and simplified qPitt scores can help predict mortality and manage geriatric patients. There is a significant increase in mortality among patients with procalcitonin (PCT) levels at ≥ 2 nm/ml.
en-copyright=
kn-copyright=

en-aut-name=KardanM Enes 
en-aut-sei=Kardan
en-aut-mei=M Enes 
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ErdemIlknur
en-aut-sei=Erdem
en-aut-mei=Ilknur
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YildizEmre
en-aut-sei=Yildiz
en-aut-mei=Emre
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KirazNuri
en-aut-sei=Kiraz
en-aut-mei=Nuri
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ÇelikkolAliye
en-aut-sei=Çelikkol
en-aut-mei=Aliye
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Infectious Diseases, Faculty of Medicine, Namik Kemal University
kn-affil=

affil-num=2
en-affil=Department of Infectious Diseases, Faculty of Medicine, Namik Kemal University
kn-affil=

affil-num=3
en-affil=Department of Infectious Diseases, Faculty of Medicine, Namik Kemal University
kn-affil=

affil-num=4
en-affil=Department of Medical Microbiology, Faculty of Medicine, Namik Kemal University
kn-affil=

affil-num=5
en-affil=Department of Biochemistry, Faculty of Medicine, Namik Kemal University
kn-affil=
en-keyword=geriatrics
kn-keyword=geriatrics
en-keyword=gram-negative bacteria
kn-keyword=gram-negative bacteria
en-keyword=epidemiology
kn-keyword=epidemiology
en-keyword=antimicrobial resistance
kn-keyword=antimicrobial resistance
en-keyword=mortality
kn-keyword=mortality
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=4
article-no=
start-page=221
end-page=229
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202508
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Organ Donation after Extracorporeal Cardiopulmonary Resuscitation: Clinical and Ethical Perspectives
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Extracorporeal cardiopulmonary resuscitation (ECPR) has evolved into a life-saving therapy for select cardiac arrest patients, yet a growing body of evidence suggests it also holds promise as a bridge to organ donation in non-survivors. This review explores the clinical outcomes, ethical complexities, and evolving policies surrounding organ donation after ECPR. We summarize recent international and Japanese data demonstrating favorable graft function from ECPR donors, with the exception of lung transplantation. The ethical challenges — particularly those involving brain death determination on extracorporeal membrane oxygenation and adherence to the dead donor rule — are discussed in the context of Japan’s recent regulatory reforms. Additionally, we highlight the importance of structured end-of-life communication through multidisciplinary team meetings in facilitating ethically sound transitions from rescue efforts to donation pathways. Moving forward, improvements in donor management, standardized legal frameworks, and public and professional education are essential to optimizing the life-saving and life-giving potential of ECPR.
en-copyright=
kn-copyright=

en-aut-name=YumotoTetsuya
en-aut-sei=Yumoto
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NaitoHiromichi
en-aut-sei=Naito
en-aut-mei=Hiromichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HongoTakashi
en-aut-sei=Hongo
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ObaraTakafumi
en-aut-sei=Obara
en-aut-mei=Takafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KosakiYoshinori
en-aut-sei=Kosaki
en-aut-mei=Yoshinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=AgetaKohei
en-aut-sei=Ageta
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NojimaTsuyoshi
en-aut-sei=Nojima
en-aut-mei=Tsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TsukaharaKohei
en-aut-sei=Tsukahara
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NakaoAtsunori
en-aut-sei=Nakao
en-aut-mei=Atsunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=9
en-affil=Department of Emergency, Critical Care and Disaster Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=brain death
kn-keyword=brain death
en-keyword=end-of-life care
kn-keyword=end-of-life care
en-keyword=ethical dilemmas
kn-keyword=ethical dilemmas
en-keyword=extracorporeal cardiopulmonary resuscitation
kn-keyword=extracorporeal cardiopulmonary resuscitation
END

start-ver=1.4
cd-journal=joma
no-vol=13
cd-vols=
no-issue=2
article-no=
start-page=159
end-page=161
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240925
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A novel de novo disease-causing variant in ATL1 in a pediatric patient with spastic paraplegia
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=NakamuraAyumi
en-aut-sei=Nakamura
en-aut-mei=Ayumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NaruseHiroya
en-aut-sei=Naruse
en-aut-mei=Hiroya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MitsutakeAkihiko
en-aut-sei=Mitsutake
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MitsuiJun
en-aut-sei=Mitsui
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MorishitaShinichi
en-aut-sei=Morishita
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IwakoshiMie
en-aut-sei=Iwakoshi
en-aut-mei=Mie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IshiuraHiroyuki
en-aut-sei=Ishiura
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TsujiShoji
en-aut-sei=Tsuji
en-aut-mei=Shoji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TodaTatsushi
en-aut-sei=Toda
en-aut-mei=Tatsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=2
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=3
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=4
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=5
en-affil=Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo
kn-affil=

affil-num=6
en-affil=Department of Nursing, Faculty of Health Sciences, Kobe Tokiwa University
kn-affil=

affil-num=7
en-affil=Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Institute of Medical Genomics, International University of Health and Welfare
kn-affil=

affil-num=9
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=12
cd-vols=
no-issue=11
article-no=
start-page=348
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241030
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Coronal Cementum and Reduced Enamel Epithelium on Occlusal Surface of Impacted Wisdom Tooth in a Human
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background: There is only limited research on the coronal cementum of a tooth, and the mechanisms of its forming process are not well-defined. This report presents a coronal cementum on the occlusal surfaces of enamel in an impacted wisdom tooth in a human, which is not nearly the cervical portion. Materials and Methods: The tooth (Tooth #1) was derived from a 46-year-old female. Histological analysis, including hematoxylin and eosin (HE) and toluidine blue (TB) staining, and Scanning Electron Microscopy and Energy Dispersive X-ray Spectrometer (SEM-EDS) analysis of the extracted tooth were conducted. Radiographic examination showed that Tooth #1 was horizontally impacted in the maxilla and had the apex of a single root placed between the buccal and palatal roots of Tooth #2. Results: Coronal cementum was distributed widely on the enamel, and reduced enamel epithelium was also found with enamel matrix proteins histologically. The formation of acellular cementum was observed to be more predominant than that of the cellular cementum in Tooth #1. SEM showed that the occlusal cementum connected directly with enamel. Calcium mapping revealed an almost similar occlusal cementum and enamel. In addition, the spectrum of elements in coronal cementum resembled the primary cementum according to SEM-EDS. Discussion: Thus, coronal cementogenesis in impacted human teeth might be related to the existence of reduced enamel epithelium.
en-copyright=
kn-copyright=

en-aut-name=HorieNaohiro
en-aut-sei=Horie
en-aut-mei=Naohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MurataMasaru
en-aut-sei=Murata
en-aut-mei=Masaru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MinamidaYasuhito
en-aut-sei=Minamida
en-aut-mei=Yasuhito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NagayasuHiroki
en-aut-sei=Nagayasu
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ShimoTsuyoshi
en-aut-sei=Shimo
en-aut-mei=Tsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=AkazawaToshiyuki
en-aut-sei=Akazawa
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TsujigiwaHidetsugu
en-aut-sei=Tsujigiwa
en-aut-mei=Hidetsugu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HaikelYoussef
en-aut-sei=Haikel
en-aut-mei=Youssef
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NagatsukaHitoshi
en-aut-sei=Nagatsuka
en-aut-mei=Hitoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Division of Reconstructive Surgery for Oral and Maxillofacial Region, School of Dentistry, Health Sciences University of Hokkaido
kn-affil=

affil-num=2
en-affil=Division of Regenerative Medicine, School of Dentistry, Health Sciences University of Hokkaido
kn-affil=

affil-num=3
en-affil=Division of Oral and Maxillofacial Surgery, School of Dentistry, Health Sciences University of Hokkaido
kn-affil=

affil-num=4
en-affil=Division of Oral and Maxillofacial Surgery, School of Dentistry, Health Sciences University of Hokkaido
kn-affil=

affil-num=5
en-affil=Division of Reconstructive Surgery for Oral and Maxillofacial Region, School of Dentistry, Health Sciences University of Hokkaido
kn-affil=

affil-num=6
en-affil=Industrial Technology and Environment Research Development, Hokkaido Research Organization
kn-affil=

affil-num=7
en-affil=Department of Life Science, Faculty of Science, Okayama University of Science
kn-affil=

affil-num=8
en-affil=Department of Biomaterials and Bioengineering, Institut National de la Santé et de la Recherche médicale Unité Mixte de Recherche (INSERM UMR) _S 1121, University of Strasbourg
kn-affil=

affil-num=9
en-affil=Department of Oral Pathology and Medicine Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=coronal cementum
kn-keyword=coronal cementum
en-keyword=human
kn-keyword=human
en-keyword=reduced epithelium
kn-keyword=reduced epithelium
en-keyword=impacted tooth
kn-keyword=impacted tooth
END

start-ver=1.4
cd-journal=joma
no-vol=20
cd-vols=
no-issue=40
article-no=
start-page=3355-
end-page=3364
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241112
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Plain language summary: tarlatamab for patients with previously treated small cell lung cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=AhnMyung-Ju
en-aut-sei=Ahn
en-aut-mei=Myung-Ju
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ChoByoung Chul
en-aut-sei=Cho
en-aut-mei=Byoung Chul
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FelipEnriqueta
en-aut-sei=Felip
en-aut-mei=Enriqueta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KorantzisIppokratis
en-aut-sei=Korantzis
en-aut-mei=Ippokratis
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OhashiKadoaki
en-aut-sei=Ohashi
en-aut-mei=Kadoaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MajemMargarita
en-aut-sei=Majem
en-aut-mei=Margarita
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=Juan-VidalOscar
en-aut-sei=Juan-Vidal
en-aut-mei=Oscar
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HandzhievSabin
en-aut-sei=Handzhiev
en-aut-mei=Sabin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=IzumiHiroki
en-aut-sei=Izumi
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=LeeJong-Seok
en-aut-sei=Lee
en-aut-mei=Jong-Seok
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=DziadziuszkoRafal
en-aut-sei=Dziadziuszko
en-aut-mei=Rafal
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=WolfJürgen
en-aut-sei=Wolf
en-aut-mei=Jürgen
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=BlackhallFiona
en-aut-sei=Blackhall
en-aut-mei=Fiona
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=ReckMartin
en-aut-sei=Reck
en-aut-mei=Martin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=AlvarezJean Bustamante
en-aut-sei=Alvarez
en-aut-mei=Jean Bustamante
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=HummelHorst-Dieter
en-aut-sei=Hummel
en-aut-mei=Horst-Dieter
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=DingemansAnne-Marie C.
en-aut-sei=Dingemans
en-aut-mei=Anne-Marie C.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=SandsJacob
en-aut-sei=Sands
en-aut-mei=Jacob
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=AkamatsuHiroaki
en-aut-sei=Akamatsu
en-aut-mei=Hiroaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=OwonikokoTaofeek K.
en-aut-sei=Owonikoko
en-aut-mei=Taofeek K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=RamalingamSuresh S.
en-aut-sei=Ramalingam
en-aut-mei=Suresh S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=BorghaeiHossein
en-aut-sei=Borghaei
en-aut-mei=Hossein
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=JohnsonMelissa L.
en-aut-sei=Johnson
en-aut-mei=Melissa L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=HuangShuang
en-aut-sei=Huang
en-aut-mei=Shuang
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=MukherjeeSujoy
en-aut-sei=Mukherjee
en-aut-mei=Sujoy
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=MinochaMukul
en-aut-sei=Minocha
en-aut-mei=Mukul
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=JiangTony
en-aut-sei=Jiang
en-aut-mei=Tony
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=MartinezPablo
en-aut-sei=Martinez
en-aut-mei=Pablo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=AndersonErik S.
en-aut-sei=Anderson
en-aut-mei=Erik S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=Paz-AresLuis
en-aut-sei=Paz-Ares
en-aut-mei=Luis
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

affil-num=1
en-affil=Samsung Medical Center, Sungkyunkwan University School of Medicine
kn-affil=

affil-num=2
en-affil=Yonsei Cancer Center, Yonsei University College of Medicine
kn-affil=

affil-num=3
en-affil=Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology
kn-affil=

affil-num=4
en-affil=Department of Medical Oncology, Saint Loukas Hospital
kn-affil=

affil-num=5
en-affil=Department of Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Hospital de la Santa Creu i Sant Pau
kn-affil=

affil-num=7
en-affil=
kn-affil=

affil-num=8
en-affil=Klinische Abteilung für Pneumologie, Universitätsklinikum Krems
kn-affil=

affil-num=9
en-affil=Department of Thoracic Oncology, National Cancer Center Hospital East
kn-affil=

affil-num=10
en-affil=Seoul National University Bundang Hospital
kn-affil=

affil-num=11
en-affil=Department of Oncology and Radiotherapy and Early Phase Clinical Trials Center, Medical University of Gdansk
kn-affil=

affil-num=12
en-affil=Department of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne
kn-affil=

affil-num=13
en-affil=Christie NHS Foundation Trust and University of Manchester
kn-affil=

affil-num=14
en-affil=Lungen Clinic, Airway Research Center North, German Center for Lung Research
kn-affil=

affil-num=15
en-affil=West Virginia University Health Sciences Center
kn-affil=

affil-num=16
en-affil=Translational Oncology–Early Clinical Trial Unit, Comprehensive Cancer Center Mainfranken and Bavarian Cancer Research Center, Universitätsklinikum Würzburg
kn-affil=

affil-num=17
en-affil=Department of Pulmonary Medicine, Erasmus MC Cancer Institute
kn-affil=

affil-num=18
en-affil=Dana–Farber Cancer Institute, Harvard Medical School
kn-affil=

affil-num=19
en-affil=Wakayama Medical University Hospital
kn-affil=

affil-num=20
en-affil=Division of Hematology–Oncology, Hillman Cancer Center, University of Pittsburgh Medical Center
kn-affil=

affil-num=21
en-affil=Winship Cancer Institute of Emory University
kn-affil=

affil-num=22
en-affil=Fox Chase Cancer Center
kn-affil=

affil-num=23
en-affil=Sarah Cannon Research Institute at Tennessee Oncology
kn-affil=

affil-num=24
en-affil=Amgen
kn-affil=

affil-num=25
en-affil=Amgen
kn-affil=

affil-num=26
en-affil=Amgen
kn-affil=

affil-num=27
en-affil=Amgen
kn-affil=

affil-num=28
en-affil=Amgen
kn-affil=

affil-num=29
en-affil=Amgen
kn-affil=

affil-num=30
en-affil=Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Unit, Complutense University and Ciberonc
kn-affil=
en-keyword=Clinical trials
kn-keyword=Clinical trials
en-keyword=DeLLphi-301
kn-keyword=DeLLphi-301
en-keyword=DLL3
kn-keyword=DLL3
en-keyword=Immunotherapy
kn-keyword=Immunotherapy
en-keyword=SCLC
kn-keyword=SCLC
en-keyword=Small cell lung cancer
kn-keyword=Small cell lung cancer
en-keyword=T cell
kn-keyword=T cell
en-keyword=Tarlatamab
kn-keyword=Tarlatamab
END

start-ver=1.4
cd-journal=joma
no-vol=106
cd-vols=
no-issue=7
article-no=
start-page=002112
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250725
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Summary of taxonomy changes ratified by the International Committee on Taxonomy of Viruses (ICTV) from the Animal dsRNA and ssRNA(−) Viruses Subcommittee, 2025
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=RNA viruses are ubiquitous in the environment and are important pathogens of humans, animals and plants. In 2024, the International Committee on Taxonomy of Viruses Animal dsRNA and ssRNA(−) Viruses Subcommittee submitted 18 taxonomic proposals for consideration. These proposals expanded the known virosphere by classifying 9 new genera and 88 species for newly detected virus genomes. Of note, newly established species expand the large family of Rhabdoviridae to 580 species. A new species in the family Arenaviridae includes a virus detected in Antarctic fish with a unique split nucleoprotein ORF. Additionally, four new species were established for historically isolated viruses with previously unsequenced genomes. Furthermore, three species were abolished due to incomplete genome sequence information, and one family was moved from being unassigned in the phylum Negarnaviricota into a subphylum and order. Herein, we summarize the 18 ratified taxonomic proposals and the general features of the current taxonomy, thereby supporting public and animal health responses.
en-copyright=
kn-copyright=

en-aut-name=HughesHolly R.
en-aut-sei=Hughes
en-aut-mei=Holly R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=BallingerMatthew J.
en-aut-sei=Ballinger
en-aut-mei=Matthew J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=BaoYiming
en-aut-sei=Bao
en-aut-mei=Yiming
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=BejermanNicolas
en-aut-sei=Bejerman
en-aut-mei=Nicolas
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=BlasdellKim R.
en-aut-sei=Blasdell
en-aut-mei=Kim R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=BrieseThomas
en-aut-sei=Briese
en-aut-mei=Thomas
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=BrignoneJulia
en-aut-sei=Brignone
en-aut-mei=Julia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=CarreraJean Paul
en-aut-sei=Carrera
en-aut-mei=Jean Paul
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=De ConinckLander
en-aut-sei=De Coninck
en-aut-mei=Lander
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=de SouzaWilliam Marciel
en-aut-sei=de Souza
en-aut-mei=William Marciel
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=DebatHumberto
en-aut-sei=Debat
en-aut-mei=Humberto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=DietzgenRalf G.
en-aut-sei=Dietzgen
en-aut-mei=Ralf G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=DürrwaldRalf
en-aut-sei=Dürrwald
en-aut-mei=Ralf
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=ErdinMert
en-aut-sei=Erdin
en-aut-mei=Mert
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=FooksAnthony R.
en-aut-sei=Fooks
en-aut-mei=Anthony R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=ForbesKristian M.
en-aut-sei=Forbes
en-aut-mei=Kristian M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=Freitas-AstúaJuliana
en-aut-sei=Freitas-Astúa
en-aut-mei=Juliana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=GarciaJorge B.
en-aut-sei=Garcia
en-aut-mei=Jorge B.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=GeogheganJemma L.
en-aut-sei=Geoghegan
en-aut-mei=Jemma L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=GrimwoodRebecca M.
en-aut-sei=Grimwood
en-aut-mei=Rebecca M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=HorieMasayuki
en-aut-sei=Horie
en-aut-mei=Masayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=HyndmanTimothy H.
en-aut-sei=Hyndman
en-aut-mei=Timothy H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=JohneReimar
en-aut-sei=Johne
en-aut-mei=Reimar
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=KlenaJohn D.
en-aut-sei=Klena
en-aut-mei=John D.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=KondoHideki
en-aut-sei=Kondo
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=KooninEugene V.
en-aut-sei=Koonin
en-aut-mei=Eugene V.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=KostygovAlexei Y.
en-aut-sei=Kostygov
en-aut-mei=Alexei Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=KrupovicMart
en-aut-sei=Krupovic
en-aut-mei=Mart
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=KuhnJens H.
en-aut-sei=Kuhn
en-aut-mei=Jens H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=LetkoMichael
en-aut-sei=Letko
en-aut-mei=Michael
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=LiJun-Min
en-aut-sei=Li
en-aut-mei=Jun-Min
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=LiuYiyun
en-aut-sei=Liu
en-aut-mei=Yiyun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=MartinMaria Laura
en-aut-sei=Martin
en-aut-mei=Maria Laura
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=MullNathaniel
en-aut-sei=Mull
en-aut-mei=Nathaniel
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=NazarYael
en-aut-sei=Nazar
en-aut-mei=Yael
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

en-aut-name=NowotnyNorbert
en-aut-sei=Nowotny
en-aut-mei=Norbert
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=36
ORCID=

en-aut-name=NunesMárcio Roberto Teixeira
en-aut-sei=Nunes
en-aut-mei=Márcio Roberto Teixeira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=37
ORCID=

en-aut-name=ØklandArnfinn Lodden
en-aut-sei=Økland
en-aut-mei=Arnfinn Lodden
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=38
ORCID=

en-aut-name=RubbenstrothDennis
en-aut-sei=Rubbenstroth
en-aut-mei=Dennis
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=39
ORCID=

en-aut-name=RussellBrandy J.
en-aut-sei=Russell
en-aut-mei=Brandy J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=40
ORCID=

en-aut-name=SchottEric
en-aut-sei=Schott
en-aut-mei=Eric
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=41
ORCID=

en-aut-name=SeifertStephanie
en-aut-sei=Seifert
en-aut-mei=Stephanie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=42
ORCID=

en-aut-name=SenCarina
en-aut-sei=Sen
en-aut-mei=Carina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=43
ORCID=

en-aut-name=ShedroffElizabeth
en-aut-sei=Shedroff
en-aut-mei=Elizabeth
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=44
ORCID=

en-aut-name=SironenTarja
en-aut-sei=Sironen
en-aut-mei=Tarja
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=45
ORCID=

en-aut-name=SmuraTeemu
en-aut-sei=Smura
en-aut-mei=Teemu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=46
ORCID=

en-aut-name=TavaresCamila Prestes Dos Santos
en-aut-sei=Tavares
en-aut-mei=Camila Prestes Dos Santos
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=47
ORCID=

en-aut-name=TeshRobert B.
en-aut-sei=Tesh
en-aut-mei=Robert B.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=48
ORCID=

en-aut-name=TilstonNatasha L.
en-aut-sei=Tilston
en-aut-mei=Natasha L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=49
ORCID=

en-aut-name=TordoNoël
en-aut-sei=Tordo
en-aut-mei=Noël
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=50
ORCID=

en-aut-name=VasilakisNikos
en-aut-sei=Vasilakis
en-aut-mei=Nikos
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=51
ORCID=

en-aut-name=WalkerPeter J.
en-aut-sei=Walker
en-aut-mei=Peter J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=52
ORCID=

en-aut-name=WangFei
en-aut-sei=Wang
en-aut-mei=Fei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=53
ORCID=

en-aut-name=WhitfieldAnna E.
en-aut-sei=Whitfield
en-aut-mei=Anna E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=54
ORCID=

en-aut-name=WhitmerShannon L.M.
en-aut-sei=Whitmer
en-aut-mei=Shannon L.M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=55
ORCID=

en-aut-name=WolfYuri I.
en-aut-sei=Wolf
en-aut-mei=Yuri I.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=56
ORCID=

en-aut-name=XiaHan
en-aut-sei=Xia
en-aut-mei=Han
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=57
ORCID=

en-aut-name=YeGong-Yin
en-aut-sei=Ye
en-aut-mei=Gong-Yin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=58
ORCID=

en-aut-name=YeZhuangxin
en-aut-sei=Ye
en-aut-mei=Zhuangxin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=59
ORCID=

en-aut-name=YurchenkoVyacheslav
en-aut-sei=Yurchenko
en-aut-mei=Vyacheslav
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=60
ORCID=

en-aut-name=ZhaoMingli
en-aut-sei=Zhao
en-aut-mei=Mingli
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=61
ORCID=

affil-num=1
en-affil=Centers for Disease Control and Prevention
kn-affil=

affil-num=2
en-affil=Biological Sciences, Mississippi State University
kn-affil=

affil-num=3
en-affil=National Genomics Data Center, China National Center for Bioinformation; Beijing Institute of Genomics, Chinese Academy of Sciences; University of Chinese Academy of Sciences
kn-affil=

affil-num=4
en-affil=Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) and Instituto Nacional de Tecnología Agropecuaria (INTA)
kn-affil=

affil-num=5
en-affil=CSIRO Health and Biosecurity
kn-affil=

affil-num=6
en-affil=Center for Infection and Immunity, and Department of Epidemiology, Mailman School of Public Health, Columbia University
kn-affil=

affil-num=7
en-affil=Instituto Nacional de Enfermedades Virales Humanas Dr. Julio I. Maiztegui. INEVH -ANLIS
kn-affil=

affil-num=8
en-affil=Instituto Conmemorativo Gorgas de Estudios de la Salud
kn-affil=

affil-num=9
en-affil=Division of Clinical and Epidemiological Virology, KU Leuven
kn-affil=

affil-num=10
en-affil=Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky
kn-affil=

affil-num=11
en-affil=Instituto Nacional de Tecnología Agropecuaria (INTA)
kn-affil=

affil-num=12
en-affil=QAAFI, The University of Queensland
kn-affil=

affil-num=13
en-affil=Robert Koch Institut
kn-affil=

affil-num=14
en-affil=Department of Virology, University of Helsinki
kn-affil=

affil-num=15
en-affil=Animal and Plant Health Agency (APHA)
kn-affil=

affil-num=16
en-affil=Department of Biological Sciences, University of Arkansas
kn-affil=

affil-num=17
en-affil=Embrapa Cassava and Fruits
kn-affil=

affil-num=18
en-affil=Instituto Nacional de Enfermedades Virales Humanas Dr. Julio I. Maiztegui. INEVH -ANLIS
kn-affil=

affil-num=19
en-affil=Department of Microbiology and Immunology, University of Otago
kn-affil=

affil-num=20
en-affil=Department of Microbiology and Immunology, University of Otago
kn-affil=

affil-num=21
en-affil=Osaka International Research Center for Infectious Diseases, Osaka Metropolitan University
kn-affil=

affil-num=22
en-affil=School of Veterinary Medicine, Murdoch University
kn-affil=

affil-num=23
en-affil=German Federal Institute for Risk Assessment
kn-affil=

affil-num=24
en-affil=Viral Special Pathogens Branch, The Centers for Disease Control and Prevention
kn-affil=

affil-num=25
en-affil=Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=26
en-affil=Computational Biology Branch, Division of Intramural Research National Library of Medicine, National Institutes of Health
kn-affil=

affil-num=27
en-affil=University of Ostrava
kn-affil=

affil-num=28
en-affil=Institut Pasteur, Université Paris Cité, CNRS UMR6047, Archaeal Virology Unit
kn-affil=

affil-num=29
en-affil=Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health
kn-affil=

affil-num=30
en-affil=Paul G. Allen School for Global Health, Washington State University
kn-affil=

affil-num=31
en-affil=Institute of Plant Virology, Ningbo University
kn-affil=

affil-num=32
en-affil=National Genomics Data Center, China National Center for Bioinformation; Beijing Institute of Genomics, Chinese Academy of Sciences; University of Chinese Academy of Sciences
kn-affil=

affil-num=33
en-affil=Instituto Nacional de Enfermedades Virales Humanas Dr. Julio I. Maiztegui. INEVH -ANLIS
kn-affil=

affil-num=34
en-affil=Department of Natural Sciences, Shawnee State University
kn-affil=

affil-num=35
en-affil=Instituto Nacional de Enfermedades Virales Humanas Dr. Julio I. Maiztegui. INEVH -ANLIS
kn-affil=

affil-num=36
en-affil=College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health
kn-affil=

affil-num=37
en-affil=Universidade Federal do Pará
kn-affil=

affil-num=38
en-affil=Pharmaq Analytiq
kn-affil=

affil-num=39
en-affil=Institute of Diagnostic Virology, Friedrich-Loeffler-Institut
kn-affil=

affil-num=40
en-affil=Centers for Disease Control and Prevention
kn-affil=

affil-num=41
en-affil=Institute of Marine and Environmental Technology, University of Maryland Center for Environmental Science
kn-affil=

affil-num=42
en-affil=Paul G. Allen School for Global Health, Washington State University
kn-affil=

affil-num=43
en-affil=Instituto Nacional de Enfermedades Virales Humanas Dr. Julio I. Maiztegui. INEVH -ANLIS
kn-affil=

affil-num=44
en-affil=Viral Special Pathogens Branch, The Centers for Disease Control and Prevention
kn-affil=

affil-num=45
en-affil=Department of Virology, University of Helsinki
kn-affil=

affil-num=46
en-affil=Department of Virology, University of Helsinki
kn-affil=

affil-num=47
en-affil=Integrated Group of Aquaculture and Environmental Studies, Federal University of Paraná
kn-affil=

affil-num=48
en-affil=Department of Pathology, The University of Texas Medical Branch
kn-affil=

affil-num=49
en-affil=Department of Microbiology and Immunology, Indiana University School of Medicine
kn-affil=

affil-num=50
en-affil=Institut Pasteur
kn-affil=

affil-num=51
en-affil=Department of Pathology, The University of Texas Medical Branch
kn-affil=

affil-num=52
en-affil=University of Queensland
kn-affil=

affil-num=53
en-affil=Wuhan Institute of Virology, Chinese Academy of Sciences
kn-affil=

affil-num=54
en-affil=North Carolina State University
kn-affil=

affil-num=55
en-affil=Viral Special Pathogens Branch, The Centers for Disease Control and Prevention
kn-affil=

affil-num=56
en-affil=Computational Biology Branch, Division of Intramural Research National Library of Medicine, National Institutes of Health
kn-affil=

affil-num=57
en-affil=Wuhan Institute of Virology, Chinese Academy of Sciences
kn-affil=

affil-num=58
en-affil=Institute of Insect Sciences, Zhejiang University
kn-affil=

affil-num=59
en-affil=Institute of Plant Virology, Ningbo University
kn-affil=

affil-num=60
en-affil=University of Ostrava
kn-affil=

affil-num=61
en-affil=Department of Pathobiology and Population Sciences, Royal Veterinary College
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=106
cd-vols=
no-issue=7
article-no=
start-page=002114
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250725
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Summary of taxonomy changes ratified by the International Committee on Taxonomy of Viruses from the Plant Viruses Subcommittee, 2025
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=In March 2025, following the annual International Committee on Taxonomy of Viruses (ICTV) ratification vote, newly proposed taxa were added to those under the mandate of the Plant Viruses Subcommittee. In brief, 1 new order, 3 new families, 6 new genera, 2 new subgenera and 206 new species were created. Some taxa were reorganized. Genus Cytorhabdovirus in the family Rhabdoviridae was abolished and its taxa were redistributed into three new genera Alphacytorhabdovirus, Betacytorhabdovirus and Gammacytorhabdovirus. Genus Waikavirus in the family Secoviridae was reorganized into two subgenera (Actinidivirus and Ritunrivirus). One family and four previously unaffiliated genera were moved to the newly established order Tombendovirales. Twelve species not assigned to a genus were abolished. To comply with the ICTV mandate of a binomial format for virus species, eight species were renamed. Demarcation criteria in the absence of biological information were defined in the genus Ilarvirus (family Bromoviridae). This article presents the updated taxonomy put forth by the Plant Viruses Subcommittee and ratified by the ICTV.
en-copyright=
kn-copyright=

en-aut-name=RubinoLuisa
en-aut-sei=Rubino
en-aut-mei=Luisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=AbrahamianPeter
en-aut-sei=Abrahamian
en-aut-mei=Peter
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=AnWenxia
en-aut-sei=An
en-aut-mei=Wenxia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ArandaMiguel A.
en-aut-sei=Aranda
en-aut-mei=Miguel A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=Ascencio-IbañezJosé T.
en-aut-sei=Ascencio-Ibañez
en-aut-mei=José T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=BejermanNicolas
en-aut-sei=Bejerman
en-aut-mei=Nicolas
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=BlouinArnaud G.
en-aut-sei=Blouin
en-aut-mei=Arnaud G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=CandresseThierry
en-aut-sei=Candresse
en-aut-mei=Thierry
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=CantoTomas
en-aut-sei=Canto
en-aut-mei=Tomas
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=CaoMengji
en-aut-sei=Cao
en-aut-mei=Mengji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=CarrJohn P.
en-aut-sei=Carr
en-aut-mei=John P.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=ChoWon Kyong
en-aut-sei=Cho
en-aut-mei=Won Kyong
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=ConstableFiona
en-aut-sei=Constable
en-aut-mei=Fiona
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=DasguptaIndranil
en-aut-sei=Dasgupta
en-aut-mei=Indranil
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=DebatHumberto
en-aut-sei=Debat
en-aut-mei=Humberto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=DietzgenRalf G.
en-aut-sei=Dietzgen
en-aut-mei=Ralf G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=DigiaroMichele
en-aut-sei=Digiaro
en-aut-mei=Michele
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=DonaireLivia
en-aut-sei=Donaire
en-aut-mei=Livia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=ElbeainoToufic
en-aut-sei=Elbeaino
en-aut-mei=Toufic
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=FargetteDenis
en-aut-sei=Fargette
en-aut-mei=Denis
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=FilardoFiona
en-aut-sei=Filardo
en-aut-mei=Fiona
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=FischerMatthias G.
en-aut-sei=Fischer
en-aut-mei=Matthias G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=FontdevilaNuria
en-aut-sei=Fontdevila
en-aut-mei=Nuria
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=FoxAdrian
en-aut-sei=Fox
en-aut-mei=Adrian
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=Freitas-AstuaJuliana
en-aut-sei=Freitas-Astua
en-aut-mei=Juliana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=FuchsMarc
en-aut-sei=Fuchs
en-aut-mei=Marc
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=GeeringAndrew D.W.
en-aut-sei=Geering
en-aut-mei=Andrew D.W.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=GhafariMahan
en-aut-sei=Ghafari
en-aut-mei=Mahan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=HafrénAnders
en-aut-sei=Hafrén
en-aut-mei=Anders
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=HammondJohn
en-aut-sei=Hammond
en-aut-mei=John
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=HammondRosemarie
en-aut-sei=Hammond
en-aut-mei=Rosemarie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=Hasiów-JaroszewskaBeata
en-aut-sei=Hasiów-Jaroszewska
en-aut-mei=Beata
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=HebrardEugenie
en-aut-sei=Hebrard
en-aut-mei=Eugenie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=HernándezCarmen
en-aut-sei=Hernández
en-aut-mei=Carmen
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=HilyJean-Michel
en-aut-sei=Hily
en-aut-mei=Jean-Michel
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

en-aut-name=HosseiniAhmed
en-aut-sei=Hosseini
en-aut-mei=Ahmed
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=36
ORCID=

en-aut-name=HullRoger
en-aut-sei=Hull
en-aut-mei=Roger
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=37
ORCID=

en-aut-name=Inoue-NagataAlice K.
en-aut-sei=Inoue-Nagata
en-aut-mei=Alice K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=38
ORCID=

en-aut-name=JordanRamon
en-aut-sei=Jordan
en-aut-mei=Ramon
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=39
ORCID=

en-aut-name=KondoHideki
en-aut-sei=Kondo
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=40
ORCID=

en-aut-name=KreuzeJan F.
en-aut-sei=Kreuze
en-aut-mei=Jan F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=41
ORCID=

en-aut-name=KrupovicMart
en-aut-sei=Krupovic
en-aut-mei=Mart
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=42
ORCID=

en-aut-name=KubotaKenji
en-aut-sei=Kubota
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=43
ORCID=

en-aut-name=KuhnJens H.
en-aut-sei=Kuhn
en-aut-mei=Jens H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=44
ORCID=

en-aut-name=LeisnerScott
en-aut-sei=Leisner
en-aut-mei=Scott
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=45
ORCID=

en-aut-name=LettJean-Michel
en-aut-sei=Lett
en-aut-mei=Jean-Michel
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=46
ORCID=

en-aut-name=LiChengyu
en-aut-sei=Li
en-aut-mei=Chengyu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=47
ORCID=

en-aut-name=LiFan
en-aut-sei=Li
en-aut-mei=Fan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=48
ORCID=

en-aut-name=LiJun Min
en-aut-sei=Li
en-aut-mei=Jun Min
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=49
ORCID=

en-aut-name=López-LambertiniPaola M.
en-aut-sei=López-Lambertini
en-aut-mei=Paola M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=50
ORCID=

en-aut-name=Lopez-MoyaJuan J.
en-aut-sei=Lopez-Moya
en-aut-mei=Juan J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=51
ORCID=

en-aut-name=MaclotFrancois
en-aut-sei=Maclot
en-aut-mei=Francois
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=52
ORCID=

en-aut-name=MäkinenKristiina
en-aut-sei=Mäkinen
en-aut-mei=Kristiina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=53
ORCID=

en-aut-name=MartinDarren
en-aut-sei=Martin
en-aut-mei=Darren
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=54
ORCID=

en-aut-name=MassartSebastien
en-aut-sei=Massart
en-aut-mei=Sebastien
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=55
ORCID=

en-aut-name=MillerW. Allen
en-aut-sei=Miller
en-aut-mei=W. Allen
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=56
ORCID=

en-aut-name=MohammadiMusa
en-aut-sei=Mohammadi
en-aut-mei=Musa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=57
ORCID=

en-aut-name=MollovDimitre
en-aut-sei=Mollov
en-aut-mei=Dimitre
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=58
ORCID=

en-aut-name=MullerEmmanuelle
en-aut-sei=Muller
en-aut-mei=Emmanuelle
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=59
ORCID=

en-aut-name=NagataTatsuya
en-aut-sei=Nagata
en-aut-mei=Tatsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=60
ORCID=

en-aut-name=Navas-CastilloJesús
en-aut-sei=Navas-Castillo
en-aut-mei=Jesús
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=61
ORCID=

en-aut-name=NeriyaYutaro
en-aut-sei=Neriya
en-aut-mei=Yutaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=62
ORCID=

en-aut-name=Ochoa-CoronaFrancisco M.
en-aut-sei=Ochoa-Corona
en-aut-mei=Francisco M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=63
ORCID=

en-aut-name=OhshimaKazusato
en-aut-sei=Ohshima
en-aut-mei=Kazusato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=64
ORCID=

en-aut-name=PallásVicente
en-aut-sei=Pallás
en-aut-mei=Vicente
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=65
ORCID=

en-aut-name=PappuHanu
en-aut-sei=Pappu
en-aut-mei=Hanu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=66
ORCID=

en-aut-name=PetrzikKarel
en-aut-sei=Petrzik
en-aut-mei=Karel
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=67
ORCID=

en-aut-name=PoogginMikhail
en-aut-sei=Pooggin
en-aut-mei=Mikhail
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=68
ORCID=

en-aut-name=PrigigalloMaria Isabella
en-aut-sei=Prigigallo
en-aut-mei=Maria Isabella
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=69
ORCID=

en-aut-name=Ramos-GonzálezPedro L.
en-aut-sei=Ramos-González
en-aut-mei=Pedro L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=70
ORCID=

en-aut-name=RibeiroSimone
en-aut-sei=Ribeiro
en-aut-mei=Simone
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=71
ORCID=

en-aut-name=Richert-PöggelerKatja R.
en-aut-sei=Richert-Pöggeler
en-aut-mei=Katja R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=72
ORCID=

en-aut-name=RoumagnacPhilippe
en-aut-sei=Roumagnac
en-aut-mei=Philippe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=73
ORCID=

en-aut-name=RoyAvijit
en-aut-sei=Roy
en-aut-mei=Avijit
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=74
ORCID=

en-aut-name=SabanadzovicSead
en-aut-sei=Sabanadzovic
en-aut-mei=Sead
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=75
ORCID=

en-aut-name=ŠafářováDana
en-aut-sei=Šafářová
en-aut-mei=Dana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=76
ORCID=

en-aut-name=SaldarelliPasquale
en-aut-sei=Saldarelli
en-aut-mei=Pasquale
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=77
ORCID=

en-aut-name=SanfaçonHélène
en-aut-sei=Sanfaçon
en-aut-mei=Hélène
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=78
ORCID=

en-aut-name=SarmientoCecilia
en-aut-sei=Sarmiento
en-aut-mei=Cecilia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=79
ORCID=

en-aut-name=SasayaTakahide
en-aut-sei=Sasaya
en-aut-mei=Takahide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=80
ORCID=

en-aut-name=ScheetsKay
en-aut-sei=Scheets
en-aut-mei=Kay
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=81
ORCID=

en-aut-name=SchravesandeWillem E.W.
en-aut-sei=Schravesande
en-aut-mei=Willem E.W.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=82
ORCID=

en-aut-name=SealSusan
en-aut-sei=Seal
en-aut-mei=Susan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=83
ORCID=

en-aut-name=ShimomotoYoshifumi
en-aut-sei=Shimomoto
en-aut-mei=Yoshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=84
ORCID=

en-aut-name=SõmeraMerike
en-aut-sei=Sõmera
en-aut-mei=Merike
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=85
ORCID=

en-aut-name=StavoloneLivia
en-aut-sei=Stavolone
en-aut-mei=Livia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=86
ORCID=

en-aut-name=StewartLucy R.
en-aut-sei=Stewart
en-aut-mei=Lucy R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=87
ORCID=

en-aut-name=TeycheneyPierre-Yves
en-aut-sei=Teycheney
en-aut-mei=Pierre-Yves
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=88
ORCID=

en-aut-name=ThomasJohn E.
en-aut-sei=Thomas
en-aut-mei=John E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=89
ORCID=

en-aut-name=ThompsonJeremy R.
en-aut-sei=Thompson
en-aut-mei=Jeremy R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=90
ORCID=

en-aut-name=TiberiniAntonio
en-aut-sei=Tiberini
en-aut-mei=Antonio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=91
ORCID=

en-aut-name=TomitakaYasuhiro
en-aut-sei=Tomitaka
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=92
ORCID=

en-aut-name=TzanetakisIoannis
en-aut-sei=Tzanetakis
en-aut-mei=Ioannis
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=93
ORCID=

en-aut-name=UmberMarie
en-aut-sei=Umber
en-aut-mei=Marie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=94
ORCID=

en-aut-name=UrbinoCica
en-aut-sei=Urbino
en-aut-mei=Cica
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=95
ORCID=

en-aut-name=van den BurgHarrold A.
en-aut-sei=van den Burg
en-aut-mei=Harrold A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=96
ORCID=

en-aut-name=Van der VlugtRené A.A.
en-aut-sei=Van der Vlugt
en-aut-mei=René A.A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=97
ORCID=

en-aut-name=VarsaniArvind
en-aut-sei=Varsani
en-aut-mei=Arvind
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=98
ORCID=

en-aut-name=VerhageAdriaan
en-aut-sei=Verhage
en-aut-mei=Adriaan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=99
ORCID=

en-aut-name=VillamorDan
en-aut-sei=Villamor
en-aut-mei=Dan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=100
ORCID=

en-aut-name=von BargenSusanne
en-aut-sei=von Bargen
en-aut-mei=Susanne
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=101
ORCID=

en-aut-name=WalkerPeter J.
en-aut-sei=Walker
en-aut-mei=Peter J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=102
ORCID=

en-aut-name=WetzelThierry
en-aut-sei=Wetzel
en-aut-mei=Thierry
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=103
ORCID=

en-aut-name=WhitfieldAnna E.
en-aut-sei=Whitfield
en-aut-mei=Anna E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=104
ORCID=

en-aut-name=WylieStephen J.
en-aut-sei=Wylie
en-aut-mei=Stephen J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=105
ORCID=

en-aut-name=YangCaixia
en-aut-sei=Yang
en-aut-mei=Caixia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=106
ORCID=

en-aut-name=ZerbiniF. Murilo
en-aut-sei=Zerbini
en-aut-mei=F. Murilo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=107
ORCID=

en-aut-name=ZhangSong
en-aut-sei=Zhang
en-aut-mei=Song
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=108
ORCID=

affil-num=1
en-affil=Istituto per la Protezione Sostenibile delle Piante, CNR
kn-affil=

affil-num=2
en-affil=USDA-ARS, BARC, National Germplasm Resources Laboratory
kn-affil=

affil-num=3
en-affil=Liaoning Key Laboratory of Urban Integrated Pest Management and Ecological Security, Shenyang University
kn-affil=

affil-num=4
en-affil=Centro de Edafología y Biología Aplicada del Segura-CSIC
kn-affil=

affil-num=5
en-affil=Department of Molecular and Structural Biochemistry, North Carolina State University
kn-affil=

affil-num=6
en-affil=Unidad de Fitopatología y Modelización Agrícola (UFYMA) INTA-CONICET
kn-affil=

affil-num=7
en-affil=Plant Protection Department
kn-affil=

affil-num=8
en-affil=UMR 1332 Biologie du Fruit et Pathologie, University of Bordeaux, INRAE
kn-affil=

affil-num=9
en-affil=Margarita Salas Center for Biological Research (CIB-CSIC) Spanish Council for Scientific Research (CSIC)
kn-affil=

affil-num=10
en-affil=National Citrus Engineering and Technology Research Center, Integrative Science Center of Germplasm Creation in Western China (CHONGQING) Science City, Citrus Research Institute, Southwest University
kn-affil=

affil-num=11
en-affil=Department of Plant Sciences, University of Cambridge
kn-affil=

affil-num=12
en-affil=Agriculture and Life Sciences Research Institute, Kangwon National University
kn-affil=

affil-num=13
en-affil=Agriculture Victoria Research, Department of Energy, Environment and Climate Action and School of Applied Systems Biology, La Trobe University
kn-affil=

affil-num=14
en-affil=University of Delhi South Campu
kn-affil=

affil-num=15
en-affil=Unidad de Fitopatología y Modelización Agrícola (UFYMA) INTA-CONICET
kn-affil=

affil-num=16
en-affil=Queensland Alliance for Agriculture and Food Innovation, The University of Queensland
kn-affil=

affil-num=17
en-affil=CIHEAM, Istituto Agronomico Mediterraneo of Bari
kn-affil=

affil-num=18
en-affil=Centro de Edafología y Biología Aplicada del Segura-CSIC
kn-affil=

affil-num=19
en-affil=CIHEAM, Istituto Agronomico Mediterraneo of Bari
kn-affil=

affil-num=20
en-affil=Virus South Data
kn-affil=

affil-num=21
en-affil=Queensland Department of Primary Industries
kn-affil=

affil-num=22
en-affil=Max Planck Institute for Marine Microbiology
kn-affil=

affil-num=23
en-affil=Plant Protection Department
kn-affil=

affil-num=24
en-affil=Fera Science Ltd (Fera), York Biotech Campus
kn-affil=

affil-num=25
en-affil=Embrapa Cassava and Fruits, Brazilian Agricultural Research Corporation
kn-affil=

affil-num=26
en-affil=Plant Pathology, Cornell University
kn-affil=

affil-num=27
en-affil=Queensland Alliance for Agriculture and Food Innovation, The University of Queensland
kn-affil=

affil-num=28
en-affil=Department of Biology, University of Oxford
kn-affil=

affil-num=29
en-affil=Swedish University of Agriculture
kn-affil=

affil-num=30
en-affil=USDA-ARS, USNA, Floral and Nursery Plants Research Unit
kn-affil=

affil-num=31
en-affil=USDA-ARS, BARC, Molecular Plant Pathology Laboratory
kn-affil=

affil-num=32
en-affil=Institute of Plant Protection-NRI
kn-affil=

affil-num=33
en-affil=PHIM Plant Health Institute, University of Montpellier, INRAE, CIRAD, IRD, Institute Agro
kn-affil=

affil-num=34
en-affil=Instituto de Biología Molecular y Celular de Plantas (IBMCP), Universitat Politècnica de Valencia-CSIC
kn-affil=

affil-num=35
en-affil=Institut Français de la Vigne et du Vin
kn-affil=

affil-num=36
en-affil=Vali-e-Asr University of Rafsanjan, Department of Plant Protection
kn-affil=

affil-num=37
en-affil=Retired from John Innes Centre
kn-affil=

affil-num=38
en-affil=Embrapa Hortaliças
kn-affil=

affil-num=39
en-affil=USDA-ARS, USNA, Floral and Nursery Plants Research Unit
kn-affil=

affil-num=40
en-affil=Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=41
en-affil=International Potato Center (CIP)
kn-affil=

affil-num=42
en-affil=Institut Pasteur, Université Paris Cité, CNRS UMR6047, Archaeal Virology Unit
kn-affil=

affil-num=43
en-affil=Institute for Plant Protection, NARO
kn-affil=

affil-num=44
en-affil=Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health
kn-affil=

affil-num=45
en-affil=Department of Biological Sciences, University of Toledo
kn-affil=

affil-num=46
en-affil=CIRAD, UMR PVBMT
kn-affil=

affil-num=47
en-affil=Liaoning Key Laboratory of Urban Integrated Pest Management and Ecological Security, Shenyang University
kn-affil=

affil-num=48
en-affil=State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, Yunnan Agricultural University
kn-affil=

affil-num=49
en-affil=Institute of Plant Virology, Ningbo University
kn-affil=

affil-num=50
en-affil=Instituto de Patología Vegetal (IPAVE), INTA, Unidad de Fitopatología y Modelización Agrícola (UFYMA) INTA-CONICET
kn-affil=

affil-num=51
en-affil=Centre for Research in Agricultural Genomics, CRAG (CSIC-IRTA-UAB-UB)
kn-affil=

affil-num=52
en-affil=UMR 1332 Biologie du Fruit et Pathologie, University of Bordeaux, INRAE
kn-affil=

affil-num=53
en-affil=Department of Agricultural Sciences, University of Helsinki
kn-affil=

affil-num=54
en-affil=Institute of Infectious Disease and Molecular Medicine, University of Cape Town
kn-affil=

affil-num=55
en-affil=Plant Pathology Laboratory, TERRA Gembloux Agro-Bio Tech, University of Liege
kn-affil=

affil-num=56
en-affil=Department of Plant Pathology, Entomology and Microbiology, Iowa State University
kn-affil=

affil-num=57
en-affil=Department of Plant Protection, Gorgan University of Agricultural Sciences and Natural Resources
kn-affil=

affil-num=58
en-affil=USDA-APHIS, Plant Protection and Quarantine
kn-affil=

affil-num=59
en-affil=CIRAD, AGAP Institut; AGAP Institut, University of Montpellier; CIRAD, INRAE
kn-affil=

affil-num=60
en-affil=Instituto de Ciências Biológicas, Universidade de Brasília
kn-affil=

affil-num=61
en-affil=Instituto de Hortofruticultura Subtropical y Mediterránea “La Mayora” (IHSM-UMA-CSIC), Consejo Superior de Investigaciones Científicas
kn-affil=

affil-num=62
en-affil=Utsunomiya University
kn-affil=

affil-num=63
en-affil=Oklahoma State University, Institute for Biosecurity & Microbial Forensics
kn-affil=

affil-num=64
en-affil=Saga University
kn-affil=

affil-num=65
en-affil=Instituto de Biología Molecular y Celular de Plantas (IBMCP), Universitat Politècnica de Valencia-CSIC
kn-affil=

affil-num=66
en-affil=Department of Plant Pathology, Washington State University
kn-affil=

affil-num=67
en-affil=Institute of Plant Molecular Biology
kn-affil=

affil-num=68
en-affil=PHIM Plant Health Institute, University of Montpellier, INRAE, CIRAD, IRD
kn-affil=

affil-num=69
en-affil=Istituto per la Protezione Sostenibile delle Piante, CNR
kn-affil=

affil-num=70
en-affil=Applied Molecular Biology Laboratory, Instituto Biológico de São Paulo
kn-affil=

affil-num=71
en-affil=Embrapa Recursos Genéticos e Biotecnologia
kn-affil=

affil-num=72
en-affil=Julius Kühn Institute, Federal Research Centre for Cultivated Plants, Institute for Epidemiology and Pathogen Diagnostics
kn-affil=

affil-num=73
en-affil=CIRAD, UMR PHIM
kn-affil=

affil-num=74
en-affil=USDA-ARS, BARC, Molecular Plant Pathology Laboratory, Beltsville, MD, USA
kn-affil=

affil-num=75
en-affil=Department of Agricultural Science and Plant Protection, Mississippi State University
kn-affil=

affil-num=76
en-affil=Department of Cell Biology and Genetics, Faculty of Science, Palacký University Olomouc
kn-affil=

affil-num=77
en-affil=Istituto per la Protezione Sostenibile delle Piante, CNR
kn-affil=

affil-num=78
en-affil=Summerland Research and Development Centre, Agriculture and Agri-Food Canada
kn-affil=

affil-num=79
en-affil=Department of Chemistry and Biotechnology, Tallinn University of Technology
kn-affil=

affil-num=80
en-affil=Strategic Planning Headquarters, NARO
kn-affil=

affil-num=81
en-affil=Department of Plant Pathology, Ecology and Evolution, Oklahoma State University
kn-affil=

affil-num=82
en-affil=Molecular Plant Pathology, University of Amsterdam
kn-affil=

affil-num=83
en-affil=Natural Resources Institute, University of Greenwich
kn-affil=

affil-num=84
en-affil=Kochi Agricultural Research Center
kn-affil=

affil-num=85
en-affil=Department of Chemistry and Biotechnology, Tallinn University of Technology
kn-affil=

affil-num=86
en-affil=Istituto per la Protezione Sostenibile delle Piante, CNR
kn-affil=

affil-num=87
en-affil=Currently unaffiliated
kn-affil=

affil-num=88
en-affil=CIRAD, UMR PVBMT & UMR PVBMT, Université de la Réunion
kn-affil=

affil-num=89
en-affil=Queensland Alliance for Agriculture and Food Innovation, The University of Queensland
kn-affil=

affil-num=90
en-affil=Plant Health and Environment Laboratory
kn-affil=

affil-num=91
en-affil=Council for Agricultural Research and Economics, Research Centre for Plant Protection and Certification
kn-affil=

affil-num=92
en-affil=Institute for Plant Protection, NARO
kn-affil=

affil-num=93
en-affil=Department of Entomology and Plant Pathology, Division of Agriculture, University of Arkansas System
kn-affil=

affil-num=94
en-affil=INRAE, UR ASTRO
kn-affil=

affil-num=95
en-affil=PHIM Plant Health Institute, University of Montpellier, INRAE, CIRAD, IRD, Institute Agro
kn-affil=

affil-num=96
en-affil=Molecular Plant Pathology, University of Amsterdam
kn-affil=

affil-num=97
en-affil=Wageningen University and Research
kn-affil=

affil-num=98
en-affil=The Biodesign Center for Fundamental and Applied Microbiomics, Center for Evolution and Medicine, School of Life Sciences, Arizona State University
kn-affil=

affil-num=99
en-affil=Rijk Zwaan Breeding B.V.
kn-affil=

affil-num=100
en-affil=Department of Entomology and Plant Pathology, Division of Agriculture, University of Arkansas System
kn-affil=

affil-num=101
en-affil=Humboldt-Universität zu Berlin, Thaer-Institute of Agricultural and Horticultural Sciences
kn-affil=

affil-num=102
en-affil=The University of Queensland
kn-affil=

affil-num=103
en-affil=Dienstleistungszentrum Ländlicher Raum Rheinpfalz
kn-affil=

affil-num=104
en-affil=North Carolina State University
kn-affil=

affil-num=105
en-affil=Food Futures Institute, Murdoch University
kn-affil=

affil-num=106
en-affil=Liaoning Key Laboratory of Urban Integrated Pest Management and Ecological Security, Shenyang University
kn-affil=

affil-num=107
en-affil=Dep. de Fitopatologia/BIOAGRO, Universidade Federal de Viçosa
kn-affil=

affil-num=108
en-affil=National Citrus Engineering and Technology Research Center, Integrative Science Center of Germplasm Creation in Western China (CHONGQING) Science City, Citrus Research Institute, Southwest University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=135
cd-vols=
no-issue=13
article-no=
start-page=e172988
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250513
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=LAG3 regulates antibody responses in a murine model of kidney transplantation
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Lymphocyte activation gene 3 (LAG3) is a coinhibitory receptor expressed by various immune cells. Although the immunomodulatory potential of LAG3 is being explored in cancer and autoimmunity, there is no information on its role after organ transplantation. Our study investigated the functions of LAG3 in a mouse model of renal allograft rejection. LAG3–/– recipients rapidly rejected MHC-mismatched renal allografts that were spontaneously accepted by WT recipients, with graft histology characteristic of antibody-mediated rejection. Depletion of recipient B cells but not CD8+ T cells significantly extended kidney allograft survival in LAG3–/– recipients. Treatment of WT recipients with an antagonistic LAG3 antibody enhanced anti-donor immune responses and induced kidney damage associated with chronic rejection. The studies of conditional LAG3–/– recipients and mixed bone marrow chimeras demonstrated that LAG3 expression on either T or B cells is sufficient to regulate anti-donor humoral immunity but not to induce acute allograft rejection. The numbers and proinflammatory functions of graft-infiltrating NK cells were markedly increased in LAG3–/– recipients, suggesting that LAG3 also regulates the effector stage of antibody-mediated rejection. These findings identified LAG3 as a regulator of immune responses to kidney allografts and a potential therapeutic target for antibody-mediated rejection prevention and treatment.
en-copyright=
kn-copyright=

en-aut-name=NicosiaMichael
en-aut-sei=Nicosia
en-aut-mei=Michael
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FanRan
en-aut-sei=Fan
en-aut-mei=Ran
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=LeeJuyeun
en-aut-sei=Lee
en-aut-mei=Juyeun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AllGabriella
en-aut-sei=All
en-aut-mei=Gabriella
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=GorbachevaVictoria
en-aut-sei=Gorbacheva
en-aut-mei=Victoria
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ValenzuelaJosé I.
en-aut-sei=Valenzuela
en-aut-mei=José I.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YamamotoYosuke
en-aut-sei=Yamamoto
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=BeaversAshley
en-aut-sei=Beavers
en-aut-mei=Ashley
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=DvorinaNina
en-aut-sei=Dvorina
en-aut-mei=Nina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=BaldwinWilliam M.
en-aut-sei=Baldwin
en-aut-mei=William M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=ChuluyanEduardo
en-aut-sei=Chuluyan
en-aut-mei=Eduardo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=ArakiMotoo
en-aut-sei=Araki
en-aut-mei=Motoo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=GaudetteBrian T.
en-aut-sei=Gaudette
en-aut-mei=Brian T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=FairchildRobert L.
en-aut-sei=Fairchild
en-aut-mei=Robert L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=MinBooki
en-aut-sei=Min
en-aut-mei=Booki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=ValujskikhAnna
en-aut-sei=Valujskikh
en-aut-mei=Anna
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

affil-num=1
en-affil=Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
kn-affil=

affil-num=2
en-affil=Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
kn-affil=

affil-num=3
en-affil=Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic
kn-affil=

affil-num=4
en-affil=Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
kn-affil=

affil-num=5
en-affil=Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
kn-affil=

affil-num=6
en-affil=Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
kn-affil=

affil-num=7
en-affil=Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
kn-affil=

affil-num=8
en-affil=Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
kn-affil=

affil-num=9
en-affil=Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
kn-affil=

affil-num=10
en-affil=Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
kn-affil=

affil-num=11
en-affil=Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Centro de Estudios Farmacológicos y Botánicos (CEFYBO), Facultad de Medicina
kn-affil=

affil-num=12
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
kn-affil=

affil-num=14
en-affil=Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
kn-affil=

affil-num=15
en-affil=Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
kn-affil=

affil-num=16
en-affil=Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=10
article-no=
start-page=2401783
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241010
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Biocompatibility of Water-Dispersible Pristine Graphene and Graphene Oxide Using a Close-to-Human Animal Model: A Pilot Study on Swine
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Graphene-based materials (GBMs) are of considerable interest for biomedical applications, and the pilot study on the toxicological and immunological impact of pristine graphene (GR) and graphene oxide (GO) using swine as a close-to-human provides valuable insights. First, ex vivo experiments are conducted on swine blood cells, then GBMs are injected intraperitoneally (i.p.) into swine. Hematological and biochemical analyses at various intervals indicate that neither GO nor GR cause systemic inflammation, pro-coagulant responses, or renal or hepatic dysfunction. Importantly, no systemic toxicity is observed. Analysis of a panel of 84 immune-related genes shows minimal impact of GO and GR. The animals are sacrificed 21 days post-injection, and transient absorption imaging and Raman mapping show the presence of GO and GR in the mesentery only. Histological evaluation reveals no signs of alterations in other organs. Thus, clusters of both materials are detected in the mesentery, and GO aggregates are surrounded only by macrophages with the formation of granulomas. In contrast, modest local reactions are observed around the GR clusters. Overall, these results reveal that i.p. injection of GBMs resulted in a modest local tissue reaction without systemic toxicity. This study, performed in swine, provides essential guidance for future biomedical applications of graphene.
en-copyright=
kn-copyright=

en-aut-name=NicolussiPaola
en-aut-sei=Nicolussi
en-aut-mei=Paola
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=PiloGiovannantonio
en-aut-sei=Pilo
en-aut-mei=Giovannantonio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=CanceddaMaria Giovanna
en-aut-sei=Cancedda
en-aut-mei=Maria Giovanna
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=PengGuotao
en-aut-sei=Peng
en-aut-mei=Guotao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ChauNgoc Do Quyen
en-aut-sei=Chau
en-aut-mei=Ngoc Do Quyen
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=De la CadenaAlejandro
en-aut-sei=De la Cadena
en-aut-mei=Alejandro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=VannaRenzo
en-aut-sei=Vanna
en-aut-mei=Renzo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SamadYarjan Abdul
en-aut-sei=Samad
en-aut-mei=Yarjan Abdul
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=AhmedTanweer
en-aut-sei=Ahmed
en-aut-mei=Tanweer
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MarcellinoJeremia
en-aut-sei=Marcellino
en-aut-mei=Jeremia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=TeddeGiuseppe
en-aut-sei=Tedde
en-aut-mei=Giuseppe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=GiroLinda
en-aut-sei=Giro
en-aut-mei=Linda
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=YlmazerAcelya
en-aut-sei=Ylmazer
en-aut-mei=Acelya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=LoiFederica
en-aut-sei=Loi
en-aut-mei=Federica
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=CartaGavina
en-aut-sei=Carta
en-aut-mei=Gavina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=SecchiLoredana
en-aut-sei=Secchi
en-aut-mei=Loredana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=Dei GiudiciSilvia
en-aut-sei=Dei Giudici
en-aut-mei=Silvia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=MacciocuSimona
en-aut-sei=Macciocu
en-aut-mei=Simona
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=PolliDario
en-aut-sei=Polli
en-aut-mei=Dario
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=NishinaYuta
en-aut-sei=Nishina
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=LigiosCiriaco
en-aut-sei=Ligios
en-aut-mei=Ciriaco
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=CerulloGiulio
en-aut-sei=Cerullo
en-aut-mei=Giulio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=FerrariAndrea
en-aut-sei=Ferrari
en-aut-mei=Andrea
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=BiancoAlberto
en-aut-sei=Bianco
en-aut-mei=Alberto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=FadeelBengt
en-aut-sei=Fadeel
en-aut-mei=Bengt
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=FranzoniGiulia
en-aut-sei=Franzoni
en-aut-mei=Giulia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=DeloguLucia Gemma
en-aut-sei=Delogu
en-aut-mei=Lucia Gemma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

affil-num=1
en-affil=Istituto Zooprofilattico Sperimentale della Sardegna
kn-affil=

affil-num=2
en-affil=Istituto Zooprofilattico Sperimentale della Sardegna
kn-affil=

affil-num=3
en-affil=Istituto Zooprofilattico Sperimentale della Sardegna
kn-affil=

affil-num=4
en-affil=Institute of Environmental Medicine, Karolinska Institutet
kn-affil=

affil-num=5
en-affil=CNRS, Immunology, Immunopathology and Therapeutic Chemistry
kn-affil=

affil-num=6
en-affil=Dipartimento di Fisica, Politecnico di Milano
kn-affil=

affil-num=7
en-affil=Istituto di Fotonica e Nanotecnologie – CNR
kn-affil=

affil-num=8
en-affil=Cambridge Graphene Centre, University of Cambridge
kn-affil=

affil-num=9
en-affil=Cambridge Graphene Centre, University of Cambridge
kn-affil=

affil-num=10
en-affil=Cambridge Graphene Centre, University of Cambridge
kn-affil=

affil-num=11
en-affil=Istituto Zooprofilattico Sperimentale della Sardegna
kn-affil=

affil-num=12
en-affil=ImmuneNano Laboratory, Department of Biomedical Sciences
kn-affil=

affil-num=13
en-affil=Department of Biomedical Engineering, Ankara University
kn-affil=

affil-num=14
en-affil=Istituto Zooprofilattico Sperimentale della Sardegna
kn-affil=

affil-num=15
en-affil=Istituto Zooprofilattico Sperimentale della Sardegna
kn-affil=

affil-num=16
en-affil=Istituto Zooprofilattico Sperimentale della Sardegna
kn-affil=

affil-num=17
en-affil=Istituto Zooprofilattico Sperimentale della Sardegna
kn-affil=

affil-num=18
en-affil=Istituto Zooprofilattico Sperimentale della Sardegna
kn-affil=

affil-num=19
en-affil=Dipartimento di Fisica, Politecnico di Milano
kn-affil=

affil-num=20
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=21
en-affil=Istituto Zooprofilattico Sperimentale della Sardegna
kn-affil=

affil-num=22
en-affil=Dipartimento di Fisica, Politecnico di Milano
kn-affil=

affil-num=23
en-affil=Cambridge Graphene Centre, University of Cambridge
kn-affil=

affil-num=24
en-affil=CNRS, Immunology, Immunopathology and Therapeutic Chemistry
kn-affil=

affil-num=25
en-affil=Institute of Environmental Medicine, Karolinska Institutet
kn-affil=

affil-num=26
en-affil=Istituto Zooprofilattico Sperimentale della Sardegna
kn-affil=

affil-num=27
en-affil=ImmuneNano Laboratory, Department of Biomedical Sciences
kn-affil=
en-keyword=2D materials
kn-keyword=2D materials
en-keyword=biocompatibility
kn-keyword=biocompatibility
en-keyword=immune system
kn-keyword=immune system
en-keyword=porcine model
kn-keyword=porcine model
en-keyword=toxicity
kn-keyword=toxicity
END

start-ver=1.4
cd-journal=joma
no-vol=4
cd-vols=
no-issue=4
article-no=
start-page=263
end-page=272
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240607
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Light-Responsive and Antibacterial Graphenic Materials as a Holistic Approach to Tissue Engineering
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=While the continuous development of advanced bioprinting technologies is under fervent study, enhancing the regenerative potential of hydrogel-based constructs using external stimuli for wound dressing has yet to be tackled. Fibroblasts play a significant role in wound healing and tissue implants at different stages, including extracellular matrix production, collagen synthesis, and wound and tissue remodeling. This study explores the synergistic interplay between photothermal activity and nanomaterial-mediated cell proliferation. The use of different graphene-based materials (GBM) in the development of photoactive bioinks is investigated. In particular, we report the creation of a skin-inspired dressing for wound healing and regenerative medicine. Three distinct GBM, namely, graphene oxide (GO), reduced graphene oxide (rGO), and graphene platelets (GP), were rigorously characterized, and their photothermal capabilities were elucidated. Our investigations revealed that rGO exhibited the highest photothermal efficiency and antibacterial properties when irradiated, even at a concentration as low as 0.05 mg/mL, without compromising human fibroblast viability. Alginate-based bioinks alongside human fibroblasts were employed for the bioprinting with rGO. The scaffold did not affect the survival of fibroblasts for 3 days after bioprinting, as cell viability was not affected. Remarkably, the inclusion of rGO did not compromise the printability of the hydrogel, ensuring the successful fabrication of complex constructs. Furthermore, the presence of rGO in the final scaffold continued to provide the benefits of photothermal antimicrobial therapy without detrimentally affecting fibroblast growth. This outcome underscores the potential of rGO-enhanced hydrogels in tissue engineering and regenerative medicine applications. Our findings hold promise for developing game-changer strategies in 4D bioprinting to create smart and functional tissue constructs with high fibroblast proliferation and promising therapeutic capabilities in drug delivery and bactericidal skin-inspired dressings.
en-copyright=
kn-copyright=

en-aut-name=FerrerasAndrea
en-aut-sei=Ferreras
en-aut-mei=Andrea
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatesanzAna
en-aut-sei=Matesanz
en-aut-mei=Ana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MendizabalJabier
en-aut-sei=Mendizabal
en-aut-mei=Jabier
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ArtolaKoldo
en-aut-sei=Artola
en-aut-mei=Koldo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NishinaYuta
en-aut-sei=Nishina
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=AcedoPablo
en-aut-sei=Acedo
en-aut-mei=Pablo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=JorcanoJosé L.
en-aut-sei=Jorcano
en-aut-mei=José L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=RuizAmalia
en-aut-sei=Ruiz
en-aut-mei=Amalia
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ReinaGiacomo
en-aut-sei=Reina
en-aut-mei=Giacomo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MartínCristina
en-aut-sei=Martín
en-aut-mei=Cristina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Bioengineering, Universidad Carlos III de Madrid
kn-affil=

affil-num=2
en-affil=Department of Electronic Technology, Universidad Carlos III de Madrid
kn-affil=

affil-num=3
en-affil=Domotek ingeniería prototipado y formación S.L.
kn-affil=

affil-num=4
en-affil=Domotek ingeniería prototipado y formación S.L.
kn-affil=

affil-num=5
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Electronic Technology, Universidad Carlos III de Madrid
kn-affil=

affil-num=7
en-affil=Department of Bioengineering, Universidad Carlos III de Madrid
kn-affil=

affil-num=8
en-affil=Institute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of Bradford
kn-affil=

affil-num=9
en-affil=Empa Swiss Federal Laboratories for Materials Science and Technology
kn-affil=

affil-num=10
en-affil=Department of Bioengineering, Universidad Carlos III de Madrid
kn-affil=
en-keyword=photothermal therapy
kn-keyword=photothermal therapy
en-keyword=graphene derivatives
kn-keyword=graphene derivatives
en-keyword=4D bioprinting
kn-keyword=4D bioprinting
en-keyword=alginate
kn-keyword=alginate
en-keyword=tissue engineering
kn-keyword=tissue engineering
END

start-ver=1.4
cd-journal=joma
no-vol=637
cd-vols=
no-issue=8046
article-no=
start-page=744
end-page=748
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250101
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Centrophilic retrotransposon integration via CENH3 chromatin in Arabidopsis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=In organisms ranging from vertebrates to plants, major components of centromeres are rapidly evolving repeat sequences, such as tandem repeats (TRs) and transposable elements (TEs), which harbour centromere-specific histone H3 (CENH3)1,2. Complete centromere structures recently determined in human and Arabidopsis suggest frequent integration and purging of retrotransposons within the TR regions of centromeres3,4,5. Despite the high impact of ‘centrophilic’ retrotransposons on the paradox of rapid centromere evolution, the mechanisms involved in centromere targeting remain poorly understood in any organism. Here we show that both Ty3 and Ty1 long terminal repeat retrotransposons rapidly turnover within the centromeric TRs of Arabidopsis species. We demonstrate that the Ty1/Copia element Tal1 (Transposon of Arabidopsis lyrata 1) integrates de novo into regions occupied by CENH3 in Arabidopsis thaliana, and that ectopic expansion of the CENH3 region results in spread of Tal1 integration regions. The integration spectra of chimeric TEs reveal the key structural variations responsible for contrasting chromatin-targeting specificities to centromeres versus gene-rich regions, which have recurrently converted during the evolution of these TEs. Our findings show the impact of centromeric chromatin on TE-mediated rapid centromere evolution, with relevance across eukaryotic genomes.
en-copyright=
kn-copyright=

en-aut-name=TsukaharaSayuri
en-aut-sei=Tsukahara
en-aut-mei=Sayuri
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=BousiosAlexandros
en-aut-sei=Bousios
en-aut-mei=Alexandros
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=Perez-RomanEstela
en-aut-sei=Perez-Roman
en-aut-mei=Estela
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamaguchiSota
en-aut-sei=Yamaguchi
en-aut-mei=Sota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=LeduqueBasile
en-aut-sei=Leduque
en-aut-mei=Basile
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakanoAimi
en-aut-sei=Nakano
en-aut-mei=Aimi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NaishMatthew
en-aut-sei=Naish
en-aut-mei=Matthew
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OsakabeAkihisa
en-aut-sei=Osakabe
en-aut-mei=Akihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ToyodaAtsushi
en-aut-sei=Toyoda
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=ItoHidetaka
en-aut-sei=Ito
en-aut-mei=Hidetaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=EderaAlejandro
en-aut-sei=Edera
en-aut-mei=Alejandro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TominagaSayaka
en-aut-sei=Tominaga
en-aut-mei=Sayaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=Juliarni
en-aut-sei=Juliarni
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=KatoKae
en-aut-sei=Kato
en-aut-mei=Kae
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=OdaShoko
en-aut-sei=Oda
en-aut-mei=Shoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=InagakiSoichi
en-aut-sei=Inagaki
en-aut-mei=Soichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=LorkovićZdravko
en-aut-sei=Lorković
en-aut-mei=Zdravko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=NagakiKiyotaka
en-aut-sei=Nagaki
en-aut-mei=Kiyotaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=BergerFrédéric
en-aut-sei=Berger
en-aut-mei=Frédéric
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=KawabeAkira
en-aut-sei=Kawabe
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=QuadranaLeandro
en-aut-sei=Quadrana
en-aut-mei=Leandro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=HendersonIan
en-aut-sei=Henderson
en-aut-mei=Ian
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=KakutaniTetsuji
en-aut-sei=Kakutani
en-aut-mei=Tetsuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

affil-num=1
en-affil=Department of Biological Sciences, The University of Tokyo
kn-affil=

affil-num=2
en-affil=School of Life Sciences, University of Sussex
kn-affil=

affil-num=3
en-affil=School of Life Sciences, University of Sussex
kn-affil=

affil-num=4
en-affil=Department of Biological Sciences, The University of Tokyo
kn-affil=

affil-num=5
en-affil=Institute of Plant Sciences Paris‐Saclay (IPS2), Centre National de la Recherche Scientifique, Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement, Université Evry, Université Paris
kn-affil=

affil-num=6
en-affil=Department of Biological Sciences, The University of Tokyo
kn-affil=

affil-num=7
en-affil=Department of Plant Sciences, University of Cambridge
kn-affil=

affil-num=8
en-affil=Department of Biological Sciences, The University of Tokyo
kn-affil=

affil-num=9
en-affil=Center for Genetic Resource Information, National Institute of Genetics
kn-affil=

affil-num=10
en-affil=Faculty of Science, Hokkaido University
kn-affil=

affil-num=11
en-affil=Institute of Plant Sciences Paris‐Saclay (IPS2), Centre National de la Recherche Scientifique, Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement, Université Evry, Université Paris
kn-affil=

affil-num=12
en-affil=Department of Biological Sciences, The University of Tokyo
kn-affil=

affil-num=13
en-affil=Department of Biological Sciences, The University of Tokyo
kn-affil=

affil-num=14
en-affil=Department of Integrated Genetics, National Institute of Genetics
kn-affil=

affil-num=15
en-affil=Department of Biological Sciences, The University of Tokyo
kn-affil=

affil-num=16
en-affil=Department of Biological Sciences, The University of Tokyo
kn-affil=

affil-num=17
en-affil=Gregor Mendel Institute (GMI), Austrian Academy of Sciences, Vienna BioCenter (VBC)
kn-affil=

affil-num=18
en-affil=Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=19
en-affil=Gregor Mendel Institute (GMI), Austrian Academy of Sciences, Vienna BioCenter (VBC)
kn-affil=

affil-num=20
en-affil=Faculty of Life Sciences, Kyoto Sangyo University
kn-affil=

affil-num=21
en-affil=Institute of Plant Sciences Paris‐Saclay (IPS2), Centre National de la Recherche Scientifique, Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement, Université Evry, Université Paris
kn-affil=

affil-num=22
en-affil=Department of Plant Sciences, University of Cambridge
kn-affil=

affil-num=23
en-affil=Department of Biological Sciences, The University of Tokyo
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=64
cd-vols=
no-issue=5
article-no=
start-page=759
end-page=762
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250301
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Novel De Novo Variant in KCNH5 in a Patient with Refractory Epileptic Encephalopathy
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We herein report a novel de novo KCNH5 variant in a patient with refractory epileptic encephalopathy. The patient exhibited seizures at 1 year and 7 months old, which gradually worsened, leading to a bedridden status. Brain magnetic resonance imaging (MRI) showed cerebral atrophy and cerebellar hypoplasia. A trio whole-exome sequence analysis identified a de novo heterozygous c.640A>C, p.Lys214Gln variant in KCNH5 that was predicted to be deleterious. Recent studies have linked KCNH5 to various epileptic encephalopathies, with many patients showing normal MRI findings. The present case expands the clinical spectrum of the disease, as it is characterized by severe neurological prognosis, cerebral atrophy, and cerebellar hypoplasia.
en-copyright=
kn-copyright=

en-aut-name=MitsutakeAkihiko
en-aut-sei=Mitsutake
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatsukawaTakashi
en-aut-sei=Matsukawa
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NaitoTatsuhiko
en-aut-sei=Naito
en-aut-mei=Tatsuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IshiuraHiroyuki
en-aut-sei=Ishiura
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MitsuiJun
en-aut-sei=Mitsui
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HaradaHiroaki
en-aut-sei=Harada
en-aut-mei=Hiroaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=FujioKeishi
en-aut-sei=Fujio
en-aut-mei=Keishi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=FujishiroJun
en-aut-sei=Fujishiro
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MoriHarushi
en-aut-sei=Mori
en-aut-mei=Harushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MorishitaShinichi
en-aut-sei=Morishita
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=TsujiShoji
en-aut-sei=Tsuji
en-aut-mei=Shoji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TodaTatsushi
en-aut-sei=Toda
en-aut-mei=Tatsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=2
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=3
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=4
en-affil=Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=6
en-affil=Department of Rheumatology and Allergy, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=7
en-affil=Department of Rheumatology and Allergy, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=8
en-affil=Department of Pediatric Surgery, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=9
en-affil=Department of Radiology, School of Medicine, Jichi Medical University
kn-affil=

affil-num=10
en-affil=Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo
kn-affil=

affil-num=11
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=

affil-num=12
en-affil=Department of Neurology, Graduate School of Medicine, The University of Tokyo
kn-affil=
en-keyword=epileptic encephalopathy
kn-keyword=epileptic encephalopathy
en-keyword=whole-exome sequencing
kn-keyword=whole-exome sequencing
en-keyword=KCNH5
kn-keyword=KCNH5
en-keyword=de novo variant
kn-keyword=de novo variant
END

start-ver=1.4
cd-journal=joma
no-vol=
cd-vols=
no-issue=
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250325
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=慢性副鼻腔炎は慢性咳嗽患者の肺機能低下と関連している可能性がある
kn-title=Chronic rhinosinusitis possibly associated with decreased lung function in chronic cough patients
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=ZHAOPENGFEI
en-aut-sei=ZHAO
en-aut-mei=PENGFEI
kn-aut-name=趙鵬飛
kn-aut-sei=趙
kn-aut-mei=鵬飛
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=岡山大学大学院医歯薬学総合研究科
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=3
article-no=
start-page=209
end-page=212
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202506
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Case of Aniline Poisoning Manifesting as Cyanosis with Unknown Cause
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A 38-year-old man was brought to the hospital for emergency treatment of cyanosis. The patient exhibited generalized cyanosis and impaired consciousness despite adequate oxygen therapy. Arterial blood was black, and arterial blood gas analysis revealed an abnormally high methemoglobin level of 67.8%. We later interviewed his colleagues regarding his exposure to aniline while working at the factory and diagnosed him with methemoglobinemia due to aniline poisoning. The patient was administered methylene blue (MB) after being transferred to another hospital, where this treatment was available, resulting in an improvement in symptoms. Although rare, methemoglobinemia is serious. A good understanding of the circumstances at disease onset, characteristic findings, and abnormal values of methemoglobinemia is important. In addition, MB is an important therapeutic for the treatment of methemoglobinemia; if MB is not available at a particular hospital, transfer of the patient to a hospital that stocks MB should be considered.
en-copyright=
kn-copyright=

en-aut-name=TaguchiKenichi
en-aut-sei=Taguchi
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NishiiKazuya
en-aut-sei=Nishii
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HataSakura
en-aut-sei=Hata
en-aut-mei=Sakura
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KuyamaShoichi
en-aut-sei=Kuyama
en-aut-mei=Shoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TanakaShoichi
en-aut-sei=Tanaka
en-aut-mei=Shoichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Gastroenterology, NHO Iwakuni Clinical Center
kn-affil=

affil-num=2
en-affil=Department of Respiratory Medicine, NHO Iwakuni Clinical Center
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology, NHO Iwakuni Clinical Center
kn-affil=

affil-num=4
en-affil=
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology, NHO Iwakuni Clinical Center
kn-affil=
en-keyword=methemoglobinemia
kn-keyword=methemoglobinemia
en-keyword=aniline
kn-keyword=aniline
en-keyword=methylene blue
kn-keyword=methylene blue
en-keyword=cyanosis
kn-keyword=cyanosis
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=3
article-no=
start-page=197
end-page=203
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202506
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Rheumatoid Arthritis with Rapid Destructive Arthropathy of the Shoulder due to Calcium Pyrophosphate Deposition
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A 67-year-old woman with rheumatoid arthritis presented with an untriggered hematoma in the right shoulder joint. Radiographic findings showed humeral head collapse and destruction of the glenoid fossa with ectopic calcification. Calcium pyrophosphate deposition (CPPD) in the synovial fluid was observed using a polarizing microscope. Histopathological findings revealed chronic inflammatory cell infiltration and giant cells surrounded by CPPD. The patient was diagnosed with rapid destructive arthropathy (RDA). Endoscopic shoulder joint debridement was performed. Postoperatively, active flexion improved from 40 to 75 degrees. This case highlights that CPPD can cause RDA in the shoulder, detectable with detailed histopathology.
en-copyright=
kn-copyright=

en-aut-name=KondoNaoki
en-aut-sei=Kondo
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KakutaniRika
en-aut-sei=Kakutani
en-aut-mei=Rika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MochizukiTomoharu
en-aut-sei=Mochizuki
en-aut-mei=Tomoharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=WakuiJunichi 
en-aut-sei=Wakui
en-aut-mei=Junichi 
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HaoNariaki
en-aut-sei=Hao
en-aut-mei=Nariaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KinoshitaEiji
en-aut-sei=Kinoshita
en-aut-mei=Eiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KawashimaHiroyuki
en-aut-sei=Kawashima
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences
kn-affil=

affil-num=2
en-affil=Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences
kn-affil=

affil-num=3
en-affil=Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences
kn-affil=

affil-num=4
en-affil=Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences
kn-affil=

affil-num=5
en-affil=Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences
kn-affil=

affil-num=6
en-affil=Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences
kn-affil=

affil-num=7
en-affil=Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences
kn-affil=
en-keyword=rheumatoid arthritis
kn-keyword=rheumatoid arthritis
en-keyword=calcium pyrophosphate deposition
kn-keyword=calcium pyrophosphate deposition
en-keyword=rapid destructive arthropathy
kn-keyword=rapid destructive arthropathy
en-keyword=case report
kn-keyword=case report
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=3
article-no=
start-page=185
end-page=195
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202506
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Emotional Changes among Young Patients with Breast Cancer to Foster Relationship-Building with Their Partners: A Qualitative Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We investigated the emotional changes that young patients with breast cancer need to undergo in order to foster relationship-building with their partners by conducting a qualitative descriptive study (March 1 to Nov. 26, 2021) and semi-structured interviews with eight postoperative patients (age 20-40 years) with breast cancer. The data were analyzed using the modified grounded theory approach (M-GTA), yielding five categories: (i) Awareness of being a breast cancer patient, (ii) Being at a loss, (iii) Support from significant others, (iv) The struggle to transition from being a patient with cancer to becoming “the person I want to be”, and (v) Reaching the “me” I want to be who can face building a relationship with a partner. These findings suggest that young breast cancer patients must feel that they can lead a normal life through activities such as work or acquiring qualifications before building relationships with their partners, and that getting closer to their desired selves is important. Nurses can provide information to young patients with breast cancer to assist them in building a solid relationship with their partners. We believe that this support may enhance the patients’ quality of life and help them achieve stronger relationships with their partners.
en-copyright=
kn-copyright=

en-aut-name=YoshikawaAyumi
en-aut-sei=Yoshikawa
en-aut-mei=Ayumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OkanagaMayumi
en-aut-sei=Okanaga
en-aut-mei=Mayumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SaitoShinya
en-aut-sei=Saito
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Faculty of Nursing, Osaka Dental University
kn-affil=

affil-num=2
en-affil=Kawasaki Medical School, Department of Breast and Thyroid Surgery
kn-affil=

affil-num=3
en-affil=Gifu College of Nursing, Nursing of Children and Child-Rearing Families
kn-affil=

affil-num=4
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=
en-keyword=breast cancer patient
kn-keyword=breast cancer patient
en-keyword=young patient
kn-keyword=young patient
en-keyword=single
kn-keyword=single
en-keyword=partners
kn-keyword=partners
en-keyword=relationships
kn-keyword=relationships
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=3
article-no=
start-page=167
end-page=176
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202506
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Promising Effectiveness of Combined Chemotherapy and Immunotherapy in Patients with Advanced Non-small Cell Lung Cancer: A Real-World Prospective Observational Study (CS-Lung-003)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This prospective observational study investigated the clinical status of patients with advanced non-small cell lung cancer (NSCLC) treated with cytotoxic chemotherapy+an immune checkpoint inhibitor (chemo + IO) as first-line treatment in a real-world setting. The cases of 98 patients treated with chemo + IO were prospectively collected and analyzed for effectiveness and safety. The response rate to chemo + IO was 46.9%, and the disease control rate was 76.5%. The median progression-free survival and overall survival (OS) in the total population were 5.2 and 22.3 months, respectively. The patients positive for PD-L1 (≥ 1%) showed significantly longer OS than the negative group (<1%) (median 26.7 vs. 18.7 months, p=0.04). Pre-existing interstitial lung disease (ILD) was associated with shorter OS than the absence of ILD (median 9.0 vs. 22.6 months, p<0.01). Immunerelated adverse events (irAEs) were observed in 28 patients (28.6%). The most frequent irAE was ILD (n=11); Grade 1 (n=1 patient), G2 (n=5), G3 (n=4), and only a single patient with a G5 irAE. In this CS-Lung-003 study, first-line chemo + IO in a real-world setting showed good effectiveness, comparable to that observed in international clinical trials. In real-world practice, chemo + IO is a promising and steadfast strategy.
en-copyright=
kn-copyright=

en-aut-name=KanajiNobuhiro
en-aut-sei=Kanaji
en-aut-mei=Nobuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NishiiKazuya
en-aut-sei=Nishii
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TsubataYukari
en-aut-sei=Tsubata
en-aut-mei=Yukari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakaoMika
en-aut-sei=Nakao
en-aut-mei=Mika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OkunoTakae
en-aut-sei=Okuno
en-aut-mei=Takae
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OkawaSachi
en-aut-sei=Okawa
en-aut-mei=Sachi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakataKenji
en-aut-sei=Takata
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KodaniMasahiro
en-aut-sei=Kodani
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YamasakiMasahiro
en-aut-sei=Yamasaki
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=FujitakaKazunori
en-aut-sei=Fujitaka
en-aut-mei=Kazunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KubotaTetsuya
en-aut-sei=Kubota
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=InoueMasaaki
en-aut-sei=Inoue
en-aut-mei=Masaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=WatanabeNaoki
en-aut-sei=Watanabe
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=HottaKatsuyuki
en-aut-sei=Hotta
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=CS-Lung-003 Investigator
en-aut-sei=CS-Lung-003 Investigator
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

affil-num=1
en-affil=Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=2
en-affil=Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=3
en-affil=Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine
kn-affil=

affil-num=4
en-affil=Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine
kn-affil=

affil-num=5
en-affil=Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine
kn-affil=

affil-num=6
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Division of Medical Oncology and Molecular Respirology, Faculty of Medicine, Tottori University
kn-affil=

affil-num=9
en-affil=Department of Respiratory Disease, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital
kn-affil=

affil-num=10
en-affil=Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=11
en-affil=Department of Respiratory Medicine and Allergology, Kochi University
kn-affil=

affil-num=12
en-affil=Department of Chest Surgery, Shimonoseki City Hospital
kn-affil=

affil-num=13
en-affil=Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=14
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=15
en-affil=
kn-affil=
en-keyword=non-small cell lung cancer
kn-keyword=non-small cell lung cancer
en-keyword=real-world
kn-keyword=real-world
en-keyword=first-line
kn-keyword=first-line
en-keyword=immune checkpoint inhibitor
kn-keyword=immune checkpoint inhibitor
en-keyword=combined immunotherapy
kn-keyword=combined immunotherapy
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=3
article-no=
start-page=157
end-page=166
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202506
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Continuous Stimulation with Glycolaldehyde-derived Advanced Glycation End Product Reduces Aggrecan and COL2A1 Production via RAGE in Human OUMS-27 Chondrosarcoma Cells
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Chondrocytes are responsible for the production of extracellular matrix (ECM) components such as collagen type II alpha-1 (COL2A1) and aggrecan, which are loosely distributed in articular cartilage. Chondrocyte dysfunction has been implicated in the pathogenesis of rheumatic diseases such as osteoarthritis (OA) and rheumatoid arthritis (RA). With age, advanced glycation end products (AGEs) accumulate in all tissues and body fluids, including cartilage and synovial fluid, causing and accelerating pathological changes associated with chronic diseases such as OA. Glycolaldehyde-derived AGE (AGE3), which is toxic to a variety of cell types, have a stronger effect on cartilage compared with other AGEs. To understand the long-term effects of AGE3 on cartilage, we stimulated a human chondrosarcoma cell line (OUMS-27), which exhibits a chondrocytic phenotype, with 10 μg/ml AGE3 for 4 weeks. As a result, the expressions of COL2A1 and aggrecan were significantly downregulated in the OUMS-27 cells without inducing cell death, but the expressions of proteases that play an important role in cartilage destruction were not affected. Inhibition of the receptor for advanced glycation end products (RAGE) suppressed the AGE3-induced reduction in cartilage component production, suggesting the involvement of RAGE in the action of AGE3.
en-copyright=
kn-copyright=

en-aut-name=HatipogluOmer Faruk
en-aut-sei=Hatipoglu
en-aut-mei=Omer Faruk
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NishinakaTakashi
en-aut-sei=Nishinaka
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YaykasliKursat Oguz
en-aut-sei=Yaykasli
en-aut-mei=Kursat Oguz
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MoriShuji
en-aut-sei=Mori
en-aut-mei=Shuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=WatanabeMasahiro
en-aut-sei=Watanabe
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ToyomuraTakao
en-aut-sei=Toyomura
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NishiboriMasahiro
en-aut-sei=Nishibori
en-aut-mei=Masahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HirohataSatoshi
en-aut-sei=Hirohata
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TakahashiHideo
en-aut-sei=Takahashi
en-aut-mei=Hideo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=WakeHidenori
en-aut-sei=Wake
en-aut-mei=Hidenori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Pharmacology, Faculty of Medicine, Kindai University
kn-affil=

affil-num=2
en-affil=Department of Pharmacology, Faculty of Medicine, Kindai University
kn-affil=

affil-num=3
en-affil=Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen
kn-affil=

affil-num=4
en-affil=Department of Pharmacology, School of Pharmacy, Shujitsu University
kn-affil=

affil-num=5
en-affil=Department of Pharmacology, School of Pharmacy, Shujitsu University
kn-affil=

affil-num=6
en-affil=Department of Pharmacology, School of Pharmacy, Shujitsu University
kn-affil=

affil-num=7
en-affil=Department of Translational Research & Dug Development, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Medical Technology, Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=9
en-affil=Department of Pharmacology, Faculty of Medicine, Kindai University
kn-affil=

affil-num=10
en-affil=Department of Pharmacology, Faculty of Medicine, Kindai University
kn-affil=
en-keyword=advanced glycation end product
kn-keyword=advanced glycation end product
en-keyword=aging
kn-keyword=aging
en-keyword=cartilage
kn-keyword=cartilage
en-keyword=collagen
kn-keyword=collagen
en-keyword=aggrecan
kn-keyword=aggrecan
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=3
article-no=
start-page=147
end-page=155
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202506
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Immunometabolic Regulation of Innate Immunity in Systemic Lupus Erythematosus
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Pathogens or their components can induce long-lasting changes in the behavior of innate immune cells, a process analogous to “training” for future threats or environmental adaptation. However, such training can sometimes have unintended consequences, such as the development of autoimmunity. Systemic lupus erythematosus (SLE) is a chronic and heterogeneous autoimmune disease characterized by the production of autoantibodies and progressive organ damage. Innate immunity plays a central role in its pathogenesis, contributing through impaired clearance of apoptotic cells, excessive type I interferon production, and dysregulated formation of neutrophil extracellular traps. Recent studies have revealed that metabolites and nucleic acids derived from mitochondria, a crucial energy production site, directly regulate type I interferon and anti-inflammatory cytokine production. These insights have fueled interest in targeting metabolic pathways as a novel therapeutic approach for SLE, offering promise for improving long-term patient outcomes.
en-copyright=
kn-copyright=

en-aut-name=WatanabeHaruki
en-aut-sei=Watanabe
en-aut-mei=Haruki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatsumotoYoshinori
en-aut-sei=Matsumoto
en-aut-mei=Yoshinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=systemic lupus erythematosus
kn-keyword=systemic lupus erythematosus
en-keyword=interferon
kn-keyword=interferon
en-keyword=tricarboxylic acid cycle
kn-keyword=tricarboxylic acid cycle
en-keyword=innate immune memory
kn-keyword=innate immune memory
en-keyword=trained immunity
kn-keyword=trained immunity
END

start-ver=1.4
cd-journal=joma
no-vol=27
cd-vols=
no-issue=4
article-no=
start-page=043024
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250428
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Characterization of the thorium-229 defect structure in CaF2 crystals
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Recent advancements in laser excitation of the low-energy thorium-229 (229Th) nuclear isomeric state in calcium fluoride (CaF2) single crystals render this system a promising candidate for a solid-state nuclear clock. Nonetheless, the precise experimental determination of the microscopic ion configuration surrounding the doped 229Th and its electronic charge state remains a critical challenge. Such characterization is essential for precisely controlling the clock transition and evaluating the performance of this solid-state nuclear clock system. In this study, we use x-ray absorption fine structure spectroscopy of 229Th:CaF2 to investigate the charge state and coordination environment of doped 229Th. The results indicate that 229Th displays a 4+ oxidation state at the substitutional site of a Ca2+ ion, with charge compensated provided by two F− ions positioned at interstitial sites adjacent to 229Th.
en-copyright=
kn-copyright=

en-aut-name=TakatoriS.
en-aut-sei=Takatori
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=PimonM.
en-aut-sei=Pimon
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=PollittS.
en-aut-sei=Pollitt
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=BartokosM.
en-aut-sei=Bartokos
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=BeeksK.
en-aut-sei=Beeks
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=GrueneisA.
en-aut-sei=Grueneis
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HirakiT.
en-aut-sei=Hiraki
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HonmaT.
en-aut-sei=Honma
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HosseiniN.
en-aut-sei=Hosseini
en-aut-mei=N.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=LeitnerA.
en-aut-sei=Leitner
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MasudaT.
en-aut-sei=Masuda
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MorawetzI
en-aut-sei=Morawetz
en-aut-mei=I
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=NittaK.
en-aut-sei=Nitta
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=OkaiK.
en-aut-sei=Okai
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=RiebnerT.
en-aut-sei=Riebner
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=SchadenF.
en-aut-sei=Schaden
en-aut-mei=F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=SchummT.
en-aut-sei=Schumm
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=SekizawaO.
en-aut-sei=Sekizawa
en-aut-mei=O.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=SikorskyT.
en-aut-sei=Sikorsky
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=TakahashiY.
en-aut-sei=Takahashi
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=De ColCol, L. Toscani
en-aut-sei=De Col
en-aut-mei=Col, L. Toscani
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=YamamotoR.
en-aut-sei=Yamamoto
en-aut-mei=R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=YomogidaT.
en-aut-sei=Yomogida
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=YoshimiA.
en-aut-sei=Yoshimi
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=YoshimuraK.
en-aut-sei=Yoshimura
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

affil-num=1
en-affil=Research Institute for Interdisciplinary Science (RIIS), Okayama University
kn-affil=

affil-num=2
en-affil=Faculty of Physics, TU Wien
kn-affil=

affil-num=3
en-affil=Faculty of Physics, TU Wien
kn-affil=

affil-num=4
en-affil=Faculty of Physics, TU Wien
kn-affil=

affil-num=5
en-affil=Faculty of Physics, TU Wien
kn-affil=

affil-num=6
en-affil=Faculty of Physics, TU Wien
kn-affil=

affil-num=7
en-affil=Research Institute for Interdisciplinary Science (RIIS), Okayama University
kn-affil=

affil-num=8
en-affil=Japan Synchrotron Radiation Research Institute
kn-affil=

affil-num=9
en-affil=Faculty of Physics, TU Wien
kn-affil=

affil-num=10
en-affil=Faculty of Physics, TU Wien
kn-affil=

affil-num=11
en-affil=Research Institute for Interdisciplinary Science (RIIS), Okayama University
kn-affil=

affil-num=12
en-affil=Faculty of Physics, TU Wien
kn-affil=

affil-num=13
en-affil=Japan Synchrotron Radiation Research Institute
kn-affil=

affil-num=14
en-affil=Research Institute for Interdisciplinary Science (RIIS), Okayama University
kn-affil=

affil-num=15
en-affil=Faculty of Physics, TU Wien
kn-affil=

affil-num=16
en-affil=Faculty of Physics, TU Wien
kn-affil=

affil-num=17
en-affil=Faculty of Physics, TU Wien
kn-affil=

affil-num=18
en-affil=Japan Synchrotron Radiation Research Institute
kn-affil=

affil-num=19
en-affil=Faculty of Physics, TU Wien
kn-affil=

affil-num=20
en-affil=Department of Earth and Planetary Science, The University of Tokyo
kn-affil=

affil-num=21
en-affil=Faculty of Physics, TU Wien
kn-affil=

affil-num=22
en-affil=Research Institute for Interdisciplinary Science (RIIS), Okayama University
kn-affil=

affil-num=23
en-affil=Department of Earth and Planetary Science, The University of Tokyo
kn-affil=

affil-num=24
en-affil=Research Institute for Interdisciplinary Science (RIIS), Okayama University
kn-affil=

affil-num=25
en-affil=Research Institute for Interdisciplinary Science (RIIS), Okayama University
kn-affil=
en-keyword=solid-state nuclear clock
kn-keyword=solid-state nuclear clock
en-keyword=thorium-229
kn-keyword=thorium-229
en-keyword=XAFS
kn-keyword=XAFS
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=2
article-no=
start-page=109
end-page=116
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202504
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Relationship between Personality Traits and Postpartum Depressive Symptoms in Women who Became Pregnant via Infertility Treatment
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The status of postpartum depression was elucidated herein with the use of the Edinburgh Postnatal Depression Scale (EPDS) in women in Shikoku, Japan who became pregnant and gave birth after undergoing infertility treatment, including assisted reproductive technology (ART). The assessment was performed during their children’s 4-month health examination. The relationships between postpartum depression and the mothers’ background factors and scores on the Big Five personality traits scale were also examined. Of the Big Five personality traits, the scores for neuroticism were significantly higher in the ART group (n=71) than in the general infertility treatment (n=118) and natural pregnancy (n=872) groups. No significant differences in EPDS scores were seen among these three groups. A logistic regression analysis showed that neuroticism was associated with an EPDS score ≧9 points, (which is suggestive of postpartum depression, ) in all groups. Moreover, although a long-standing marriage had an inhibitory effect on postpartum depression in the natural pregnancy group, no such trend was seen in the ART group, which included many women with long-standing marriages. Particularly for women who become pregnant by ART, an individualized response that pays close attention to the woman’s personality traits is needed.
en-copyright=
kn-copyright=

en-aut-name=AwaiKyoko
en-aut-sei=Awai
en-aut-mei=Kyoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakatsukaMikiya
en-aut-sei=Nakatsuka
en-aut-mei=Mikiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Faculty of Health Sciences, Okayama University
kn-affil=
en-keyword=infertility treatment
kn-keyword=infertility treatment
en-keyword=assisted reproductive technology
kn-keyword=assisted reproductive technology
en-keyword=postpartum
kn-keyword=postpartum
en-keyword=postpartum depression
kn-keyword=postpartum depression
en-keyword=personality trait
kn-keyword=personality trait
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=2
article-no=
start-page=101
end-page=107
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202504
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effectiveness of Postoperative Irradiation in Patients with cN0 Early Breast Cancer Treated with Sentinel Lymph Node Surgery
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=To evaluate the effectiveness of postoperative irradiation (POI) for patients with cN0 early breast cancer, we retrospectively analyzed the cases of 650 consecutive breast cancer patients who underwent sentinel lymph node (SLN)-guided surgery (2005-2022) at our hospital. In this cohort, 53% (278/521) of the patients who underwent breast conservative surgery (BCS) and 96% (124/129) of those treated with mastectomy did not receive POI. The patients who underwent BCS were treated with POI using opposing tangential field irradiation. A false negative (FN) SLN was retrospectively defined as a negative metastasis in SLN plus positive recurrence in the axillary lymph nodes. Recurrence was detected in 83 patients. A logistic regression analysis revealed that the nuclear grade (odds ratio [OR] 1.69), POI (OR 0.41), and postoperative hormone therapy (OR 0.40) were each significantly related to recurrence. The 26.1% (12/46) FN rate of the non-POI patients decreased to 5.8% (1/17) compared to those treated with POI. The rate of axillary recurrence was significantly lower in the POI group (0.4%) versus the non-POI group (2.7%) (p=0.0355). The rate of locoregional recurrence was also significantly lower in the POI group (2.0%) versus the non-POI group (13.4%) (p<0.0001). No significant difference was observed in the rate of distant recurrence between the POI (4.0%) and non-POI (3.3%) (p=0.831) groups. These results indicated that the postoperative opposing tangential field irradiation of conserved breast tissue inhibited recurrence in the axillary lymph nodes.
en-copyright=
kn-copyright=

en-aut-name=IsozakiHiroshi
en-aut-sei=Isozaki
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatsumotoSasau
en-aut-sei=Matsumoto
en-aut-mei=Sasau
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakamaTakehiro
en-aut-sei=Takama
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IsozakiYuka
en-aut-sei=Isozaki
en-aut-mei=Yuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Surgery, Oomoto Hospital
kn-affil=

affil-num=2
en-affil=Department of Surgery, Oomoto Hospital
kn-affil=

affil-num=3
en-affil=Department of Surgery, Oomoto Hospital
kn-affil=

affil-num=4
en-affil=Department of Surgery, Oomoto Hospital
kn-affil=
en-keyword=breast cancer
kn-keyword=breast cancer
en-keyword=postoperative irradiation
kn-keyword=postoperative irradiation
en-keyword=radiation therapy
kn-keyword=radiation therapy
en-keyword=sentinel lymph nodes
kn-keyword=sentinel lymph nodes
en-keyword=recurrence
kn-keyword=recurrence
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=2
article-no=
start-page=81
end-page=92
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202504
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Clinical Outcomes of Neoadjuvant Paclitaxel/Cisplatin/Gemcitabine Compared with Gemcitabine/Cisplatin for Muscle-Invasive Bladder Cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We retrospectively evaluated the oncologic outcomes of paclitaxel, cisplatin, and gemcitabine (PCG) with those of gemcitabine and cisplatin (GC) as neoadjuvant chemotherapy in muscle-invasive bladder cancer (MIBC) patients. The primary outcome was efficacy: pathological complete response (pCR), ypT0N0; and pathological objective response (pOR), ypT0N0, ≤ ypT1N0, or ypT0N1. Secondary outcomes included overall survival (OS), recurrence-free survival (RFS), predictive factors for pOR, OS, and RFS, and hematologic adverse events (AEs). Among 113 patients treated (PCG, n=28; GC, n=85), similar pOR and pCR rates were achieved by the groups (pOR: PCG, 57.1% vs. GC, 49. 4%; p=0.52; pCR: PCG, 39.3% vs. GC, 29.4%; p=0.36). No significant differences were observed in OS (p=1.0) or RFS (p=0.20). Multivariate logistic regression analysis showed that hydronephrosis (odds ratio [OR] 0.32, 95%CI: 0.11-0.92) and clinical node-positive status (cN+) (OR 0.22, 95%CI: 0.050-0.99) were significantly associated with a decreased probability of pOR. On multivariate Cox regression analyses, pOR achievement was associated with improved OS (hazard ratio [HR] 0.23, 95%CI: 0.10-0.56) and RFS (HR 0.30, 95%CI: 0.13-0.67). There were no significant between-group differences in the incidence of grade ≥ 3 hematologic AEs or dose-reduction required, but the PCG group had a higher incidence of grade 4 neutropenia.
en-copyright=
kn-copyright=

en-aut-name=KawadaTatsushi
en-aut-sei=Kawada
en-aut-mei=Tatsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KobayashiYasuyuki
en-aut-sei=Kobayashi
en-aut-mei=Yasuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TsugawaTakuji
en-aut-sei=Tsugawa
en-aut-mei=Takuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TsuboiKazuma
en-aut-sei=Tsuboi
en-aut-mei=Kazuma
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KatayamaSatoshi
en-aut-sei=Katayama
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IwataTakehiro
en-aut-sei=Iwata
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=BekkuKensuke
en-aut-sei=Bekku
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KobayashiTomoko
en-aut-sei=Kobayashi
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=EdamuraKohei
en-aut-sei=Edamura
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=EbaraShin
en-aut-sei=Ebara
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=ArakiMotoo
en-aut-sei=Araki
en-aut-mei=Motoo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Urology, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=5
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Urology, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=11
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=urothelial carcinoma
kn-keyword=urothelial carcinoma
en-keyword=paclitaxel
kn-keyword=paclitaxel
en-keyword=cisplatin
kn-keyword=cisplatin
en-keyword=gemcitabine
kn-keyword=gemcitabine
en-keyword=neoadjuvant
kn-keyword=neoadjuvant
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=2
article-no=
start-page=75
end-page=80
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202504
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Potential for Radiation Dose Reduction in Temporal Bone CT Imaging Using Photon-Counting Detector CT
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Temporal bone computed tomography (CT) is frequently performed for pediatric patients with ear diseases. Advances in CT technology have improved diagnostic imaging quality, but reduction of radiation exposure remains a goal. We evaluated the potential for radiation dose reduction in temporal bone CT examinations using porcine ear ossicles and a photon-counting detector CT system. Three scans of the bilateral temporal bone were performed on each of three pig cadaver heads. In each of seven successive imaging sessions, the radiation dose was reduced by an additional one-seventh of the recommended dose (RD). Two board-certified radiologists independently scored the resulting images on a scale of 1 to 5 points, where 5 represented the image quality at the RD. Images scoring ≥4.5 points were considered acceptable. Noise was assessed in a 2-cm-diameter region near the ear ossicles, and standard deviation was measured for each of the seven decrements from the RD. As the radiation dose decreased, the noise progressively increased, and visual assessment scores progressively decreased. Acceptable image scores were obtained at six-sevenths (4.9), five-sevenths (4.8), four-sevenths (4.7), and three-sevenths (4.6) of the RD. Thus, acceptable porcine temporal bone CT images were obtained with a radiation dose reduction of approximately 50%.
en-copyright=
kn-copyright=

en-aut-name=HigakiFumiyo
en-aut-sei=Higaki
en-aut-mei=Fumiyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MorimitsuYusuke
en-aut-sei=Morimitsu
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IguchiToshihiro
en-aut-sei=Iguchi
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HwangSung Il
en-aut-sei=Hwang
en-aut-mei=Sung Il
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KitayamaTakahiro
en-aut-sei=Kitayama
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TakahashiYuka
en-aut-sei=Takahashi
en-aut-mei=Yuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=UkaMayu
en-aut-sei=Uka
en-aut-mei=Mayu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=AkagiNoriaki
en-aut-sei=Akagi
en-aut-mei=Noriaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SugayaAkiko
en-aut-sei=Sugaya
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MitsuhashiToshiharu
en-aut-sei=Mitsuhashi
en-aut-mei=Toshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MatsuiYusuke
en-aut-sei=Matsui
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HirakiTakao
en-aut-sei=Hiraki
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Radiological Technology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Radiological Technology, Faculty of Health Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Radiology, Seoul National University Bundang Hospital
kn-affil=

affil-num=5
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Radiological Technology, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Otolaryngology-Head and Neck Surgery, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=11
en-affil=Department of Radiology, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Radiology, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=computed tomography
kn-keyword=computed tomography
en-keyword=photon-counting detector computed tomography
kn-keyword=photon-counting detector computed tomography
en-keyword=ear ossicle
kn-keyword=ear ossicle
en-keyword=energy-integrating detector computed tomography
kn-keyword=energy-integrating detector computed tomography
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=2
article-no=
start-page=65
end-page=73
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202504
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Association between the Pretreatment Body Mass Index and Anamorelin’s Efficacy in Patients with Cancer Cachexia: A Retrospective Cohort Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Anamorelin (ANAM) is used to treat cancer-associated cachexia, a syndrome involving muscle loss and anorexia. The timing of the initiation of ANAM treatment is crucial to its efficacy. Although the body mass index (BMI) is a diagnostic criterion for cancer cachexia, no studies have explored its association with ANAM efficacy. We conducted a single-center, retrospective cohort study to investigate the association between the pre-treatment BMI and ANAM efficacy in patients with cancer-associated cachexia (n=47). The ANAM treatment was considered effective if the patient’s appetite improved within 30 days of treatment initiation. We calculated a BMI cutoff value (19.5 kg/m2) and used it to divide the patients into high- and low-BMI groups. Their background, clinical laboratory values, cancer types, and treatment lines were investigated. Twenty (42.6%) had a high BMI (≥ 19.5 kg/m2) and 27 (57.4%) had a low BMI (< 19.5 kg/m2). High BMI was significantly associated with ANAM effectiveness (odds ratio 7.86, 95% confidence interval 1.99-31.00, p=0.003). Together these results indicate that it is beneficial to initiate ANAM treatment before a patient’s BMI drops below 19.5 kg/m2. Our findings will help advance cancer cachexia treatment and serve as a reference for clinicians to predict ANAM’s efficacy.
en-copyright=
kn-copyright=

en-aut-name=MakiMasatoshi
en-aut-sei=Maki
en-aut-mei=Masatoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakadaRyo
en-aut-sei=Takada
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IshigoTomoyuki
en-aut-sei=Ishigo
en-aut-mei=Tomoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FujiwaraMiki
en-aut-sei=Fujiwara
en-aut-mei=Miki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakahashiYoko
en-aut-sei=Takahashi
en-aut-mei=Yoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OtsukaShinya
en-aut-sei=Otsuka
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TamuraKoji
en-aut-sei=Tamura
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HamaokaTerutaka
en-aut-sei=Hamaoka
en-aut-mei=Terutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Hospital Pharmacy, NHO Fukuyama Medical Center
kn-affil=

affil-num=2
en-affil=Department of Hospital Pharmacy, NHO Fukuyama Medical Center
kn-affil=

affil-num=3
en-affil=Department of Pharmacy, Sapporo Medical University Hospital
kn-affil=

affil-num=4
en-affil=Department of Hospital Pharmacy, NHO Fukuyama Medical Center
kn-affil=

affil-num=5
en-affil=Department of Hospital Pharmacy, NHO Fukuyama Medical Center
kn-affil=

affil-num=6
en-affil=Department of Surgery, NHO Fukuyama Medical Center
kn-affil=

affil-num=7
en-affil=Department of Hospital Pharmacy, NHO Fukuyama Medical Center
kn-affil=

affil-num=8
en-affil=Department of Hospital Pharmacy, NHO Fukuyama Medical Center
kn-affil=
en-keyword=anamorelin
kn-keyword=anamorelin
en-keyword=cancer-associated cachexia
kn-keyword=cancer-associated cachexia
en-keyword=body mass index
kn-keyword=body mass index
en-keyword=albumin
kn-keyword=albumin
en-keyword=efficacy rate
kn-keyword=efficacy rate
END

start-ver=1.4
cd-journal=joma
no-vol=87
cd-vols=
no-issue=
article-no=
start-page=63
end-page=83
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=1991
dt-pub=19910715
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Daily Social Support among Canberra Residents
kn-title=日常生活における援助希求行動 ―キャンベラの事例―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=　This paper reports a study that investigated perceived sources of daily support. To gather empirical evidence, a sample survey of women in four study areas of Canberra was conducted in 1986-1987. Three hundred and ninety-four women who were under 55 years of age and who were married or in a de facto relationship were interviewed. They responded to six hypothetical difficult situations by identifying the first source from which they would seek support. Analysis of the data has revealed the following ;<br>
　(1) When respondents had their relatives in Canberra, they regarded their relatives as the chief source of daily support. However, there were many residents without local relatives in Canberra. For such respondents, their relatives were not so helpful in daily support. Incidentally, workmates were thought of as much less important providers of support than relatives, neighbours or friends.<br>
　(2) Social networks were differentiated in that respondents tended to depend on types of people appropriate to individual difficult situations.<br>
　(3) Dependable friends and workmates tended to live closer than dependable relatives.<br>
　(4) Dependable relatives were usually limited to immediate family, such as parents (-in-law), brothers (-in-law) or sisters (-in-law).
en-copyright=
kn-copyright=

en-aut-name=NOBEMASAO
en-aut-sei=NOBE
en-aut-mei=MASAO
kn-aut-name=野邊政雄
kn-aut-sei=野邊
kn-aut-mei=政雄
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=74
cd-vols=
no-issue=3-4
article-no=
start-page=189
end-page=252
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250324
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Les extinctions des droits réels grevés sur l’immeuble qui est acquis par usucapion : La recherche historique sur la jurisprudence au XIXe siècle.
kn-title=所有権の時効取得と他物権の帰趨 ― 一九世紀フランス法の議論構造に照らして―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=ShimazuG. 
en-aut-sei=Shimazu
en-aut-mei=G. 
kn-aut-name=嶋津元
kn-aut-sei=嶋津
kn-aut-mei=元
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学学術研究院社会文化科学学域
END

start-ver=1.4
cd-journal=joma
no-vol=56
cd-vols=
no-issue=3
article-no=
start-page=65
end-page=86
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250321
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Die Grundlagen der wirtschaftlichen Entwicklung des Königreichs Sachsen（ 7 und Schluß）
kn-title=ザクセン王国経済発展の基礎（７・完）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=MatsuoNobushige
en-aut-sei=Matsuo
en-aut-mei=Nobushige
kn-aut-name=松尾展成
kn-aut-sei=松尾
kn-aut-mei=展成
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学名誉教授
END

start-ver=1.4
cd-journal=joma
no-vol=99
cd-vols=
no-issue=3
article-no=
start-page=e02166-24
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250213
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A capsidless (+)RNA yadokarivirus hosted by a dsRNA virus is infectious as particles, cDNA, and dsRNA
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Capsidless yadokariviruses (members of the order Yadokarivirales) with (+)RNA genomes divert the capsid of their partner icosahedral double-stranded RNA (dsRNA) viruses in different families of the order Ghabrivirales into the replication site. A yadokarivirus, AfSV2, has been reported from a German strain of the ascomycete fungus Aspergillus foetidus coinfected by two dsRNA viruses, a victorivirus (AfSV1, family Pseudototiviridae) and an alternavirus (AfFV, family Alternaviridae). Here, we identified AfSV1 as the partner of AfSV2 in a Japanese A. foetidus strain after showing the infectiousness of AfSV2 in three forms: virus particles (heterocapsid), transforming full-length complementary DNA (cDNA), and purified replicated form (RF) dsRNA that is believed to be inactive as a translational template. Virion transfection of virus-free A. foetidus protoplasts resulted in the generation of two strains infected either by AfSV1 alone or by both AfSV1 and AfSV2. Transformants with AfSV2 full-length cDNA launched AfSV2 infection only in the presence of AfSV1, but not those with AfSV2 RNA-directed RNA polymerase mutant cDNA. The purified fractions containing AfSV2 RF dsRNA also launched infection when transfected into protoplasts infected by AfSV1. Treatment with dsRNA-specific RNase III, but not with proteinase K, S1 nuclease, or DNase I, abolished the infectivity of AfSV2 RF dsRNA. Furthermore, we confirmed the infectiousness of gel-purified AfSV2 RF dsRNA in the presence of AfSV1. Taken together, our results show the unique infectious entity of AfSV2 and the expansion of yadokarivirus partners in the family Pseudototiviridae and provide interesting evolutionary insights.
en-copyright=
kn-copyright=

en-aut-name=FadliMuhammad
en-aut-sei=Fadli
en-aut-mei=Muhammad
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HisanoSakae
en-aut-sei=Hisano
en-aut-mei=Sakae
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NovoaGuy
en-aut-sei=Novoa
en-aut-mei=Guy
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=CastónJosé R.
en-aut-sei=Castón
en-aut-mei=José R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KondoHideki
en-aut-sei=Kondo
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SuzukiNobuhiro
en-aut-sei=Suzuki
en-aut-mei=Nobuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Agrivirology Laboratory, Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=2
en-affil=Agrivirology Laboratory, Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Structure of Macromolecules, Centro Nacional Biotecnología (CNB-CSIC), Campus de Cantoblanco
kn-affil=

affil-num=4
en-affil=Department of Structure of Macromolecules, Centro Nacional Biotecnología (CNB-CSIC), Campus de Cantoblanco
kn-affil=

affil-num=5
en-affil=Agrivirology Laboratory, Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=6
en-affil=Agrivirology Laboratory, Institute of Plant Science and Resources, Okayama University
kn-affil=
en-keyword=yadokarivirus
kn-keyword=yadokarivirus
en-keyword=hetero-encapsidation
kn-keyword=hetero-encapsidation
en-keyword=partner dsRNA virus
kn-keyword=partner dsRNA virus
en-keyword=fungal virus
kn-keyword=fungal virus
en-keyword=Aspergillus foetidus
kn-keyword=Aspergillus foetidus
en-keyword=neo-lifestyle
kn-keyword=neo-lifestyle
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=1
article-no=
start-page=21
end-page=30
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202502
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Prediction of Prostate Cancer Grades Using Radiomic Features
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We developed a machine learning model for predicting prostate cancer (PCa) grades using radiomic features of magnetic resonance imaging. 112 patients diagnosed with PCa based on prostate biopsy between January 2014 and December 2021 were evaluated. Logistic regression was used to construct two prediction models, one using radiomic features and prostate-specific antigen (PSA) values (Radiomics model) and the other Prostate Imaging-Reporting and Data System (PI-RADS) scores and PSA values (PI-RADS model), to differentiate high-grade (Gleason score [GS] ≥ 8) from intermediate or low-grade (GS < 8) PCa. Five imaging features were selected for the Radiomics model using the Gini coefficient. Model performance was evaluated using AUC, sensitivity, and specificity. The models were compared by leave-one-out cross-validation with Ridge regularization. Furthermore, the Radiomics model was evaluated using the holdout method and represented by a nomogram. The AUC of the Radiomics and PI-RADS models differed significantly (0.799, 95% CI: 0.712-0.869; and 0.710, 95% CI: 0.617-0.792, respectively). Using holdout method, the Radiomics model yielded AUC of 0.778 (95% CI: 0.552-0.925), sensitivity of 0.769, and specificity of 0.778. It outperformed the PI-RADS model and could be useful in predicting PCa grades, potentially aiding in determining appropriate treatment approaches in PCa patients.
en-copyright=
kn-copyright=

en-aut-name=YamamotoYasuhiro
en-aut-sei=Yamamoto
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HaraguchiTakafumi
en-aut-sei=Haraguchi
en-aut-mei=Takafumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatsudaKaori
en-aut-sei=Matsuda
en-aut-mei=Kaori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OkazakiYoshio
en-aut-sei=Okazaki
en-aut-mei=Yoshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KimotoShin
en-aut-sei=Kimoto
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TanjiNozomu
en-aut-sei=Tanji
en-aut-mei=Nozomu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MatsumotoAtsushi
en-aut-sei=Matsumoto
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KobayashiYasuyuki
en-aut-sei=Kobayashi
en-aut-mei=Yasuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MimuraHidefumi
en-aut-sei=Mimura
en-aut-mei=Hidefumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HirakiTakao
en-aut-sei=Hiraki
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Radiology, Houshasen Daiichi Hospital
kn-affil=

affil-num=2
en-affil=Department of Advanced Biomedical Imaging and Informatics, St. Marianna University School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Radiology, Houshasen Daiichi Hospital
kn-affil=

affil-num=4
en-affil=Department of Radiology, Houshasen Daiichi Hospital
kn-affil=

affil-num=5
en-affil=Department of Radiology, Houshasen Daiichi Hospital
kn-affil=

affil-num=6
en-affil=Department of Urology, Houshasen Daiichi Hospital
kn-affil=

affil-num=7
en-affil=Department of Urology, Houshasen Daiichi Hospital
kn-affil=

affil-num=8
en-affil=Department of Medical Information and Communication Technology Research, St. Marianna University School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Radiology, St. Marianna University School of Medicine
kn-affil=

affil-num=10
en-affil=Department of Radiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=prostate cancer
kn-keyword=prostate cancer
en-keyword=machine learning
kn-keyword=machine learning
en-keyword=prostate Imaging-Reporting and Data System
kn-keyword=prostate Imaging-Reporting and Data System
en-keyword=radiomics
kn-keyword=radiomics
en-keyword=Gleason score
kn-keyword=Gleason score
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=1
article-no=
start-page=9
end-page=19
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202502
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Gastrectomy Causes an Imbalance in the Trunk Muscles
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Muscle loss negatively affects gastrectomy prognosis. However, muscle loss is recognized as a systemic change, and individual muscle function is often overlooked. We investigated changes in the muscle volume of individual muscles after gastrectomy to identify clues for prognostic factors and optimal rehabilitation programs. Patients who underwent R0 gastrectomy for Stage I gastric cancer at our hospital from 2015 to 2021 were retrospectively selected to minimize the effects of malignancy and chemotherapy. Trunk muscle volume was measured by computed tomography to analyze body composition changes. Statistical analysis was performed to identify risk factors related to body composition changes. We compared the preoperative and 6-month postoperative conditions of 59 patients after gastrectomy. There was no difference in the psoas major muscle, a conventional surrogate marker of sarcopenia. There were significant decreases in the erector spinae (p=0.01) and lateral abdominal (p=0.01) muscles, and a significant increase in the rectus abdominis muscle (p=0.02). No significant correlation was found between these muscle changes and nutritional status. Body composition imbalance may serve as a new indicator of the general condition of patients after gastrectomy. Rehabilitation to correct this imbalance may improve prognosis after gastrectomy.
en-copyright=
kn-copyright=

en-aut-name=IkeyaNanami
en-aut-sei=Ikeya
en-aut-mei=Nanami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OkitaAtsushi
en-aut-sei=Okita
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HashidaShinsuke
en-aut-sei=Hashida
en-aut-mei=Shinsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YamamotoSumiharu
en-aut-sei=Yamamoto
en-aut-mei=Sumiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IkedaHirokuni
en-aut-sei=Ikeda
en-aut-mei=Hirokuni
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TsukudaKazunori
en-aut-sei=Tsukuda
en-aut-mei=Kazunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ToyookaShinichi
en-aut-sei=Toyooka
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Surgery, Okayama City Hospital
kn-affil=

affil-num=3
en-affil=Department of Surgery, Okayama City Hospital
kn-affil=

affil-num=4
en-affil=Department of Surgery, Okayama City Hospital
kn-affil=

affil-num=5
en-affil=Department of Surgery, Okayama City Hospital
kn-affil=

affil-num=6
en-affil=Department of Surgery, Okayama City Hospital
kn-affil=

affil-num=7
en-affil=Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=sarcopenia
kn-keyword=sarcopenia
en-keyword=skeletal muscle
kn-keyword=skeletal muscle
en-keyword=gastric cancer
kn-keyword=gastric cancer
en-keyword=gastrectomy
kn-keyword=gastrectomy
en-keyword=erector spinae muscle
kn-keyword=erector spinae muscle
END

start-ver=1.4
cd-journal=joma
no-vol=79
cd-vols=
no-issue=1
article-no=
start-page=1
end-page=7
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=202502
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Endothelial Cell Polarity in Health and Disease
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Endothelial cell polarity is fundamental to the organization and function of blood vessels, influencing processes such as angiogenesis, vascular stability, and response to shear stress. This review elaborates on the molecular mechanisms that regulate endothelial cell polarity, focusing on key players like the PAR polarity complex and Rho family GTPases. These pathways coordinate the front–rear, apical–basal and planar polarity of endothelial cells, which are essential for the proper formation and maintenance of vascular structures. In health, endothelial polarity ensures not only the orderly development of blood vessels, with tip cells adopting distinct polarities during angiogenesis, but also ensures proper vascular integrity and function. In disease states, however, disruptions in polarity contribute to pathologies such as coronary artery disease, where altered planar polarity exacerbates atherosclerosis, and cancer, where disrupted polarity in tumor vasculature leads to abnormal vessel growth and function. Understanding cell polarity and its disruption is fundamental not only to comprehending how cells interact with their microenvironment and organize themselves into complex, organ-specific tissues but also to developing novel, targeted, and therapeutic strategies for a range of diseases, from cardiovascular disorders to malignancies, ultimately improving patient outcomes.
en-copyright=
kn-copyright=

en-aut-name=ThihaMoe
en-aut-sei=Thiha
en-aut-mei=Moe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HikitaTakao
en-aut-sei=Hikita
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NakayamaMasanori
en-aut-sei=Nakayama
en-aut-mei=Masanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Department of Pathophysiology and Drug Discovery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Pathophysiology and Drug Discovery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Pathophysiology and Drug Discovery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=blood vessel
kn-keyword=blood vessel
en-keyword=endothelial cell
kn-keyword=endothelial cell
en-keyword=cell polarity
kn-keyword=cell polarity
en-keyword=atherosclerosis
kn-keyword=atherosclerosis
en-keyword=cancer
kn-keyword=cancer
END

start-ver=1.4
cd-journal=joma
no-vol=234
cd-vols=
no-issue=
article-no=
start-page=120015
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2025
dt-pub=20250305
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Reversible chemical modifications of graphene oxide for enhanced viral capture and release in water
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Detecting low concentrations of viruses in sewage water is crucial for monitoring the spread of emerging viral diseases. However, current detection methods, which involve concentrating viruses using traditional materials such as gauze or cotton, have limitations in effectively accomplishing this task. This study demonstrates that graphene oxide (GO), a two-dimensional carbon material, possesses strong viral adsorption capabilities. However, it lacks efficiency for effective viral release. Therefore, we designed a series of new GO-based materials, which exhibited a viral adsorption similar to pristine GO, while significantly enhancing their release performance by attaching alkyl chains and hydrophilic functional groups. Among the synthesized materials, 1,8-aminooctanol grafted to GO (GO-NH2C8OH) has emerged as the most promising candidate, achieving a viral release rate higher than 50 %. This superior performance can be attributed to the synergistic effect of the alkyl chain and the terminal OH group, which enhances both its affinity for viruses and water dispersibility. Furthermore, we have successfully applied GO-NH2C8OH in a new protocol for concentrating viruses from sewage wastewater. This approach has demonstrated a 200-fold increase in virus concentration, allowing PCR detection of this type of pathogens present in wastewater below the detection limit by direct analysis, underscoring its significant potential for virus surveillance.
en-copyright=
kn-copyright=

en-aut-name=Ferré-PujolPilar
en-aut-sei=Ferré-Pujol
en-aut-mei=Pilar
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ObataSeiji
en-aut-sei=Obata
en-aut-mei=Seiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=RayaJésus
en-aut-sei=Raya
en-aut-mei=Jésus
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=BiancoAlberto
en-aut-sei=Bianco
en-aut-mei=Alberto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KatayamaHiroyuki
en-aut-sei=Katayama
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KatoTakashi
en-aut-sei=Kato
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NishinaYuta
en-aut-sei=Nishina
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=2
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=3
en-affil=Institut de Chimie, UMR 7177 CNRS, Université de Strasbourg
kn-affil=

affil-num=4
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Urban Engineering, School of Engineering, The University of Tokyo
kn-affil=

affil-num=6
en-affil=Research Center for Water Environment Technology, School of Engineering, The University of Tokyo
kn-affil=

affil-num=7
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=
en-keyword=Carbon nanomaterials
kn-keyword=Carbon nanomaterials
en-keyword=Functionalization
kn-keyword=Functionalization
en-keyword=Adsorption
kn-keyword=Adsorption
en-keyword=Desorption
kn-keyword=Desorption
en-keyword=Pathogens
kn-keyword=Pathogens
END

start-ver=1.4
cd-journal=joma
no-vol=58
cd-vols=
no-issue=
article-no=
start-page=195
end-page=212
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241227
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=On the Usage Patterns of 'de' in Conversations by Japanese Language Learners: An Analysis Based on the "International Corpus of Japanese as a Second Language（I-JAS）"
kn-title=「多言語母語の日本語学習者横断コーパス（I − JAS）」から見た日本語学習者の会話における「で」の使用実態について―日本語母語話者との比較を通じて―
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=LIUYang
en-aut-sei=LIU
en-aut-mei=Yang
kn-aut-name=劉洋
kn-aut-sei=劉
kn-aut-mei=洋
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院社会文化科学研究科
END

start-ver=1.4
cd-journal=joma
no-vol=2024
cd-vols=
no-issue=12
article-no=
start-page=
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202412
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Multi-dimensional optimisation of the scanning strategy for the LiteBIRD space mission
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Large angular scale surveys in the absence of atmosphere are essential for measuring the primordial B-mode power spectrum of the Cosmic Microwave Background (CMB). Since this proposed measurement is about three to four orders of magnitude fainter than the temperature anisotropies of the CMB, in-flight calibration of the instruments and active suppression of systematic effects are crucial. We investigate the effect of changing the parameters of the scanning strategy on the in-flight calibration effectiveness, the suppression of the systematic effects themselves, and the ability to distinguish systematic effects by null-tests. Next-generation missions such as LiteBIRD, modulated by a Half-Wave Plate (HWP), will be able to observe polarisation using a single detector, eliminating the need to combine several detectors to measure polarisation, as done in many previous experiments and hence avoiding the consequent systematic effects. While the HWP is expected to suppress many systematic effects, some of them will remain. We use an analytical approach to comprehensively address the mitigation of these systematic effects and identify the characteristics of scanning strategies that are the most effective for implementing a variety of calibration strategies in the multi-dimensional space of common spacecraft scan parameters. We verify that LiteBIRD's standard configuration yields good performance on the metrics we studied. We also present Falcons.jl, a fast spacecraft scanning simulator that we developed to investigate this scanning parameter space.
en-copyright=
kn-copyright=

en-aut-name=TakaseY.
en-aut-sei=Takase
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=VacherL.
en-aut-sei=Vacher
en-aut-mei=L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IshinoH.
en-aut-sei=Ishino
en-aut-mei=H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=PatanchonG.
en-aut-sei=Patanchon
en-aut-mei=G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MontierL.
en-aut-sei=Montier
en-aut-mei=L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SteverS.L.
en-aut-sei=Stever
en-aut-mei=S.L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IshizakaK.
en-aut-sei=Ishizaka
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NaganoY.
en-aut-sei=Nagano
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=WangW.
en-aut-sei=Wang
en-aut-mei=W.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=AumontJ.
en-aut-sei=Aumont
en-aut-mei=J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=AizawaK.
en-aut-sei=Aizawa
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=AnandA.
en-aut-sei=Anand
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=BaccigalupiC.
en-aut-sei=Baccigalupi
en-aut-mei=C.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=BallardiniM.
en-aut-sei=Ballardini
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=BandayA.J.
en-aut-sei=Banday
en-aut-mei=A.J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=BarreiroR.B.
en-aut-sei=Barreiro
en-aut-mei=R.B.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=BartoloN.
en-aut-sei=Bartolo
en-aut-mei=N.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=BasakS.
en-aut-sei=Basak
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=BersanelliM.
en-aut-sei=Bersanelli
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=BortolamiM.
en-aut-sei=Bortolami
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=BrinckmannT.
en-aut-sei=Brinckmann
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=CalabreseE.
en-aut-sei=Calabrese
en-aut-mei=E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=CampetiP.
en-aut-sei=Campeti
en-aut-mei=P.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=CarinosE.
en-aut-sei=Carinos
en-aut-mei=E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=CaronesA.
en-aut-sei=Carones
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=CasasF.J.
en-aut-sei=Casas
en-aut-mei=F.J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=CheungK.
en-aut-sei=Cheung
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=ClermontL.
en-aut-sei=Clermont
en-aut-mei=L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=ColumbroF.
en-aut-sei=Columbro
en-aut-mei=F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=CoppolecchiaA.
en-aut-sei=Coppolecchia
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

en-aut-name=CuttaiaF.
en-aut-sei=Cuttaia
en-aut-mei=F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=31
ORCID=

en-aut-name=D'AlessandroG.
en-aut-sei=D'Alessandro
en-aut-mei=G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=32
ORCID=

en-aut-name=de BernardisP.
en-aut-sei=de Bernardis
en-aut-mei=P.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=33
ORCID=

en-aut-name=de HaanT.
en-aut-sei=de Haan
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=34
ORCID=

en-aut-name=de la HozE.
en-aut-sei=de la Hoz
en-aut-mei=E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=35
ORCID=

en-aut-name=Della TorreS.
en-aut-sei=Della Torre
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=36
ORCID=

en-aut-name=Diego-PalazuelosP.
en-aut-sei=Diego-Palazuelos
en-aut-mei=P.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=37
ORCID=

en-aut-name=EriksenH.K.
en-aut-sei=Eriksen
en-aut-mei=H.K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=38
ORCID=

en-aut-name=ErrardJ.
en-aut-sei=Errard
en-aut-mei=J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=39
ORCID=

en-aut-name=FinelliF.
en-aut-sei=Finelli
en-aut-mei=F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=40
ORCID=

en-aut-name=FuskelandU.
en-aut-sei=Fuskeland
en-aut-mei=U.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=41
ORCID=

en-aut-name=GalloniG.
en-aut-sei=Galloni
en-aut-mei=G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=42
ORCID=

en-aut-name=GallowayM.
en-aut-sei=Galloway
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=43
ORCID=

en-aut-name=GervasiM.
en-aut-sei=Gervasi
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=44
ORCID=

en-aut-name=GhignaT.
en-aut-sei=Ghigna
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=45
ORCID=

en-aut-name=GiardielloS.
en-aut-sei=Giardiello
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=46
ORCID=

en-aut-name=Gimeno-AmoC.
en-aut-sei=Gimeno-Amo
en-aut-mei=C.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=47
ORCID=

en-aut-name=GjerløwE.
en-aut-sei=Gjerløw
en-aut-mei=E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=48
ORCID=

en-aut-name=González GonzálezR.
en-aut-sei=González González
en-aut-mei=R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=49
ORCID=

en-aut-name=GruppusoA.
en-aut-sei=Gruppuso
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=50
ORCID=

en-aut-name=HazumiM.
en-aut-sei=Hazumi
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=51
ORCID=

en-aut-name=Henrot-VersilléS.
en-aut-sei=Henrot-Versillé
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=52
ORCID=

en-aut-name=HergtL.T.
en-aut-sei=Hergt
en-aut-mei=L.T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=53
ORCID=

en-aut-name=IkumaK.
en-aut-sei=Ikuma
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=54
ORCID=

en-aut-name=KohriK.
en-aut-sei=Kohri
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=55
ORCID=

en-aut-name=LamagnaL.
en-aut-sei=Lamagna
en-aut-mei=L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=56
ORCID=

en-aut-name=LattanziM.
en-aut-sei=Lattanzi
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=57
ORCID=

en-aut-name=LeloupC.
en-aut-sei=Leloup
en-aut-mei=C.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=58
ORCID=

en-aut-name=LemboM.
en-aut-sei=Lembo
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=59
ORCID=

en-aut-name=LevrierF.
en-aut-sei=Levrier
en-aut-mei=F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=60
ORCID=

en-aut-name=LonappanA.I.
en-aut-sei=Lonappan
en-aut-mei=A.I.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=61
ORCID=

en-aut-name=López-CaniegoM.
en-aut-sei=López-Caniego
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=62
ORCID=

en-aut-name=LuzziG.
en-aut-sei=Luzzi
en-aut-mei=G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=63
ORCID=

en-aut-name=MaffeiB.
en-aut-sei=Maffei
en-aut-mei=B.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=64
ORCID=

en-aut-name=Martínez-GonzálezE.
en-aut-sei=Martínez-González
en-aut-mei=E.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=65
ORCID=

en-aut-name=MasiS.
en-aut-sei=Masi
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=66
ORCID=

en-aut-name=MatarreseS.
en-aut-sei=Matarrese
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=67
ORCID=

en-aut-name=MatsudaF.T.
en-aut-sei=Matsuda
en-aut-mei=F.T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=68
ORCID=

en-aut-name=MatsumuraT.
en-aut-sei=Matsumura
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=69
ORCID=

en-aut-name=MicheliS.
en-aut-sei=Micheli
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=70
ORCID=

en-aut-name=MigliaccioM.
en-aut-sei=Migliaccio
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=71
ORCID=

en-aut-name=MonelliM.
en-aut-sei=Monelli
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=72
ORCID=

en-aut-name=MorganteG.
en-aut-sei=Morgante
en-aut-mei=G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=73
ORCID=

en-aut-name=MotB.
en-aut-sei=Mot
en-aut-mei=B.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=74
ORCID=

en-aut-name=NagataR.
en-aut-sei=Nagata
en-aut-mei=R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=75
ORCID=

en-aut-name=NamikawaT.
en-aut-sei=Namikawa
en-aut-mei=T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=76
ORCID=

en-aut-name=NovelliA.
en-aut-sei=Novelli
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=77
ORCID=

en-aut-name=OdagiriK.
en-aut-sei=Odagiri
en-aut-mei=K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=78
ORCID=

en-aut-name=OguriS.
en-aut-sei=Oguri
en-aut-mei=S.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=79
ORCID=

en-aut-name=OmaeR.
en-aut-sei=Omae
en-aut-mei=R.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=80
ORCID=

en-aut-name=PaganoL.
en-aut-sei=Pagano
en-aut-mei=L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=81
ORCID=

en-aut-name=PaolettiD.
en-aut-sei=Paoletti
en-aut-mei=D.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=82
ORCID=

en-aut-name=PiacentiniF.
en-aut-sei=Piacentini
en-aut-mei=F.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=83
ORCID=

en-aut-name=PincheraM.
en-aut-sei=Pinchera
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=84
ORCID=

en-aut-name=PolentaG.
en-aut-sei=Polenta
en-aut-mei=G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=85
ORCID=

en-aut-name=PorcelliL.
en-aut-sei=Porcelli
en-aut-mei=L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=86
ORCID=

en-aut-name=RaffuzziN.
en-aut-sei=Raffuzzi
en-aut-mei=N.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=87
ORCID=

en-aut-name=RemazeillesM.
en-aut-sei=Remazeilles
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=88
ORCID=

en-aut-name=RitaccoA.
en-aut-sei=Ritacco
en-aut-mei=A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=89
ORCID=

en-aut-name=Ruiz-GrandaM.
en-aut-sei=Ruiz-Granda
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=90
ORCID=

en-aut-name=SakuraiY.
en-aut-sei=Sakurai
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=91
ORCID=

en-aut-name=ScottD.
en-aut-sei=Scott
en-aut-mei=D.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=92
ORCID=

en-aut-name=SekimotoY.
en-aut-sei=Sekimoto
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=93
ORCID=

en-aut-name=ShiraishiM.
en-aut-sei=Shiraishi
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=94
ORCID=

en-aut-name=SignorelliG.
en-aut-sei=Signorelli
en-aut-mei=G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=95
ORCID=

en-aut-name=SullivanR.M.
en-aut-sei=Sullivan
en-aut-mei=R.M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=96
ORCID=

en-aut-name=TakakuraH.
en-aut-sei=Takakura
en-aut-mei=H.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=97
ORCID=

en-aut-name=TerenziL.
en-aut-sei=Terenzi
en-aut-mei=L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=98
ORCID=

en-aut-name=TomasiM.
en-aut-sei=Tomasi
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=99
ORCID=

en-aut-name=TristramM.
en-aut-sei=Tristram
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=100
ORCID=

en-aut-name=van TentB.
en-aut-sei=van Tent
en-aut-mei=B.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=101
ORCID=

en-aut-name=VielvaP.
en-aut-sei=Vielva
en-aut-mei=P.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=102
ORCID=

en-aut-name=WehusI.K.
en-aut-sei=Wehus
en-aut-mei=I.K.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=103
ORCID=

en-aut-name=WestbrookB.
en-aut-sei=Westbrook
en-aut-mei=B.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=104
ORCID=

en-aut-name=Weymann-DespresG.
en-aut-sei=Weymann-Despres
en-aut-mei=G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=105
ORCID=

en-aut-name=WollackE.J.
en-aut-sei=Wollack
en-aut-mei=E.J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=106
ORCID=

en-aut-name=ZannoniM.
en-aut-sei=Zannoni
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=107
ORCID=

en-aut-name=ZhouY.
en-aut-sei=Zhou
en-aut-mei=Y.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=108
ORCID=

affil-num=1
en-affil=Okayama University, Department of Physics
kn-affil=

affil-num=2
en-affil=International School for Advanced Studies (SISSA)
kn-affil=

affil-num=3
en-affil=Okayama University, Department of Physics
kn-affil=

affil-num=4
en-affil=ILANCE, CNRS, University of Tokyo International Research Laboratory
kn-affil=

affil-num=5
en-affil=IRAP, Université de Toulouse, CNRS, CNES, UPS
kn-affil=

affil-num=6
en-affil=Okayama University, Department of Physics
kn-affil=

affil-num=7
en-affil=Okayama University, Department of Physics
kn-affil=

affil-num=8
en-affil=Okayama University, Department of Physics
kn-affil=

affil-num=9
en-affil=Université Paris Cité, CNRS, Astroparticule et Cosmologie
kn-affil=

affil-num=10
en-affil=IRAP, Université de Toulouse, CNRS, CNES, UPS
kn-affil=

affil-num=11
en-affil=The University of Tokyo, Department of Physics
kn-affil=

affil-num=12
en-affil=Dipartimento di Fisica, Università di Roma Tor Vergata
kn-affil=

affil-num=13
en-affil=International School for Advanced Studies (SISSA)
kn-affil=

affil-num=14
en-affil=Dipartimento di Fisica e Scienze della Terra, Università di Ferrara
kn-affil=

affil-num=15
en-affil=IRAP, Université de Toulouse, CNRS, CNES, UPS
kn-affil=

affil-num=16
en-affil=Instituto de Fisica de Cantabria (IFCA, CSIC-UC)
kn-affil=

affil-num=17
en-affil=Dipartimento di Fisica e Astronomia "G. Galilei", Università degli Studi di Padova
kn-affil=

affil-num=18
en-affil=School of Physics, Indian Institute of Science Education and Research Thiruvananthapuram
kn-affil=

affil-num=19
en-affil=Dipartimento di Fisica, Università degli Studi di Milano
kn-affil=

affil-num=20
en-affil=Dipartimento di Fisica e Scienze della Terra, Università di Ferrara
kn-affil=

affil-num=21
en-affil=Dipartimento di Fisica e Scienze della Terra, Università di Ferrara
kn-affil=

affil-num=22
en-affil=School of Physics and Astronomy, Cardiff University
kn-affil=

affil-num=23
en-affil=INFN Sezione di Ferrara
kn-affil=

affil-num=24
en-affil=IRAP, Université de Toulouse, CNRS, CNES, UPS
kn-affil=

affil-num=25
en-affil=International School for Advanced Studies (SISSA)
kn-affil=

affil-num=26
en-affil=Instituto de Fisica de Cantabria (IFCA, CSIC-UC)
kn-affil=

affil-num=27
en-affil=Jodrell Bank Centre for Astrophysics, Department of Physics and Astronomy, School of Natural Sciences, The University of Manchester
kn-affil=

affil-num=28
en-affil=Centre Spatial de Liège, Université de Liège
kn-affil=

affil-num=29
en-affil=Dipartimento di Fisica, Università La Sapienza
kn-affil=

affil-num=30
en-affil=Dipartimento di Fisica, Università La Sapienza
kn-affil=

affil-num=31
en-affil=INAF, OAS Bologna
kn-affil=

affil-num=32
en-affil=Dipartimento di Fisica, Università La Sapienza
kn-affil=

affil-num=33
en-affil=Dipartimento di Fisica, Università La Sapienza
kn-affil=

affil-num=34
en-affil=Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK)
kn-affil=

affil-num=35
en-affil=CNRS-UCB International Research Laboratory, Centre Pierre Binétruy, UMI2007
kn-affil=

affil-num=36
en-affil=INFN Sezione Milano Bicocca
kn-affil=

affil-num=37
en-affil=Max Planck Institute for Astrophysics
kn-affil=

affil-num=38
en-affil=Institute of Theoretical Astrophysics, University of Oslo
kn-affil=

affil-num=39
en-affil=Université Paris Cité, CNRS, Astroparticule et Cosmologie
kn-affil=

affil-num=40
en-affil=INAF, OAS Bologna
kn-affil=

affil-num=41
en-affil=Institute of Theoretical Astrophysics, University of Oslo
kn-affil=

affil-num=42
en-affil=Dipartimento di Fisica e Scienze della Terra, Università di Ferrara
kn-affil=

affil-num=43
en-affil=Institute of Theoretical Astrophysics, University of Oslo
kn-affil=

affil-num=44
en-affil=University of Milano Bicocca, Physics Department
kn-affil=

affil-num=45
en-affil=International Center for Quantum-field Measurement Systems for Studies of the Universe and Particles (QUP), High Energy Accelerator Research Organization (KEK)
kn-affil=

affil-num=46
en-affil=School of Physics and Astronomy, Cardiff University
kn-affil=

affil-num=47
en-affil=Instituto de Fisica de Cantabria (IFCA, CSIC-UC)
kn-affil=

affil-num=48
en-affil=Institute of Theoretical Astrophysics, University of Oslo
kn-affil=

affil-num=49
en-affil=Instituto de Astrofísica de Canarias
kn-affil=

affil-num=50
en-affil=INAF, OAS Bologna
kn-affil=

affil-num=51
en-affil=International Center for Quantum-field Measurement Systems for Studies of the Universe and Particles (QUP), High Energy Accelerator Research Organization (KEK)
kn-affil=

affil-num=52
en-affil=Université Paris-Saclay, CNRS/IN2P3, IJCLab
kn-affil=

affil-num=53
en-affil=Department of Physics and Astronomy, University of British Columbia
kn-affil=

affil-num=54
en-affil=Okayama University, Department of Physics
kn-affil=

affil-num=55
en-affil=Institute of Particle and Nuclear Studies (IPNS), High Energy Accelerator Research Organization (KEK)
kn-affil=

affil-num=56
en-affil=Dipartimento di Fisica, Università La Sapienza
kn-affil=

affil-num=57
en-affil=INFN Sezione di Ferrara
kn-affil=

affil-num=58
en-affil=Kavli Institute for the Physics and Mathematics of the Universe (Kavli IPMU, WPI), UTIAS, The University of Tokyo
kn-affil=

affil-num=59
en-affil=Dipartimento di Fisica e Scienze della Terra, Università di Ferrara
kn-affil=

affil-num=60
en-affil=Laboratoire de Physique de l'École Normale Supérieure, ENS, Université PSL, CNRS, Sorbonne Université, Université de Paris
kn-affil=

affil-num=61
en-affil=University of California, San Diego, Department of Physics
kn-affil=

affil-num=62
en-affil=Aurora Technology for the European Space Agency
kn-affil=

affil-num=63
en-affil=Space Science Data Center, Italian Space Agency
kn-affil=

affil-num=64
en-affil=Université Paris-Saclay, CNRS, Institut d'Astrophysique Spatiale
kn-affil=

affil-num=65
en-affil=Instituto de Fisica de Cantabria (IFCA, CSIC-UC)
kn-affil=

affil-num=66
en-affil=Dipartimento di Fisica, Università La Sapienza
kn-affil=

affil-num=67
en-affil=Dipartimento di Fisica e Astronomia "G. Galilei", Università degli Studi di Padova
kn-affil=

affil-num=68
en-affil=Japan Aerospace Exploration Agency (JAXA), Institute of Space and Astronautical Science (ISAS)
kn-affil=

affil-num=69
en-affil=Kavli Institute for the Physics and Mathematics of the Universe (Kavli IPMU, WPI), UTIAS, The University of Tokyo
kn-affil=

affil-num=70
en-affil=Dipartimento di Fisica, Università La Sapienza
kn-affil=

affil-num=71
en-affil=Dipartimento di Fisica, Università di Roma Tor Vergata
kn-affil=

affil-num=72
en-affil=Max Planck Institute for Astrophysics
kn-affil=

affil-num=73
en-affil=INAF, OAS Bologna
kn-affil=

affil-num=74
en-affil=IRAP, Université de Toulouse, CNRS, CNES, UPS
kn-affil=

affil-num=75
en-affil=Japan Aerospace Exploration Agency (JAXA), Institute of Space and Astronautical Science (ISAS)
kn-affil=

affil-num=76
en-affil=Kavli Institute for the Physics and Mathematics of the Universe (Kavli IPMU, WPI), UTIAS, The University of Tokyo
kn-affil=

affil-num=77
en-affil=Dipartimento di Fisica, Università La Sapienza
kn-affil=

affil-num=78
en-affil=Japan Aerospace Exploration Agency (JAXA), Institute of Space and Astronautical Science (ISAS)
kn-affil=

affil-num=79
en-affil=Japan Aerospace Exploration Agency (JAXA), Institute of Space and Astronautical Science (ISAS)
kn-affil=

affil-num=80
en-affil=Okayama University, Department of Physics
kn-affil=

affil-num=81
en-affil=Dipartimento di Fisica e Scienze della Terra, Università di Ferrara
kn-affil=

affil-num=82
en-affil=INAF, OAS Bologna
kn-affil=

affil-num=83
en-affil=Dipartimento di Fisica, Università La Sapienza
kn-affil=

affil-num=84
en-affil=INFN Sezione di Pisa
kn-affil=

affil-num=85
en-affil=Space Science Data Center, Italian Space Agency
kn-affil=

affil-num=86
en-affil=Istituto Nazionale di Fisica Nucleare-aboratori Nazionali di Frascati (INFN-LNF)
kn-affil=

affil-num=87
en-affil=Dipartimento di Fisica e Scienze della Terra, Università di Ferrara
kn-affil=

affil-num=88
en-affil=Instituto de Fisica de Cantabria (IFCA, CSIC-UC)
kn-affil=

affil-num=89
en-affil=Dipartimento di Fisica, Università di Roma Tor Vergata
kn-affil=

affil-num=90
en-affil=Instituto de Fisica de Cantabria (IFCA, CSIC-UC)
kn-affil=

affil-num=91
en-affil=Suwa University of Science
kn-affil=

affil-num=92
en-affil=Department of Physics and Astronomy, University of British Columbia
kn-affil=

affil-num=93
en-affil=Japan Aerospace Exploration Agency (JAXA), Institute of Space and Astronautical Science (ISAS)
kn-affil=

affil-num=94
en-affil=Suwa University of Science
kn-affil=

affil-num=95
en-affil=Dipartimento di Fisica, Università di Pisa
kn-affil=

affil-num=96
en-affil=Department of Physics and Astronomy, University of British Columbia
kn-affil=

affil-num=97
en-affil=Japan Aerospace Exploration Agency (JAXA), Institute of Space and Astronautical Science (ISAS)
kn-affil=

affil-num=98
en-affil=INAF, OAS Bologna
kn-affil=

affil-num=99
en-affil=Dipartimento di Fisica, Università degli Studi di Milano
kn-affil=

affil-num=100
en-affil=Université Paris-Saclay, CNRS/IN2P3, IJCLab
kn-affil=

affil-num=101
en-affil=Université Paris-Saclay, CNRS/IN2P3, IJCLab
kn-affil=

affil-num=102
en-affil=Instituto de Fisica de Cantabria (IFCA, CSIC-UC)
kn-affil=

affil-num=103
en-affil=Institute of Theoretical Astrophysics, University of Oslo
kn-affil=

affil-num=104
en-affil=University of California, Berkeley, Department of Physics, Berkeley
kn-affil=

affil-num=105
en-affil=Université Paris-Saclay, CNRS/IN2P3, IJCLab
kn-affil=

affil-num=106
en-affil=NASA Goddard Space Flight Center
kn-affil=

affil-num=107
en-affil=University of Milano Bicocca, Physics Department
kn-affil=

affil-num=108
en-affil=International Center for Quantum-field Measurement Systems for Studies of the Universe and Particles (QUP), High Energy Accelerator Research Organization (KEK)
kn-affil=
en-keyword=CMBR experiments
kn-keyword=CMBR experiments
en-keyword=CMBR polarisation
kn-keyword=CMBR polarisation
en-keyword=gravitational waves and CMBR polarization
kn-keyword=gravitational waves and CMBR polarization
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=6
article-no=
start-page=475
end-page=483
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202412
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=C-arm Free Unilateral Biportal Endoscopic Discectomy: A Technical Note
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This report presents a new unilateral biportal endoscopic (UBE) technique for lumbar disc herniation without C-arm guidance. Lumbar disc herniation requires surgical intervention when conservative methods fail. Shifts towards minimally invasive percutaneous endoscopic lumbar discectomy, including uniportal and biportal approaches, have been hindered by challenges such as steep learning curves and reliance on radiation-intensive C-arm guidance. We here describe the use of standard intraoperative navigation in UBE to reduce radiation exposure and increase surgical accuracy. A 24-year-old man with low back and bilateral leg pain with gait disturbance was referred to our hospital. He had had conservative treatment for 12 months in another hospital before admission, but this proved unsuccessful. On admission he had low back pain (VAS 4/10) and bilateral leg pain (VAS 8/10), muscle weakness of the bilateral legs (manual muscle testing (MMT) grade of the extensor hallucis longus: 4/4), and numbness of the bilateral lower legs. Preoperative lumbar MRI showed L4/5 large central disc herniation. He underwent C-arm free UBE discectomy under the guidance of O-arm navigation. The surgery was successful, with postoperative lumbar MRI showing good decompression of the dural sac and bilateral L5 nerve roots. The MMT grade and sensory function of both legs had recovered fully on final follow-up at one year. The new UBE technique under navigation guidance was shown to be useful for lumbar disc herniation. This innovative technique was safe and accurate for the treatment of lumbar intervertebral disc herniation, and minimized radiation exposure to surgeons.
en-copyright=
kn-copyright=

en-aut-name=XiangHongfei
en-aut-sei=Xiang
en-aut-mei=Hongfei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=LatkaKajetan
en-aut-sei=Latka
en-aut-mei=Kajetan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MastePraful
en-aut-sei=Maste
en-aut-mei=Praful
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TanakaMasato
en-aut-sei=Tanaka
en-aut-mei=Masato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KumawatChetan
en-aut-sei=Kumawat
en-aut-mei=Chetan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=AratakiShinya
en-aut-sei=Arataki
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=FujiwaraYoshihiro
en-aut-sei=Fujiwara
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TaokaTakuya
en-aut-sei=Taoka
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MiyamotoAkiyoshi
en-aut-sei=Miyamoto
en-aut-mei=Akiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=2
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=4
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=5
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=6
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=9
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=
en-keyword=lumbar disc herniation
kn-keyword=lumbar disc herniation
en-keyword=unilateral biportal endoscopic technique
kn-keyword=unilateral biportal endoscopic technique
en-keyword=navigation
kn-keyword=navigation
en-keyword=O-arm
kn-keyword=O-arm
en-keyword=minimally invasive spine surgery (MISS)
kn-keyword=minimally invasive spine surgery (MISS)
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=6
article-no=
start-page=469
end-page=474
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202412
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Treatment of Tenosynovial Giant Cell Tumor of the Cervical Spine with Postoperative Anti-RANKL Antibody (Denosumab) Administration
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Tenosynovial giant cell tumor (TGCT) is a fibrous histiocytic tumor originating in the synovial membrane. While cervical TGCT may not be considered a common diagnosis preoperatively because it is relatively rare, it has a high recurrence rate and should be considered. Total resection is preferable, but it can be challenging due to the risk of damaging the vertebral artery. Denosumab has shown effectiveness as a postoperative treatment for osteolytic bone lesion. Denosumab administration coupled with close follow-up might offer an effective postoperative treatment option for unresectable TGCT with bone invasion.
en-copyright=
kn-copyright=

en-aut-name=HirataYuichi
en-aut-sei=Hirata
en-aut-mei=Yuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NagaseTakayuki
en-aut-sei=Nagase
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SasadaSusumu
en-aut-sei=Sasada
en-aut-mei=Susumu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AyadaYoshiyuki
en-aut-sei=Ayada
en-aut-mei=Yoshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MiyakeHayato
en-aut-sei=Miyake
en-aut-mei=Hayato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SugaharaChiaki
en-aut-sei=Sugahara
en-aut-mei=Chiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YamamotoHidetaka
en-aut-sei=Yamamoto
en-aut-mei=Hidetaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OdaYoshinao
en-aut-sei=Oda
en-aut-mei=Yoshinao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YasuharaTakao
en-aut-sei=Yasuhara
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TanakaShota
en-aut-sei=Tanaka
en-aut-mei=Shota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Pathology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Pathology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University
kn-affil=

affil-num=9
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=tenosynovial giant cell tumor
kn-keyword=tenosynovial giant cell tumor
en-keyword=bone tumor
kn-keyword=bone tumor
en-keyword=spine
kn-keyword=spine
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=6
article-no=
start-page=465
end-page=468
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202412
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Secondary Polymyalgia Rheumatica Following SARS-CoV-2 Infection
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=An 81-year-old Japanese man with a medical history of diabetes mellitus and hypertension was diagnosed with the novel coronavirus disease 2019 (COVID-19). The patient developed pain in the bilateral shoulders and hips 3 days after the disease onset and presented to our outpatient clinic after 1 month. Referring to diagnostic criteria, we diagnosed him with polymyalgia rheumatica (PMR). We initiated prednisolone at 15 mg per day and his symptoms improved immediately. The clinical course of the patient indicated that the SARS-CoV-2 infection triggered the onset of autoimmune disease, PMR in this case.
en-copyright=
kn-copyright=

en-aut-name=OchoKazuki
en-aut-sei=Ocho
en-aut-mei=Kazuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IshikawaHisashi
en-aut-sei=Ishikawa
en-aut-mei=Hisashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OtsukaFumio
en-aut-sei=Otsuka
en-aut-mei=Fumio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Internal Medicine, Ishikawa Hospital
kn-affil=

affil-num=2
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Internal Medicine, Ishikawa Hospital
kn-affil=

affil-num=4
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=COVID-19
kn-keyword=COVID-19
en-keyword=SARS-CoV-2
kn-keyword=SARS-CoV-2
en-keyword=polymyalgia rheumatica
kn-keyword=polymyalgia rheumatica
en-keyword=autoimmune diseases
kn-keyword=autoimmune diseases
en-keyword=human leukocyte antigen
kn-keyword=human leukocyte antigen
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=6
article-no=
start-page=459
end-page=464
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202412
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Traumatic Neuroma Arising from Surgical Trauma during Conversion from Laparoscopic to Open Cholecystectomy
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Traumatic neuroma is an abnormal proliferation of injured nerves resulting from trauma or surgery. We present a case of traumatic neuroma arising in the cystic duct after cholecystectomy. A 66-year-old man was referred to our department due to a biliary tumor. He had undergone cholecystectomy 20 years prior. Cholangioscopy showed an elevated lesion covered with smooth mucosa. Histological examination revealed normal bile duct mucosa. Although benign disease was suspected, the possibilities of malignant disease could not be excluded. Extrahepatic bile duct resection was planned to include intraoperative rapid-freezing of a biopsy specimen followed by histopathological examination. These intraoperative histology results showed proliferation of nerve and fibrous tissue only, resulting in the diagnosis of traumatic neuroma, so no lymph nodes were removed. To avoid excessive surgical intervention, histopathological examination of an intraoperative rapid-frozen biopsy specimen may be important for diagnosing traumatic neuroma.
en-copyright=
kn-copyright=

en-aut-name=SakamotoShinya
en-aut-sei=Sakamoto
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TabuchiMotoyasu
en-aut-sei=Tabuchi
en-aut-mei=Motoyasu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YoshimatsuRika
en-aut-sei=Yoshimatsu
en-aut-mei=Rika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MatsumotoManabu
en-aut-sei=Matsumoto
en-aut-mei=Manabu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IwataJun
en-aut-sei=Iwata
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=OkabayashiTakehiro
en-aut-sei=Okabayashi
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=3
en-affil=Department of Radiology, Kochi Health Sciences Center
kn-affil=

affil-num=4
en-affil=Department of Diagnostic Pathology, Kochi Health Sciences Center
kn-affil=

affil-num=5
en-affil=Department of Diagnostic Pathology, Kochi Health Sciences Center
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=
en-keyword=traumatic neuroma
kn-keyword=traumatic neuroma
en-keyword=biliary stricture
kn-keyword=biliary stricture
en-keyword=cholecystectomy
kn-keyword=cholecystectomy
en-keyword=cholangiography
kn-keyword=cholangiography
en-keyword=intraoperative rapid-frozen biopsy
kn-keyword=intraoperative rapid-frozen biopsy
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=6
article-no=
start-page=453
end-page=458
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202412
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Case of Radiation-Induced Angiosarcoma after Breast-Conserving Surgery with Hypofractionated Radiotherapy in a Japanese Patient
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Radiation-induced angiosarcoma (RIAS) is a rare, late adverse event of radiotherapy comprising approximately half of all radiation-induced sarcomas. It has a relatively short latency period and generally unfavorable prognosis. This study presents a case of RIAS that developed 5 years and 11 months after the completion of hypofractionated radiotherapy (42.56 Gy/16 fractions) following partial mastectomy. The patient was diagnosed with RIAS 10 months after the onset of skin redness. She underwent skin tumor resection, followed by paclitaxel, then pazopanib administration, but no radiotherapy. At 6 years and 2 months after surgery, no RIAS recurrence has been detected.
en-copyright=
kn-copyright=

en-aut-name=KawataYujiro
en-aut-sei=Kawata
en-aut-mei=Yujiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=WatanabeKenta
en-aut-sei=Watanabe
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TokiyaRyoji
en-aut-sei=Tokiya
en-aut-mei=Ryoji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MatsunoTakeshi
en-aut-sei=Matsuno
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TanakaRyo
en-aut-sei=Tanaka
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KatsuiKuniaki
en-aut-sei=Katsui
en-aut-mei=Kuniaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Radiology, Kawasaki Medical School
kn-affil=

affil-num=2
en-affil=Department of Radiology, Kawasaki Medical School
kn-affil=

affil-num=3
en-affil=Department of Radiology, Kawasaki Medical School
kn-affil=

affil-num=4
en-affil=Department of Pathology, Kawasaki Medical School
kn-affil=

affil-num=5
en-affil=Department of Dermatology, Kawasaki Medical School
kn-affil=

affil-num=6
en-affil=Department of Breast and Thyroid Surgery, Kawasaki Medical School
kn-affil=

affil-num=7
en-affil=Department of Radiology, Kawasaki Medical School
kn-affil=
en-keyword=breast cancer
kn-keyword=breast cancer
en-keyword=hypofractionated radiotherapy
kn-keyword=hypofractionated radiotherapy
en-keyword=radiation-induced angiosarcoma
kn-keyword=radiation-induced angiosarcoma
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=6
article-no=
start-page=429
end-page=437
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202412
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Partial versus Radical Nephrectomy for Small Renal Cancer: Comparative Propensity Score-Matching Analysis of Cardiovascular Event Risk
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Although partial nephrectomy (PN) is preferred over radical nephrectomy (RN) for preserving renal function in patients with cT1 renal cancer, its impact on cardiovascular events (CVe) remains controversial. This study aimed to compare PN and RN in regard to the occurrence of CVe, including cerebrovascular events and exacerbation of hypertension (HT). We retrospectively analyzed 418 consecutive patients who underwent PN or RN for cT1 renal cancer. Propensity score-matching analysis was used to adjust for imbalances between patients who underwent PN and RN, leaving 102 patients in each group. The 5-year probability of cumulative CVe incidence was 6% in the PN group and 12% in the RN group (p=0.03), with a median follow-up of 73.5 months. The statistical significance was retained after propensity score matching for patients without preoperative proteinuria (p=0.03). For all CVe including cerebrovascular events and exacerbation of HT analyzed, PN provided a lower probability of occurrence than RN in patients with small renal cancers.
en-copyright=
kn-copyright=

en-aut-name=KubotaRisa
en-aut-sei=Kubota
en-aut-mei=Risa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=BekkuKensuke
en-aut-sei=Bekku
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KatayamaSatoshi
en-aut-sei=Katayama
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IwataTakehiro
en-aut-sei=Iwata
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NishimuraShingo
en-aut-sei=Nishimura
en-aut-mei=Shingo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=EdamuraKohei
en-aut-sei=Edamura
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KobayashiTomoko
en-aut-sei=Kobayashi
en-aut-mei=Tomoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KobayashiYasuyuki
en-aut-sei=Kobayashi
en-aut-mei=Yasuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=ArakiMotoo
en-aut-sei=Araki
en-aut-mei=Motoo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=chronic kidney disease
kn-keyword=chronic kidney disease
en-keyword=hypertension
kn-keyword=hypertension
en-keyword=nephrectomy
kn-keyword=nephrectomy
en-keyword=proteinuria
kn-keyword=proteinuria
END

start-ver=1.4
cd-journal=joma
no-vol=36
cd-vols=
no-issue=10
article-no=
start-page=4585
end-page=4606
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241029
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Mobile Augmented Reality Interface for Instruction-based Disaster Preparedness Guidelines
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Disaster preparedness guidelines help citizens protect themselves against disasters. Nonetheless, the general public has been found not to read them. Augmented reality (AR) interfaces are known to improve knowledge transfer in studies of education, industry, and elderly assistance. However, this is achieved this by creating specific interfaces for users, not the general public. To test the performance of these interfaces for general public guidance, we designed and implemented a novel AR-assisted disaster prevention guideline that leverages object detection models to identify targets of disaster preparedness advice. We then had a diverse-age audience compare our design against a real traditional paper-based preparedness guide in a room arranged as a common remote work bedroom. By testing their usability, task load, and capacity to make users aware of their environmental hazards, we gained important insights into the performance of different age groups following media developed for the general public. Regardless of different age groups achieving similar usability scores, we found minors improving their performance scores with our novel interface and adults from 20 to 49 years old seemingly performing better than other age groups. In this study, we highlight the importance of guidance alternatives for the young and the less-technology-aware population, contributing to the under-explored area of AR interfaces for the general public.
en-copyright=
kn-copyright=

en-aut-name=AguilarSergio De León
en-aut-sei=Aguilar
en-aut-mei=Sergio De León
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatsudaYuki
en-aut-sei=Matsuda
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YasumotoKeiichi
en-aut-sei=Yasumoto
en-aut-mei=Keiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Graduate School of Information Science, Nara Institute of Science and Technology
kn-affil=

affil-num=2
en-affil=Faculty of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Information Science, Nara Institute of Science and Technology
kn-affil=
en-keyword=guidelines
kn-keyword=guidelines
en-keyword=augmented reality
kn-keyword=augmented reality
en-keyword=disaster preparedness
kn-keyword=disaster preparedness
en-keyword=object recognition
kn-keyword=object recognition
en-keyword=user interface
kn-keyword=user interface
en-keyword=knowledge transfer
kn-keyword=knowledge transfer
END

start-ver=1.4
cd-journal=joma
no-vol=106
cd-vols=
no-issue=5
article-no=
start-page=972
end-page=984
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202411
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Demonstrating drug efficacy in slowing kidney disease progression requires large clinical trials when targeting participants with an early stage of chronic kidney disease (CKD). In this randomized, parallel-group, open-labeled trial (CANPIONE study), we assessed the effect of the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin using the individual’s change in estimated glomerular filtration rate (eGFR) slope before (pre-intervention slope) and during treatment (chronic slope). We randomly assigned (1:1) participants with type 2 diabetes, urinary albumin-to-creatinine ratio (UACR) of 50 to under 300 mg/g, and an eGFR of at least 45 ml/min/1.73m2 to receive canagliflozin or guideline-recommended treatment except for SGLT2 inhibitors (control). The first and second primary outcomes were the geometric mean percentage change from baseline in UACR and the change in eGFR slope, respectively. Of 98 randomized participants, 96 received at least one study treatment. The least-squares mean change from baseline in log-transformed geometric mean UACR was significantly greater in the canagliflozin group than the control group (between group-difference, −30.8% (95% confidence interval −42.6 to −16.8). The between-group difference (canagliflozin group – control group) of change in eGFR slope (chronic – pre-intervention) was 4.4 (1.6 to 7.3) ml/min/1.73 m2 per year, which was more pronounced in participants with faster eGFR decline. In summary, canagliflozin reduced albuminuria and the participant-specific natural course of eGFR decline in participants with type 2 diabetes and microalbuminuria. Thus, the CANPIONE study suggests that the within-individual change in eGFR slope may be a novel approach to determine the kidney protective potential of new therapies in early stages of CKD.
en-copyright=
kn-copyright=

en-aut-name=MiyamotoSatoshi
en-aut-sei=Miyamoto
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HeerspinkHiddo J.L.
en-aut-sei=Heerspink
en-aut-mei=Hiddo J.L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=de ZeeuwDick
en-aut-sei=de Zeeuw
en-aut-mei=Dick
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SakamotoKota
en-aut-sei=Sakamoto
en-aut-mei=Kota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YoshidaMichihiro
en-aut-sei=Yoshida
en-aut-mei=Michihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ToyodaMasao
en-aut-sei=Toyoda
en-aut-mei=Masao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SuzukiDaisuke
en-aut-sei=Suzuki
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HatanakaTakashi
en-aut-sei=Hatanaka
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NakamuraTohru
en-aut-sei=Nakamura
en-aut-mei=Tohru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KameiShinji
en-aut-sei=Kamei
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MuraoSatoshi
en-aut-sei=Murao
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HidaKazuyuki
en-aut-sei=Hida
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=AndoShinichiro
en-aut-sei=Ando
en-aut-mei=Shinichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=AkaiHiroaki
en-aut-sei=Akai
en-aut-mei=Hiroaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=TakahashiYasushi
en-aut-sei=Takahashi
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=KitadaMunehiro
en-aut-sei=Kitada
en-aut-mei=Munehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=SuganoHisashi
en-aut-sei=Sugano
en-aut-mei=Hisashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=NunoueTomokazu
en-aut-sei=Nunoue
en-aut-mei=Tomokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=NakamuraAkihiko
en-aut-sei=Nakamura
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=SasakiMotofumi
en-aut-sei=Sasaki
en-aut-mei=Motofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=NakatouTatsuaki
en-aut-sei=Nakatou
en-aut-mei=Tatsuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=FujimotoKei
en-aut-sei=Fujimoto
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=KawanamiDaiji
en-aut-sei=Kawanami
en-aut-mei=Daiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=WadaTakashi
en-aut-sei=Wada
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=MiyatakeNobuyuki
en-aut-sei=Miyatake
en-aut-mei=Nobuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=KuramotoHiromi
en-aut-sei=Kuramoto
en-aut-mei=Hiromi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=ShikataKenichi
en-aut-sei=Shikata
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

affil-num=1
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen
kn-affil=

affil-num=3
en-affil=Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen
kn-affil=

affil-num=4
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine
kn-affil=

affil-num=7
en-affil=Suzuki Diadetes Clinic
kn-affil=

affil-num=8
en-affil=Department of Diabetes and Endocrinology, National Hospital Organization Fukuyama Medical Center
kn-affil=

affil-num=9
en-affil=Diabetes Internal Medicine, Sumitomo Besshi Hospital
kn-affil=

affil-num=10
en-affil=Department of Diabetic Medicine, Kurashiki Central Hospital
kn-affil=

affil-num=11
en-affil=Department of Diabetes and Endocrinology, Takamatsu Hospital
kn-affil=

affil-num=12
en-affil=Department of Diabetology and Metabolism, National Hospital Organization Okayama Medical Center
kn-affil=

affil-num=13
en-affil=Department of Internal Medicine Diabetic Center, Okayama City Hospital
kn-affil=

affil-num=14
en-affil=Division of Diabetes and Metabolism, Faculty of Medicine, Tohoku Medical and Pharmaceutical University
kn-affil=

affil-num=15
en-affil=Department of Diabetes, Ochiai General Hospital
kn-affil=

affil-num=16
en-affil=Department of Diabetology and Endocrinology, Kanazawa Medical University
kn-affil=

affil-num=17
en-affil=Department of Diabetes and Endocrinology, Kochi Health Sciences Center
kn-affil=

affil-num=18
en-affil=Nunoue Clinic
kn-affil=

affil-num=19
en-affil=Internal Medicine, Osafune Clinic
kn-affil=

affil-num=20
en-affil=Department of Diabetes and Endocrinology, Matsue City Hospital
kn-affil=

affil-num=21
en-affil=Diabetes Center, Okayama Saiseikai General Hospital
kn-affil=

affil-num=22
en-affil=Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, The Jikei University Kashiwa Hospital
kn-affil=

affil-num=23
en-affil=Department of Endocrinology and Diabetes, Fukuoka University School of Medicine
kn-affil=

affil-num=24
en-affil=Department of Nephrology and Laboratory Medicine, Graduate School of Medical Sciences, Kanazawa University
kn-affil=

affil-num=25
en-affil=Department of Hygiene, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=26
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=27
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=
en-keyword=canagliflozin
kn-keyword=canagliflozin
en-keyword=CANPIONE study
kn-keyword=CANPIONE study
en-keyword=chronic kidney disease microalbuminuria
kn-keyword=chronic kidney disease microalbuminuria
en-keyword=preintervention eGFR slope
kn-keyword=preintervention eGFR slope
en-keyword=sodium-glucose cotransporter 2 inhibitor
kn-keyword=sodium-glucose cotransporter 2 inhibitor
END

start-ver=1.4
cd-journal=joma
no-vol=56
cd-vols=
no-issue=2
article-no=
start-page=73
end-page=88
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241125
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Die Grundlagen der wirtschaftlichen Entwicklung des Königreichs Sachsen（6）
kn-title=ザクセン王国経済発展の基礎（６）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=MatsuoNobushige
en-aut-sei=Matsuo
en-aut-mei=Nobushige
kn-aut-name=松尾展成
kn-aut-sei=松尾
kn-aut-mei=展成
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学名誉教授
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=20
article-no=
start-page=1677
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241018
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Colossal Dielectric Constant of Nanocrystalline/Amorphous Homo-Composite BaTiO3 Films Deposited via Pulsed Laser Deposition Technique
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We report the pulsed laser deposition (PLD) of nanocrystalline/amorphous homo-composite BaTiO3 (BTO) films exhibiting an unprecedented combination of a colossal dielectric constant (epsilon(r)) and extremely low dielectric loss (tan delta). By varying the substrate deposition temperature (T-d) over a wide range (300-800 degrees C), we identified T-d = 550 degrees C as the optimal temperature for growing BTO films with an epsilon(r) as high as similar to 3060 and a tan delta as low as 0.04 (at 20 kHz). High-resolution transmission electron microscopy revealed that the PLD-BTO films consist of BTO nanocrystals (similar to 20-30 nm size) embedded within an otherwise amorphous BTO matrix. The impressive dielectric behavior is attributed to the combination of highly crystallized small BTO nanograins, which amplify interfacial polarization, and the surrounding amorphous matrix, which effectively isolates the nanograins from charge carrier transport. Our findings could facilitate the development of next-generation integrated dielectric devices.
en-copyright=
kn-copyright=

en-aut-name=KondoShinya
en-aut-sei=Kondo
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MurakamiTaichi
en-aut-sei=Murakami
en-aut-mei=Taichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=PichonLoick
en-aut-sei=Pichon
en-aut-mei=Loick
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=Leblanc-LavoieJoel
en-aut-sei=Leblanc-Lavoie
en-aut-mei=Joel
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TeranishiTakashi
en-aut-sei=Teranishi
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KishimotoAkira
en-aut-sei=Kishimoto
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=El KhakaniKhakani, My Ali
en-aut-sei=El Khakani
en-aut-mei=Khakani, My Ali
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=3
en-affil=Institut National de la Recherche Scientifique (INRS), Centre Énergie, Matériaux et Télécommunications
kn-affil=

affil-num=4
en-affil=Institut National de la Recherche Scientifique (INRS), Centre Énergie, Matériaux et Télécommunications
kn-affil=

affil-num=5
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=6
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=7
en-affil=Institut National de la Recherche Scientifique (INRS), Centre Énergie, Matériaux et Télécommunications
kn-affil=
en-keyword=BaTiO3
kn-keyword=BaTiO3
en-keyword=thin film
kn-keyword=thin film
en-keyword=colossal dielectric constant
kn-keyword=colossal dielectric constant
en-keyword=nanocrystalline/amorphous homo-composite
kn-keyword=nanocrystalline/amorphous homo-composite
en-keyword=pulsed laser deposition
kn-keyword=pulsed laser deposition
END

start-ver=1.4
cd-journal=joma
no-vol=5
cd-vols=
no-issue=22
article-no=
start-page=8953
end-page=8960
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20241007
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Enhanced piezo-response of mixed-cation copper perovskites with Cl/Br halide engineering
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Halide and cation engineering of organic-inorganic hybrid perovskites has shown a great potential for structural modulation of perovskites and enhancing their optoelectronic properties. Here, we studied the impact of Cl/Br halide engineering on the structural and piezoelectric properties of MA/Cs mixed-cation Cu-perovskite crystals. X-ray diffraction, Raman spectroscopy, and 133Cs solid-state NMR were utilized to find out the nature of the perovskite crystal structure formation. Three distinct crystal structures were obtained depending on the Cl/Br content. High Cl content resulted in the formation of Br-doped (Cs/MA)CuCl3 perovskite with the presence of paramagnetic Cu2+ ions. High Br content led to the formation of Cl-doped (MA/Cs)2CuBr4 perovskite with the presence of diamagnetic Cu+ ions. Equimolar Cl/Br perovskite content gave a novel crystal structure with the formation of well-dispersed diamagnetic domains. Compared to the high Cl/Br containing perovskites, the equimolar Cl/Br perovskite revealed the highest potential for piezoelectric applications with a maximum recordable piezoelectric output voltage of 5.0 V. The results provide an insight into the importance of mixed-halide and mixed-cation engineering for tailoring the perovskite structural properties towards a wide range of efficient optoelectronics.
en-copyright=
kn-copyright=

en-aut-name=ElattarAmr
en-aut-sei=Elattar
en-aut-mei=Amr
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MunozChristopher
en-aut-sei=Munoz
en-aut-mei=Christopher
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KoberaLibor
en-aut-sei=Kobera
en-aut-mei=Libor
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MahunAndrii
en-aut-sei=Mahun
en-aut-mei=Andrii
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=BrusJiri
en-aut-sei=Brus
en-aut-mei=Jiri
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=UddinMohammed Jasim
en-aut-sei=Uddin
en-aut-mei=Mohammed Jasim
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HayashiYasuhiko
en-aut-sei=Hayashi
en-aut-mei=Yasuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OkoliOkenwa
en-aut-sei=Okoli
en-aut-mei=Okenwa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=DickensTarik
en-aut-sei=Dickens
en-aut-mei=Tarik
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=2
en-affil=Industrial & Manufacturing Engineering, FAMU-FSU College of Engineering
kn-affil=

affil-num=3
en-affil=Institute of Macromolecular Chemistry of the Czech Academy of Sciences
kn-affil=

affil-num=4
en-affil=Institute of Macromolecular Chemistry of the Czech Academy of Sciences
kn-affil=

affil-num=5
en-affil=Institute of Macromolecular Chemistry of the Czech Academy of Sciences
kn-affil=

affil-num=6
en-affil=Photonics and Energy Research Laboratory (PERL), Department of Mechanical Engineering, The University of Texas
kn-affil=

affil-num=7
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=8
en-affil=Industrial & Manufacturing Engineering, FAMU-FSU College of Engineering
kn-affil=

affil-num=9
en-affil=Industrial & Manufacturing Engineering, FAMU-FSU College of Engineering
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=5
article-no=
start-page=413
end-page=421
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202410
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Focal Cerebral Hypoperfusion Detected by Arterial Spin-Labeled Magnetic Resonance Imaging in Patients with Migraine Presenting with Neurological Symptoms Concomitant with or without Headache
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We investigated patients with migraine or migraine variants who exhibited focal cerebral hypoperfusion on arterial spin-labeled (ASL) magnetic resonance (MR) imaging along with neurological symptoms. Fourteen patients with migraine demonstrated focal cerebral hypoperfusion. Three other patients did not have a history of recurrent headaches but exhibited comparable cerebral hypoperfusion to migraine patients on ASL-MRI in addition to neurological symptoms. Patients with migraine may present with neurological symptoms associated with cortical spreading depression during, after, or even without a headache phase. Additionally, the isolated neurological symptoms may be caused by a pathophysiology identical to that of migraine but without presenting with recurrent headaches.
en-copyright=
kn-copyright=

en-aut-name=KashiharaKenichi
en-aut-sei=Kashihara
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IrisawaMinoru
en-aut-sei=Irisawa
en-aut-mei=Minoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakaoWataru
en-aut-sei=Takao
en-aut-mei=Wataru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

affil-num=1
en-affil=Okayama Neurology Clinic
kn-affil=

affil-num=2
en-affil=Department of Radiology, Okayama Kyokuto Hospital
kn-affil=

affil-num=3
en-affil=Division of Radiology, Okayama Kyokuto Hospital
kn-affil=
en-keyword=arterial spin-labeled magnetic resonance imaging
kn-keyword=arterial spin-labeled magnetic resonance imaging
en-keyword=cortical spreading depression
kn-keyword=cortical spreading depression
en-keyword=migraine complex
kn-keyword=migraine complex
en-keyword=migraine without headache
kn-keyword=migraine without headache
en-keyword=vertigo
kn-keyword=vertigo
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=5
article-no=
start-page=387
end-page=399
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202410
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effect of Radon Inhalation on Murine Brain Proteins: Investigation Using Proteomic and Multivariate Analyses
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Radon is a known risk factor for lung cancer; however, it can be used beneficially, such as in radon therapy. We have previously reported the enhancement of antioxidant effects associated with trace amounts of oxidative stress as one of the positive biological effects of radon inhalation. However, the biological effects of radon inhalation are incompletely understood, and more detailed and comprehensive studies are required. Although several studies have used proteomics to investigate the effects of radon inhalation on body proteins, none has focused on brain proteins. In this study, we evaluated the expression status of proteins in murine brains using proteomic and multivariate analyses to identify those whose expressions changed following two days of radon inhalation at a concentration of 1,500 Bq/m3. We found associations of radon inhalation with the expressions of seven proteins related to neurotransmission and heat shock. These proteins may be proposed as biomarkers indicative of radon inhalation. Although further studies are required to obtain the detailed biological significance of these protein alterations, this study contributes to the elucidation of the biological effects of radon
inhalation as a low-dose radiation.
en-copyright=
kn-copyright=

en-aut-name=NaoeShota
en-aut-sei=Naoe
en-aut-mei=Shota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TanakaAyumi
en-aut-sei=Tanaka
en-aut-mei=Ayumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KanzakiNorie
en-aut-sei=Kanzaki
en-aut-mei=Norie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TakenakaReiju
en-aut-sei=Takenaka
en-aut-mei=Reiju
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SakodaAkihiro
en-aut-sei=Sakoda
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MiyajiTakaaki
en-aut-sei=Miyaji
en-aut-mei=Takaaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YamaokaKiyonori
en-aut-sei=Yamaoka
en-aut-mei=Kiyonori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KataokaTakahiro
en-aut-sei=Kataoka
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Ningyo-toge Environmental Engineering Center, Japan Atomic Energy Agency
kn-affil=

affil-num=4
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Ningyo-toge Environmental Engineering Center, Japan Atomic Energy Agency
kn-affil=

affil-num=6
en-affil=Advanced Science Research Center, Okayama University
kn-affil=

affil-num=7
en-affil=Faculty of Health Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Faculty of Health Sciences, Okayama University
kn-affil=
en-keyword=radon inhalation
kn-keyword=radon inhalation
en-keyword=proteomics
kn-keyword=proteomics
en-keyword=multivariate analysis
kn-keyword=multivariate analysis
en-keyword=brain
kn-keyword=brain
en-keyword=oxidative stress
kn-keyword=oxidative stress
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=
article-no=
start-page=1339958
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240829
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Illumina-based transcriptomic analysis of the fast-growing leguminous tree Acacia crassicarpa: functional gene annotation and identification of novel SSR-markers
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Acacia crassicarpa is a fast-growing leguminous tree that is widely cultivated in tropical areas such as Indonesia, Malaysia, Australia, and southern China. This tree has versatile utility in timber, furniture, and pulp production. Illumina sequencing of A. crassicarpa was conducted, and the raw data of 124,410,892 reads were filtered and assembled de novo into 93,317 unigenes, with a total of 84,411,793 bases. Blast2GO annotation, Benchmark Universal Single-Copy Ortholog evaluation, and GO-term classification produced a catalogue of unigenes for studying primary metabolism, phytohormone signaling, and transcription factors. Massive transcriptomic analysis has identified microsatellites composed of simple sequence repeat (SSR) loci representing di-, tri-, and tetranucleotide repeat units in the predicted open reading frames. Polymorphism was induced by PCR amplification of microsatellite loci located in several genes encoding auxin response factors and other transcription factors, which successfully distinguished 16 local trees of A. crassicarpa tested, representing potentially exploitable molecular markers for efficient tree breeding for plantation and biomass exploitation.
en-copyright=
kn-copyright=

en-aut-name=IshioShougo
en-aut-sei=Ishio
en-aut-mei=Shougo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KusunokiKazutaka
en-aut-sei=Kusunoki
en-aut-mei=Kazutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=NemotoMichiko
en-aut-sei=Nemoto
en-aut-mei=Michiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KanaoTadayoshi
en-aut-sei=Kanao
en-aut-mei=Tadayoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TamuraTakashi
en-aut-sei=Tamura
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Tsukuba Research Institute, Sumitomo Forestry Co. Ltd.
kn-affil=

affil-num=2
en-affil=Tsukuba Research Institute, Sumitomo Forestry Co. Ltd.
kn-affil=

affil-num=3
en-affil=Graduate School of Environment, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=4
en-affil=Graduate School of Environment, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=5
en-affil=Institute of Global Human Resource Development, Okayama University
kn-affil=
en-keyword=Acacia crassicarpa
kn-keyword=Acacia crassicarpa
en-keyword= illumina sequencing
kn-keyword= illumina sequencing
en-keyword= polymorphism
kn-keyword= polymorphism
en-keyword= auxin response factor
kn-keyword= auxin response factor
en-keyword= lignin
kn-keyword= lignin
END

start-ver=1.4
cd-journal=joma
no-vol=12
cd-vols=
no-issue=8
article-no=
start-page=1835
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240812
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Surface Pre-Reacted Glass-Ionomer Eluate Suppresses Osteoclastogenesis through Downregulation of the MAPK Signaling Pathway
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Surface pre-reacted glass-ionomer (S-PRG) is a new bioactive filler utilized for the restoration of decayed teeth by its ability to release six bioactive ions that prevent the adhesion of dental plaque to the tooth surface. Since ionic liquids are reported to facilitate transepithelial penetration, we reasoned that S-PRG applied to root caries could impact the osteoclasts (OCs) in the proximal alveolar bone. Therefore, this study aimed to investigate the effect of S-PRG eluate solution on RANKL-induced OC-genesis and mineral dissolution in vitro. Using RAW264.7 cells as OC precursor cells (OPCs), TRAP staining and pit formation assays were conducted to monitor OC-genesis and mineral dissolution, respectively, while OC-genesis-associated gene expression was measured using quantitative real-time PCR (qPCR). Expression of NFATc1, a master regulator of OC differentiation, and the phosphorylation of MAPK signaling molecules were measured using Western blotting. S-PRG eluate dilutions at 1/200 and 1/400 showed no cytotoxicity to RAW264.7 cells but did significantly suppress both OC-genesis and mineral dissolution. The same concentrations of S-PRG eluate downregulated the RANKL-mediated induction of OCSTAMP and CATK mRNAs, as well as the expression of NFATc1 protein and the phosphorylation of ERK, JNK, and p38. These results demonstrate that S-PRG eluate can downregulate RANKL-induced OC-genesis and mineral dissolution, suggesting that its application to root caries might prevent alveolar bone resorption.
en-copyright=
kn-copyright=

en-aut-name=ChandraJanaki
en-aut-sei=Chandra
en-aut-mei=Janaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NakamuraShin
en-aut-sei=Nakamura
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ShindoSatoru
en-aut-sei=Shindo
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=LeonElizabeth
en-aut-sei=Leon
en-aut-mei=Elizabeth
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=CastellonMaria
en-aut-sei=Castellon
en-aut-mei=Maria
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=PastoreMaria Rita
en-aut-sei=Pastore
en-aut-mei=Maria Rita
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HeidariAlireza
en-aut-sei=Heidari
en-aut-mei=Alireza
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=WitekLukasz
en-aut-sei=Witek
en-aut-mei=Lukasz
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=CoelhoPaulo G.
en-aut-sei=Coelho
en-aut-mei=Paulo G.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NakatsukaToshiyuki
en-aut-sei=Nakatsuka
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=KawaiToshihisa
en-aut-sei=Kawai
en-aut-mei=Toshihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=2
en-affil=Department of Pathophysiology-Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=4
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=5
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=6
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=7
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=

affil-num=8
en-affil=Biomaterials Division, NYU Dentistry
kn-affil=

affil-num=9
en-affil=Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami
kn-affil=

affil-num=10
en-affil=R&D Department, Shofu Inc.
kn-affil=

affil-num=11
en-affil=Department of Oral Science and Translational Research, College of Dental Medicine, Nova Southeastern University
kn-affil=
en-keyword=S-PRG
kn-keyword=S-PRG
en-keyword=osteoclast
kn-keyword=osteoclast
en-keyword=hydroxyapatite
kn-keyword=hydroxyapatite
en-keyword=TRAP staining
kn-keyword=TRAP staining
en-keyword=bioactive filler
kn-keyword=bioactive filler
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=4
article-no=
start-page=349
end-page=355
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202408
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Middle-Ear Salivary Gland Choristoma with Congenital, Single-Sided Hearing Loss
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Middle-ear salivary gland choristoma (SGCh) is a rare, benign tumor that causes conductive hearing loss owing to middle-ear morphological abnormalities. Early diagnosis is challenging, and surgical resection is indispensable for a definitive diagnosis. We report the case of a 3-year-old boy diagnosed with middle-ear SGCh during the follow-up period for left-sided hearing loss discovered at newborn hearing screening (NHS). Long-term follow-up after the NHS result, subsequent computed tomography/magnetic resonance imaging, and surgical resection led to its relatively early diagnosis and treatment.
en-copyright=
kn-copyright=

en-aut-name=TominagaYuichiro
en-aut-sei=Tominaga
en-aut-mei=Yuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SugayaAkiko
en-aut-sei=Sugaya
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KariyaShin
en-aut-sei=Kariya
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ShimizuAiko
en-aut-sei=Shimizu
en-aut-mei=Aiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KataokaYuko
en-aut-sei=Kataoka
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=AndoMizuo
en-aut-sei=Ando
en-aut-mei=Mizuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Otolaryngology, Head and Neck Surgery, Hiroshima City, Hiroshima Citizens Hospital
kn-affil=

affil-num=2
en-affil=Department of Otolaryngology, Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Otolaryngology, Head and Neck Surgery, Kawasaki Medical School Hospital
kn-affil=

affil-num=4
en-affil=Department of Otolaryngology, Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Otolaryngology, Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Otolaryngology, Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=middle-ear salivary gland choristoma
kn-keyword=middle-ear salivary gland choristoma
en-keyword=middle-ear morphological abnormalities
kn-keyword=middle-ear morphological abnormalities
en-keyword=newborn hearing screening
kn-keyword=newborn hearing screening
en-keyword=unilateral hearing loss
kn-keyword=unilateral hearing loss
en-keyword=surgical resection
kn-keyword=surgical resection
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=4
article-no=
start-page=323
end-page=330
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202408
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effect of Recipient Age on Perioperative Complications after Pediatric Liver Transplantation: A Single-Center Retrospective Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=It has not been clear how recipient age affects the incidence of serious complications after pediatric living donor liver transplantation (LDLT). We investigated the records of 42 pediatric patients receiving LDLT, dividing our sample into two groups: the infant group (aged < 1 year) and the non-infant group (aged ≥ 1 year and ≤15 years). The primary outcome was postoperative complications assessed using the Clavien-Dindo classification. Multivariate analysis using the Cox regression model was applied to adjust for confounding factors in assessing the incidence of Clavien-Dindo grade ≥ III (C-D ≥ III) complications. The incidence of C-D ≥ III complications was higher in the non-infant group (46.2%) than in the infant group (12.5%) (odds ratio 6.00, 95% confidence interval [CI] 1.13-31.88, p=0.03). In multivariate analysis using the Cox regression model, the Graft-to-Recipient Weight Ratio (GRWR) was independently associated with the incidence of C-D ≥ III complications (hazard ratio [HR] 0.62, 95%CI 0.40-0.95, p=0.03), but being an infant was not (HR 0.84, 95%CI 0.35-1.98, p=0.68). In conclusion, the incidence of C-D ≥ III complications was higher in the non-infant group than in the infant group, but this was largely a function of GRWR: multivariate analysis revealed that GRWR was independently associated with complications.
en-copyright=
kn-copyright=

en-aut-name=KatayamaAkira
en-aut-sei=Katayama
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KimuraSatoshi
en-aut-sei=Kimura
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatsusakiTakashi
en-aut-sei=Matsusaki
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MorimatsuHiroshi
en-aut-sei=Morimatsu
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Anesthesia, Kyoto University Hospital
kn-affil=

affil-num=3
en-affil=Department of Anesthesiology, Mie University Hospital
kn-affil=

affil-num=4
en-affil=Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=pediatric liver transplantation
kn-keyword=pediatric liver transplantation
en-keyword=postoperative severe complications
kn-keyword=postoperative severe complications
en-keyword=Graft-to-Recipient Weight Ratio
kn-keyword=Graft-to-Recipient Weight Ratio
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=4
article-no=
start-page=313
end-page=322
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202408
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Multicenter Remote-Access Simulation of Vaginal Delivery for High-Flexibility Medical Education during the Coronavirus Pandemic
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=During the coronavirus pandemic, face-to-face simulation education became impossible. Therefore, we aimed to develop remote-access simulation education with a sense of realism through Information and Communication Technology (ICT) using a perinatal whole-body management and delivery simulator. In September 2021, we administered a multi-center simultaneous remote simulation based on our developed model. Ten universities in the Chugoku–Shikoku region were connected via a web-conferencing system to a live broadcast of a virtual vaginal birth in which a fictional hospitalized pregnant woman experienced accelerated labor and gave birth through vacuum delivery for fetal distress. A Video on Demand (VOD) was made beforehand using a new simulator that allowed for a visual understanding of the process of the inter-vaginal examination. We provided a participatory program that enhanced the sense of realism by combining VOD and real-time lectures on each scenario, with two-way communication between participants and trainee doctors using a chat function. Most participants answered “satisfied” or “very satisfied” with the content, level of difficulty, and level of understanding. From November 2021, we have used the videos of all processes in face-to-face classes. Our construction of a high-flexibility education system using remote simulation in the field of obstetrics and gynecology, especially in the vaginal delivery module, is unique, creative, and sustainable.
en-copyright=
kn-copyright=

en-aut-name=EtoEriko
en-aut-sei=Eto
en-aut-mei=Eriko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MakiJota
en-aut-sei=Maki
en-aut-mei=Jota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamashitaNoriyuki
en-aut-sei=Yamashita
en-aut-mei=Noriyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HasegawaToru
en-aut-sei=Hasegawa
en-aut-mei=Toru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SuemoriAyano
en-aut-sei=Suemori
en-aut-mei=Ayano
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakatoHikari
en-aut-sei=Nakato
en-aut-mei=Hikari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ObaHikaru
en-aut-sei=Oba
en-aut-mei=Hikaru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=MitomaTomohiro
en-aut-sei=Mitoma
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MishimaSakurako
en-aut-sei=Mishima
en-aut-mei=Sakurako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KirinoSatoe
en-aut-sei=Kirino
en-aut-mei=Satoe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=OhiraAkiko
en-aut-sei=Ohira
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MasuyamaHisashi
en-aut-sei=Masuyama
en-aut-mei=Hisashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Center for Education in Medicine and Health Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=remote simulator education
kn-keyword=remote simulator education
en-keyword=perinatal simulator
kn-keyword=perinatal simulator
en-keyword=information and communication technology
kn-keyword=information and communication technology
en-keyword=high-flexibility education
kn-keyword=high-flexibility education
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=4
article-no=
start-page=307
end-page=312
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202408
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Can Pelvic Lymph Node Dissection in Prostate Cancer Patients with a 5% Briganti Nomogram Cut-off Value Provide an Oncological Benefit? A Large Multi-Institutional Cohort Study in Japan
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The Briganti nomogram (cut-off value 5%) is commonly used to determine the indications for pelvic lymph node dissection (PLND) in patients with prostate cancer. We retrospectively analyzed the potential oncological benefit of PLND based on the 5% cut-off value on the Briganti nomogram. We obtained the data from the Medical Investigation Cancer Network (MICAN) Study, which included 3,463 patients who underwent a radical prostatectomy (RP) at nine institutions in Japan between 2010 and 2020. We included patients with Briganti scores ≥ 5% and a follow-up period ≥6 months and excluded patients categorized in the very high-risk group (based on NCCN categories); a final total of the cases of 1,068 patients were analyzed. The biochemical recurrence (BCR)-free survival was significantly worse in the patients who underwent PLND compared to those who did not (p=0.019). A multivariate analysis showed that high prostate-specific antigen (PSA) levels (p<0.001) and an advanced T-stage (p=0.018) were significant prognostic factors for BCR, whereas PLND had no effect on BCR (p=0.059). Thus, PLND in patients with prostate cancer whose Briganti score was 5% did not provide any oncological benefit. Further research is necessary to determine the indication criteria for conducting PLND.
en-copyright=
kn-copyright=

en-aut-name=SugiharaNaoya
en-aut-sei=Sugihara
en-aut-mei=Naoya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HashineKatsuyoshi
en-aut-sei=Hashine
en-aut-mei=Katsuyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YamashitaNatsumi
en-aut-sei=Yamashita
en-aut-mei=Natsumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SakamotoMiki
en-aut-sei=Sakamoto
en-aut-mei=Miki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TerashitaMasato
en-aut-sei=Terashita
en-aut-mei=Masato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FunakiKeisuke
en-aut-sei=Funaki
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SaikiKaori
en-aut-sei=Saiki
en-aut-mei=Kaori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SawadaTakatora
en-aut-sei=Sawada
en-aut-mei=Takatora
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KakudaToshio
en-aut-sei=Kakuda
en-aut-mei=Toshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=NishimuraKenichi
en-aut-sei=Nishimura
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=FukumotoTetsuya
en-aut-sei=Fukumoto
en-aut-mei=Tetsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MiuraNoriyosi
en-aut-sei=Miura
en-aut-mei=Noriyosi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=MiyauchiYuki
en-aut-sei=Miyauchi
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=KikugawaTadahiko
en-aut-sei=Kikugawa
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=SaikaTakashi
en-aut-sei=Saika
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

affil-num=1
en-affil=Department of Urology, Ehime University
kn-affil=

affil-num=2
en-affil=Department of Urology, National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=3
en-affil=Division of Epidemiology, National Hospital Organization Shikoku Cancer Center
kn-affil=

affil-num=4
en-affil=Department of Urology, Ehime University
kn-affil=

affil-num=5
en-affil=Department of Urology, Ehime University
kn-affil=

affil-num=6
en-affil=Department of Urology, Ehime University
kn-affil=

affil-num=7
en-affil=Department of Urology, Ehime University
kn-affil=

affil-num=8
en-affil=Department of Urology, Ehime University
kn-affil=

affil-num=9
en-affil=Department of Urology, Ehime University
kn-affil=

affil-num=10
en-affil=Department of Urology, Ehime University
kn-affil=

affil-num=11
en-affil=Department of Urology, Ehime University
kn-affil=

affil-num=12
en-affil=Department of Urology, Ehime University
kn-affil=

affil-num=13
en-affil=Department of Urology, Ehime University
kn-affil=

affil-num=14
en-affil=Department of Urology, Ehime University
kn-affil=

affil-num=15
en-affil=Department of Urology, Ehime University
kn-affil=
en-keyword=Briganti nomogram
kn-keyword=Briganti nomogram
en-keyword=pelvic lymph node dissection
kn-keyword=pelvic lymph node dissection
en-keyword=prostate cancer
kn-keyword=prostate cancer
en-keyword=radical prostatectomy
kn-keyword=radical prostatectomy
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=1
article-no=
start-page=5536
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240716
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Controlling 229Th isomeric state population in a VUV transparent crystal
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The radioisotope thorium-229 (Th-229) is renowned for its extraordinarily low-energy, long-lived nuclear first-excited state. This isomeric state can be excited by vacuum ultraviolet (VUV) lasers and Th-229 has been proposed as a reference transition for ultra-precise nuclear clocks. To assess the feasibility and performance of the nuclear clock concept, time-controlled excitation and depopulation of the Th-229 isomer are imperative. Here we report the population of the Th-229 isomeric state through resonant X-ray pumping and detection of the radiative decay in a VUV transparent Th-229-doped CaF2 crystal. The decay half-life is measured to 447(25) s, with a transition wavelength of 148.18(42) nm and a radiative decay fraction consistent with unity. Furthermore, we report a new "X-ray quenching" effect which allows to de-populate the isomer on demand and effectively reduce the half-life. Such controlled quenching can be used to significantly speed up the interrogation cycle in future nuclear clock schemes.
en-copyright=
kn-copyright=

en-aut-name=HirakiTakahiro
en-aut-sei=Hiraki
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OkaiKoichi
en-aut-sei=Okai
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=BartokosMichael
en-aut-sei=Bartokos
en-aut-mei=Michael
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=BeeksKjeld
en-aut-sei=Beeks
en-aut-mei=Kjeld
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FujimotoHiroyuki
en-aut-sei=Fujimoto
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FukunagaYuta
en-aut-sei=Fukunaga
en-aut-mei=Yuta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HabaHiromitsu
en-aut-sei=Haba
en-aut-mei=Hiromitsu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KasamatsuYoshitaka
en-aut-sei=Kasamatsu
en-aut-mei=Yoshitaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KitaoShinji
en-aut-sei=Kitao
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=LeitnerAdrian
en-aut-sei=Leitner
en-aut-mei=Adrian
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MasudaTakahiko
en-aut-sei=Masuda
en-aut-mei=Takahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=GuanMing
en-aut-sei=Guan
en-aut-mei=Ming
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=NagasawaNobumoto
en-aut-sei=Nagasawa
en-aut-mei=Nobumoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=OgakeRyoichiro
en-aut-sei=Ogake
en-aut-mei=Ryoichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=PimonMartin
en-aut-sei=Pimon
en-aut-mei=Martin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=PresslerMartin
en-aut-sei=Pressler
en-aut-mei=Martin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=SasaoNoboru
en-aut-sei=Sasao
en-aut-mei=Noboru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=SchadenFabian
en-aut-sei=Schaden
en-aut-mei=Fabian
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=SchummThorsten
en-aut-sei=Schumm
en-aut-mei=Thorsten
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=SetoMakoto
en-aut-sei=Seto
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=ShigekawaYudai
en-aut-sei=Shigekawa
en-aut-mei=Yudai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=ShimizuKotaro
en-aut-sei=Shimizu
en-aut-mei=Kotaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=SikorskyTomas
en-aut-sei=Sikorsky
en-aut-mei=Tomas
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=TamasakuKenji
en-aut-sei=Tamasaku
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=TakatoriSayuri
en-aut-sei=Takatori
en-aut-mei=Sayuri
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=WatanabeTsukasa
en-aut-sei=Watanabe
en-aut-mei=Tsukasa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=YamaguchiAtsushi
en-aut-sei=Yamaguchi
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

en-aut-name=YodaYoshitaka
en-aut-sei=Yoda
en-aut-mei=Yoshitaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=28
ORCID=

en-aut-name=YoshimiAkihiro
en-aut-sei=Yoshimi
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=29
ORCID=

en-aut-name=YoshimuraKoji
en-aut-sei=Yoshimura
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=30
ORCID=

affil-num=1
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=2
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=3
en-affil=Institute for Atomic and Subatomic Physics, TU Wien
kn-affil=

affil-num=4
en-affil=Institute for Atomic and Subatomic Physics, TU Wien
kn-affil=

affil-num=5
en-affil=National Institute of Advanced Industrial Science and Technology (AIST)
kn-affil=

affil-num=6
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=7
en-affil=RIKEN
kn-affil=

affil-num=8
en-affil=Graduate School of Science, Osaka University
kn-affil=

affil-num=9
en-affil=Institute for Integrated Radiation and Nuclear Science, Kyoto University
kn-affil=

affil-num=10
en-affil=Institute for Atomic and Subatomic Physics, TU Wien
kn-affil=

affil-num=11
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=12
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=13
en-affil=Japan Synchrotron Radiation Research Institute
kn-affil=

affil-num=14
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=15
en-affil=Institute for Atomic and Subatomic Physics, TU Wien
kn-affil=

affil-num=16
en-affil=Institute for Atomic and Subatomic Physics, TU Wien
kn-affil=

affil-num=17
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=18
en-affil=Institute for Atomic and Subatomic Physics, TU Wien
kn-affil=

affil-num=19
en-affil=Institute for Atomic and Subatomic Physics, TU Wien
kn-affil=

affil-num=20
en-affil=Institute for Integrated Radiation and Nuclear Science, Kyoto University
kn-affil=

affil-num=21
en-affil=RIKEN
kn-affil=

affil-num=22
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=23
en-affil=Institute for Atomic and Subatomic Physics, TU Wien
kn-affil=

affil-num=24
en-affil=RIKEN SPring-8 Center
kn-affil=

affil-num=25
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=26
en-affil=National Institute of Advanced Industrial Science and Technology (AIST)
kn-affil=

affil-num=27
en-affil=RIKEN
kn-affil=

affil-num=28
en-affil=Japan Synchrotron Radiation Research Institute
kn-affil=

affil-num=29
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=30
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=56
cd-vols=
no-issue=1
article-no=
start-page=59
end-page=72
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240724
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Die Grundlagen der wirtschaftlichen Entwicklung des Königreichs Sachsen（5）
kn-title=ザクセン王国経済発展の基礎（５）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=MatsuoNobushige
en-aut-sei=Matsuo
en-aut-mei=Nobushige
kn-aut-name=松尾展成
kn-aut-sei=松尾
kn-aut-mei=展成
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学名誉教授
END

start-ver=1.4
cd-journal=joma
no-vol=15
cd-vols=
no-issue=1
article-no=
start-page=4600
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240530
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Photoinduced dynamics during electronic transfer from narrow to wide bandgap layers in one-dimensional heterostructured materials
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Electron transfer is a fundamental energy conversion process widely present in synthetic, industrial, and natural systems. Understanding the electron transfer process is important to exploit the uniqueness of the low-dimensional van der Waals (vdW) heterostructures because interlayer electron transfer produces the function of this class of material. Here, we show the occurrence of an electron transfer process in one-dimensional layer-stacking of carbon nanotubes (CNTs) and boron nitride nanotubes (BNNTs). This observation makes use of femtosecond broadband optical spectroscopy, ultrafast time-resolved electron diffraction, and first-principles theoretical calculations. These results reveal that near-ultraviolet photoexcitation induces an electron transfer from the conduction bands of CNT to BNNT layers via electronic decay channels. This physical process subsequently generates radial phonons in the one-dimensional vdW heterostructure material. The gathered insights unveil the fundamentals physics of interfacial interactions in low dimensional vdW heterostructures and their photoinduced dynamics, pushing their limits for photoactive multifunctional applications.
en-copyright=
kn-copyright=

en-aut-name=SaidaYuri
en-aut-sei=Saida
en-aut-mei=Yuri
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=GauthierThomas
en-aut-sei=Gauthier
en-aut-mei=Thomas
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SuzukiHiroo
en-aut-sei=Suzuki
en-aut-mei=Hiroo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OhmuraSatoshi
en-aut-sei=Ohmura
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ShikataRyo
en-aut-sei=Shikata
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IwasakiYui
en-aut-sei=Iwasaki
en-aut-mei=Yui
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NoyamaGodai
en-aut-sei=Noyama
en-aut-mei=Godai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KishibuchiMisaki
en-aut-sei=Kishibuchi
en-aut-mei=Misaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TanakaYuichiro
en-aut-sei=Tanaka
en-aut-mei=Yuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=YajimaWataru
en-aut-sei=Yajima
en-aut-mei=Wataru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=GodinNicolas
en-aut-sei=Godin
en-aut-mei=Nicolas
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=PrivaultGael
en-aut-sei=Privault
en-aut-mei=Gael
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TokunagaTomoharu
en-aut-sei=Tokunaga
en-aut-mei=Tomoharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=OnoShota
en-aut-sei=Ono
en-aut-mei=Shota
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=KoshiharaShin-Ya
en-aut-sei=Koshihara
en-aut-mei=Shin-Ya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=TsurutaKenji
en-aut-sei=Tsuruta
en-aut-mei=Kenji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=HayashiYasuhiko
en-aut-sei=Hayashi
en-aut-mei=Yasuhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=BertoniRoman
en-aut-sei=Bertoni
en-aut-mei=Roman
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=HadaMasaki
en-aut-sei=Hada
en-aut-mei=Masaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

affil-num=1
en-affil=Graduate School of Science and Technology, University of Tsukuba
kn-affil=

affil-num=2
en-affil=Univ Rennes, CNRS, IPR (Institut de Physique de Rennes) UMR 6251
kn-affil=

affil-num=3
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=4
en-affil=Faculty of Engineering, Hiroshima Institute of Technology
kn-affil=

affil-num=5
en-affil=Graduate School of Science and Technology, University of Tsukuba
kn-affil=

affil-num=6
en-affil=Graduate School of Science and Technology, University of Tsukuba
kn-affil=

affil-num=7
en-affil=Graduate School of Science and Technology, University of Tsukuba
kn-affil=

affil-num=8
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=9
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=10
en-affil=Graduate School of Science and Technology, University of Tsukuba
kn-affil=

affil-num=11
en-affil=Univ Rennes, CNRS, IPR (Institut de Physique de Rennes) UMR 6251
kn-affil=

affil-num=12
en-affil=Univ Rennes, CNRS, IPR (Institut de Physique de Rennes) UMR 6251
kn-affil=

affil-num=13
en-affil=Graduate School of Engineering, Nagoya University
kn-affil=

affil-num=14
en-affil=Institute for Materials Research, Tohoku University 
kn-affil=

affil-num=15
en-affil=School of Science, Tokyo Institute of Technology
kn-affil=

affil-num=16
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=17
en-affil=Graduate School of Environmental, Life, Natural Science and Technology, Okayama University
kn-affil=

affil-num=18
en-affil=Univ Rennes, CNRS, IPR (Institut de Physique de Rennes) UMR 6251
kn-affil=

affil-num=19
en-affil=Institute of Pure and Applied Science and Tsukuba Research Center for Energy Materials Science (TREMS), University of Tsukuba
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=3
article-no=
start-page=281
end-page=284
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202406
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Spontaneous Bilateral Pneumothorax in a Patient with Anorexia Nervosa: The Management of Prolonged Postoperative Air Leakage
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A 24-year-old Japanese female with anorexia nervosa presented to our hospital for bilateral pneumothorax, and 12-Fr thoracostomy catheters were inserted into the bilateral pleural cavities. On hospital day 9, a thoracoscopic bullectomy was performed. However, air leakage relapsed on both sides on postoperative day 1. The air leakage on the right side was particularly persistent, and we switched the drainage to a Heimlich valve. Both lungs expanded gradually and the chest tube was removed on postoperative day 19. Passive pleural drainage might be an option for prolonged air leakage after a bullectomy in patients with anorexia nervosa.
en-copyright=
kn-copyright=

en-aut-name=OkadaKazuhiro
en-aut-sei=Okada
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MakiYuho
en-aut-sei=Maki
en-aut-mei=Yuho
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatsubaraKei
en-aut-sei=Matsubara
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=HiranoYutaka
en-aut-sei=Hirano
en-aut-mei=Yutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=FujiwaraToshiya
en-aut-sei=Fujiwara
en-aut-mei=Toshiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MatsuuraMotoki
en-aut-sei=Matsuura
en-aut-mei=Motoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=2
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=3
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=4
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=5
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=6
en-affil=Department of Thoracic Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=
en-keyword=spontaneous pneumothorax
kn-keyword=spontaneous pneumothorax
en-keyword=anorexia nervosa
kn-keyword=anorexia nervosa
en-keyword=Heimlich valve
kn-keyword=Heimlich valve
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=3
article-no=
start-page=271
end-page=279
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202406
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Effect of Humidified High-Flow Nasal Cannula Oxygen Therapy with a Pulmonary Infection Control Window as a Ventilation Switching Indication in Combination with Atomizing Inhalation of Terbutaline on the Lung Function of Patients with Acute Exacerbation of COPD
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We investigated how humidified high-flow nasal cannula oxygen therapy (HFNC) with a pulmonary infection control (PIC) window as a ventilation switching indication in combination with atomizing inhalation of terbutaline affects the lung function of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). We examined 140 hospitalized AECOPD patients randomized to control and observation groups. Conventional supportive therapy and invasive mechanical ventilation with tracheal intubation were conducted in both groups, with a PIC window as the indication for ventilation switching. Noninvasive positive pressure ventilation (NIPPV) plus atomizing inhalation of terbutaline was used in the control group. In the observation group, HFNC combined with atomizing inhalation of terbutaline was used. Compared to the control group, after 48-hr treatment and treatment completion, the observation group had significantly increased levels of lung function indicators (maximal voluntary ventilation [MVV] plus forced vital capacity [FVC], p<0.05) and oxygen metabolism indicators (arterial oxygen partial pressure [PaO2], arterial oxygen content [CaO2], and oxygenation index, p<0.05). The comparison of the groups revealed that the levels of airway remodeling indicators (matrix metalloproteinase-2 [MMP-2], tissue inhibitor of metalloproteinase 2 [TIMP-2] plus MMP-9) and inflammatory indicators (interferon gamma [IFN-γ] together with interleukin-17 [IL-17], IL-10 and IL-4) were significantly lower after 48 h of treatment as well as after treatment completion (both p<0.05). These results demonstrate that HFNC with a PIC window as the indication for ventilation switching combined with atomizing inhalation of terbutaline can relieve the disorder of oxygen metabolism and correct airway hyper-reactivity.
en-copyright=
kn-copyright=

en-aut-name=YeMengjiao
en-aut-sei=Ye
en-aut-mei=Mengjiao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ZhangRenwei
en-aut-sei=Zhang
en-aut-mei=Renwei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Department of Respiratory and Critical Care Medicine, Tiantai Hospital of Traditional Chinese Medicine
kn-affil=

affil-num=2
en-affil=Department of Respiratory and Critical Care Medicine, Tiantai Hospital of Traditional Chinese Medicine
kn-affil=
en-keyword=chronic obstructive pulmonary disease
kn-keyword=chronic obstructive pulmonary disease
en-keyword=inhalation
kn-keyword=inhalation
en-keyword=oxygen therapy
kn-keyword=oxygen therapy
en-keyword=pulmonary function
kn-keyword=pulmonary function
en-keyword=ventilation
kn-keyword=ventilation
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=3
article-no=
start-page=259
end-page=270
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202406
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Role of the Lipid Profile and Oxidative Stress in Fatigue, Sleep Disorders and Cognitive Impairment in Patients with Multiple Sclerosis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The aim of this study is to investigate the relationship of the lipid profile, dysfunctional high-density lipoprotein, ischaemia-modified albumin and thiol–disulfide homeostasis with cognitive impairment, fatigue and sleep disorders in patients with multiple sclerosis. The cognitive functions of patients were evaluated with the Brief International Cognitive Assessment for Multiple Sclerosis battery. Fatigue was evaluated with the Fatigue Severity Scale and the Fatigue Impact Scale. The Pittsburgh Sleep Quality Index and the Epworth Sleepiness Scale were used to assess patients’ sleep disturbance. Peripheral blood samples were collected, and lipid levels and myeloperoxidase and paraoxonase activity were measured. The myeloperoxidase/paraoxonase ratio, which indicates dysfunctional high-density lipoprotein, was calculated. Thiol–disulfide homeostasis and ischaemia-modified albumin were measured.<br>
We did not identify any relationship between dysfunctional high-density lipoprotein and the physical disability, cognitive decline, fatigue and sleep problems of multiple sclerosis. Thiol–disulfide homeostasis was associated with cognitive scores. The shift of the balance towards disulfide was accompanied by a decrease in cognitive scores. On the other hand, we did not detect any relationship between fatigue and sleep disorders and thiol–disulfide homeostasis. Our findings revealed a possible correlation between cognitive dysfunction and thiol–disulfide homeostasis in multiple sclerosis patients.
en-copyright=
kn-copyright=

en-aut-name=VuralGonul
en-aut-sei=Vural
en-aut-mei=Gonul
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=DemirEsra
en-aut-sei=Demir
en-aut-mei=Esra
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=GumusyaylaSadiye
en-aut-sei=Gumusyayla
en-aut-mei=Sadiye
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ErenFunda
en-aut-sei=Eren
en-aut-mei=Funda
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=BarakliSerdar
en-aut-sei=Barakli
en-aut-mei=Serdar
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NeseliogluSalim
en-aut-sei=Neselioglu
en-aut-mei=Salim
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ErelOzcan
en-aut-sei=Erel
en-aut-mei=Ozcan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Neurology, Faculty of Medicine, Ankara Yildirim Beyazit University
kn-affil=

affil-num=2
en-affil=Department of Neurology, Ankara City Hospital
kn-affil=

affil-num=3
en-affil=Department of Neurology, Faculty of Medicine, Ankara Yildirim Beyazit University
kn-affil=

affil-num=4
en-affil=Department of Clinical Biochemistry, Ankara City Hospital
kn-affil=

affil-num=5
en-affil=Department of Neurology, Ankara City Hospital
kn-affil=

affil-num=6
en-affil=Department of Clinical Biochemistry, Ankara City Hospital
kn-affil=

affil-num=7
en-affil=Department of Clinical Biochemistry, Ankara City Hospital
kn-affil=
en-keyword=multiple sclerosis
kn-keyword=multiple sclerosis
en-keyword=dysfunctional HDL
kn-keyword=dysfunctional HDL
en-keyword=thiol–disulfide homeostasis
kn-keyword=thiol–disulfide homeostasis
en-keyword=cognitive decline
kn-keyword=cognitive decline
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=3
article-no=
start-page=245
end-page=250
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202406
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Impact of Reduced Skeletal Muscle Mass on Patients with Knee Osteoarthritis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Although several studies have suggested a possible association between sarcopenia and knee osteoarthritis (OA) in the elderly, there remains no definitive evidence. Recently, however, the serum creatinine/cystatin C ratio (sarcopenia index: SI) was reported to correlate with skeletal muscle mass. The present retrospective study therefore investigated the impact of reduced skeletal muscle mass on advanced knee OA using SI. In 55 individuals scheduled for knee osteotomy or knee arthroplasty, correlations between SI and patient-reported outcomes such as the Knee Society Score (KSS), Knee Injury and Osteoarthritis Outcome Score (KOOS), and Oxford Knee Score (OKS) were explored. Significant associations were found between SI and the KSS functional activity score (β=0.37; p=0.022), KOOS subscale for activities of daily living (β=0.42; p=0.0096), and OKS (β=0.42; p=0.0095). This study underscores the role of reduced muscle mass in functional outcomes and introduces SI as a valuable marker for assessing muscle loss in knee OA patients.
en-copyright=
kn-copyright=

en-aut-name=AkagawaManabu
en-aut-sei=Akagawa
en-aut-mei=Manabu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SaitoHidetomo
en-aut-sei=Saito
en-aut-mei=Hidetomo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakahashiYasuhiro
en-aut-sei=Takahashi
en-aut-mei=Yasuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=IwamotoYosuke
en-aut-sei=Iwamoto
en-aut-mei=Yosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=IidaJunpei
en-aut-sei=Iida
en-aut-mei=Junpei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=YoshikawaTakayuki
en-aut-sei=Yoshikawa
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=AbeToshiki
en-aut-sei=Abe
en-aut-mei=Toshiki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=SaitoKimio
en-aut-sei=Saito
en-aut-mei=Kimio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KijimaHiroaki
en-aut-sei=Kijima
en-aut-mei=Hiroaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KasukawaYuji
en-aut-sei=Kasukawa
en-aut-mei=Yuji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HongoMichio
en-aut-sei=Hongo
en-aut-mei=Michio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=MiyakoshiNaohisa
en-aut-sei=Miyakoshi
en-aut-mei=Naohisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Department of Orthopedic Surgery, Omagari Kousei Medical Center
kn-affil=

affil-num=2
en-affil=Department of Orthopedic Surgery, Akita University Graduate School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Orthopedic Surgery, Omagari Kousei Medical Center
kn-affil=

affil-num=4
en-affil=Department of Orthopedic Surgery, Omagari Kousei Medical Center
kn-affil=

affil-num=5
en-affil=Department of Orthopedic Surgery, Omagari Kousei Medical Center
kn-affil=

affil-num=6
en-affil=Department of Orthopedic Surgery, Omagari Kousei Medical Center
kn-affil=

affil-num=7
en-affil=Department of Orthopedic Surgery, Omagari Kousei Medical Center
kn-affil=

affil-num=8
en-affil=Department of Orthopedic Surgery, Akita University Graduate School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Orthopedic Surgery, Akita University Graduate School of Medicine
kn-affil=

affil-num=10
en-affil=Department of Orthopedic Surgery, Akita University Graduate School of Medicine
kn-affil=

affil-num=11
en-affil=Department of Orthopedic Surgery, Akita University Graduate School of Medicine
kn-affil=

affil-num=12
en-affil=Department of Orthopedic Surgery, Akita University Graduate School of Medicine
kn-affil=
en-keyword=knee osteoarthritis
kn-keyword=knee osteoarthritis
en-keyword=sarcopenia index
kn-keyword=sarcopenia index
en-keyword=reduced muscle mass
kn-keyword=reduced muscle mass
en-keyword=activities of daily living
kn-keyword=activities of daily living
en-keyword=functional activity
kn-keyword=functional activity
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=4
article-no=
start-page=394
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240410
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Changes of Temperature and Moisture Distribution over Time by Thermo-Hydro-Chemical (T-H-C)-Coupled Analysis in Buffer Material Focusing on Montmorillonite Content
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Bentonite is used as a buffer material in engineered barriers for the geological disposal of high-level radioactive waste. The buffer material will be made of bentonite, a natural clay, mixed with silica sand. The buffer material is affected by decay heat from high-level radioactive waste, infiltration of groundwater, and swelling of the buffer material. The analysis of these factors requires coupled analysis of heat transfer, moisture transfer, and groundwater chemistry. The purpose of this study is to develop a model to evaluate bentonite types and silica sand content in a unified manner for thermo-hydro-chemical (T-H-C)-coupled analysis in buffer materials. We focused on the content of the clay mineral montmorillonite, which is the main component of bentonite, and developed a model to derive the moisture diffusion coefficient of liquid water and water vapor based on Philip and de Vries, and Kozeny-Carman. The evolutions of the temperature and moisture distribution in the buffer material were analyzed, and the validity of each distribution was confirmed by comparison with the measured data obtained from an in situ experiment at 350 m in depth at the Horonobe Underground Research Center, Hokkaido, Japan.
en-copyright=
kn-copyright=

en-aut-name=OuchiKohei
en-aut-sei=Ouchi
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SatoHaruo
en-aut-sei=Sato
en-aut-mei=Haruo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=
en-keyword=geological disposal
kn-keyword=geological disposal
en-keyword=buffer material
kn-keyword=buffer material
en-keyword=T-H-C-coupled analysis
kn-keyword=T-H-C-coupled analysis
en-keyword=montmorillonite
kn-keyword=montmorillonite
en-keyword=bentonite
kn-keyword=bentonite
END

start-ver=1.4
cd-journal=joma
no-vol=24
cd-vols=
no-issue=1
article-no=
start-page=140
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240422
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Endoscopic manifestation of intestinal transplant-associated microangiopathy after stem cell transplantation
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Background Endoscopic features of intestinal transplant-associated microangiopathy (iTAM) have not been comprehensively investigated. This study aimed to examine the endoscopic characteristics of patients diagnosed with iTAM.<br>
Methods This retrospective analysis included 14 patients pathologically diagnosed with iTAM after stem cell transplantation for hematolymphoid neoplasms (n = 13) or thalassemia (n = 1). The sex, age at diagnosis, endoscopic features, and prognosis of each patient were assessed. Serological markers for diagnosing transplant-associated thrombotic microangiopathy were also evaluated.<br>
Results The mean age at the time of iTAM diagnosis was 40.2 years. Patients diagnosed based on the pathognomonic pathological changes of iTAM presented with diverse symptoms at the times of endoscopic examinations, including diarrhea (n = 10), abdominal pain (n = 5), nausea (n = 4), appetite loss (n = 2), bloody stools (n = 2), abdominal discomfort (n = 1), and vomiting (n = 1). At the final follow-up, six patients survived, while eight patients succumbed, with a median time of 100.5 days (range: 52-247) post-diagnosis. Endoscopic manifestations included erythematous mucosa (n = 14), erosions (n = 13), ulcers (n = 9), mucosal edema (n = 9), granular mucosa (n = 9), and villous atrophy (n = 4). Erosions and/or ulcers were primarily observed in the colon (10/14, 71%), followed by the ileum (9/13, 69%), stomach (4/10, 40%), cecum (5/14, 36%), duodenum (3/10, 30%), rectum (4/14, 29%), and esophagus (1/10, 10%). Cytomegalovirus infection (n = 4) and graft-versus-host disease (n = 2) coexisted within the gastrointestinal tract. Patients had de novo prolonged or progressive thrombocytopenia (6/14, 43%), decreased hemoglobin concentration (4/14, 29%), reduced serum haptoglobin level (3/14, 21%), and a sudden and persistent increase in lactate dehydrogenase level (2/14, 14%). Peripheral blood samples from 12 patients were evaluated for schistocytes, with none exceeding 4%.<br>
Conclusions This study provides a comprehensive exploration of the endoscopic characteristics of iTAM. Notably, all patients exhibited erythematous mucosa throughout the gastrointestinal tract, accompanied by prevalent manifestations, such as erosions (93%), ulcers (64%), mucosal edema (64%), granular mucosa (64%), and villous atrophy (29%). Because of the low positivity for serological markers of transplant-associated thrombotic microangiopathy in patients with iTAM, endoscopic evaluation and biopsy of these lesions are crucial, even in the absence of these serological features.
en-copyright=
kn-copyright=

en-aut-name=IwamuroMasaya
en-aut-sei=Iwamuro
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=EnnishiDaisuke
en-aut-sei=Ennishi
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FujiiNobuharu
en-aut-sei=Fujii
en-aut-mei=Nobuharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MatsuokaKen-Ichi
en-aut-sei=Matsuoka
en-aut-mei=Ken-Ichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TanakaTakehiro
en-aut-sei=Tanaka
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=InokuchiToshihiro
en-aut-sei=Inokuchi
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HiraokaSakiko
en-aut-sei=Hiraoka
en-aut-mei=Sakiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OtsukaMotoyuki
en-aut-sei=Otsuka
en-aut-mei=Motoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University  Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Hematology and Oncology, Okayama University  Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Hematology and Oncology, Okayama University  Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Hematology and Oncology, Okayama University  Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Pathology, Okayama University Graduate School of  Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology and Hepatology, Okayama University  Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology and Hepatology, Okayama University  Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology and Hepatology, Okayama University  Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=
en-keyword=Colonoscopy
kn-keyword=Colonoscopy
en-keyword=Esophagogastroduodenoscopy
kn-keyword=Esophagogastroduodenoscopy
en-keyword=Graft-versus-host disease
kn-keyword=Graft-versus-host disease
en-keyword=Hematopoietic stem cell transplantation
kn-keyword=Hematopoietic stem cell transplantation
en-keyword=Intestinal transplant-associated microangiopathy
kn-keyword=Intestinal transplant-associated microangiopathy
en-keyword=iTAM
kn-keyword=iTAM
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=2
article-no=
start-page=185
end-page=191
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202404
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Reduced Immunogenicity of COVID-19 Vaccine in Obese Patients with Type 2 Diabetes: A Cross-Sectional Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The global pandemic of coronavirus infection 2019 (COVID-19) was an unprecedented public health emergency. Several clinical studies reported that heart disease, lung disease, diabetes, hypertension, dyslipidemia, and obesity are critical risk factors for increased severity of and hospitalization for COVID-19. This is largely because patients with these underlying medical conditions can show poor immune responses to the COVID-19 vaccinations. Diabetes is one of the underlying conditions most highly associated with COVID-19 susceptibility and is considered a predictor of poor prognosis of COVID-19. We therefore investigated factors that influence the anti-SARS-CoV-2 spike IgG antibody titer after three doses of vaccination in patients with type 2 diabetes. We found that obesity was associated with low anti-SARS-CoV-2 spike IgG antibody titers following three-dose vaccination in type 2 diabetics. Obese patients with type 2 diabetes may have attenuated vaccine efficacy and require additional vaccination; continuous infection control should be considered in such patients.
en-copyright=
kn-copyright=

en-aut-name=TakahashiHiroko
en-aut-sei=Takahashi
en-aut-mei=Hiroko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=EguchiJun
en-aut-sei=Eguchi
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=WatanabeMayu
en-aut-sei=Watanabe
en-aut-mei=Mayu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakayamaMasanori
en-aut-sei=Nakayama
en-aut-mei=Masanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=WadaJun
en-aut-sei=Wada
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Office of Innovative Medicine, Organization for Research Strategy and Development, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=obesity
kn-keyword=obesity
en-keyword=type 2 diabetes
kn-keyword=type 2 diabetes
en-keyword=COVID-19
kn-keyword=COVID-19
en-keyword=vaccination
kn-keyword=vaccination
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=2
article-no=
start-page=163
end-page=170
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202404
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Impact of Light Touch and Pin Prick on Functional Outcomes in Patients with Traumatic Spinal Cord Injury
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A spinal cord injury (SCI) can cause severe lifelong functional disability and profoundly affect an individual’s daily life. We investigated the prediction of patients’ post-SCI functional outcomes by evaluating sensory scores rather than motor scores, as the latter’s association with functional outcomes is well established. We examined patients’ responses to a light touch (LT) and pin prick (PP) at admission and the response data’s usefulness as predictors of functional outcomes (i.e., ability to perform activities of daily living) at discharge. This exploratory observational study used data from the Japanese National Spinal Cord Injury Database (SCI-J). Data from 3,676 patients who met the inclusion criteria and were admitted for an SCI between 1997 and 2020 were analyzed. The motor score of the Functional Independence Measure (mFIM) at discharge was used as an index of functional outcome. A multiple regression analysis revealed that the mFIM was associated with both the LT response (β=0.07 (0.01), p<0.001) and the PP response (β=0.07 (0.01), p<0.001) at admission. The false discovery rate log-worth values for LT and PP were 6.6 and 8.5, respectively. Our findings demonstrate that LT and PP scores at admission can help predict patients’ functional outcomes after an SCI, although the magnitude of their contributions is not high.
en-copyright=
kn-copyright=

en-aut-name=DeguchiTakayuki
en-aut-sei=Deguchi
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KandaKanae
en-aut-sei=Kanda
en-aut-mei=Kanae
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FurusawaKazunari
en-aut-sei=Furusawa
en-aut-mei=Kazunari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=Nlandu Roger Ngatu
en-aut-sei=Nlandu Roger Ngatu
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HiraoTomohiro
en-aut-sei=Hirao
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Rehabilitation, Kagawa Rosai Hospital
kn-affil=

affil-num=2
en-affil=Department of Public Health, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=3
en-affil=Department of Rehabilitation Medicine, Kibikogen Rehabilitation Center for Employment Injuries
kn-affil=

affil-num=4
en-affil=Department of Public Health, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=5
en-affil=Department of Public Health, Faculty of Medicine, Kagawa University
kn-affil=
en-keyword=functional independence measure
kn-keyword=functional independence measure
en-keyword=light touch
kn-keyword=light touch
en-keyword=pin prick
kn-keyword=pin prick
en-keyword=spinal cord injury
kn-keyword=spinal cord injury
en-keyword=Japanese National Spinal Cord Injury Database
kn-keyword=Japanese National Spinal Cord Injury Database
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=2
article-no=
start-page=151
end-page=161
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202404
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=p53-Armed Oncolytic Virotherapy Improves Radiosensitivity in Soft-Tissue Sarcoma by Suppressing BCL-xL Expression
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Soft-tissue sarcoma (STS) is a heterogeneous group of rare tumors originating predominantly from the embryonic mesoderm. Despite the development of combined modalities including radiotherapy, STSs are often refractory to antitumor modalities, and novel strategies that improve the prognosis of STS patients are needed. We previously demonstrated the therapeutic potential of two telomerase-specific replication-competent oncolytic adenoviruses, OBP-301 and tumor suppressor p53-armed OBP-702, in human STS cells. Here, we demonstrate in vitro and in vivo antitumor effects of OBP-702 in combination with ionizing radiation against human STS cells (HT1080, NMS-2, SYO-1). OBP-702 synergistically promoted the antitumor effect of ionizing radiation in the STS cells by suppressing the expression of B-cell lymphoma-X large (BCL-xL) and enhancing ionizing radiation-induced apoptosis. The in vivo experiments demonstrated that this combination therapy significantly suppressed STS tumors’ growth. Our results suggest that OBP-702 is a promising antitumor reagent for promoting the radiosensitivity of STS tumors.
en-copyright=
kn-copyright=

en-aut-name=KomatsubaraTadashi
en-aut-sei=Komatsubara
en-aut-mei=Tadashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TazawaHiroshi
en-aut-sei=Tazawa
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HaseiJoe
en-aut-sei=Hasei
en-aut-mei=Joe
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OmoriToshinori
en-aut-sei=Omori
en-aut-mei=Toshinori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SugiuKazuhisa
en-aut-sei=Sugiu
en-aut-mei=Kazuhisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MochizukiYusuke
en-aut-sei=Mochizuki
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=DemiyaKoji
en-aut-sei=Demiya
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YoshidaAki
en-aut-sei=Yoshida
en-aut-mei=Aki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=FujiwaraTomohiro
en-aut-sei=Fujiwara
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KunisadaToshiyuki
en-aut-sei=Kunisada
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=UrataYasuo
en-aut-sei=Urata
en-aut-mei=Yasuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=KagawaShunsuke
en-aut-sei=Kagawa
en-aut-mei=Shunsuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Oncolys BioPharma, Inc.
kn-affil=

affil-num=12
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=13
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=14
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=soft-tissue sarcoma
kn-keyword=soft-tissue sarcoma
en-keyword=radiotherapy
kn-keyword=radiotherapy
en-keyword=oncolytic adenovirus
kn-keyword=oncolytic adenovirus
en-keyword=p53
kn-keyword=p53
en-keyword=BCL-xL
kn-keyword=BCL-xL
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=2
article-no=
start-page=135
end-page=142
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202404
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Photon-Counting Detector CT: Potential for 75% Reduction in Contrast Medium Amount: A Phantom Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This study aimed to evaluate the potential reduction in contrast medium utilization using photon-counting detector computed tomography (PCD-CT). One PCD-CT scan (CT1) and three conventional (non-PCD-CT) CT scans (CT2-CT4) were performed using a multi-energy CT phantom that contained eight rods with different iodine concentrations (0.2, 0.5, 1, 2, 5, 10, 15, and 20 mg/ml). The CT values of the seven groups (CT1 for 40, 50, 60, and 70 keV; and CT2-4) were measured. Noise and contrast-to-noise ratio (CNR) were assessed for the eight rods at various iodine concentrations. CT2 and CT1 (40 keV) respectively required 20 mg/ml and 5 mg/ml of iodine, indicating that a comparable contrast effect could be obtained with approximately one-fourth of the contrast medium amount. The standard deviation values increased at lower energy levels irrespective of the iodine concentration. The CNR exhibited a decreasing trend with lower iodine concentrations, while it remained relatively stable across all iodine levels (40-70 keV). This study demonstrated that virtual monochromatic 40 keV images offer a similar contrast effect with a reduced contrast medium amount when compared to conventional CT systems at 120 kV.
en-copyright=
kn-copyright=

en-aut-name=HigakiFumiyo
en-aut-sei=Higaki
en-aut-mei=Fumiyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MorimitsuYusuke
en-aut-sei=Morimitsu
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IguchiToshihiro
en-aut-sei=Iguchi
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SaitoHayato
en-aut-sei=Saito
en-aut-mei=Hayato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TakakiHaruhiko
en-aut-sei=Takaki
en-aut-mei=Haruhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NakagoshiAyako
en-aut-sei=Nakagoshi
en-aut-mei=Ayako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=WadaMaki
en-aut-sei=Wada
en-aut-mei=Maki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=UkaMayu
en-aut-sei=Uka
en-aut-mei=Mayu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=AkagiNoriaki
en-aut-sei=Akagi
en-aut-mei=Noriaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=MitsuhashiToshiharu
en-aut-sei=Mitsuhashi
en-aut-mei=Toshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MatsuiYusuke
en-aut-sei=Matsui
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=HirakiTakao
en-aut-sei=Hiraki
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

affil-num=1
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Radiological Technology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Radiological Technology, Faculty of Health Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Radiological Technology, Okayama University Medical School
kn-affil=

affil-num=5
en-affil=Department of Radiological Technology, Okayama University Medical School
kn-affil=

affil-num=6
en-affil=Department of Radiological Technology, Okayama University Medical School
kn-affil=

affil-num=7
en-affil=Department of Radiological Technology, Okayama University Medical School
kn-affil=

affil-num=8
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Radiological Technology, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=11
en-affil=Department of Radiology, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=12
en-affil=Department of Radiology, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=photon-counting detector CT
kn-keyword=photon-counting detector CT
en-keyword=energy integrating detector CT
kn-keyword=energy integrating detector CT
en-keyword=computed tomography
kn-keyword=computed tomography
en-keyword=contrast medium amount
kn-keyword=contrast medium amount
en-keyword=reduction
kn-keyword=reduction
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=2
article-no=
start-page=123
end-page=134
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202404
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Sigle Agent of Posttransplant Cyclophosphamide Without Calcineurin Inhibitor Controls Severity of Experimental Chronic GVHD
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HCT), but its pathogenesis remains unclear. Recently, haplo-identical HCT with post-transplant cyclophosphamide (Haplo-HCT with PTCY) was found to achieve a low incidence rate of acute GVHD and chronic GVHD. However, while the pathogenesis of acute GVHD following Haplo-HCT with PTCY has been well investigated, that of chronic GVHD remains to be elucidated, especially in HLA-matched HCT with PTCY. Based on its safety profile, PTCY is currently applied for the human leucocyte antigen (HLA)-matched HCT setting. Here, we investigated the mechanisms of chronic GVHD following HLA-matched HCT with PTCY using a well-defined mouse chronic GVHD model. PTCY attenuated clinical and pathological chronic GVHD by suppressing effector T-cells and preserving regulatory T-cells compared with a control group. Additionally, we demonstrated that cyclosporine A (CsA) did not show any additional positive effects on attenuation of GVHD in PTCY-treated recipients. These results suggest that monotherapy with PTCY without CsA could be a promising strategy for the prevention of chronic GVHD following HLA-matched HCT.
en-copyright=
kn-copyright=

en-aut-name=SaekiKyosuke
en-aut-sei=Saeki
en-aut-mei=Kyosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FujiwaraHideaki
en-aut-sei=Fujiwara
en-aut-mei=Hideaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SeikeKeisuke
en-aut-sei=Seike
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KuroiTaiga
en-aut-sei=Kuroi
en-aut-mei=Taiga
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NishimoriHisakazu
en-aut-sei=Nishimori
en-aut-mei=Hisakazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TanakaTakehiro
en-aut-sei=Tanaka
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=MatsuokaKen-ichi
en-aut-sei=Matsuoka
en-aut-mei=Ken-ichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=FujiiNobuharu
en-aut-sei=Fujii
en-aut-mei=Nobuharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MaedaYoshinobu
en-aut-sei=Maeda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Hematology and Oncology, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Division of Transfusion, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=GVHD
kn-keyword=GVHD
en-keyword=posttransplant cyclophosphamide
kn-keyword=posttransplant cyclophosphamide
en-keyword=hematopoietic cell transplantation
kn-keyword=hematopoietic cell transplantation
en-keyword=HLA-identical
kn-keyword=HLA-identical
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=2
article-no=
start-page=95
end-page=106
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202404
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The Roles of Neuropeptide Y in Respiratory Disease Pathogenesis via the Airway Immune Response
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The lungs are very complex organs, and the respiratory system performs the dual roles of repairing tissue while protecting against infection from various environmental stimuli. Persistent external irritation disrupts the immune responses of tissues and cells in the respiratory system, ultimately leading to respiratory disease. Neuropeptide Y (NPY) is a 36-amino-acid polypeptide and a neurotransmitter that regulates homeostasis. The NPY receptor is a seven-transmembrane-domain G-protein-coupled receptor with six subtypes (Y1, Y2, Y3, Y4, Y5, and Y6). Of these receptors, Y1, Y2, Y4, and Y5 are functional in humans, and Y1 plays important roles in the immune responses of many organs, including the respiratory system. NPY and the Y1 receptor have critical roles in the pathogenesis of asthma, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The effects of NPY on the airway immune response and pathogenesis differ among respiratory diseases. This review focuses on the involvement of NPY in the airway immune response and pathogenesis of various respiratory diseases.
en-copyright=
kn-copyright=

en-aut-name=ItanoJunko
en-aut-sei=Itano
en-aut-mei=Junko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KiuraKatsuyuki
en-aut-sei=Kiura
en-aut-mei=Katsuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MaedaYoshinobu
en-aut-sei=Maeda
en-aut-mei=Yoshinobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MiyaharaNobuaki
en-aut-sei=Miyahara
en-aut-mei=Nobuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Allergy and Respiratory Medicine, Okayama University Hospital
kn-affil=
en-keyword=neuropeptide y
kn-keyword=neuropeptide y
en-keyword=Y1 receptor
kn-keyword=Y1 receptor
en-keyword=airway immune response
kn-keyword=airway immune response
en-keyword=bronchial epithelial cells
kn-keyword=bronchial epithelial cells
en-keyword=respiratory disease
kn-keyword=respiratory disease
END

start-ver=1.4
cd-journal=joma
no-vol=14
cd-vols=
no-issue=1
article-no=
start-page=6723
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240320
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Development of a novel AAK1 inhibitor via Kinobeads-based screening
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A chemical proteomics approach using Ca2+/calmodulin-dependent protein kinase kinase (CaMKK) inhibitor-immobilized sepharose (TIM-063-Kinobeads) identified main targets such as CaMKK alpha/1 and beta/2, and potential off-target kinases, including AP2-associated protein kinase 1 (AAK1), as TIM-063 interactants. Because TIM-063 interacted with the AAK1 catalytic domain and inhibited its enzymatic activity moderately (IC50 = 8.51 mu M), we attempted to identify potential AAK1 inhibitors from TIM-063-derivatives and found a novel AAK1 inhibitor, TIM-098a (11-amino-2-hydroxy-7H-benzo[de]benzo[4,5]imidazo[2,1-a]isoquinolin-7-one) which is more potent (IC50 = 0.24 mu M) than TIM-063 without any inhibitory activity against CaMKK isoforms and a relative AAK1-selectivity among the Numb-associated kinases family. TIM-098a could inhibit AAK1 activity in transfected cultured cells (IC50 = 0.87 mu M), indicating cell-membrane permeability of the compound. Overexpression of AAK1 in HeLa cells significantly reduced the number of early endosomes, which was blocked by treatment with 10 mu M TIM-098a. These results indicate TIM-063-Kinobeads-based chemical proteomics is efficient for identifying off-target kinases and re-evaluating the kinase inhibitor (TIM-063), leading to the successful development of a novel inhibitory compound (TIM-098a) for AAK1, which could be a molecular probe for AAK1. TIM-098a may be a promising lead compound for a more potent, selective and therapeutically useful AAK1 inhibitor.
en-copyright=
kn-copyright=

en-aut-name=YoshidaAkari
en-aut-sei=Yoshida
en-aut-mei=Akari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=OhtsukaSatomi
en-aut-sei=Ohtsuka
en-aut-mei=Satomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MatsumotoFumiya
en-aut-sei=Matsumoto
en-aut-mei=Fumiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MiyagawaTomoyuki
en-aut-sei=Miyagawa
en-aut-mei=Tomoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OkinoRei
en-aut-sei=Okino
en-aut-mei=Rei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=IkedaYumeya
en-aut-sei=Ikeda
en-aut-mei=Yumeya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TadaNatsume
en-aut-sei=Tada
en-aut-mei=Natsume
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=GotohAkira
en-aut-sei=Gotoh
en-aut-mei=Akira
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MagariMasaki
en-aut-sei=Magari
en-aut-mei=Masaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HatanoNaoya
en-aut-sei=Hatano
en-aut-mei=Naoya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=MorishitaRyo
en-aut-sei=Morishita
en-aut-mei=Ryo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=SatohAyano
en-aut-sei=Satoh
en-aut-mei=Ayano
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=SunatsukiYukinari
en-aut-sei=Sunatsuki
en-aut-mei=Yukinari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=NilssonUlf J.
en-aut-sei=Nilsson
en-aut-mei=Ulf J.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=IshikawaTeruhiko
en-aut-sei=Ishikawa
en-aut-mei=Teruhiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=TokumitsuHiroshi
en-aut-sei=Tokumitsu
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

affil-num=1
en-affil=Applied Cell Biology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=2
en-affil=Applied Cell Biology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=3
en-affil=Department of Science Education, Graduate School of Education, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Science Education, Graduate School of Education, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Science Education, Graduate School of Education, Okayama University
kn-affil=

affil-num=6
en-affil=Applied Cell Biology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=7
en-affil=Applied Cell Biology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=8
en-affil=Applied Cell Biology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=9
en-affil=Applied Cell Biology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=10
en-affil=Applied Cell Biology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=11
en-affil=CellFree Sciences Co. Ltd
kn-affil=

affil-num=12
en-affil=Organelle Systems Biotechnology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=

affil-num=13
en-affil=Graduate School of Natural Science and Technology, Okayama University
kn-affil=

affil-num=14
en-affil=Department of Chemistry, Lund University
kn-affil=

affil-num=15
en-affil=Department of Science Education, Graduate School of Education, Okayama University
kn-affil=

affil-num=16
en-affil=Applied Cell Biology, Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=73
cd-vols=
no-issue=4
article-no=
start-page=295
end-page=339
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240321
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Étude fondamentale et philosophique sur lʼopposabilité du droit de propriété
kn-title=所有権の帰属概念に関する序論的考察―所有権の絶対性はいかにして現実のものとなるか？
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=ShimazuG. 
en-aut-sei=Shimazu
en-aut-mei=G. 
kn-aut-name=嶋津元
kn-aut-sei=嶋津
kn-aut-mei=元
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学学術研究院社会文化科学学域
END

start-ver=1.4
cd-journal=joma
no-vol=55
cd-vols=
no-issue=3
article-no=
start-page=41
end-page=61
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240321
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Die Grundlagen der wirtschaftlichen Entwicklung des Königreichs Sachsen（4）
kn-title=ザクセン王国経済発展の基礎（４）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=MatsuoNobushige
en-aut-sei=Matsuo
en-aut-mei=Nobushige
kn-aut-name=松尾展成
kn-aut-sei=松尾
kn-aut-mei=展成
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学名誉教授
END

start-ver=1.4
cd-journal=joma
no-vol=371
cd-vols=
no-issue=
article-no=
start-page=fnae007
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Knockout of adenylosuccinate synthase purA increases susceptibility to colistin in Escherichia coli
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Colistin is a cationic cyclic antimicrobial peptide used as a last resort against multidrug-resistant gram-negative bacteria. To understand the factors involved in colistin susceptibility, we screened colistin-sensitive mutants from an E. coli gene-knockout library (Keio collection). The knockout of purA, whose product catalyzes the synthesis of adenylosuccinate from IMP in the de novo purine synthesis pathway, resulted in increased sensitivity to colistin. Adenylosuccinate is subsequently converted to AMP, which is phosphorylated to produce ADP, a substrate for ATP synthesis. The amount of ATP was lower in the purA-knockout mutant than that in the wild-type strain. ATP synthesis is coupled with proton transfer, and it contributes to the membrane potential. Using the membrane potential probe, 3,3′-diethyloxacarbocyanine iodide [DiOC2(3)], we found that the membrane was hyperpolarized in the purA-knockout mutant compared to that in the wild-type strain. Treatment with the proton uncoupler, carbonyl cyanide m-chlorophenyl hydrazone (CCCP), abolished the hyperpolarization and colistin sensitivity in the mutant. The purA-knockout mutant exhibited increased sensitivity to aminoglycosides, kanamycin, and gentamicin; their uptake requires a membrane potential. Therefore, the knockout of purA, an adenylosuccinate synthase, decreases ATP synthesis concurrently with membrane hyperpolarization, resulting in increased sensitivity to colistin.
en-copyright=
kn-copyright=

en-aut-name=KanoTomonori
en-aut-sei=Kano
en-aut-mei=Tomonori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IshikawaKazuya
en-aut-sei=Ishikawa
en-aut-mei=Kazuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=FurutaKazuyuki
en-aut-sei=Furuta
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KaitoChikara
en-aut-sei=Kaito
en-aut-mei=Chikara
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=colistin
kn-keyword=colistin
en-keyword=adenylosuccinate synthase
kn-keyword=adenylosuccinate synthase
en-keyword=de novo purine synthesis
kn-keyword=de novo purine synthesis
en-keyword=membrane potential
kn-keyword=membrane potential
en-keyword=ATP synthesis
kn-keyword=ATP synthesis
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=1
article-no=
start-page=63
end-page=70
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202402
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Significance of Continuous Low-Dose Lenvatinib for the Treating of the Patients with Unresectable Thyroid Carcinoma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The tyrosine kinase inhibitor lenvatinib has been confirmed as an effective treatment option for patients with unresectable thyroid carcinoma. We conducted a retrospective analysis of the significance of the effect of continued lenvatinib treatment for the longest duration possible at a reasonable daily dose and with a minimum discontinuation period in 42 patients with unresectable thyroid carcinoma treated with lenvatinib between 2015 and 2020. A Cox proportional hazard model-based analysis revealed that the overall survival of the patients treated with a <8 mg/day mean dose of lenvatinib was significantly better than that of the patients treated with 8-24 mg/day (hazard ratio [HR] 0.38 for 1.14-4.54 mg/day, and HR 0.01 for 4.56-7.97 mg/day) adjusted for various factors (e.g., sex, age, drug interruption period). The cumulative dose of lenvatinib administered tended to be higher in the patients treated with low doses (< 8 mg/day) than in the patients treated with relatively high doses (8-24 mg/day). Considering its adverse events, the continuation of lenvatinib treatment with an adequate daily dose and drug interruption may help prolong the survival of patients with unresectable thyroid carcinoma.
en-copyright=
kn-copyright=

en-aut-name=MurakamiDaizo
en-aut-sei=Murakami
en-aut-mei=Daizo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NishimotoKohei
en-aut-sei=Nishimoto
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakaoSoshi
en-aut-sei=Takao
en-aut-mei=Soshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MiyamaruSatoru
en-aut-sei=Miyamaru
en-aut-mei=Satoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KadowakiTomoka
en-aut-sei=Kadowaki
en-aut-mei=Tomoka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SaitoHaruki
en-aut-sei=Saito
en-aut-mei=Haruki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakedaHiroki
en-aut-sei=Takeda
en-aut-mei=Hiroki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=IseMomoko
en-aut-sei=Ise
en-aut-mei=Momoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SuyamaKoichi
en-aut-sei=Suyama
en-aut-mei=Koichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OritaYorihisa
en-aut-sei=Orita
en-aut-mei=Yorihisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Otolaryngology-Head and Neck Surgery, Kumamoto University Graduate School of Medicine
kn-affil=

affil-num=2
en-affil=Department of Otolaryngology-Head and Neck Surgery, Kumamoto University Graduate School of Medicine
kn-affil=

affil-num=3
en-affil=Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Otolaryngology-Head and Neck Surgery, Kumamoto University Graduate School of Medicine
kn-affil=

affil-num=5
en-affil=Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Otolaryngology-Head and Neck Surgery, Kumamoto University Graduate School of Medicine
kn-affil=

affil-num=7
en-affil=Department of Otolaryngology-Head and Neck Surgery, Kumamoto University Graduate School of Medicine
kn-affil=

affil-num=8
en-affil=Department of Otolaryngology-Head and Neck Surgery, Kumamoto University Graduate School of Medicine
kn-affil=

affil-num=9
en-affil=Department of Medical Oncology, Toranomon Hospital
kn-affil=

affil-num=10
en-affil=Department of Otolaryngology-Head and Neck Surgery, Kumamoto University Graduate School of Medicine
kn-affil=
en-keyword=thyroid carcinoma
kn-keyword=thyroid carcinoma
en-keyword=lenvatinib
kn-keyword=lenvatinib
en-keyword=adverse effect
kn-keyword=adverse effect
en-keyword=survival
kn-keyword=survival
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=1
article-no=
start-page=47
end-page=52
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202402
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Long-Term Follow-up Data of a Multi-Institutional Phase-2 Study of S-1/oxaliplatin and Bevacizumab Therapy in Patients with Advanced Colorectal Cancer: The HiSCO-02 Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Oral fluoropyrimidines (FUs) have certain advantages over intravenous FUs, such as longer intervals between outpatient visits, no requirement for central venous port (CVP) implantation, and lower incidence of neutropenia. We previously reported the efficacy of S-1/oxaliplatin (SOX) with bevacizumab therapy as a first-line treatment for advanced colorectal cancer (CRC) in a prospective phase-II multi-institutional clinical trial (HiSCO-02 study). However, our prognostic data at the time lacked a sufficient observation period. Herein, we analyze the longer-term follow-up data, focusing on the status of eventual CVP implantation via an open-label, non-randomized, multicenter study. This study enrolled 55 patients (mean age, 64 years), of whom 43 died (41 of primary cancer). The median overall survival was 22.7 months (95% CI: 20.1-34.7 months). Post-treatment regimens after failure of first-line treatment were initiated in 43 patients; CPT11-based regimens were selected in most cases, and other oral FU combinations in nine. CVP was implanted in 35 patients prior to first-line treatment; eleven of the remaining 20 patients did not require CVP implantation. In conclusion, we report here the final prognostic update of the Phase II clinical trial examining the efficacy of SOX plus bevacizumab therapy, the results of which confirm the clinical efficacy of this regimen.
en-copyright=
kn-copyright=

en-aut-name=ShimomuraManabu
en-aut-sei=Shimomura
en-aut-mei=Manabu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShinozakiKatsunori
en-aut-sei=Shinozaki
en-aut-mei=Katsunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YanoTakuya
en-aut-sei=Yano
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AkabaneShintaro
en-aut-sei=Akabane
en-aut-mei=Shintaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OhdanHideki
en-aut-sei=Ohdan
en-aut-mei=Hideki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=Hiroshima Surgical study group of Clinical Oncology (HiSCO)
en-aut-sei=Hiroshima Surgical study group of Clinical Oncology (HiSCO)
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=2
en-affil=Division of Clinical Oncology, Hiroshima Prefectural Hospital
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=5
en-affil=Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University
kn-affil=

affil-num=6
en-affil=
kn-affil=
en-keyword=metastatic colorectal cancer
kn-keyword=metastatic colorectal cancer
en-keyword=chemotherapy
kn-keyword=chemotherapy
en-keyword=S-1
kn-keyword=S-1
en-keyword=prospective phase II study
kn-keyword=prospective phase II study
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=1
article-no=
start-page=37
end-page=46
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202402
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Is Proximal Triangular Fixation Better than the Conventional Method in Adult Spinal Deformity Surgery?
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=In adult spinal deformity (ASD) surgery, one of the key factors working to prevent proximal junctional kyphosis is the proximal anchor. The aim of this study was to compare clinical and radiographic outcomes of triangular fixation with conventional fixation as proximal anchoring techniques in ASD surgery. We retrospectively evaluated 54 patients who underwent corrective spinal fusion for ASD. Fourteen patients underwent proximal triangular fixation (Group T; average 74.6 years), and 40 patients underwent the conventional method (Group C; average 70.5 years). Clinical and radiographic outcomes were assessed using visual analogue scale (VAS) values for back pain and the Oswestry disability index (ODI). Radiographic evaluation was also collected preoperatively and postoperatively. Surgical times and intraoperative blood loss of the two groups were not significantly different (493 vs 490 min, 1,260 vs 1,173 mL). Clinical outcomes such as VAS and ODI were comparable in the two groups. Proximal junctional kyphosis in group T was slightly lower than that of group C (28.5% vs 47.5%, p=0.491). However, based on radiology, proximal screw pullout occurred significantly less frequently in the triangular fixation group than the conventional group (0.0% vs 22.5%, p=0.049). Clinical outcomes in the two groups were not significantly different.
en-copyright=
kn-copyright=

en-aut-name=TanakaMasato
en-aut-sei=Tanaka
en-aut-mei=Masato
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MeenaUmesh
en-aut-sei=Meena
en-aut-mei=Umesh
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TaokaTakuya
en-aut-sei=Taoka
en-aut-mei=Takuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FujiwaraYoshihiro
en-aut-sei=Fujiwara
en-aut-mei=Yoshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YokomizoDaiichiro
en-aut-sei=Yokomizo
en-aut-mei=Daiichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=BashyalSantosh Kumar
en-aut-sei=Bashyal
en-aut-mei=Santosh Kumar
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SakeNaveen
en-aut-sei=Sake
en-aut-mei=Naveen
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=AratakiShinya
en-aut-sei=Arataki
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=2
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=4
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=5
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=6
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, Okayama Rosai Hospital
kn-affil=
en-keyword=adult spinal deformity
kn-keyword=adult spinal deformity
en-keyword=proximal junctional kyphosis
kn-keyword=proximal junctional kyphosis
en-keyword=triangular fixation
kn-keyword=triangular fixation
en-keyword=minimally invasive surgery
kn-keyword=minimally invasive surgery
en-keyword=C arm free
kn-keyword=C arm free
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=1
article-no=
start-page=29
end-page=36
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202402
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Regression of Necrotic Lesions after Methotrexate Withdrawal in Patients with Methotrexate-Associated Lymphoproliferative Disorders: A Retrospective CT Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This retrospective study investigated whether necrotic lesions detected on a computed tomography (CT) scan are more regressive than non-necrotic lesions after methotrexate withdrawal in patients pathologically diagnosed with methotrexate-associated lymphoproliferative disorders (MTX-LPD). In total, 89 lesions extracted from 24 patients on CT scans were included in the analysis. All patients had been evaluated for the presence of necrosis within lesions via CT scan upon first suspicion of MTX-LPD (baseline CT scan). The percentage lesion size reduction between the baseline and initial follow-up CT scan was calculated. The association between necrosis within lesions and size changes was estimated via linear regression analyses using both crude and adjusted models. Necrosis was significantly more common in extranodal lesions (27 out of 30 lesions, 90%) than in nodal lesions (9 out of 59 lesions, 15%, p<0.001). In the crude model, the regression of necrotic lesions was 58.5% greater than that of non-necrotic lesions; the difference was statistically significant (p<0.001). Additionally, the longest diameter of necrotic lesions at the baseline CT scan was significantly greater than that of non-necrotic lesions (p<0.001). Based on the adjusted model, necrotic lesions showed 49.3% greater regression than non-necrotic lesions (p=0.017). Necrosis detected on a CT scan was found to be an independent predictor of regression after MTX withdrawal in patients with MTX-LPD.
en-copyright=
kn-copyright=

en-aut-name=KitayamaTakahiro
en-aut-sei=Kitayama
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TanakaTakashi
en-aut-sei=Tanaka
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KanieYuichiro
en-aut-sei=Kanie
en-aut-mei=Yuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MarukawaYohei
en-aut-sei=Marukawa
en-aut-mei=Yohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KojimaKatsuhide
en-aut-sei=Kojima
en-aut-mei=Katsuhide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TanakaTakehiro
en-aut-sei=Tanaka
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakaoSoshi
en-aut-sei=Takao
en-aut-mei=Soshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=HirakiTakao
en-aut-sei=Hiraki
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Radiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Radiology, Okayama City Hospital
kn-affil=

affil-num=3
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Radiology, Okayama Saiseikai General Hospital
kn-affil=

affil-num=5
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Pathology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=8
en-affil=Department of Radiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=methotrexate
kn-keyword=methotrexate
en-keyword=lymphoproliferative disorder
kn-keyword=lymphoproliferative disorder
en-keyword=computed tomography
kn-keyword=computed tomography
en-keyword=necrosis
kn-keyword=necrosis
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=1
article-no=
start-page=21
end-page=27
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202402
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Assessing the Frequency and Effectiveness of Various Arthroscopic Treatments in the Management of Symptomatic Isolated Medial Meniscus Injuries Including Medial Meniscus Posterior Root Tear: A Retrospective Observational Cohort Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The use of various strategies for arthroscopic meniscal repairs to save the meniscus and prevent the progression of knee osteoarthritis has gradually increased. We investigated the frequency of various arthroscopic treatments and the short-term clinical outcomes of symptomatic isolated medial meniscus (MM) injuries. This retrospective observational study included 193 patients (197 knees) who underwent arthroscopic meniscal treatment for isolated MM injuries between January 2016 and April 2019. Arthroscopic meniscal repairs were divided into two groups: transtibial pullout repairs of MM posterior root tears (MMPRTs) and arthroscopic meniscal repairs for other types of MM injuries. MMPRT pullout repair, other meniscal repairs, and partial meniscectomy were performed in 71.0%, 16.8%, and 12.2% of the knees, respectively. The ratio of women to men and the patient age were higher in the pullout-repair group than the meniscal-repair group. The Preoperative Knee Injury and Osteoarthritis Outcome Score subscale (as an index of daily living activities) was significantly lower in the pullout-repair group than the meniscus-repair group. However, no significant differences were observed in these scores among the two groups postoperatively. Our results suggest that familiarity with the diagnosis and treatment of MMPRTs is necessary for orthopedic surgeons to manage isolated MM injuries.
en-copyright=
kn-copyright=

en-aut-name=TamuraMasanori
en-aut-sei=Tamura
en-aut-mei=Masanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FurumatsuTakayuki
en-aut-sei=Furumatsu
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YokoyamaYusuke
en-aut-sei=Yokoyama
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KintakaKeisuke
en-aut-sei=Kintaka
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HigashiharaNaohiro
en-aut-sei=Higashihara
en-aut-mei=Naohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KawadaKoki
en-aut-sei=Kawada
en-aut-mei=Koki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=knee
kn-keyword=knee
en-keyword=medial meniscus
kn-keyword=medial meniscus
en-keyword=posterior root tear
kn-keyword=posterior root tear
en-keyword=arthroscopy
kn-keyword=arthroscopy
en-keyword=pullout repair
kn-keyword=pullout repair
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=1
article-no=
start-page=15
end-page=20
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202402
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Lung Oligometastasis of Breast Cancer: Prospective Cohort Study of Treatment Strategies (SBP-06)
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=While local treatment of metastases is considered to be unrelated to prognosis, previous studies have suggested that local treatment of isolated lung metastases may have positive prognostic impact. We designed this prospective cohort study to investigate the clinical situation and its outcomes. We enrolled patients with fewer than 3 lung nodules suspected of being oligometastases after curative breast cancer surgery. Treatments, including local and systemic therapy, were selected by the physician and patient in consultation. The primary outcome was overall survival (OS); secondary outcomes were the efficacy and the safety of the surgery for lung oligometastases. Between May 2015 and May 2019, 14 patients were enrolled. Resection of lung nodules (metastasectomy) was performed in 11 (78.6%) of 14 patients, and one of these cases was diagnosed as primary lung cancer. Metastasectomies were all performed employing video-assisted thoracic surgery (VATS) without perioperative complications. Systemic therapies were administered to all patients except one. The respective 3-year and 5-year OS rates of patients with lung oligometastases were 91.6% and 81.5%, respectively. Progression occurred in 6 patients: 3 of the 10 with metastasectomy and all 3 without this surgical procedure. Lung metastasectomy was worthwhile as a diagnostic evaluation and may provide long-term benefit in some patients.
en-copyright=
kn-copyright=

en-aut-name=MaedaReina
en-aut-sei=Maeda
en-aut-mei=Reina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShienTadahiko
en-aut-sei=Shien
en-aut-mei=Tadahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakahashiMina
en-aut-sei=Takahashi
en-aut-mei=Mina
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KawadaKengo
en-aut-sei=Kawada
en-aut-mei=Kengo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KajiwaraYukiko
en-aut-sei=Kajiwara
en-aut-mei=Yukiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KuboShinichiro
en-aut-sei=Kubo
en-aut-mei=Shinichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakabatakeDaisuke
en-aut-sei=Takabatake
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OhtaniShoichiro
en-aut-sei=Ohtani
en-aut-mei=Shoichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MatsuokaKinya
en-aut-sei=Matsuoka
en-aut-mei=Kinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HikinoHajime
en-aut-sei=Hikino
en-aut-mei=Hajime
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=OgasawaraYutaka
en-aut-sei=Ogasawara
en-aut-mei=Yutaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TairaNaruto
en-aut-sei=Taira
en-aut-mei=Naruto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=OsumiShozo
en-aut-sei=Osumi
en-aut-mei=Shozo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=IkedaMasahiko
en-aut-sei=Ikeda
en-aut-mei=Masahiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=DoiharaHiroyoshi
en-aut-sei=Doihara
en-aut-mei=Hiroyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

affil-num=1
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Breast Oncology, NHO Shikoku Cancer Center
kn-affil=

affil-num=4
en-affil=Department of Breast and Endocrine Surgery, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=5
en-affil=Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=6
en-affil=Department of Breast and Thyroid Surgery, Fukuyama City Hospital
kn-affil=

affil-num=7
en-affil=Department of Breast Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=8
en-affil=Department of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=9
en-affil=Department of Breast and Thyroid Surgery, Ehime Prefectural Central Hospital
kn-affil=

affil-num=10
en-affil=Department of Breast Surgery, Matsue Red Cross Hospital
kn-affil=

affil-num=11
en-affil=Department of Breast and Endocrine Surgery, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=12
en-affil=Department of Breast and Thyroid Surgery, Kawasaki Medical School
kn-affil=

affil-num=13
en-affil=Department of Breast Oncology, NHO Shikoku Cancer Center
kn-affil=

affil-num=14
en-affil=Department of Breast and Thyroid Surgery, Fukuyama City Hospital
kn-affil=

affil-num=15
en-affil=Department of Breast and Endocrine Surgery, Okayama University Hospital
kn-affil=
en-keyword=oligometastasis
kn-keyword=oligometastasis
en-keyword=breast cancer
kn-keyword=breast cancer
en-keyword=lung
kn-keyword=lung
en-keyword=metastasectomy
kn-keyword=metastasectomy
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=1
article-no=
start-page=9
end-page=13
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202402
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Prostate Biopsy May Not Be Indicated Early after Bacillus Calmette Guérin Treatment
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Bacillus Calmette-Guérin (BCG) treatment for non-muscle-invasive bladder cancer frequently causes an intraprostatic BCG granuloma. We investigated the optimal timing for a prostate biopsy after BCG treatment by retrospectively analyzing the cases of 22 patients with non-muscle-invasive bladder cancer who underwent a prostate biopsy after BCG treatment at our institute (2013-2017). Biopsies were indicated for a rising prostate-specific antigen (PSA) level, positive digital rectal examination findings, or the appearance of de novo low apparent diffusion coefficient lesions on MRI. The control group was comprised of 28 age- and PSA-matched patients. The relationships among the cancer detection rate and the patients’ PSA levels and MRI findings were analyzed. Prostate cancer was detected by biopsy in only 13.9% (3/22) of the patients in the BCG group but in 78.5% (22/28) of the control patients (p=0.0001). The three patients in the BCG group in whom prostate cancer was detected had all undergone the biopsy > 1 year after their BCG treatment. The remaining biopsies were performed within 1 year after BCG treatment and resulted in no diagnoses of prostate cancer. We suggest that performing a prostate biopsy early after BCG treatment is not informative or useful.
en-copyright=
kn-copyright=

en-aut-name=AkagiNaoki
en-aut-sei=Akagi
en-aut-mei=Naoki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KanematsuAkihiro
en-aut-sei=Kanematsu
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ShigesakaKoji
en-aut-sei=Shigesaka
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ShimataniKimihiro
en-aut-sei=Shimatani
en-aut-mei=Kimihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=YamamotoShingo
en-aut-sei=Yamamoto
en-aut-mei=Shingo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Department of Urology, Hyogo Medical University
kn-affil=

affil-num=2
en-affil=Department of Urology, Hyogo Medical University
kn-affil=

affil-num=3
en-affil=Department of Urology, Hyogo Medical University
kn-affil=

affil-num=4
en-affil=Department of Urology, Hyogo Medical University
kn-affil=

affil-num=5
en-affil=Department of Urology, Hyogo Medical University
kn-affil=
en-keyword=bacillus Calmette-Guérin
kn-keyword=bacillus Calmette-Guérin
en-keyword=prostate granuloma
kn-keyword=prostate granuloma
en-keyword=prostate cancer
kn-keyword=prostate cancer
en-keyword=bladder cancer
kn-keyword=bladder cancer
en-keyword=prostate biopsy
kn-keyword=prostate biopsy
END

start-ver=1.4
cd-journal=joma
no-vol=78
cd-vols=
no-issue=1
article-no=
start-page=1
end-page=8
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202402
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Role of Macrophages in Liver Fibrosis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Liver fibrosis, which ultimately leads to liver cirrhosis and hepatocellular carcinoma, is a major health burden worldwide. The progression of liver fibrosis is the result of the wound-healing response of liver to repeated injury. Hepatic macrophages are cells with high heterogeneity and plasticity and include tissue-resident macrophages termed Kupffer cells, and recruited macrophages derived from circulating monocytes, spleen and peritoneal cavity. Studies have shown that hepatic macrophages play roles in the initiation and progression of liver fibrosis by releasing inflammatory cytokines/chemokines and pro-fibrogenic factors. Furthermore, the development of liver fibrosis has been shown to be reversible. Hepatic macrophages have been shown to alternately regulate both the regression and turnover of liver fibrosis by changing their phenotypes during the dynamic progression of liver fibrosis. In this review, we summarize the role of hepatic macrophages in the progression and regression of liver fibrosis.
en-copyright=
kn-copyright=

en-aut-name=SunCuiming
en-aut-sei=Sun
en-aut-mei=Cuiming
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatsukawaAkihiro
en-aut-sei=Matsukawa
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Department of Pathology and Experimental Medicine, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Pathology and Experimental Medicine, Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=ERK-MAPK
kn-keyword=ERK-MAPK
en-keyword=SPRED2
kn-keyword=SPRED2
en-keyword=fibrosis
kn-keyword=fibrosis
en-keyword=macrophages
kn-keyword=macrophages
END

start-ver=1.4
cd-journal=joma
no-vol=31
cd-vols=
no-issue=1
article-no=
start-page=dsad027
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20231222
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=MCPtaggR: R package for accurate genotype calling in reduced representation sequencing data by eliminating error-prone markers based on genome comparison
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Reduced representation sequencing (RRS) offers cost-effective, high-throughput genotyping platforms such as genotyping-by-sequencing (GBS). RRS reads are typically mapped onto a reference genome. However, mapping reads harbouring mismatches against the reference can potentially result in mismapping and biased mapping, leading to the detection of error-prone markers that provide incorrect genotype information. We established a genotype-calling pipeline named mappable collinear polymorphic tag genotyping (MCPtagg) to achieve accurate genotyping by eliminating error-prone markers. MCPtagg was designed for the RRS-based genotyping of a population derived from a biparental cross. The MCPtagg pipeline filters out error-prone markers prior to genotype calling based on marker collinearity information obtained by comparing the genome sequences of the parents of a population to be genotyped. A performance evaluation on real GBS data from a rice F2 population confirmed its effectiveness. Furthermore, our performance test using a genome assembly that was obtained by genome sequence polishing on an available genome assembly suggests that our pipeline performs well with converted genomes, rather than necessitating de novo assembly. This demonstrates its flexibility and scalability. The R package, MCPtaggR, was developed to provide functions for the pipeline and is available at https://github.com/tomoyukif/MCPtaggR.
en-copyright=
kn-copyright=

en-aut-name=FurutaTomoyuki
en-aut-sei=Furuta
en-aut-mei=Tomoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=YamamotoToshio
en-aut-sei=Yamamoto
en-aut-mei=Toshio
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Institute of Plant Science and Resources, Okayama University
kn-affil=

affil-num=2
en-affil=Institute of Plant Science and Resources, Okayama University
kn-affil=
en-keyword=genotyping
kn-keyword=genotyping
en-keyword=genome comparison
kn-keyword=genome comparison
en-keyword=next-generation sequencing
kn-keyword=next-generation sequencing
en-keyword=R package
kn-keyword=R package
END

start-ver=1.4
cd-journal=joma
no-vol=64
cd-vols=
no-issue=1
article-no=
start-page=1
end-page=9
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=2024
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Analysis of Notch1 protein expression in methotrexate-associated lymphoproliferative disorders
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Methotrexate (MTX)-associated lymphoproliferative disorder (MTX-LPD) is a lymphoproliferative disorder in patients treated with MTX. The mechanism of pathogenesis is still elusive, but it is thought to be a complex interplay of factors, such as underlying autoimmune disease activity, MTX use, Epstein-Barr virus infection, and aging. The NOTCH genes encode receptors for a signaling pathway that regulates various fundamental cellular processes, such as proliferation and differentiation during embryonic development. Mutations of NOTCH1 have been reported in B-cell tumors, including chronic lymphocytic leukemia/ lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma (DLBCL). Recently, it has also been reported that NOTCH1 mutations are found in post-transplant lymphoproliferative disorders, and in CD20-positive cells in angioimmunoblastic T-cell lymphoma, which might be associated with lymphomagenesis in immunodeficiency. In this study, to investigate the association of NOTCH1 in the pathogenesis of MTX-LPD, we evaluated protein expression of Notch1 in nuclei immunohistochemically in MTX-LPD cases [histologically DLBCL-type (n = 24) and classical Hodgkin lymphoma (CHL)-type (n = 24)] and de novo lymphoma cases [DLBCL (n = 19) and CHL (n = 15)]. The results showed that among MTX-LPD cases, the expression of Notch1 protein was significantly higher in the DLBCL type than in the CHL type (P < 0.001). In addition, among DLBCL morphology cases, expression of Notch1 tended to be higher in MTX-LPD than in the de novo group; however this difference was not significant (P = 0.0605). The results showed that NOTCH1 may be involved in the proliferation and tumorigenesis of B cells under the use of MTX. Further research, including genetic studies, is necessary.
en-copyright=
kn-copyright=

en-aut-name=OkataniTakeshi
en-aut-sei=Okatani
en-aut-mei=Takeshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=NishimuraMidori Filiz
en-aut-sei=Nishimura
en-aut-mei=Midori Filiz
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=EgusaYuria
en-aut-sei=Egusa
en-aut-mei=Yuria
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YoshidaSayako
en-aut-sei=Yoshida
en-aut-mei=Sayako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NishimuraYoshito
en-aut-sei=Nishimura
en-aut-mei=Yoshito
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=NishikoriAsami
en-aut-sei=Nishikori
en-aut-mei=Asami
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YoshinoTadashi
en-aut-sei=Yoshino
en-aut-mei=Tadashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YamamotoHidetaka
en-aut-sei=Yamamoto
en-aut-mei=Hidetaka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SatoYasuharu
en-aut-sei=Sato
en-aut-mei=Yasuharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Pathology and Oncology, Okayama University  Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Molecular Hematopathology, Okayama University Graduate School of  Health Sciences
kn-affil=

affil-num=3
en-affil=Department of Molecular Hematopathology, Okayama University Graduate School of  Health Sciences
kn-affil=

affil-num=4
en-affil=Department of Molecular Hematopathology, Okayama University Graduate School of  Health Sciences
kn-affil=

affil-num=5
en-affil=Department of General Medicine, Okayama University Graduate School  of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Molecular Hematopathology, Okayama University Graduate School of  Health Sciences
kn-affil=

affil-num=7
en-affil=Department of Pathology and Oncology, Okayama University  Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Pathology and Oncology, Okayama University  Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Molecular Hematopathology, Okayama University Graduate School of  Health Sciences
kn-affil=
en-keyword=methotrexate-associated lymphoproliferative disorders
kn-keyword=methotrexate-associated lymphoproliferative disorders
en-keyword=other iatrogenic immunodeficiency-associated lymphoproliferative disorders
kn-keyword=other iatrogenic immunodeficiency-associated lymphoproliferative disorders
en-keyword=lymphoproliferative disorders arising in immune deficiency/dysregulation
kn-keyword=lymphoproliferative disorders arising in immune deficiency/dysregulation
en-keyword=NOTCH1
kn-keyword=NOTCH1
END

start-ver=1.4
cd-journal=joma
no-vol=115
cd-vols=
no-issue=3
article-no=
start-page=871
end-page=882
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=20240126
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Role of catecholamine synthases in the maintenance of cancer stem-like cells in malignant peripheral nerve sheath tumors
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Malignant peripheral nerve sheath tumors (MPNSTs) are malignant tumors that are derived from Schwann cell lineage around peripheral nerves. As in many other cancer types, cancer stem cells (CSCs) have been identified in MPNSTs, and they are considered the cause of treatment resistance, recurrence, and metastasis. As an element defining the cancer stemness of MPNSTs, we previously reported a molecular mechanism by which exogenous adrenaline activates a core cancer stemness factor, YAP/TAZ, through β2 adrenoceptor (ADRB2). In this study, we found that MPNST cells express catecholamine synthases and that these enzymes are essential for maintaining cancer stemness, such as the ability to self-renew and maintain an undifferentiated state. Through gene knockdown and inhibition of these enzymes, we confirmed that catecholamines are indeed synthesized in MPNST cells. The results confirmed that catecholamine synthase knockdown in MPNST cells reduces the activity of YAP/TAZ. These data suggest that a mechanism of YAP/TAZ activation by de novo synthesized adrenaline, as well as exogenous adrenaline, may exist in the maintenance of cancer stemness of MPNST cells. This mechanism not only helps to understand the pathology of MPNST, but could also contribute to the development of therapeutic strategies for MPNST.
en-copyright=
kn-copyright=

en-aut-name=KatayamaHaruyoshi
en-aut-sei=Katayama
en-aut-mei=Haruyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FujimuraAtsushi
en-aut-sei=Fujimura
en-aut-mei=Atsushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HuangRongsheng
en-aut-sei=Huang
en-aut-mei=Rongsheng
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=OtaniYusuke
en-aut-sei=Otani
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=ItanoTakuto
en-aut-sei=Itano
en-aut-mei=Takuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FujiwaraTomohiro
en-aut-sei=Fujiwara
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KunisadaToshiyuki
en-aut-sei=Kunisada
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NakataEiji
en-aut-sei=Nakata
en-aut-mei=Eiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Orthopedic Surgery,  Okayama University Graduate School of  Medicine, Dentistry, and Pharmaceutical  Sciences
kn-affil=

affil-num=2
en-affil=Department of Cellular Physiology,  Okayama University Graduate School of  Medicine, Dentistry, and Pharmaceutical  Sciences
kn-affil=

affil-num=3
en-affil=Department of Trauma Orthopedics,  The Second Hospital of Dalian Medical  University
kn-affil=

affil-num=4
en-affil=Department of General Thoracic Surgery  and Breast and Endocrinological Surgery,  Okayama University Graduate School of  Medicine, Dentistry, and Pharmaceutical  Sciences
kn-affil=

affil-num=5
en-affil=Department of Orthopedic Surgery,  Okayama University Graduate School of  Medicine, Dentistry, and Pharmaceutical  Sciences
kn-affil=

affil-num=6
en-affil=Department of Orthopedic Surgery,  Okayama University Graduate School of  Medicine, Dentistry, and Pharmaceutical  Sciences
kn-affil=

affil-num=7
en-affil=Department of Orthopedic Surgery,  Okayama University Graduate School of  Medicine, Dentistry, and Pharmaceutical  Sciences
kn-affil=

affil-num=8
en-affil=Department of Orthopedic Surgery,  Okayama University Graduate School of  Medicine, Dentistry, and Pharmaceutical  Sciences
kn-affil=

affil-num=9
en-affil=Department of Orthopedic Surgery,  Okayama University Graduate School of  Medicine, Dentistry, and Pharmaceutical  Sciences
kn-affil=
en-keyword=benserazide
kn-keyword=benserazide
en-keyword=cancer stem cell
kn-keyword=cancer stem cell
en-keyword=catecholamine synthase
kn-keyword=catecholamine synthase
en-keyword=malignant peripheral nerve sheath tumor
kn-keyword=malignant peripheral nerve sheath tumor
en-keyword=Schwann cell
kn-keyword=Schwann cell
en-keyword=vesicular monoamine transporter
kn-keyword=vesicular monoamine transporter
END

start-ver=1.4
cd-journal=joma
no-vol=24
cd-vols=
no-issue=18
article-no=
start-page=14128
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20230915
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Advanced Techniques Using In Vivo Electroporation to Study the Molecular Mechanisms of Cerebral Development Disorders
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The mammalian cerebral cortex undergoes a strictly regulated developmental process. Detailed in situ visualizations, imaging of these dynamic processes, and in vivo functional gene studies significantly enhance our understanding of brain development and related disorders. This review introduces basic techniques and recent advancements in in vivo electroporation for investigating the molecular mechanisms underlying cerebral diseases. In utero electroporation (IUE) is extensively used to visualize and modify these processes, including the forced expression of pathological mutants in human diseases; thus, this method can be used to establish animal disease models. The advent of advanced techniques, such as genome editing, including de novo knockout, knock-in, epigenetic editing, and spatiotemporal gene regulation, has further expanded our list of investigative tools. These tools include the iON expression switch for the precise control of timing and copy numbers of exogenous genes and TEMPO for investigating the temporal effects of genes. We also introduce the iGONAD method, an improved genome editing via oviductal nucleic acid delivery approach, as a novel genome-editing technique that has accelerated brain development exploration. These advanced in vivo electroporation methods are expected to provide valuable insights into pathological conditions associated with human brain disorders.
en-copyright=
kn-copyright=

en-aut-name=YangChen
en-aut-sei=Yang
en-aut-mei=Chen
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ShitamukaiAtsunori
en-aut-sei=Shitamukai
en-aut-mei=Atsunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YangShucai
en-aut-sei=Yang
en-aut-mei=Shucai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KawaguchiAyano
en-aut-sei=Kawaguchi
en-aut-mei=Ayano
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Department of Human Morphology, Okayama University Graduate School of Medicine, Density and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Human Morphology, Okayama University Graduate School of Medicine, Density and Pharmaceutical Sciences
kn-affil=

affil-num=3
en-affil=Human Anatomy and Histology and Embryology, School of Basic Medicine, Harbin Medical University
kn-affil=

affil-num=4
en-affil=Department of Human Morphology, Okayama University Graduate School of Medicine, Density and Pharmaceutical Sciences
kn-affil=
en-keyword=in vivo electroporation
kn-keyword=in vivo electroporation
en-keyword=in utero electroporation
kn-keyword=in utero electroporation
en-keyword=genome editing
kn-keyword=genome editing
en-keyword=IUE
kn-keyword=IUE
en-keyword=iON
kn-keyword=iON
en-keyword=TEMPO
kn-keyword=TEMPO
en-keyword=iGONAD
kn-keyword=iGONAD
END

start-ver=1.4
cd-journal=joma
no-vol=53
cd-vols=
no-issue=
article-no=
start-page=104348
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2024
dt-pub=202402
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Multi-isotopic analysis of domestic burials from sin Cabezas, Escuintla, Guatemala
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We present the results from the stable isotope measurements of strontium (87Sr/86Sr) and oxygen (δ 18O) in tooth enamel from 36 individuals from the site of Sin Cabezas, Escuintla, Guatemala. This is the first contribution of isotopic proveniencing from the Pacific Coast of Guatemala and offers new solid baseline reference data from a large archaeological sample. Although some outlier cases are identified, the high homogeneity is the most evident feature in the sample. Based on this homogeneity, we discuss a critical issue of baseline data between Teotihuacan and the Pacific Coast, where the material culture has indicated intimate cultural interactions. A critical overlap for both strontium and oxygen reference between the Mexican metropolis and the coastal region is pointed out. This is why detecting human movement between both regions is still elusive. A case study of a possible Mexican individual is introduced. We also assess the outlier cases in terms of proveniencing and add several osteobiographic notes for the most relevant cases whose origin could be seen among the Northern - Eastern part of the Guatemalan Highlands, the Soconusco border region, or Central Honduras.
en-copyright=
kn-copyright=

en-aut-name=SuzukiShintaro
en-aut-sei=Suzuki
en-aut-mei=Shintaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=BarrientosTomás
en-aut-sei=Barrientos
en-aut-mei=Tomás
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MejíaHéctor
en-aut-sei=Mejía
en-aut-mei=Héctor
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=PriceT. Douglas
en-aut-sei=Price
en-aut-mei=T. Douglas
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

affil-num=1
en-affil=Research Institute for the Dynamics of Civilizations, Okayama University
kn-affil=

affil-num=2
en-affil=Centro de Investigaciones Arqueológicas y Antropológicas, Universidad del Valle de Guatemala
kn-affil=

affil-num=3
en-affil=Transportadora de Energía de Centroamérica, Universidad de San Carlos de Guatemala
kn-affil=

affil-num=4
en-affil=University of Wisconsin
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=56
cd-vols=
no-issue=
article-no=
start-page=89
end-page=106
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20231228
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Context Development Function of the Conjunction "de" in Conversation
kn-title=会話における接続詞「で」の文脈展開機能
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=LIUYANG
en-aut-sei=LIU
en-aut-mei=YANG
kn-aut-name=劉洋
kn-aut-sei=劉
kn-aut-mei=洋
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学大学院社会文化科学研究科
END

start-ver=1.4
cd-journal=joma
no-vol=12
cd-vols=
no-issue=
article-no=
start-page=RP88822
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20231121
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Characterization of tryptophan oxidation affecting D1 degradation by FtsH in the photosystem II quality control of chloroplasts
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Photosynthesis is one of the most important reactions for sustaining our environment. Photosystem II (PSII) is the initial site of photosynthetic electron transfer by water oxidation. Light in excess, however, causes the simultaneous production of reactive oxygen species (ROS), leading to photo-oxidative damage in PSII. To maintain photosynthetic activity, the PSII reaction center protein D1, which is the primary target of unavoidable photo-oxidative damage, is efficiently degraded by FtsH protease. In PSII subunits, photo-oxidative modifications of several amino acids such as Trp have been indeed documented, whereas the linkage between such modifications and D1 degradation remains elusive. Here, we show that an oxidative post-translational modification of Trp residue at the N-terminal tail of D1 is correlated with D1 degradation by FtsH during high-light stress. We revealed that Arabidopsis mutant lacking FtsH2 had increased levels of oxidative Trp residues in D1, among which an N-terminal Trp-14 was distinctively localized in the stromal side. Further characterization of Trp-14 using chloroplast transformation in Chlamydomonas indicated that substitution of D1 Trp-14 to Phe, mimicking Trp oxidation enhanced FtsH-mediated D1 degradation under high light, although the substitution did not affect protein stability and PSII activity. Molecular dynamics simulation of PSII implies that both Trp-14 oxidation and Phe substitution cause fluctuation of D1 N-terminal tail. Furthermore, Trp-14 to Phe modification appeared to have an additive effect in the interaction between FtsH and PSII core in vivo. Together, our results suggest that the Trp oxidation at its N-terminus of D1 may be one of the key oxidations in the PSII repair, leading to processive degradation by FtsH.
en-copyright=
kn-copyright=

en-aut-name=KatoYusuke
en-aut-sei=Kato
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KurodaHiroshi
en-aut-sei=Kuroda
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=OzawaShin-Ichiro
en-aut-sei=Ozawa
en-aut-mei=Shin-Ichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SaitoKeisuke
en-aut-sei=Saito
en-aut-mei=Keisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=DograVivek
en-aut-sei=Dogra
en-aut-mei=Vivek
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ScholzMartin
en-aut-sei=Scholz
en-aut-mei=Martin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=ZhangGuoxian
en-aut-sei=Zhang
en-aut-mei=Guoxian
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=de VitryCatherine
en-aut-sei=de Vitry
en-aut-mei=Catherine
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=IshikitaHiroshi
en-aut-sei=Ishikita
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KimChanhong
en-aut-sei=Kim
en-aut-mei=Chanhong
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=HipplerMichael
en-aut-sei=Hippler
en-aut-mei=Michael
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=TakahashiYuichiro
en-aut-sei=Takahashi
en-aut-mei=Yuichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=SakamotoWataru
en-aut-sei=Sakamoto
en-aut-mei=Wataru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Institute of Plant Science and Resources (IPSR), Okayama University
kn-affil=

affil-num=2
en-affil=Research Institute  for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=3
en-affil=Institute of Plant Science and Resources (IPSR), Okayama University
kn-affil=

affil-num=4
en-affil=Research Center  for Advanced Science and Technology, The University of Tokyo
kn-affil=

affil-num=5
en-affil=Shanghai Center for Plant Stress Biology, Center for Excellence in Molecular Plant  Sciences, Chinese Academy of Sciences
kn-affil=

affil-num=6
en-affil=Institute of  Plant Biology and Biotechnology, University of Münster
kn-affil=

affil-num=7
en-affil=Institute of Plant Science and Resources (IPSR), Okayama University
kn-affil=

affil-num=8
en-affil=Institut  de Biologie Physico-Chimique, Unité Mixte de Recherche 7141, Centre National de la  Recherche Scientifique and Sorbonne Université Pierre et Marie Curie
kn-affil=

affil-num=9
en-affil=Research Center  for Advanced Science and Technology, The University of Tokyo
kn-affil=

affil-num=10
en-affil=Shanghai Center for Plant Stress Biology, Center for Excellence in Molecular Plant  Sciences, Chinese Academy of Sciences
kn-affil=

affil-num=11
en-affil=Institute of Plant Science and Resources (IPSR), Okayama University
kn-affil=

affil-num=12
en-affil=Research Institute  for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=13
en-affil=Institute of Plant Science and Resources (IPSR), Okayama University
kn-affil=
en-keyword=post-translational modification
kn-keyword=post-translational modification
en-keyword=Arabidopsis thaliana
kn-keyword=Arabidopsis thaliana
en-keyword=protein degradation
kn-keyword=protein degradation
en-keyword=photosystem II
kn-keyword=photosystem II
en-keyword=photo-oxidative damage
kn-keyword=photo-oxidative damage
en-keyword=tryptophan oxidation
kn-keyword=tryptophan oxidation
en-keyword=Chlamydomonas reinhardtii
kn-keyword=Chlamydomonas reinhardtii
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=6
article-no=
start-page=665
end-page=669
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202312
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Omental Abscess after Laparoscopic Proximal Gastrectomy Successfully Treated with Percutaneous Drainage
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We report the case details of a 65-year-old Japanese man with an omental abscess that was discovered 43 days after he underwent a laparoscopic proximal gastrectomy for gastric cancer. His chief complaint was mild abdominal pain that had persisted for several days. The abscess was diagnosed as a rare postoperative complication. We hesitated to perform a reoperation given the invasiveness of general anesthesia and surgery, plus the possibility of postoperative adhesions and because the patient’s general condition was stable and he had only mild abdominal pain. Percutaneous drainage using a 10.2-F catheter was performed with the patient under conscious sedation and computed tomography–fluoroscopy guidance, with no complications. After the procedure, the size of the abscess cavity was remarkably reduced, and 23 days later the catheter was withdrawn.
en-copyright=
kn-copyright=

en-aut-name=SakuraiAtsunobu
en-aut-sei=Sakurai
en-aut-mei=Atsunobu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=UkaMayu
en-aut-sei=Uka
en-aut-mei=Mayu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=IguchiToshihiro
en-aut-sei=Iguchi
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TomitaKoji
en-aut-sei=Tomita
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=MatsuiYusuke
en-aut-sei=Matsui
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=KakiuchiYoshihiko
en-aut-sei=Kakiuchi
en-aut-mei=Yoshihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KurodaShinji
en-aut-sei=Kuroda
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=FujiwaraToshiyoshi
en-aut-sei=Fujiwara
en-aut-mei=Toshiyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HirakiTakao
en-aut-sei=Hiraki
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Radiological Technology, Faculty of Health Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=6
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
kn-affil=

affil-num=7
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
kn-affil=

affil-num=8
en-affil=Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
kn-affil=

affil-num=9
en-affil=Department of Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=drainage
kn-keyword=drainage
en-keyword=omental abscess
kn-keyword=omental abscess
en-keyword=omental infarction
kn-keyword=omental infarction
en-keyword=proximal gastrectomy
kn-keyword=proximal gastrectomy
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=6
article-no=
start-page=647
end-page=650
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202312
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Case of Migration of a Hydrogel Spacer for Radiotherapy into the Pulmonary Artery
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A 67-year-old man was referred to our hospital for the diagnosis and treatment of prostate cancer. Multidisciplinary discussion led to intensity-modulated radiotherapy preceded by hormone therapy. Before radiotherapy, a biodegradable hydrogel spacer (HS) was placed between the prostate and rectum to reduce radiation injury risk. Three weeks postplacement, pelvic magnetic resonance imaging revealed HS migration into the pelvic vein. Subsequent whole-body contrast-enhanced computed tomography (CECT) revealed HS migration into the pulmonary artery. The patient showed no symptoms or clinical signs. Radiotherapy was completed uneventfully. Complete absorption of the migrated HS was confirmed using CECT images 5 months postplacement.
en-copyright=
kn-copyright=

en-aut-name=KojimaKatsuhide
en-aut-sei=Kojima
en-aut-mei=Katsuhide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TakahashiYuka
en-aut-sei=Takahashi
en-aut-mei=Yuka
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=SugiyamaSoichi
en-aut-sei=Sugiyama
en-aut-mei=Soichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=AsanoYudai
en-aut-sei=Asano
en-aut-mei=Yudai
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OkawaNanako
en-aut-sei=Okawa
en-aut-mei=Nanako
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MakimotoSatoko
en-aut-sei=Makimoto
en-aut-mei=Satoko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HigakiFumiyo
en-aut-sei=Higaki
en-aut-mei=Fumiyo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=IguchiToshihiro
en-aut-sei=Iguchi
en-aut-mei=Toshihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=HirakiTakao
en-aut-sei=Hiraki
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Proton Beam Therapy, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Radiology, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Radiological Technology, Faculty of Health Sciences, Okayama University
kn-affil=

affil-num=9
en-affil=Department of Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=hydrogel spacer
kn-keyword=hydrogel spacer
en-keyword=prostate cancer
kn-keyword=prostate cancer
en-keyword=radiotherapy
kn-keyword=radiotherapy
en-keyword=pulmonary embolism
kn-keyword=pulmonary embolism
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=6
article-no=
start-page=627
end-page=634
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202312
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Abnormal Vaginal Cytology after Total Laparoscopic Hysterectomy in Patients with Cervical Intraepithelial Neoplasia
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=To explore the incidence of abnormal vaginal cytology after total laparoscopic hysterectomy for the treatment of cervical intraepithelial neoplasia 3, we retrospectively analyzed the medical records of patients treated at NHO Shikoku Cancer Center (Japan) in 2014-2019. The cases of 99 patients who underwent a laparoscopic (n=36) or open (n=63) hysterectomy and postoperative follow-up were examined. Abnormal vaginal cytology was detected in 13.9% (5/36) of the laparoscopic-surgery (LS) group and 14.3% (9/63) of the open-surgery (OS) group. A vaginal biopsy was performed at the physicians’ discretion; one LS patient and six OS patients were diagnosed with vaginal intraepithelial neoplasia. The cumulative incidence of abnormal vaginal cytology at 3 years post-hysterectomy was 21.4% (LS group) and 20.5% (OS group), a nonsignificant difference. A multivariate analysis showed that age > 50 years was the only independent risk factor for abnormal vaginal cytology among the covariates examined including age; body mass index; histories of vaginal delivery, abdominal surgery, and smoking; and surgical approach (hazard ratio 8.11; 95% confidence interval 1.73-37.98; p=0.01). These results suggest that the occurrence of abnormal vaginal cytology after a hysterectomy may not be influenced by the laparoscopic procedure but is associated with older age.
en-copyright=
kn-copyright=

en-aut-name=HibinoYumi
en-aut-sei=Hibino
en-aut-mei=Yumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=Okazawa-SakaiMika
en-aut-sei=Okazawa-Sakai
en-aut-mei=Mika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YokoyamaTakanori
en-aut-sei=Yokoyama
en-aut-mei=Takanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FujimotoEtsuko
en-aut-sei=Fujimoto
en-aut-mei=Etsuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OkameShinichi
en-aut-sei=Okame
en-aut-mei=Shinichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TeramotoNorihiro
en-aut-sei=Teramoto
en-aut-mei=Norihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=TakeharaKazuhiro
en-aut-sei=Takehara
en-aut-mei=Kazuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Gynecologic Oncology, NHO Shikoku Cancer Center
kn-affil=

affil-num=2
en-affil=Department of Gynecologic Oncology, NHO Shikoku Cancer Center
kn-affil=

affil-num=3
en-affil=Department of Gynecologic Oncology, NHO Shikoku Cancer Center
kn-affil=

affil-num=4
en-affil=Department of Gynecologic Oncology, NHO Shikoku Cancer Center
kn-affil=

affil-num=5
en-affil=Department of Gynecologic Oncology, NHO Shikoku Cancer Center
kn-affil=

affil-num=6
en-affil=Department of Pathology, NHO Shikoku Cancer Center
kn-affil=

affil-num=7
en-affil=Department of Gynecologic Oncology, NHO Shikoku Cancer Center
kn-affil=
en-keyword=total laparoscopic hysterectomy
kn-keyword=total laparoscopic hysterectomy
en-keyword=vaginal intraepithelial neoplasia
kn-keyword=vaginal intraepithelial neoplasia
en-keyword=cervical intraepithelial neoplasia
kn-keyword=cervical intraepithelial neoplasia
en-keyword=vaginal cytology
kn-keyword=vaginal cytology
en-keyword=risk factor
kn-keyword=risk factor
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=6
article-no=
start-page=589
end-page=593
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202312
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Cochlear Implantation in the Poorer-Hearing Ear Is a Reasonable Choice
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Choosing the optimal side for cochlear implantation (CI) remains a major challenge because of the lack of evidence. We investigated the choice of the surgery side for CI (i.e., the better- or poorer-hearing ear) in patients with asymmetric hearing. Audiological records of 74 adults with a unilateral hearing aid who had undergone surgery at Okayama University Hospital were reviewed. The definition of ‘better-hearing ear’ was the aided ear, and the unaided ear was considered the poorer-hearing ear. We performed a multiple regression analysis to identify potential predictors of speech recognition performance after unilateral CI in the patients. Fifty-two patients underwent CI in the poorer-hearing ear. The post-Ci bimodal hearing rate was far higher in the poorer-ear group (77.8% vs. 22.2%). A multivariate analysis revealed that prelingual hearing loss and the patient’s age at CI significantly affected the speech recognition outcome (beta coefficients: 24.6 and −0.33, 95% confidence intervals [11.75-37.45] and [−0.58 to −0.09], respectively), but the CI surgery side did not (−6.76, [−14.92-1.39]). Unilateral CI in the poorer-hearing ear may therefore be a reasonable choice for adult patients with postlingual severe hearing loss, providing a greater opportunity for postoperative bimodal hearing.
en-copyright=
kn-copyright=

en-aut-name=OmichiRyotaro
en-aut-sei=Omichi
en-aut-mei=Ryotaro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KariyaShin
en-aut-sei=Kariya
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MaedaYukihide
en-aut-sei=Maeda
en-aut-mei=Yukihide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=FukushimaKunihiro
en-aut-sei=Fukushima
en-aut-mei=Kunihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KataokaYuko
en-aut-sei=Kataoka
en-aut-mei=Yuko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=SugayaAkiko
en-aut-sei=Sugaya
en-aut-mei=Akiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NishizakiKazunori
en-aut-sei=Nishizaki
en-aut-mei=Kazunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=AndoMizuo
en-aut-sei=Ando
en-aut-mei=Mizuo
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

affil-num=1
en-affil=Department of Otolaryngology-Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Otolaryngology-Head and Neck Surgery, Kawasaki Medial University
kn-affil=

affil-num=3
en-affil=Department of Otolaryngology-Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=4
en-affil=Hayashima Clinic of Otolaryngology and Dermatology
kn-affil=

affil-num=5
en-affil=Department of Otolaryngology-Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=6
en-affil=Department of Otolaryngology-Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=7
en-affil=Department of Otolaryngology-Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Otolaryngology-Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=cochlear implantation
kn-keyword=cochlear implantation
en-keyword=poorer hearing ear
kn-keyword=poorer hearing ear
en-keyword=better hearing ear
kn-keyword=better hearing ear
en-keyword=hearing aids
kn-keyword=hearing aids
en-keyword=speech recognition
kn-keyword=speech recognition
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=6
article-no=
start-page=577
end-page=587
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202312
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Japanese Nursing Staff’s Knowledge and Attitude toward Bereavement Care for Couples with Miscarriage/Stillbirth and Its Associated Factors
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Bereavement care is conducted to meet the emotional needs of grieving couples who are devastated by the experience of a miscarriage or stillbirth. From January to April 2022, we distributed a questionnaire that assessed the knowledge and attitudes of Japanese nursing staff (nurses and midwives) in Japan’s Chugoku-Shikoku region toward bereavement care for couples with miscarriage/stillbirth. The 370 survey respondents’ answers revealed that the nursing staff’s knowledge regarding recurrent pregnancy loss and subsequent bereavement care was insufficient. About 41.1% and 64.1% of the respondents had received school and on-the-job education in bereavement care, respectively, and 79.2% expressed willingness to provide such care. Our analyses revealed that the following factors were associated with the nursing staff’s knowledge level: parent status, age, reproductive history, midwifery license, work experience and environment, and on-the-job education. The following were correlated with the staff’s willingness to provide bereavement care: work environment, midwifery license, bereavement care knowledge, and on-the-job education. Together our findings indicate that education plays a significant role in equipping caregivers to provide effective bereavement care for couples who have experienced a miscarriage or stillbirth.
en-copyright=
kn-copyright=

en-aut-name=LiuSiyu
en-aut-sei=Liu
en-aut-mei=Siyu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=AthurupanaRukmali
en-aut-sei=Athurupana
en-aut-mei=Rukmali
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=HanHongmei
en-aut-sei=Han
en-aut-mei=Hongmei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=YangTiti
en-aut-sei=Yang
en-aut-mei=Titi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=NakatsukaMikiya
en-aut-sei=Nakatsuka
en-aut-mei=Mikiya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

affil-num=1
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=3
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=

affil-num=4
en-affil=Graduate School of Medicine, Density and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Graduate School of Health Sciences, Okayama University
kn-affil=
en-keyword=midwife
kn-keyword=midwife
en-keyword=nurse
kn-keyword=nurse
en-keyword=miscarriage
kn-keyword=miscarriage
en-keyword=bereavement
kn-keyword=bereavement
en-keyword=knowledge
kn-keyword=knowledge
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=6
article-no=
start-page=567
end-page=575
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202312
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Review of a Series of Surveys on Adverse Reactions to the COVID-19 mRNA-1273 Vaccine at Okayama University
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This paper presents the results of a series of surveys conducted from July 2021 to March 2023 to investigate the post-vaccination adverse reactions to the mRNA-1273 (Moderna) vaccine among faculty, staff, and students at Okayama University. These studies complement the official surveys conducted by the Ministry of Health, Labour and Welfare (MHLW) and provide a more representative picture of adverse reactions in the general population including large numbers of healthy young people. Pain, swelling, redness at the injection site, fever, headache, and malaise were the main adverse reactions reported. The proportion of adverse reactions was generally higher after the second vaccination and decreased with each additional vaccination. No statistically significant differences in the adverse reactions were found for males and females and those with/without a history of allergy, but a lower proportion of fever was observed in older participants and those with underlying medical conditions. We also evaluated the association between adverse reactions and antibody titers after the third vaccination and found no significant differences in antibody levels one month after vaccination. This series of studies highlights the importance of conducting surveys in diverse populations to provide a more representative picture of post-vaccination adverse reactions during a pandemic.
en-copyright=
kn-copyright=

en-aut-name=MatsumotoNaomi
en-aut-sei=Matsumoto
en-aut-mei=Naomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HiguchiChigusa
en-aut-sei=Higuchi
en-aut-mei=Chigusa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MiyajiChikara
en-aut-sei=Miyaji
en-aut-mei=Chikara
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MitsuhashiToshiharu
en-aut-sei=Mitsuhashi
en-aut-mei=Toshiharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=HagiyaHideharu
en-aut-sei=Hagiya
en-aut-mei=Hideharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TakaoSoshi
en-aut-sei=Takao
en-aut-mei=Soshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YorifujiTakashi
en-aut-sei=Yorifuji
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Okayama University Health Service Center
kn-affil=

affil-num=3
en-affil=Okayama University Health Service Center
kn-affil=

affil-num=4
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Infectious Diseases, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=7
en-affil=Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=coronavirus disease 2019
kn-keyword=coronavirus disease 2019
en-keyword=adverse reactions
kn-keyword=adverse reactions
en-keyword=mRNA vaccine
kn-keyword=mRNA vaccine
en-keyword=antibody titers
kn-keyword=antibody titers
en-keyword=young adults
kn-keyword=young adults
END

start-ver=1.4
cd-journal=joma
no-vol=55
cd-vols=
no-issue=2
article-no=
start-page=33
end-page=52
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20231124
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=Die Grundlagen der wirtschaftlichen Entwicklung des Königreichs Sachsen（3）
kn-title=ザクセン王国経済発展の基礎（３）
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=
en-copyright=
kn-copyright=

en-aut-name=MatsuoNobushige
en-aut-sei=Matsuo
en-aut-mei=Nobushige
kn-aut-name=松尾展成
kn-aut-sei=松尾
kn-aut-mei=展成
aut-affil-num=1
ORCID=

affil-num=1
en-affil=
kn-affil=岡山大学名誉教授
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=5
article-no=
start-page=553
end-page=559
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202310
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Favorable Outcome of Repeated Salvage Surgeries for Rare Metastasis to the Ligamentum Teres Hepatis and the Upper Abdominal Wall in a Stage IV Gastric Cancer Patient
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Gastric cancer with peritoneal metastases is typically a devastating diagnosis. Ligamentum teres hepatis (LTH) metastasis is an extremely rare presentation with only four known cases. Herein, we report salvage surgery of successive metastases to the abdominal wall and LTH in a patient originally presenting with advanced gastric cancer with peritoneal metastasis, leading to long-term survival. A 72-year-old man with advanced gastric cancer underwent curative-intent distal gastrectomy with D2 lymph node dissection for gastric outlet obstruction. During this procedure, three small peritoneal metastases were detected in the lesser omentum, the small mesentery, and the mesocolon; however, intraoperative abdominal lavage cytology was negative. We added cytoreductive surgery for peritoneal metastasis. The pathological diagnosis of the gastric cancer was tubular adenocarcinoma with pT4aN1pM1(PER/P1b)CY0 stage IV (Japanese classification of gastric carcinoma/JCGC 15th), or T4N1M1b stage IV (UICC 7th). Post-operative adjuvant chemotherapy with S-1 (TS-1)+cisplatin (CDDP) was administered for 8 months followed by S-1 monotherapy for 4 months. At 28 months after the initial surgery, a follow-up computed tomography (CT) detected a small mass beneath the upper abdominal wall. The ass showed mild avidity on 18F-fluorodeoxyglucose positron-emission (FDG-PET) CT. Salvage resection was performed for diagnosis and treatment, and pathological findings were consistent with primary gastric cancer metastasis. At 49 months after the initial gastrectomy, a new lesion was detected in the LTH with a similar level of avidity on FDG-PET CT as the abdominal wall metastatic lesion. We performed a second salvage surgery for the LTH tumor, which also showed pathology of gastric cancer metastasis. There has been no recurrence up to 1 year after the LTH surgery. With multidisciplinary treatment the patient has survived almost 5 years after the initial gastrectomy. Curative-intent gastrectomy with cytoreductive surgery followed by adjuvant chemotherapy for advanced gastric cancer with localized peritoneal metastasis might have had a survival benefit in our patient. Successive salvage surgeries for oligometastatic lesions in the abdominal wall and the LTH also yielded favorable outcomes.
en-copyright=
kn-copyright=

en-aut-name=MurokawaTakahiro
en-aut-sei=Murokawa
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=SakamotoShinya
en-aut-sei=Sakamoto
en-aut-mei=Shinya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TabuchiMotoyasu
en-aut-sei=Tabuchi
en-aut-mei=Motoyasu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=SuiKenta
en-aut-sei=Sui
en-aut-mei=Kenta
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OzakiKazuhide
en-aut-sei=Ozaki
en-aut-mei=Kazuhide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MatsumotoManabu
en-aut-sei=Matsumoto
en-aut-mei=Manabu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=IwataJun
en-aut-sei=Iwata
en-aut-mei=Jun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OkabayashiTakehiro
en-aut-sei=Okabayashi
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=YoshidaHiroshi
en-aut-sei=Yoshida
en-aut-mei=Hiroshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=2
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=3
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=4
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=5
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=6
en-affil=Department of Diagnostic Pathology, Kochi Health Sciences Center
kn-affil=

affil-num=7
en-affil=Department of Diagnostic Pathology, Kochi Health Sciences Center
kn-affil=

affil-num=8
en-affil=Department of Gastroenterological Surgery, Kochi Health Sciences Center
kn-affil=

affil-num=9
en-affil=Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School
kn-affil=
en-keyword=gastric cancer
kn-keyword=gastric cancer
en-keyword=peritoneal metastasis
kn-keyword=peritoneal metastasis
en-keyword=ligamentum teres hepatis
kn-keyword=ligamentum teres hepatis
en-keyword=oligometastasis
kn-keyword=oligometastasis
en-keyword=salvage surgery
kn-keyword=salvage surgery
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=5
article-no=
start-page=545
end-page=552
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202310
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Endoscopic Manifestations and Clinical Characteristics of Localized Gastric Light-Chain Amyloidosis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=To determine the endoscopic and clinical features of localized gastric amyloid light-chain (AL) amyloidosis, we retrospectively examined the characteristics of nine patients (eight men and one woman) encountered by the hospitals in our network. Lesions were predominantly flat and depressed with surface vascular dilatation (n=5); others were characterized by subepithelial lesions (n=2), mucosal color change (n=1), and a mass-like morphology with swollen mucosal folds (n=1). Colonoscopy (n=7), video capsule enteroscopy (n=2), serum (n=5) and urine immunoelectrophoresis (n=4), and bone marrow examination (n=3) were performed to exclude involvement of organs other than the stomach. As treatment for gastric lesions of AL amyloidosis, one patient each underwent endoscopic submucosal dissection (n=1) and argon plasma coagulation (n=1), while the remaining seven patients underwent no specific treatment. During a mean follow-up of 4.2 years, one patient died 3.2 years after diagnosis, but the cause of death, which occurred in another hospital, was unknown. The remaining eight patients were alive at the last visit. In conclusion, although localized gastric AL amyloidosis can show various macroscopic features on esophagogastroduodenoscopy, flat, depressed lesions with vascular dilatation on the surface are predominant.
en-copyright=
kn-copyright=

en-aut-name=IwamuroMasaya
en-aut-sei=Iwamuro
en-aut-mei=Masaya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TanakaShouichi
en-aut-sei=Tanaka
en-aut-mei=Shouichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=ToyokawaTatsuya
en-aut-sei=Toyokawa
en-aut-mei=Tatsuya
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NishimuraMamoru
en-aut-sei=Nishimura
en-aut-mei=Mamoru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TsuzukiTakao
en-aut-sei=Tsuzuki
en-aut-mei=Takao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=MiyaharaKoji
en-aut-sei=Miyahara
en-aut-mei=Koji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NegishiShin
en-aut-sei=Negishi
en-aut-mei=Shin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=OhyaShogen
en-aut-sei=Ohya
en-aut-mei=Shogen
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=TanakaTakehiro
en-aut-sei=Tanaka
en-aut-mei=Takehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=OtsukaMotoyuki
en-aut-sei=Otsuka
en-aut-mei=Motoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology, National Hospital Organization Iwakuni Clinical Center
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology, National Hospital Organization Fukuyama Medical Center
kn-affil=

affil-num=4
en-affil=Department of Internal Medicine, Okayama City Hospital
kn-affil=

affil-num=5
en-affil=Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital
kn-affil=

affil-num=6
en-affil=Department of Internal Medicine, Hiroshima City Hiroshima Citizens Hospital
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology, Kagawa Prefectural Central Hospital
kn-affil=

affil-num=8
en-affil=Kawaguchi Medical Clinic
kn-affil=

affil-num=9
en-affil=Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=10
en-affil=Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=esophagogastroduodenoscopy
kn-keyword=esophagogastroduodenoscopy
en-keyword=gastric lesion
kn-keyword=gastric lesion
en-keyword=amyloidosis
kn-keyword=amyloidosis
en-keyword=light chain
kn-keyword=light chain
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=5
article-no=
start-page=517
end-page=525
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202310
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Association between BRCA Gene Variants and the Response to Modified FOLFIRINOX in Patients with Unresectable Pancreatic Cancer
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We investigated the effect of modified FOLFIRINOX (mFFX) in unresectable pancreatic cancer by retrospectively analyzing the cases of 43 patients who underwent BRCA testing (germline, n=11; somatic, n=26; both germline and somatic, n=6). The association between BRCA mutations and therapeutic effect was clarified. Six patients tested positive for germline pathogenic variants. Familial pancreatic cancer (33% vs. 3%, p=0.006) and peritoneal disseminated lesions (66% vs. 8%, p<0.001) were significantly more common in patients with germline pathogenic variants. The partial response (PR) rate was 100% in the germline BRCA-positive patients, and 27% in the germline BRCA-negative patients (p<0.001). The median progression-free survival (PFS) was not reached for any germline BRCA-positive patients but was 9.0 months for the germline BRCA-negative patients (p=0.042). Patients with stage IV BRCA-associated pancreatic cancer had better overall survival than those with non-BRCA-associated pancreatic cancer, although the difference was nonsignificant (not reached vs. 655 days, p=0.061). Our results demonstrate that a PR and prolonged PFS can be expected in germline BRCA-positive patients after treatment with mFFX. Our findings also suggest that germline BRCA pathogenic variants may be useful as biomarkers for the therapeutic effect of mFFX in patients with pancreatic cancer.
en-copyright=
kn-copyright=

en-aut-name=HoriguchiShigeru
en-aut-sei=Horiguchi
en-aut-mei=Shigeru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=MatsumotoKazuyuki
en-aut-sei=Matsumoto
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=MorimotoKosaku
en-aut-sei=Morimoto
en-aut-mei=Kosaku
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=MatsumiAkihiro
en-aut-sei=Matsumi
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=TerasawaHiroyuki
en-aut-sei=Terasawa
en-aut-mei=Hiroyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FujiiYuki
en-aut-sei=Fujii
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=YamazakiTatsuhiro
en-aut-sei=Yamazaki
en-aut-mei=Tatsuhiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=TsutsumiKoichiro
en-aut-sei=Tsutsumi
en-aut-mei=Koichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=KatoHironari
en-aut-sei=Kato
en-aut-mei=Hironari
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=8
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Gastroenterology and Hepatology, Okayama University Hospital
kn-affil=
en-keyword=BRCA
kn-keyword=BRCA
en-keyword=FOLFIRINOX
kn-keyword=FOLFIRINOX
en-keyword=pancreatic cancer
kn-keyword=pancreatic cancer
en-keyword=progression-free survival
kn-keyword=progression-free survival
en-keyword=pathogenic variant
kn-keyword=pathogenic variant
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=5
article-no=
start-page=511
end-page=516
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202310
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Associations among Preoperative Malnutrition, Muscle Loss, and Postoperative Walking Ability in Intertrochanteric Fractures: A Retrospective Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Sarcopenia and malnutrition are increasing in older adults and are reported risk factors for functional impairment after hip fracture surgery. This study aimed to investigate the associations between skeletal muscle mass loss, malnutrition, and postoperative walking ability in patients with hip fracture. We retrospectively reviewed patients who underwent intertrochanteric fracture surgery at our institute. The psoas muscle index, controlling nutritional status score, and functional ambulation category (FAC) were used to evaluate skeletal muscle mass, nutritional status, and walking ability, respectively. Six months after surgery, walking ability was assessed as either “gait disturbance” or “independent gait”. Multivariate binomial logistic regression analysis, with skeletal muscle mass, nutritional status, and other factors, was used to predict the risk of being assigned to the gait disturbance group. This study included 95 patients (mean age, 85.2 years; 70 women). Sixty-six patients had low skeletal muscle mass, 35 suffered from malnutrition, and 28 had both. Malnutrition and low skeletal muscle mass were significantly associated with postoperative gait disturbance (FAC < 3). Preoperative low skeletal muscle mass and malnutrition were risk factors for postoperative poor walking ability. Further preventive interventions focusing on skeletal muscle mass and nutritional status are required.
en-copyright=
kn-copyright=

en-aut-name=SatoKohei
en-aut-sei=Sato
en-aut-mei=Kohei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TsujiHironori
en-aut-sei=Tsuji
en-aut-mei=Hironori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=YorimitsuMasanori
en-aut-sei=Yorimitsu
en-aut-mei=Masanori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=UeharaTakenori
en-aut-sei=Uehara
en-aut-mei=Takenori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OkazakiYuki
en-aut-sei=Okazaki
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TakaoShinichiro
en-aut-sei=Takao
en-aut-mei=Shinichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HataToshiaki
en-aut-sei=Hata
en-aut-mei=Toshiaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=FukuokaShiro
en-aut-sei=Fukuoka
en-aut-mei=Shiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=NodaTomoyuki
en-aut-sei=Noda
en-aut-mei=Tomoyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=KandaHideyuki
en-aut-sei=Kanda
en-aut-mei=Hideyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

affil-num=1
en-affil=Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=Department of Orthopedic Surgery, Japanese Red Cross Okayama Hospital
kn-affil=

affil-num=3
en-affil=Department of Orthopedic Surgery, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=5
en-affil=Department of Orthopedic Surgery, Tsuyama Chuo Hospital
kn-affil=

affil-num=6
en-affil=Department of Orthopedic Surgery, Okayama Medical Center
kn-affil=

affil-num=7
en-affil=Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=8
en-affil=Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=9
en-affil=Department of Orthopedic Surgery, Kawasaki Medical School, General Medical Center
kn-affil=

affil-num=10
en-affil=Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=

affil-num=11
en-affil=Department of Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
kn-affil=
en-keyword=sarcopenia
kn-keyword=sarcopenia
en-keyword=nutrition
kn-keyword=nutrition
en-keyword=geriatric hip fracture
kn-keyword=geriatric hip fracture
en-keyword=psoas muscle index
kn-keyword=psoas muscle index
en-keyword=controlling nutritional status score
kn-keyword=controlling nutritional status score
END

start-ver=1.4
cd-journal=joma
no-vol=71
cd-vols=
no-issue=2
article-no=
start-page=154
end-page=164
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20230201
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Identification of a Functionally Efficient and Thermally Stable Outward Sodium-Pumping Rhodopsin (BeNaR) from a Thermophilic Bacterium
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Rhodopsins are transmembrane proteins with retinal chromophores that are involved in photo-energy conversion and photo-signal transduction in diverse organisms. In this study, we newly identified and characterized a rhodopsin from a thermophilic bacterium, Bellilinea sp. Recombinant Escherichia coli cells expressing the rhodopsin showed light-induced alkalization of the medium only in the presence of sodium ions (Na+), and the alkalization signal was enhanced by addition of a protonophore, indicating an outward Na+ pump function across the cellular membrane. Thus, we named the protein Bellilinea Na+-pumping rhodopsin, BeNaR. Of note, its Na+-pumping activity is significantly greater than that of the known Na+-pumping rhodopsin, KR2. We further characterized its photochemical properties as follows: (i) Visible spectroscopy and HPLC revealed that BeNaR has an absorption maximum at 524 nm with predominantly (>96%) the all-trans retinal conformer. (ii) Time-dependent thermal denaturation experiments revealed that BeNaR showed high thermal stability. (iii) The time-resolved flash-photolysis in the nanosecond to millisecond time domains revealed the presence of four kinetically distinctive photointermediates, K, L, M and O. (iv) Mutational analysis revealed that Asp101, which acts as a counterion, and Asp230 around the retinal were essential for the Na+-pumping activity. From the results, we propose a model for the outward Na+-pumping mechanism of BeNaR. The efficient Na+-pumping activity of BeNaR and its high stability make it a useful model both for ion transporters and optogenetics tools.
en-copyright=
kn-copyright=

en-aut-name=KuriharaMarie
en-aut-sei=Kurihara
en-aut-mei=Marie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=ThielVera
en-aut-sei=Thiel
en-aut-mei=Vera
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TakahashiHirona
en-aut-sei=Takahashi
en-aut-mei=Hirona
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=KojimaKeiichi
en-aut-sei=Kojima
en-aut-mei=Keiichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=WardDavid M.
en-aut-sei=Ward
en-aut-mei=David M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=BryantDonald A.
en-aut-sei=Bryant
en-aut-mei=Donald A.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=SakaiMakoto
en-aut-sei=Sakai
en-aut-mei=Makoto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=YoshizawaSusumu
en-aut-sei=Yoshizawa
en-aut-mei=Susumu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=SudoYuki
en-aut-sei=Sudo
en-aut-mei=Yuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

affil-num=1
en-affil=Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=2
en-affil=Department of Biological Sciences, Tokyo Metropolitan University
kn-affil=

affil-num=3
en-affil=Department of Chemistry, Graduate School of Science, Okayama University of Science
kn-affil=

affil-num=4
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=

affil-num=5
en-affil=Department of Land Resources and Environmental Sciences, Montana State University
kn-affil=

affil-num=6
en-affil=Department of Biochemistry and Molecular Biology, The Pennsylvania State University
kn-affil=

affil-num=7
en-affil=Department of Chemistry, Graduate School of Science, Okayama University of Science
kn-affil=

affil-num=8
en-affil=Atmosphere and Ocean Research Institute, The University of Tokyo
kn-affil=

affil-num=9
en-affil=Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
kn-affil=
en-keyword=rhodopsin
kn-keyword=rhodopsin
en-keyword=ion transport
kn-keyword=ion transport
en-keyword=retinal
kn-keyword=retinal
en-keyword=isomerization
kn-keyword=isomerization
en-keyword=optogenetics
kn-keyword=optogenetics
END

start-ver=1.4
cd-journal=joma
no-vol=8
cd-vols=
no-issue=12
article-no=
start-page=eabm2225
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=20220325
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Structure and dynamics of Odinarchaeota tubulin and the implications for eukaryotic microtubule evolution
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Tubulins are critical for the internal organization of eukaryotic cells, and understanding their emergence is an important question in eukaryogenesis. Asgard archaea are the closest known prokaryotic relatives to eukaryotes. Here, we elucidated the apo and nucleotide-bound x-ray structures of an Asgard tubulin from hydrothermal living Odinarchaeota (OdinTubulin). The guanosine 5′-triphosphate (GTP)–bound structure resembles a microtubule protofilament, with GTP bound between subunits, coordinating the “+” end subunit through a network of water molecules and unexpectedly by two cations. A water molecule is located suitable for GTP hydrolysis. Time course crystallography and electron microscopy revealed conformational changes on GTP hydrolysis. OdinTubulin forms tubules at high temperatures, with short curved protofilaments coiling around the tubule circumference, more similar to FtsZ, rather than running parallel to its length, as in microtubules. Thus, OdinTubulin represents an evolutionary stage intermediate between prokaryotic FtsZ and eukaryotic microtubule-forming tubulins.
en-copyright=
kn-copyright=

en-aut-name=AkılCaner
en-aut-sei=Akıl
en-aut-mei=Caner
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=AliSamson
en-aut-sei=Ali
en-aut-mei=Samson
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TranLinh T.
en-aut-sei=Tran
en-aut-mei=Linh T.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=GaillardJérémie
en-aut-sei=Gaillard
en-aut-mei=Jérémie
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=LiWenfei
en-aut-sei=Li
en-aut-mei=Wenfei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HayashidaKenichi
en-aut-sei=Hayashida
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=HiroseMika
en-aut-sei=Hirose
en-aut-mei=Mika
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KatoTakayuki
en-aut-sei=Kato
en-aut-mei=Takayuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=OshimaAtsunori
en-aut-sei=Oshima
en-aut-mei=Atsunori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=FujishimaKosuke
en-aut-sei=Fujishima
en-aut-mei=Kosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=BlanchoinLaurent
en-aut-sei=Blanchoin
en-aut-mei=Laurent
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=NaritaAkihiro
en-aut-sei=Narita
en-aut-mei=Akihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=RobinsonRobert C.
en-aut-sei=Robinson
en-aut-mei=Robert C.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

affil-num=1
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=2
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=3
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=

affil-num=4
en-affil=University of Grenoble-Alpes, CEA, CNRS, INRA, Interdisciplinary Research Institute of Grenoble, Laboratoire de Physiologie Cellulaire & Végétale, CytoMorpho Lab
kn-affil=

affil-num=5
en-affil=National Laboratory of Solid State Microstructure, Department of Physics, Collaborative Innovation Center of Advanced Microstructures, Nanjing University
kn-affil=

affil-num=6
en-affil=Cellular and Structural Physiology Institute (CeSPI), Nagoya University
kn-affil=

affil-num=7
en-affil=Institute for Protein Research, Osaka University
kn-affil=

affil-num=8
en-affil=Institute for Protein Research, Osaka University
kn-affil=

affil-num=9
en-affil=Cellular and Structural Physiology Institute (CeSPI), Nagoya University
kn-affil=

affil-num=10
en-affil=Tokyo Institute of Technology, Earth-Life Science Institute (ELSI)
kn-affil=

affil-num=11
en-affil=University of Grenoble-Alpes, CEA, CNRS, INRA, Interdisciplinary Research Institute of Grenoble, Laboratoire de Physiologie Cellulaire & Végétale, CytoMorpho Lab
kn-affil=

affil-num=12
en-affil=Division of Biological Science, Graduate School of Science, Nagoya University
kn-affil=

affil-num=13
en-affil=Research Institute for Interdisciplinary Science, Okayama University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=24
cd-vols=
no-issue=8
article-no=
start-page=1429
end-page=1438
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2022
dt-pub=20220518
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Aim: To evaluate the effect of canagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, on albuminuria and the decline of estimated glomerular filtration rate (eGFR) in participants with type 2 diabetes and microalbuminuria.<br>
Methods: The CANPIONE study is a multicentre, randomized, parallel-group and open-labelled study consisting of a unique 24-week preintervention period, during which the rate of eGFR decline before intervention is estimated, followed by a 52-week intervention and a 4-week washout period. Participants with a geometric mean urinary albumin-to-creatinine ratio (UACR) of 50 and higher and less than 300 mg/g in two consecutive first-morning voids at two different time points, and an eGFR of 45 ml/min/1.73m2 or higher, are randomly assigned to receive canagliflozin 100 mg daily or to continue guideline-recommended treatment, except for SGLT2 inhibitors. The first primary outcome is the change in UACR, and the second primary outcome is the change in eGFR slope.<br>
Results: A total of 258 participants were screened and 98 were randomized at 21 sites in Japan from August 2018 to May 2021. The mean baseline age was 61.4 years and 25.8% were female. The mean HbA1c was 7.9%, mean eGFR was 74.1 ml/min/1.73m2 and median UACR was 104.2 mg/g.<br>
Conclusions: The CANPIONE study will determine whether the SGLT2 inhibitor canagliflozin can reduce albuminuria and slow eGFR decline in participants with type 2 diabetes and microalbuminuria.
en-copyright=
kn-copyright=

en-aut-name=MiyamotoSatoshi
en-aut-sei=Miyamoto
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=HeerspinkHiddo J. L.
en-aut-sei=Heerspink
en-aut-mei=Hiddo J. L.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=de ZeeuwDick
en-aut-sei=de Zeeuw
en-aut-mei=Dick
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=ToyodaMasao
en-aut-sei=Toyoda
en-aut-mei=Masao
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=SuzukiDaisuke
en-aut-sei=Suzuki
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=HatanakaTakashi
en-aut-sei=Hatanaka
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=NakamuraTohru
en-aut-sei=Nakamura
en-aut-mei=Tohru
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=KameiShinji
en-aut-sei=Kamei
en-aut-mei=Shinji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=MuraoSatoshi
en-aut-sei=Murao
en-aut-mei=Satoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=HidaKazuyuki
en-aut-sei=Hida
en-aut-mei=Kazuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

en-aut-name=AndoShinichiro
en-aut-sei=Ando
en-aut-mei=Shinichiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=11
ORCID=

en-aut-name=AkaiHiroaki
en-aut-sei=Akai
en-aut-mei=Hiroaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=12
ORCID=

en-aut-name=TakahashiYasushi
en-aut-sei=Takahashi
en-aut-mei=Yasushi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=13
ORCID=

en-aut-name=KoyaDaisuke
en-aut-sei=Koya
en-aut-mei=Daisuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=14
ORCID=

en-aut-name=KitadaMunehiro
en-aut-sei=Kitada
en-aut-mei=Munehiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=15
ORCID=

en-aut-name=SuganoHisashi
en-aut-sei=Sugano
en-aut-mei=Hisashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=16
ORCID=

en-aut-name=NunoueTomokazu
en-aut-sei=Nunoue
en-aut-mei=Tomokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=17
ORCID=

en-aut-name=NakamuraAkihiko
en-aut-sei=Nakamura
en-aut-mei=Akihiko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=18
ORCID=

en-aut-name=SasakiMotofumi
en-aut-sei=Sasaki
en-aut-mei=Motofumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=19
ORCID=

en-aut-name=NakatouTatsuaki
en-aut-sei=Nakatou
en-aut-mei=Tatsuaki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=20
ORCID=

en-aut-name=FujimotoKei
en-aut-sei=Fujimoto
en-aut-mei=Kei
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=21
ORCID=

en-aut-name=KawanamiDaiji
en-aut-sei=Kawanami
en-aut-mei=Daiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=22
ORCID=

en-aut-name=WadaTakashi
en-aut-sei=Wada
en-aut-mei=Takashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=23
ORCID=

en-aut-name=MiyatakeNobuyuki
en-aut-sei=Miyatake
en-aut-mei=Nobuyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=24
ORCID=

en-aut-name=YoshidaMichihiro
en-aut-sei=Yoshida
en-aut-mei=Michihiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=25
ORCID=

en-aut-name=ShikataKenichi
en-aut-sei=Shikata
en-aut-mei=Kenichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=26
ORCID=

en-aut-name=the CANPIONE study Investigators
en-aut-sei=the CANPIONE study Investigators
en-aut-mei=
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=27
ORCID=

affil-num=1
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen
kn-affil=

affil-num=3
en-affil=Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen
kn-affil=

affil-num=4
en-affil=Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine
kn-affil=

affil-num=5
en-affil=Suzuki Diadetes Clinic
kn-affil=

affil-num=6
en-affil=Department of Diabetes and Endocrinology, National Hospital Organization Fukuyama Medical Center
kn-affil=

affil-num=7
en-affil=Diabetes Internal Medicine, Sumitomo Besshi Hospital
kn-affil=

affil-num=8
en-affil=Department of Diabetic Medicine, Kurashiki Central Hospital
kn-affil=

affil-num=9
en-affil=Department of Diabetes and Endocrinology, Takamatsu Hospital
kn-affil=

affil-num=10
en-affil=Department of Diabetology and Metabolism, National Hospital Organization Okayama Medical Center
kn-affil=

affil-num=11
en-affil=Department of Internal Medicine Diabetic Center, Okayama City Hospital
kn-affil=

affil-num=12
en-affil=Division of Diabetes and Metabolism, Faculty of Medicine, Tohoku Medical and Pharmaceutical University
kn-affil=

affil-num=13
en-affil=Department of Diabetes, Ochiai General Hospital
kn-affil=

affil-num=14
en-affil=Department of Diabetology and Endocrinology, Kanazawa Medical University
kn-affil=

affil-num=15
en-affil=Department of Diabetology and Endocrinology, Kanazawa Medical University
kn-affil=

affil-num=16
en-affil=Department of Diabetes and Endocrinology, Kochi Health Sciences Center
kn-affil=

affil-num=17
en-affil=Nunoue Clinic
kn-affil=

affil-num=18
en-affil=Internal Medicine, Osafune Clinic, Setouchi
kn-affil=

affil-num=19
en-affil=Department of Diabetes and Endocrinology, Matsue City Hospital
kn-affil=

affil-num=20
en-affil=Diabetes Center, Okayama Saiseikai General Hospital
kn-affil=

affil-num=21
en-affil=Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, The Jikei University Kashiwa Hospital
kn-affil=

affil-num=22
en-affil=Department of Endocrinology and Diabetes Mellitus, Fukuoka University School of Medicine
kn-affil=

affil-num=23
en-affil=Department of Nephrology and Laboratory Medicine, Graduate School of Medical Sciences, Kanazawa University
kn-affil=

affil-num=24
en-affil=Department of Hygiene, Faculty of Medicine, Kagawa University
kn-affil=

affil-num=25
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=26
en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital
kn-affil=

affil-num=27
en-affil=
kn-affil=
en-keyword=canagliflozin
kn-keyword=canagliflozin
en-keyword=CANPIONE study
kn-keyword=CANPIONE study
en-keyword=diabetic kidney disease
kn-keyword=diabetic kidney disease
en-keyword=eGFR slope
kn-keyword=eGFR slope
en-keyword=SGLT2 inhibitor
kn-keyword=SGLT2 inhibitor
en-keyword=urinary albumin-to-creatinine ratio
kn-keyword=urinary albumin-to-creatinine ratio
END

start-ver=1.4
cd-journal=joma
no-vol=18
cd-vols=
no-issue=1
article-no=
start-page=599
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20230814
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Results of resection of forearm soft tissue sarcoma
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Purpose　Soft tissue sarcomas (STS) of the forearm are rare. We aim to assess their oncological and functional outcomes.<br>
Methods　We retrospectively evaluated 34 patients who underwent surgical excision for forearm STS at our institution between 1993 and 2020. We analyzed postoperative Musculoskeletal Tumor Society rating scale (MSTS) and local recurrence-free survival (LRFS), metastasis-free survival, and overall survival (OS) rates. The significance of the following variables was determined: age, sex, histology, tumor size, Federation Nationale des Centres de Lutte contre le Cancer grade, American Joint Committee on Cancer stage, surgical margin, unplanned excision, metastases upon initial presentation, receipt of chemotherapy, and radiotherapy (RT).<br>
Results　The postoperative median MSTS score was 28. Bone resection or major nerve palsy was the only factor that influenced MSTS scores. The median MSTS scores in patients with or without bone resection or major nerve palsy were 24 and 29, respectively (P < 0.001). The 5-year LRFS rates was 87%. Univariate analysis revealed that the histological diagnosis of myxofibrosarcoma was the only factor that influenced LRFS (P = 0.047). The 5-year MFS rates was 71%. In univariate analysis, no factors were associated with MFS. The 5-year OS rates was 79%. Age was the only factor that influenced OS (P = 0.01).<br>
Conclusion　In the treatment of forearm STS, reconstruction of the skin and tendon can compensate for function, while bone resection and major nerve disturbance cannot. Careful follow-up is important, especially in patients with myxofibrosarcoma, due to its likelihood of local recurrence.
en-copyright=
kn-copyright=

en-aut-name=NakataEiji
en-aut-sei=Nakata
en-aut-mei=Eiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=FujiwaraTomohiro
en-aut-sei=Fujiwara
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=KunisadaToshiyuki
en-aut-sei=Kunisada
en-aut-mei=Toshiyuki
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=NakaharaRyuichi
en-aut-sei=Nakahara
en-aut-mei=Ryuichi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=KatayamaHaruyoshi
en-aut-sei=Katayama
en-aut-mei=Haruyoshi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=ItanoTakuto
en-aut-sei=Itano
en-aut-mei=Takuto
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=OzakiToshifumi
en-aut-sei=Ozaki
en-aut-mei=Toshifumi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Department of Orthopedic Surgery, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Orthopedic Surgery, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Orthopedic Surgery, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Orthopedic Surgery, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Orthopedic Surgery, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Orthopedic Surgery, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Orthopedic Surgery, Okayama University Hospital
kn-affil=
en-keyword=Soft tissue sarcomas
kn-keyword=Soft tissue sarcomas
en-keyword=Forearm
kn-keyword=Forearm
en-keyword=Function
kn-keyword=Function
en-keyword=Prognosis
kn-keyword=Prognosis
END

start-ver=1.4
cd-journal=joma
no-vol=951
cd-vols=
no-issue=2
article-no=
start-page=L27
end-page=
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=20230707
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Search for Astrophysical Electron Antineutrinos in Super-Kamiokande with 0.01% Gadolinium-loaded Water
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=We report the first search result for the flux of astrophysical electron antineutrinos for energies O(10) MeV in the gadolinium-loaded Super-Kamiokande (SK) detector. In 2020 June, gadolinium was introduced to the ultrapure water of the SK detector in order to detect neutrons more efficiently. In this new experimental phase, SK-Gd, we can search for electron antineutrinos via inverse beta decay with efficient background rejection thanks to the high efficiency of the neutron tagging technique. In this paper, we report the result for the initial stage of SK-Gd, during 2020 August 26, and 2022 June 1 with a 22.5 x 552 kton center dot day exposure at 0.01% Gd mass concentration. No significant excess over the expected background in the observed events is found for the neutrino energies below 31.3 MeV. Thus, the flux upper limits are placed at the 90% confidence level. The limits and sensitivities are already comparable with the previous SK result with pure water (22.5 x 2970 kton center dot day) owing to the enhanced neutron tagging. Operation with Gd increased to 0.03% started in 2022 June.
en-copyright=
kn-copyright=

en-aut-name=HaradaM.
en-aut-sei=Harada
en-aut-mei=M.
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

affil-num=1
en-affil=Department of Physics, Okayama University
kn-affil=
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=4
article-no=
start-page=439
end-page=442
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202308
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=A Boy Safely Treated with Tyrosine Kinase Inhibitors for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Osteolysis
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=A three-year-old boy with Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ALL) presented with an osteolytic lesion in his right upper arm. Tyrosine kinase inhibitors (TKIs) such as imatinib and dasatinib are an essential component throughout the course of treatment for Ph+ALL. However, TKIs are reported to affect the bone metabolism. In the treatment course of the current patient, the osteolytic lesion quickly improved despite the continuous use of TKIs, even during the concomitant use of corticosteroids. This suggests that TKIs can be safely given with concomitant corticosteroids to children with Ph+ALL, even when osteolytic lesions are present.
en-copyright=
kn-copyright=

en-aut-name=ShiwakuTakahiro
en-aut-sei=Shiwaku
en-aut-mei=Takahiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=IshidaHisashi
en-aut-sei=Ishida
en-aut-mei=Hisashi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=TatebeYasuhisa
en-aut-sei=Tatebe
en-aut-mei=Yasuhisa
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=TamefusaKosuke
en-aut-sei=Tamefusa
en-aut-mei=Kosuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=OchiMotoharu
en-aut-sei=Ochi
en-aut-mei=Motoharu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=FujiwaraKaori
en-aut-sei=Fujiwara
en-aut-mei=Kaori
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=KuboToshihide
en-aut-sei=Kubo
en-aut-mei=Toshihide
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

en-aut-name=NakataEiji
en-aut-sei=Nakata
en-aut-mei=Eiji
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=8
ORCID=

en-aut-name=WashioKana
en-aut-sei=Washio
en-aut-mei=Kana
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=9
ORCID=

en-aut-name=TsukaharaHirokazu
en-aut-sei=Tsukahara
en-aut-mei=Hirokazu
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=10
ORCID=

affil-num=1
en-affil=Department of Pediatrics, Okayama University Hospital
kn-affil=

affil-num=2
en-affil=Department of Pediatrics, Okayama University Hospital
kn-affil=

affil-num=3
en-affil=Department of Pharmacy, Okayama University Hospital
kn-affil=

affil-num=4
en-affil=Department of Pediatrics, Okayama University Hospital
kn-affil=

affil-num=5
en-affil=Department of Pediatrics, Okayama University Hospital
kn-affil=

affil-num=6
en-affil=Department of Pediatrics, Okayama University Hospital
kn-affil=

affil-num=7
en-affil=Department of Pediatrics, National Hospital Organization Okayama Medical Center
kn-affil=

affil-num=8
en-affil=Department of Orthopaedic Surgery, Okayama University Hospital
kn-affil=

affil-num=9
en-affil=Department of Pediatrics, Okayama University Hospital
kn-affil=

affil-num=10
en-affil=Department of Pediatrics, Okayama University Hospital
kn-affil=
en-keyword=acute lymphoblastic leukemia
kn-keyword=acute lymphoblastic leukemia
en-keyword=children
kn-keyword=children
en-keyword=tyrosine kinase inhibitor
kn-keyword=tyrosine kinase inhibitor
en-keyword=osteolysis
kn-keyword=osteolysis
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=4
article-no=
start-page=415
end-page=422
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202308
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Immunohistochemical Expression of Placental Vitamin D Receptors in Pregnancies Complicated by Early and Late-Onset Preeclampsia
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=The aim of our study was to determine whether the immunohistochemical expression of placental vitamin D receptors is altered in pregnancies complicated by preeclampsia. Vitamin D receptor expression was immunohistochemically analysed in the placentas of three groups: a control group, and early- and late-onset preeclampsia groups. Total immunohistochemical intensity staining of placentas showed that the control group had a median vitamin D receptor (VDR) expression significantly higher than the placentas of mothers with early- and late-onset preeclampsia. There was no difference among the three groups in a semiquantitative analysis of VDR staining of the stroma only. Vitamin D receptors showed lower median expression in preeclampsia-affected pregnancies, especially early-onset preeclampsia. Therefore, Vitamin D receptor expression may be an important marker for normal placentation and preeclampsia onset.
en-copyright=
kn-copyright=

en-aut-name=JelcicDzenis
en-aut-sei=Jelcic
en-aut-mei=Dzenis
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=PuzovicVelibor
en-aut-sei=Puzovic
en-aut-mei=Velibor
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=BenzonBenjamin
en-aut-sei=Benzon
en-aut-mei=Benjamin
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=PaladaIvan
en-aut-sei=Palada
en-aut-mei=Ivan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=JerkovićJelena
en-aut-sei=Jerković
en-aut-mei=Jelena
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=VulicMarko
en-aut-sei=Vulic
en-aut-mei=Marko
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

affil-num=1
en-affil=Department of Gynecology and Obstetrics, University Hospital of Split
kn-affil=

affil-num=2
en-affil=General Hospital Dubrovnik, Department of Pathology and Cytology
kn-affil=

affil-num=3
en-affil=University of Split School of Medicine
kn-affil=

affil-num=4
en-affil=University Department of Health Studies of the University of Split
kn-affil=

affil-num=5
en-affil=Department of Gynecology and Obstetrics, University Hospital of Split
kn-affil=

affil-num=6
en-affil=Department of Gynecology and Obstetrics, University Hospital of Split
kn-affil=
en-keyword=vitamin D receptor
kn-keyword=vitamin D receptor
en-keyword=immunohistochemistry
kn-keyword=immunohistochemistry
en-keyword=early and late-onset preeclampsia
kn-keyword=early and late-onset preeclampsia
END

start-ver=1.4
cd-journal=joma
no-vol=77
cd-vols=
no-issue=4
article-no=
start-page=407
end-page=414
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2023
dt-pub=202308
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=Usefulness of Force-Controlled Pelvic Stress Radiograph in the Evaluation and Treatment of Fragility Fractures of the Pelvis in Geriatric Patients: A Pilot Study
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=This study aimed to investigate the usefulness of force-controlled pelvic stress radiographs in the evaluation and treatment of fragility fractures of the pelvis (FFP) using a functional treatment strategy. We conducted a retrospective study of 55 geriatric patients with FFP who underwent pelvic stress radiographs on admission. The differences in the sacral width, pelvic ring width, and medial femoral head width between the radiographs with and without the Sam Sling II M size were defined as Δ sacral width, Δ pelvic ring width, and Δ medial femoral head width, respectively. We used Pearson’s correlation test to assess the relationship between the degree of radiographic instability and the Johns Hopkins highest level of mobility scale (JH-HLM) at 10-days postadmission. Conventional receiver-operating-characteristic curve analysis was used to identify cases requiring surgery using the best cutoff value for radiographic instability. The JH-HLM was significantly correlated with Δ sacral width (r=−0.401, p=0.017), but not with Δ pelvic ring width (r=−0.298, p=0.080) nor with Δ medial femoral head width (r= −0.261, p=0.128). The best cutoff value of Δ sacral width in identifying surgical cases was 10.7 mm (sensitivity 75.0%, specificity 98.0%). Force-controlled pelvic stress radiographs could be helpful in assessing the need for surgery on admission.
en-copyright=
kn-copyright=

en-aut-name=HottaKensuke
en-aut-sei=Hotta
en-aut-mei=Kensuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=KobayashiTakaomi
en-aut-sei=Kobayashi
en-aut-mei=Takaomi
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

affil-num=1
en-affil=Department of Orthopaedic Surgery, Amagi Chuo Hospital
kn-affil=

affil-num=2
en-affil=Department of Orthopaedic Surgery, Karatsu Red Cross Hospital
kn-affil=
en-keyword=fragility fracture of the pelvis
kn-keyword=fragility fracture of the pelvis
en-keyword=functional treatment strategy
kn-keyword=functional treatment strategy
en-keyword=Sam Sling
kn-keyword=Sam Sling
en-keyword=stress radiograph
kn-keyword=stress radiograph
en-keyword=Johns Hopkins highest level of mobility scale
kn-keyword=Johns Hopkins highest level of mobility scale
END